

AstraZeneca


Annual Report and Form 20-F Information 2025



We
follow the
science



and put
patients
first




Welcome

What science can do



We are a global, science-led, patient-focused pharmaceutical business. We are committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life.



Trade marks

Brand names shown in *italics* are trade marks owned by or licensed to the Group.

Supplements

Detailed information on our Development Pipeline, Patent Expiries of Key Marketed Products and Risk.

 See our website, www.astrazeneca.com/annualreport2025.



Front cover image:

Our Values include following the science and putting patients first. They help us achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines. For more information, see page 8.

Use of terms:

In this Annual Report, unless the context otherwise requires, 'AstraZeneca', 'the Group', 'we', 'us' and 'our' refer to AstraZeneca PLC and its consolidated entities.

Financial highlights

// Denotes a scale break. Throughout this Annual Report, all bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

For more information in relation to the inclusion of Reported performance, Core financial measures and constant exchange rate (CER) growth rates as used in this Annual Report, see the Financial Review from page 50 and for more information on the reconciliation between Reported and Core performance, see the Reconciliation of Reported results to Core results in the Financial Review on page 55.

Total Revenue¹

Up 9% at actual rate of exchange to \$58,739 million (up 8% at CER), comprising Product Sales of \$55,573 million (up 9%; 9% at CER), Alliance Revenue of \$3,067 million (up 39%; 38% at CER) and Collaboration Revenue of \$99 million (down 89%; 89% at CER)

\$58.7bn

2025	\$58,739m
2024	\$54,073m
2023	\$45,811m

Net cash inflow from operating activities

Up 23% at actual rate of exchange to \$14,575 million

\$14.6bn

2025	\$14,575m
2024	\$11,861m
2023	\$10,345m

Reported Operating profit

Up 37% at actual rate of exchange to \$13,743 million (up 36% at CER)

\$13.7bn

2025	\$13,743m
2024	\$10,003m
2023	\$8,193m

Core Operating profit

Up 9% at actual rate of exchange to \$18,478 million (up 9% at CER)

\$18.5bn

2025	\$18,478m
2024	\$16,928m
2023	\$14,534m

Reported EPS

Up 45% at actual rate of exchange to \$6.60 (up 43% at CER)

\$6.60

2025	\$6.60
2024	\$4.54
2023	\$3.84

Core EPS

Up 12% at actual rate of exchange to \$9.16 (up 11% at CER)

\$9.16

2025	\$9.16
2024	\$8.21
2023	\$7.26

¹ As detailed from page 129, Total Revenue consists of Product Sales, Alliance Revenue and Collaboration Revenue.

Contents

Key

For more information within this Annual Report.

For more information, see www.astrazeneca.com.

Strategic Report

AstraZeneca at a Glance 2
Chair's Statement 3
Chief Executive Officer's Review 4
Healthcare in a Changing World 6
Our Purpose, Values and Business Model 8
Our Strategy and Key Performance Indicators 10
Therapy Area Review 12
Business Review 26
Section 172(1) Statement 46
Viability Statement 46
Risk Overview 47
Financial Review 50

Corporate Governance

Chair's Introduction 66
Corporate Governance Overview 67
Board of Directors 68
Senior Executive Team (SET) 70
Corporate Governance Report 71
Nomination and Governance Committee Report 79
Science Committee Report 81
Sustainability Committee Report 82
Audit Committee Report 83
Directors' Remuneration Report 90

Financial Statements

Preparation of the Financial Statements and Directors' Responsibilities 115
Directors' Annual Report on Internal Controls over Financial Reporting 115
Independent Auditors' Report 116
Consolidated Statements 125
Group Accounting Policies 129
Notes to the Group Financial Statements 137
Group Subsidiaries and Holdings 192
Company Statements 197
Company Accounting Policies 199
Notes to the Company Financial Statements 201

Sustainability Statement

General disclosures 205
Topical disclosures 211
Environmental disclosures 211
Social disclosures 217
Governance disclosures 219
Independent Sustainability Assurance Report 220

Additional Information

Shareholder information 223
Directors' Report 224
Glossary 227
Cautionary statement regarding forward-looking statements 228

AstraZeneca at a Glance

We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

Our purpose

We push the boundaries of science to deliver life-changing medicines.

Our strategic priorities

Our priorities reflect how we are working to deliver our Growth Through Innovation strategy.



1. Science and Innovation



2. Growth and Therapy Area Leadership



3. People and Sustainability

Science and innovation-led

We invest in new technologies and modalities to deliver the next wave of pipeline innovation and life-changing medicines.

197

projects in our development pipeline¹

20

new molecular entities (NMEs) in our late-stage pipeline

125

NME or major life-cycle management (LCM) projects in Phase II and Phase III

\$14.2bn

invested in our science

¹ Includes NME and major LCM projects up to launch in all applicable markets.

Leading in our therapy areas

We focus on areas where we can transform patient outcomes through novel medicines and combinations.

Oncology

Leading a revolution to transform cancer care.


BioPharmaceuticals

Transforming care for billions of people living with chronic diseases and delivering long-lasting immunity.

Rare Disease

Pioneering new possibilities for the rare disease community.

Total Revenue by therapy area²




² Due to rounding, the sum of subtotals and percentages may not agree to totals.

Diversified portfolio and global reach


We deliver a diversified portfolio of medicines across primary care, specialty care and rare diseases through our broad-based global network.

Total Revenue growth by reporting region³



³ Actual growth percentage.

Total Revenue by reporting region⁴



⁴ See page 32 for how we define our regions.

Positively impacting the health of people, society and the planet

We operate responsibly, harnessing the power of science and innovation, and our global reach, to help build a healthier, more sustainable future.

320 million

people have been positively impacted⁵

⁵ See page 218 for methodology and definitions.

88.1%

reduction in Scope 1 and 2 GHG emissions since 2015

Chair's Statement



“We have more than 100 Phase III studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.”

\$3.20

Full-year dividend of \$3.20 per share (2024: \$3.10)

AstraZeneca's many scientific and commercial achievements in 2025 were underpinned by our continuous adaptation to a rapidly changing external environment.

Those achievements start with our continued strong commercial performance in 2025, with Total Revenue up 9% (8% at CER). Reported EPS was up 45% (43% at CER) and Core EPS, which excludes certain items, was up 12% (11% at CER). The Board has declared a second interim dividend of \$2.17 per share (159.5 pence, 19.49 SEK). Total dividend declared for 2025 increased by 3% to \$3.20 per share.

A global company

Our financial performance reflects the depth and breadth of our portfolio and pipeline of life-changing medicines. It also reflects our leading global presence and footprint.

In November 2025, our plans to deliver a global listing for global investors were overwhelmingly approved by shareholders at the General Meeting with a vote of 99.36% in favour. From 2 February 2026 shareholders have been able to trade their interests in AstraZeneca Ordinary Shares across all three exchanges in New York, London and Stockholm. This harmonised listing structure will help us reach a broader mix of global investors, making it more attractive for all shareholders to participate in our future and giving us flexibility to access the widest pool of capital.

Global opportunities and challenges

The world continues to be in flux. Geopolitical shifts, crises, and conflict intersect with economic, demographic, societal, environmental, and technological change – reshaping the context in which companies operate. While no business can predict every shock, active risk management strengthens our capacity to absorb disruption and adapt, enabling us to execute our strategy, drive innovation, grow, and reach more patients.

At the same time, we face a more economically diverse landscape as economic power evolves, including the rise of emerging, populous markets. Governments are also prioritising strategic autonomy for security, resilience, and competitiveness, with pressure to build climate-resilient supply chains. These interlinked trends bring risks to manage and significant opportunities for innovation, partnerships, and sustainable growth. Our industry-leading role in negotiating an agreement with the US administration to lower the cost of medicines for American patients illustrates our agility in responding to the changes we are seeing.

A shared drive for innovation

The pace of scientific progress today is nothing short of extraordinary, with transformative new technologies and modalities redefining what is possible for patients. Yet, these advances are not reaching everyone equally. Across continents, access to life-changing treatments remains inconsistent. For example, over the past five years, about 40% of medicines launched in the US did not launch in key European countries, whereas only 7% of medicines launched in Europe did not reach the US.

To harness the promise of this scientific golden age, we need to adapt and rethink how we value health. Treating it as a strategic investment – rather than a budgetary expense – can unlock immense economic and societal benefits. For example, an additional \$3 per person each year to tackle chronic diseases could yield economic benefits of up to \$1 trillion by 2030.

However, the responsibility for driving innovation must be shared. A more balanced, global approach to funding and risk-sharing is essential. We need policymakers to modernise regulations, foster public-private partnerships, and prioritise health as a pillar of national strength and sovereignty. By aligning policy and investment with scientific readiness, we can deliver longer, healthier lives and a more resilient global economy.

A dedicated team

As reflected throughout this Annual Report, 2025 was a year of exceptional progress for AstraZeneca, delivering impact for people, society, and the planet. On behalf of the Board, I extend our gratitude to Pascal, the Senior Executive Team, and every colleague whose work made these results possible.

Outlook

As we look ahead, we have more than 100 Phase III studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.

Michel Demaré
Chair

Chief Executive Officer's Review



“In addition to delivering medicines today, we are following the science to deliver medicines for tomorrow and the day after.”

\$58.7bn

Total Revenue (2024: \$54.1bn)

97

Regulatory events – submissions or approvals in major markets

2025 was exceptional as we advanced science and delivered innovation that benefited people, society, and the planet.

It was a year that saw sustained momentum with Total Revenue increasing by 9% (8% at CER) to \$58.7 billion while Product Revenue was up 10% (10% at CER), reflecting broad-based growth across all therapy areas and major regions. We also saw excellent pipeline delivery in a continuing catalyst-rich period, with 16 positive Phase III clinical trial readouts.

Beyond delivering on our pipeline, 2025 was significant for other reasons: we announced our largest investment plans ever; partnered with governments and key stakeholders across the world to strengthen healthcare ecosystems; and took centre stage at many major congresses, demonstrating leadership across all our therapy areas.

Diverse and resilient

Our strong financial performance reflects our diverse portfolio and our geographic breadth. In our therapy areas, Total Revenue for Oncology increased 15% (14% at CER) to \$25.6 billion and Rare Disease delivered growth of 4% (4% at CER) to \$9.1 billion. Overall, BioPharmaceuticals Total Revenue grew by 5% (5% at CER) to \$23.0 billion, with Cardiovascular, Renal & Metabolism growing by 3% (2% at CER) and Respiratory & Immunology by 13% (12% at CER). Vaccines & Immune Therapies decreased by 13% (14% at CER). We now have 16 blockbuster medicines that each generate more than \$1 billion in annual sales.

Across our regions, we saw balanced growth with Product Revenue in the US up 10%, Europe up 11% (7% at CER), Emerging Markets up 12% (14% at CER)

and Established Rest of World up 5% (5% at CER). Our performance in Emerging Markets outside China (up 19%, 22% at CER) was particularly impressive, demonstrating the strength of our global footprint.

AstraZeneca's momentum is continuing in 2026 and we are looking forward to the results of more than 20 Phase III trial readouts during the year.

Changing lives

At the heart of AstraZeneca is our delivery of innovative medicines that change lives. Following the approval of *Datroway* and *Kavigale* at the start of the year, the approval of *Beyontra* in March for transthyretin amyloid cardiomyopathy (ATTR-CM) in Japan, represented the ninth new medicine against our ambition to deliver 20 by 2030. During 2025, we also achieved 12 first approvals for life-cycle management projects.

Our global reach means we can set new standards for the accessibility of our medicines and help more patients. For example, in 2025 we received six world-first approvals for our medicines in emerging markets – *Datroway*, *Tezspire* and *Imfinzi* with new indications, *Saphnelo* for a line extension, and a first approval, for camizestrant, in the UAE.

Transforming healthcare

There are other ways in which we are helping patients. Our 'Transform Care' initiative accelerated the adoption of clinical guideline-based therapy even further during 2025, enabling millions more patients to receive innovative medicines. By the end of the year, we had established more than 200 health system partnerships across 50 countries. We are finding and treating high-risk patients, accelerating the time to diagnosis and treatment, and improving outcomes for millions of people, all the while helping healthcare systems to become more resilient.

Operational excellence

Our medicines can only help patients if they are in their hands when they are needed. In 2025, we maintained an impressive track record with 217 on-time launches, more than 99% supply performance, zero patient level recalls and zero critical observations from 42 external inspections.

Investing to deliver our medicines

We are also investing to support our growth ambitions and ensure we can continue to deliver our medicines, especially in markets where healthcare is seen as a strategic priority and there is funding for innovation.

US agreement

The US remains our largest market and is projected to represent approximately 50% of our Total Revenue by 2030. During 2025, we took action to strengthen our position and secure our long-term growth there. In October, we announced an agreement with the US administration which provides greater clarity around pricing and a three-year exemption from tariffs. The agreement will lower the cost of many prescription medicines in America while safeguarding its pharmaceutical innovation.

Expanding globally

In the US, we plan to invest \$50 billion in manufacturing and R&D, including our \$4.5 billion facility in Virginia – our largest single manufacturing investment where we broke ground in October. We followed this with plans to invest \$2 billion to expand our manufacturing footprint in Maryland. This includes expansion of our biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg. In October, we also opened our newly expanded manufacturing facility in Coppell, Texas.

Our efforts are not restricted to the US. In March, we announced plans to establish a new global strategic R&D centre in Beijing, our second in China and sixth worldwide. Our \$2.5 billion investment expands early discovery and development and incorporates an AI and data science laboratory. At the same time, agreements with Harbour BioMed and Syneron Bio, together with a pioneering Cambridge Beijing ecosystem collaboration, aim to accelerate our science and innovation.

Additionally, we are making good progress with the construction of our \$1.5 billion antibody drug conjugate manufacturing facility in Singapore and opened our new global hub in Barcelona, as well as expanding our manufacturing capabilities in China, Sweden and the Netherlands.

Reshaping the future of healthcare

In addition to delivering medicines today, we are following the science to deliver medicines for tomorrow and the day after.

Oncology

We are proud of our science and the American Society of Clinical Oncology annual meeting provided a remarkable moment in 2025, marking our seventh consecutive year with a plenary session, and the second consecutive year in which we had two: SERENA-6 on camizestrant for the treatment of 1st-line advanced HR-positive breast cancer; and MATTERHORN which showcased perioperative treatment with *Imfinzi* in early gastric and gastroesophageal junction cancers and for which it was approved in the US by the FDA.

We also had back-to-back presidential presentations for the DESTINY-Breast05 and DESTINY-Breast11 Phase III trials at the European Society for Medical Oncology Congress that demonstrated the transformative potential of *Enhertu* in early HER2-positive breast cancer – a setting where there is a greater opportunity for cure. Together with DESTINY-Breast09, SERENA-6 and TROPION-Breast02 for *Datroway*, these five studies demonstrate the difference we are making for people with breast cancer and illustrate our strategy to bring novel treatments to early cancer settings where patients can benefit most.

BioPharmaceuticals

In BioPharmaceuticals, baxdrostat has the potential to be a best and first-in-class medicine that would have a very real impact for the hundreds of millions of people worldwide living with hard-to-control hypertension. We acquired baxdrostat from CinCor in 2023 and advanced it from Phase II to delivery of Phase III data and filing by the end of 2025. Phase III trials showed statistically significant and clinically meaningful blood pressure reductions and baxdrostat represents one of the most significant innovations in the hypertension field in over two decades.

Rare Disease

In Rare Disease, positive results from the global PREVAIL Phase III trial showed that gefurilumab met its primary and all secondary endpoints, demonstrating a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo. Findings from the trial offer valuable insights into how early and sustained complement inhibition with gefurilumab may translate into meaningful, functional improvement for people living with gMG. A once-weekly self-administered treatment option would advance greater convenience and independence for patients in managing their condition, as well as strengthening our scientific leadership in complement inhibition.

Following the science

While we had remarkable success in 2025, pushing boundaries sometimes means setbacks. For example, we did not achieve the primary endpoints in the Phase III RESOLUTE trial for *Fasenra* in COPD and the LATIFY trial of ceralasertib plus *Imfinzi* in previously treated advanced NSCLC. True to our Values of following the science and putting patients first, we learn from every trial and share data with the wider scientific community.

Overall, our vision extends well beyond our ambitions for 2030, and we are investing significantly in transformative technologies that will shape the future of medicine and sustain our growth into the next decade. This includes harnessing the power of AI where, for example, 90% of our small molecule discovery pipeline is already AI-assisted, potentially improving the probability of clinical success.

Delivering in the right way

At AstraZeneca, how we work is as important to us as what we do. I was therefore proud to introduce our refreshed sustainability strategy in May. It focuses on how we make a sustainable impact by acting on nature, health equity and health systems resilience and how we work by living our Values, investing in our people and operating responsibly, ethically and with robust governance.

We are making good progress in these areas. In 2025, we continued to deliver against Ambition Zero Carbon, with a reduction in Scope 1 and 2 greenhouse gas emissions of 88.1% since 2015. We are now especially focused on cutting Scope 3 emissions with the aim of achieving science-based net zero by 2045. On health equity, we have a 2030 ambition to positively impact one billion people, including 400 million from underserved communities. We have achieved our target of 40.4% of genomics data coming from understudied global communities, and, so far, have reached more than 49 million people since 2024 with health education, screening and early detection.

Investing in people

None of our achievements would be possible without the dedication and talent of AstraZeneca colleagues worldwide. I am proud that 86% of our people believe AstraZeneca is a great place to work, and we continue to make progress in creating an inclusive environment where everyone feels they belong.

We are embracing AI to accelerate our progress and have set up a new AI unit to reinforce our efforts. The uptake of AI tools continues to grow and, in 2025, more than 50,000 employees participated in our 'Thriving in the Age of AI' programme. These technologies are enabling us to discover and deliver new treatments faster than ever before and drive step-changes in how we diagnose, monitor and treat patients – as well as transform how we all work.


I would like to thank each of my colleagues for the contributions they have made and firmly believe we have the best team in the industry. Together, we are on track to deliver our Ambition 2030, addressing unmet medical need, reshaping the future of healthcare and changing lives around the world.

Pascal Soriot

Chief Executive Officer

Healthcare in a Changing World

The external environment presents both challenges and opportunities that require us to adapt, innovate and build trust.



A growing pharmaceutical sector

The pharmaceutical sector continues to grow against a backdrop of increasing demand for healthcare. Global healthcare spending is projected to increase at an annual rate of 7.1% from 2025 to 2029.

10.0%

Global pharmaceutical sales grew by 10.0% in 2025

(Source: IQVIA, IQVIA Midas Quantum Q3 2025)

Global trends

Against the background of broad structural trends, the pharmaceutical sector is navigating economic challenges and political uncertainty as well as the impacts of social changes and the climate crisis. Rapidly-advancing technologies offer both risks and benefits, while successful organisations are building trust with stakeholders.

These risks are explored further in the Risk Overview from page 47 and Accessible and affordable healthcare from page 41.

Shifting economic power

Economic power is shifting from the G7 to the largest emerging markets, such as China and countries with large populations, including India and Indonesia, altering global economic dynamics and creating new opportunities and challenges. For example, the G7 comprised some 65% of global GDP in 2000 which is expected to drop to less than one third by 2050.

<1/3

The G7's share of global GDP fell from roughly two thirds (~65%) in 2000 to about half today, and is projected to shrink to less than one third by 2050.

(Source: Global Trade Outlook, February 2023)

Global instability

Continuing geopolitical tensions and shifting alliances are creating a more volatile global landscape, impacting international relations and stability. This includes the rise of economic nationalism, sustained strategic rivalry between the US and China, as well as conflicts, such as the war in Ukraine, and 'grey zone' conflict – the contested arena between routine diplomacy and open warfare.

Changing populations

The UN predicts the global population will reach 9.7 billion by 2050. Key trends include continued urbanisation, falling birth rates in many countries, notably South Korea, Japan and within Western Europe, and an ageing population, with those aged 65 and older set to triple by 2100. Furthermore, the ratio of retirees to workers will rise dramatically as the share of younger people declines, putting structural pressure on pay-as-you-go pensions and on health and long-term care financing. Population growth is also becoming more concentrated, with much of the growth coming from Africa and South Asia.

9.7 billion

The UN predicts the global population will reach about 9.7 billion by 2050.

(Source: United Nations)

Trend		Impact
Politics Increasing international friction	Two thirds More than two thirds of respondents believe we will face a world in which middle and great powers contest, set and enforce regional rules and norms. (Source: World Economic Forum Global Risk Report, January 2026)	The political climate has acute consequences for security, trade and global collaboration. Some governments deliberately use economic ties, such as access to critical minerals, to gain strategic leverage over others, thereby increasing the risk of supply chain disruption. However, such trends also present opportunities as companies are encouraged to localise operations to mitigate supply chain risks. As a consequence, AstraZeneca is investing in robust and flexible supply chains and a strong global manufacturing footprint, see Operations on page 33 of the Business Review.
Economics Global economy in flux	3.3% Global GDP growth forecast at 3.3% for 2026 and 3.2% in 2027. (Source: IMF, January 2026)	Global growth is projected to remain resilient at 3.3% in 2026 and at 3.2% in 2027 – rates similar to the estimated 3.3% outturn in 2025. In addition, healthcare budgets are under pressure which is leading to downward pressure on pricing. We work closely with payers and policymakers to deliver locally affordable medicines. In 2025, we reached an agreement with the US Government to lower the cost of medicines for US patients, see Our regions from page 32 of the Business Review.
Society Increasing healthcare demands	43 million Non-communicable diseases (NCDs) were the cause of death for 43 million people in 2021. (Source: WHO, September 2025)	Demographic change is driving an increased demand for healthcare across all age groups. However, people in low- and middle-income countries are disproportionately affected by NCDs, as 82% of NCD deaths occur in these countries. In total, NCDs represent 75% of non-pandemic-related deaths globally. Through our health equity programme, we aim to close healthcare gaps and to give people everywhere the chance to be as healthy as possible, see Accessible and affordable healthcare on page 41 of the Business Review.
Technology Changing the way we work	\$4-7 billion/year Generative AI is estimated to unlock \$4-7 billion in value annually for pharmaceutical companies. (Source: McKinsey & Company, January 2025)	Rapid advances in the field of AI and machine learning are enhancing our ability to process and understand vast amounts of data. AI will unlock value and bring new risks. Guided by our principles of ethical and responsible data and AI use, new technologies enable us to deliver better medicines and treatments, more quickly, to more patients, see Digital technologies on page 36 of the Business Review.
Environment Deep interconnection between climate and health	53.2Gt CO₂ emissions are at a record high globally as 53.2 gigatonnes of CO₂e were emitted into the atmosphere in 2024. (Source: Joint Research Centre, September 2025)	The climate crisis is amplifying health inequities and putting additional strain on health systems. Older adults, children, outdoor workers, and low- and middle-income communities face heightened risks from heat-related cardiovascular, respiratory, renal and neurological harms. We are pursuing ambitious science-based decarbonisation targets to achieve net zero by 2045, see Climate change from page 42 of the Business Review.
Outlook Opportunities and challenges for the sector	71% In a 28-country survey, 71% of people questioned rated the healthcare industry trustworthy, and 76% of people trusted scientists. (Source: 2025 Edelman Trust Barometer, January 2026)	The use of advancements in science and digital technologies offer the potential to revolutionise the healthcare industry. However, coupled with growing distrust of governments, political leaders and more generally, information, concerns around the politicisation of science can exacerbate existing trust issues. Our Code of Ethics and Values determine how we work together and the behaviours that drive our success and improve trust, see Business conduct from page 34 of the Business Review.

Our Purpose, Values and Business Model

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders.

Our Purpose

We push the boundaries of science to deliver life-changing medicines.

Our Values

Our Values determine how we work together and the behaviours that drive our success. They guide our decision making and define our beliefs.



We follow the science

Pushing the boundaries of science and working creatively with partners and collaborators.



We put patients first

Striving to understand patients' needs and considering them in every decision we take.



We play to win

Building high-performing, inclusive and diverse teams and making the right choices to win.



We do the right thing

Employing high ethical standards when carrying out all aspects of our business globally.



We are entrepreneurial

Acting with urgency, bravery, resilience and taking smart risks.

Our business model

We are a global pharmaceutical business with a science-led and patient-focused value proposition committed to excellence in the research, development, manufacturing and commercialisation of prescription medicines across primary care, specialty care and rare diseases. We are also committed to operating responsibly, and in an ethical and transparent way, to help build a healthier, more sustainable future. We invest resources to create financial and non-financial value that benefits patients, society, the planet and our business.

For more information, see Business Review from page 26.

Value outcome

Inputs >>>

R&D

We invest in the science and effective collaborations to build a strong pipeline of innovative medicines.

Commercialisation

We have a global commercial presence and skills to ensure our medicines reach patients as quickly and as broadly as appropriate.

Manufacturing and distribution

We have robust global supply chains and manufacturing footprint to ensure medicines are delivered to patients.

Enabled by

People

We acquire, retain and develop a talented and diverse workforce.

Technology

We invest in transformative new technologies and platforms, including AI, to develop and deliver medicines more efficiently.

Outputs >>>

Improved health

We are transforming the future of healthcare, improving health outcomes and quality of life globally. Through innovation and partnerships, we tackle health challenges, close care gaps and create healthier communities.

Returns to shareholders

Revenue from our Product Sales and collaboration activities generates cash flow, which helps us:

- Fund our investment in science and the business to drive long-term value.
- Follow our progressive dividend policy.
- Meet our debt service obligations.

320 million

people positively impacted¹

¹ See page 218 for methodology and definitions.

Life-cycle of a medicine

We create financial value throughout the life-cycle of a medicine

This is a high-level overview of a medicine's life-cycle and is illustrative only.



Research and development phases – duration: 5-15 years

1. Undertake scientific research to identify potential new medicines.
2. Preclinical studies in the laboratory and in animals to understand if the potential medicine is safe to introduce into humans.
3. Phase I trials with small groups of healthy human volunteers (small molecules) or patients (biologics) to understand how the potential medicine is absorbed into the body, distributed and excreted.
4. Phase II trials on small- to medium-sized groups of patients to test effectiveness, safety and tolerability of the medicine and determine optimal dose.
5. Phase III trials in a larger group of patients to gather information about effectiveness and safety of the medicine and evaluate the overall benefit/risk profile.
6. Seek regulatory approvals for manufacturing, marketing and selling the medicine.

Launch phase – duration: 5-15 years

7. Launch new medicine while continuously monitoring, recording and analysing reported side effects.
8. Post-launch R&D to further understand the benefit/risk profile of the medicine and life-cycle management activities to understand its full potential.

Post-exclusivity – duration: 20+ years

9. Patent expiry and generic medicine entry.

For more information on our pipeline progression, see our Development Pipeline Supplement on our website, www.astrazeneca.com/annualreport2025.

Our Strategy and Key Performance Indicators

Our ambition is to launch at least 20 new medicines by 2030.

Our Growth Through Innovation strategy has three priorities, whose effective delivery will help us achieve our financial targets.

Our capital allocation priorities include: investing in the business and pipeline; maintaining a strong, investment-grade credit rating; potential value-enhancing business development opportunities; and supporting the progressive dividend policy.

Growth Through Innovation strategy



1. Science and Innovation



2. Growth and Therapy Area Leadership



3. People and Sustainability



Achieve Group Financial Targets

Ambition 2030

Our ambition is to be pioneers in science, lead in our disease areas and transform patient outcomes. By 2030, we aim to launch at least 20 new medicines and achieve \$80 billion in Total Revenue with sustained growth thereafter.

9

NMEs delivered against our Ambition 2030 of launching at least 20 new medicines¹.

Our Key Performance Indicators and remuneration

We measure our productivity and success against our Key Performance Indicators (KPIs), which are aligned to our strategic priorities. Several KPIs are used to measure Executive Directors' remuneration, allowing us to disclose aggregated targets without disclosing sensitive commercial information at the individual KPI level. Variances between the KPI and values used in determining remuneration are explained in the Directors' Remuneration Report from page 90. Our Ambition Zero Carbon strategy is reflected in our executive incentive arrangements.

Achieve Group Financial Targets

Key Performance Indicators

Earnings per share (EPS) is an important profitability metric and a key driver of shareholder value.

Cash generation is a key driver of long-term shareholder returns and facilitates reinvestment in our pipeline, which is critical for delivering new medicines and future value.

Key

● Used for remuneration of Executive Directors

□ For more information on:

Our Core measures, see the Financial Review from page 50.

How Group financial targets are considered when calculating the annual bonus, see page 99.

Reported EPS

\$6.60

2025	\$6.60
2024	\$4.54
2023	\$3.84

Actual growth

2025 +45%
2024 +18%
2023 +81%

CER growth

2025 +43%
2024 +29%
2023 +96%

Core EPS

\$9.16

2025	\$9.16
2024	\$8.21
2023	\$7.26

Actual growth

2025 +12%
2024 +13%
2023 +9%

CER growth

2025 +11%
2024 +19%
2023 +15%

Net cash inflow from operating activities

\$14,575m

2025	\$14,575m
2024	\$11,861m
2023	\$10,345m

Actual growth

2025 +23%
2024 +15%
2023 +5%

¹ The target of 20 reflects medicines approved since October 2022.

Science and Innovation

Advances in science and technology are revolutionising the way we work, enabling us to push the boundaries to deliver new and better medicines and treatments more quickly to more patients.

Our strategic focus areas

- Deliver the next wave of pipeline innovation
- Accelerate platform of therapeutic modalities
- Transform R&D ways of working

Key Performance Indicators

Our science measures incentivise the development of NMEs and the maximisation of the potential of existing medicines. Pipeline progression events (Phase II NME starts/progressions and Pivotal Phase II/Phase III investment decisions) measure innovation and sustainability. Regulatory events (regulatory submissions and approvals) demonstrate the advancement of this innovation to patients and the value to the Group.

Pipeline progression events

38

2025	38 ¹
2024	24 ²
2023	30 ³

- ¹ 36 against our Group scorecard for determining annual bonus.
² 24 against our Group scorecard for determining annual bonus.
³ 30 against our Group scorecard for determining annual bonus.

Regulatory events

97

2025	97 ¹
2024	74 ²
2023	56 ³

- ¹ 69 against our Group scorecard for determining annual bonus.
² 52 against our Group scorecard for determining annual bonus.
³ 46 against our Group scorecard for determining annual bonus.

For more information on our developments in 2025, see:

Research & Development from page 28 of the Business Review.

2025 Group scorecard assessment on page 99 for performance against the Group scorecard.

Growth and Therapy Area Leadership

We are working across our therapy areas to transform care and meet the increasing demand for healthcare by improving access to our medicines, expanding treatment options and enabling patients to take control of their own health.

Our strategic focus areas

- Deliver industry-leading growth in our therapy areas
- Improve patient outcomes by transforming care
- Realise world-class supply chains

Key Performance Indicators

Our Total Revenue measure reflects the importance of incentivising sustainable growth in both the short and long term.

Total Revenue

\$58,739m

2025	\$58,739m
2024	\$54,073m
2023	\$45,811m

Actual growth	CER growth
2025 +9%	2025 +8%
2024 +18%	2024 +21%
2023 +3%	2023 +6%

For details of how Total Revenue is considered when calculating the annual bonus, see from page 99.

For more information on our developments in 2025, see:

Therapy Area Review from page 12.

Affordability and pricing on page 41 and Operations on page 33 of the Business Review.

People and Sustainability

Recognising the interconnection between business growth and societal needs, our sustainability strategy is focused on action on climate and nature, health equity and health systems resilience. We cultivate an inclusive, diverse workplace where employees thrive and are empowered to make an impact for people, society and the planet.

Our strategic focus areas

- Deliver a great employee experience
- Lead on climate, equity and resilience
- Enable an agile organisation

Key Performance Indicators

Our People KPI is based on our Pulse survey measure of those employees who believe that AstraZeneca is a great place to work.

Our Sustainability KPI is our reduction in Scope 1 and 2 greenhouse gas (GHG) emissions (since 2015 baseline), part of our Ambition Zero Carbon strategy.

Employee belief that AstraZeneca is a great place to work¹

86%

2025	86%
2024	84%
2023	86%

¹ Source: November Pulse survey for each year.

Reduction in Scope 1 and 2 GHG emissions since 2015

-88.1%

-88.1%	2025
-77.5%	2024
-67.6%	2023

For more information on our developments in 2025, see:

People and Sustainability from page 38 of the Business Review.

Therapy Area Review

Redefining cancer care

Oncology

We are leading a revolution to transform cancer care.

Total Revenue

\$25,619m

up 15% (14% at CER)

2024: \$22,353m

2023: \$18,447m

2025 overview

- Commercial delivery and sales performance driven by five multi-blockbuster medicines: *Tagrisso*, *Imfinzi*, *Calquence*, *Lynparza* and *Enhertu*.
- Broad penetration of our Oncology medicines with 13 major market approvals across 10 indications.
- 10 positive Phase III readouts across multiple tumour types including lung, breast, bladder and gastric cancers.

Full details are given in the Development Pipeline and Patent Expiries of Key Marketed Products Supplements on our website, www.astrazeneca.com/annualreport2025.

Unmet medical need and world market

2nd

Cancer is the second leading cause of death worldwide.

Over 30 million

The global burden of cancer is expected to grow, with over 30 million newly diagnosed patients estimated by 2040. Two thirds of those patients are expected to be in low- and middle-income countries.

Key marketed products

Product	Disease	Total Revenue	Commentary
Tagrisso (osimertinib)	Lung cancer	↑ \$7,254m, up 10% (10% at CER)	World-leading third-generation tyrosine kinase inhibitor (TKI) and backbone therapy for epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) across multiple stages with continued demand growth in both the adjuvant and metastatic settings. Approved in more than 120 countries across multiple indications.
Imfinzi (durvalumab)	Lung, liver, biliary tract, gastric, gastroesophageal junction, bladder and endometrial cancers	↑ \$6,063m, up 29% (28% at CER)	A leading immunotherapy approved for 11 different indications across several tumour types including NSCLC, small cell lung cancer (SCLC), multiple gastrointestinal cancers and endometrial and bladder cancers. Approved in 98 countries.
Calquence (acalabrutinib)	Chronic lymphocytic leukaemia (CLL); mantle cell lymphoma (MCL); small lymphocytic lymphoma (SLL)	↑ \$3,518m, up 12% (12% at CER)	A second-generation, selective inhibitor of Bruton's tyrosine kinase that is the current standard of care (SoC) across multiple forms of blood cancer. Approved in 94 countries.
Lynparza (olaparib)	Ovarian, breast, pancreatic, prostate and endometrial cancers	↓ \$3,279m, down 11% (12% at CER) ¹	Remains the leading PARP inhibitor across five tumour types as measured by total prescription volume, the SoC in advanced ovarian cancer, and the only PARP inhibitor to improve survival in early breast cancer. Also approved in combination with abiraterone and prednisone in 1st-line metastatic castration-resistant prostate cancer (mCRPC) and in combination with <i>Imfinzi</i> in advanced or recurrent mismatch repair proficient endometrial cancer. Approved in 114 countries.
Enhertu (trastuzumab deruxtecan) ²	Breast, lung, gastric and a tumour-agnostic approval in metastatic HER2-positive solid tumours	↑ \$2,775m, up 40% (40% at CER)	Market leadership in HER2-positive and HER2-low metastatic breast cancer, HER2-positive metastatic gastric cancer and HER2-mutant metastatic lung cancer, as well as the first HER2-directed therapy approved for tumour agnostic cancers. Approved in more than 90 countries.
Zoladex (goserelin acetate implant)	Prostate and breast cancers	↑ \$1,151m, up 5% (6% at CER)	Approved in 122 countries for the treatment of prostate cancer and in 108 countries for the treatment of breast cancer in premenopausal women.
Truqap (capivasertib)	Breast cancer	↑ \$728m, up 69% (68% at CER)	Approved in combination with <i>Faslodex</i> in more than 85 countries in a biomarker-altered subgroup of HR-positive, HER2-negative metastatic breast cancer.
Imjudo (tremelimumab)	Liver and lung cancers	↑ \$346m, up 23% (23% at CER)	Approved in 74 countries in combination with <i>Imfinzi</i> for unresectable hepatocellular carcinoma and in 63 countries in combination with <i>Imfinzi</i> and chemotherapy for metastatic NSCLC.
Datroway (datopotamab deruxtecan) ²	Breast and lung cancers	n/m \$78m	Approved in 38 countries for patients with previously treated metastatic HR-positive, HER2-negative breast cancer, and in the US for patients with previously treated advanced EGFRm NSCLC.

¹ In 2024, we recognised Collaboration Revenue of \$600 million in respect of a *Lynparza* sales-related milestone, of which no similar milestones were recognised in 2025. In 2025, *Lynparza* Product Sales increased by 7% (CER: 6%). For further details, see page 56.

² Jointly developed and commercialised with Daiichi Sankyo.

Therapy Area Review | Oncology *continued*

Our strategy in Oncology

Our ambition is to eliminate cancer as a cause of death. We seek to transform outcomes for people living with cancer through innovative medicines, powerful combinations and a world-class, purpose-driven team.

Our commercial strategy to transform patient outcomes centres on three key areas:

- Medicines that matter: building transformative brands that raise the standard of care for patients.
- Leveraging scale: strengthening leadership and expertise in key tumour types (lung, haematology, genitourinary/ gynaecological, breast and gastrointestinal).
- Transforming patient care: closing the care gaps to deliver optimal care for every patient, improving access and building more resilient healthcare systems through partnerships.

Our R&D strategy to transform outcomes focuses on three key pillars:

1. Attacking cancer from multiple angles and unlocking the potential of combination therapies (including tumour drivers and resistance, DNA damage response, antibody drug conjugates (ADCs) and radioconjugates, epigenetics, immuno-oncology, cell therapies and immune engagers).
2. Treating cancer earlier and smarter with early detection and personalised treatments.
3. Pioneering new technologies to help us advance science and achieve the next wave of breakthroughs.

2025 review – strategy in action Lung cancer

Scientific advances in early detection and precision medicine are strengthening the potential to offer meaningful patient outcomes and long-term survival in lung cancer. We have a comprehensive portfolio, along with a promising pipeline of potential new medicines and combinations across diverse mechanisms of action. By 2030, we aim to have an AstraZeneca medicine for more than half of all patients treated for lung cancer.

- *Tagrisso* is the world-leading third-generation TKI and backbone therapy for EGFRm NSCLC across multiple stages. Across markets we see continued demand growth for *Tagrisso* in both the adjuvant and metastatic settings.
- Final overall survival (OS) results from the FLAURA2 Phase III trial were presented at the World Conference on Lung Cancer, showing that *Tagrisso* plus chemotherapy demonstrated a median OS of nearly four years in 1st-line EGFRm NSCLC.

- Positive results from the Phase III NeoADAURA trial in patients with resectable, early-stage EGFRm NSCLC shared at the American Society of Clinical Oncology (ASCO) showed *Tagrisso* with or without chemotherapy demonstrated a statistically significant and clinically meaningful improvement in major pathologic response versus neoadjuvant chemotherapy alone.
- Results from the SAVANNAH Phase II trial showed *Tagrisso* plus *Orpathys* demonstrated a highly clinically meaningful and durable objective response rate in EGFRm NSCLC with high levels of MET overexpression and/or amplification in those whose disease progressed on treatment with *Tagrisso*.
- Since its first approval, more than 414,000 patients have been treated with *Imfinzi*, including 300,000 people with lung cancer. It is the global SoC in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiation therapy (CRT) and is the first and only immunotherapy approved for both limited- and extensive-stage SCLC.
- *Imfinzi* was approved in the EU, Japan, China and several other countries for the perioperative treatment of resectable, early-stage (IIa-IIIb) NSCLC with no known EGFRm or ALK rearrangements, based on the AEGEAN Phase III trial.
- Additionally, *Imfinzi* was approved in the EU, Japan and China for patients with limited-stage SCLC whose disease had not progressed following platinum-based concurrent CRT based on the ADRIATIC Phase III trial results.
- *Datroway* was granted its first approval in the US in lung cancer for the treatment of patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy based on results from the TROPION-Lung05 Phase II trial and supported by data from the TROPION-Lung01 Phase III trial.
- The LATIFY Phase III trial of ceralasertib in combination with *Imfinzi* did not meet the primary endpoint of OS versus SoC docetaxel in patients with advanced NSCLC whose tumours did not have actionable genomic alterations and whose disease progressed on or after prior immunotherapy and platinum-based chemotherapy.
- Updated results from the first-in-human ARTEMIDE-01 Phase I trial presented at the European Society for Medical Oncology (ESMO) meeting showed encouraging safety and efficacy for rilvegostomig, our anti-PD-1/TIGIT bispecific antibody, in patients with immunotherapy-naïve metastatic NSCLC.

Breast cancer

We are aiming to redefine clinical practice and transform outcomes across all subtypes and stages of breast cancer. Our portfolio of approved medicines and promising potential new medicines in development leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment.

- *Enhertu* is the established SoC in HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY-Breast04) metastatic breast cancer.
- Following approvals this year in the US, EU, Japan and several other countries based on the DESTINY-Breast06 Phase III trial, *Enhertu* is rapidly replacing chemotherapy in the post-endocrine setting for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.
- *Enhertu* also reported positive data from three Phase III trials, highlighting its role in earlier treatment settings, and cementing its benefit across all stages of HER2-positive disease. In the DESTINY-Breast09 Phase III trial, *Enhertu* plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus taxane, trastuzumab and pertuzumab (THP) as 1st-line therapy for patients with HER2-positive metastatic breast cancer. *Enhertu* is now approved in the US based upon DESTINY-Breast09. Positive results from the DESTINY-Breast11 Phase III trial showed *Enhertu* followed by THP in the neoadjuvant setting showed a statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer. The DESTINY-Breast05 Phase III trial in the post-neoadjuvant setting showed *Enhertu* demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus T-DM1 in patients with high-risk early breast cancer.
- Positive results from the TROPION-Breast02 Phase III trial showed *Datroway* demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of OS and PFS compared to chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option. With these results, *Datroway* is the first therapy to significantly improve OS versus chemotherapy in this patient population.
- *Datroway* was approved in the US, EU, China and several other countries for the treatment of patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy. Approval was based on the results of the TROPION-Breast01 Phase III trial.

- Positive results from the SERENA-6 Phase III trial showed that camizestran in combination with a cyclin-dependent kinase 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in PFS in the 1st-line treatment of patients with HR-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation.
- *Truqap* was approved in China in combination with *Faslodex* as the first AKT-inhibitor for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN) following disease progression or recurrence, based on the CAPItello-291 Phase III trial.

Genitourinary/gynaecological cancers

In genitourinary cancers, we aim to transform treatment paradigms with our portfolio of approved medicines and a diverse pipeline of innovative treatments to help more patients. This includes improving care for people with muscle-invasive and non-muscle-invasive bladder cancer with *Imfinzi* and solidifying *Lynparza* plus abiraterone and prednisone as a SoC in 1st-line mCRPC. In gynaecological cancers, we will continue to redefine survival expectations, maximising *Lynparza*'s position as a SoC in advanced ovarian cancer, and advancing in combination with *Imfinzi* in endometrial cancer.

- *Imfinzi* was approved in several markets including the US, EU and Japan for the treatment of muscle-invasive bladder cancer (MIBC), based on the NIAGARA Phase III trial results.
- Results from the POTOMAC Phase III trial showed that adding one year of treatment with *Imfinzi* to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG treatment alone. Regulatory reviews are underway.
- Full results from the Phase III trial of *Truqap* in combination with abiraterone and ADT in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer were presented at the 2025 ESMO meeting.
- The CAPItello-280 Phase III trial evaluating *Truqap* in combination with docetaxel and ADT in patients with mCRPC was discontinued following an Independent Data Monitoring Committee review of data from a prespecified interim analysis, which concluded that the *Truqap* combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival (rPFS) and OS versus the comparator arm upon trial completion.

- Encouraging data from our next wave of potential new oncology medicines was presented at the ESMO meeting, including:
 - FONTANA Phase I/IIa first-in-human trial of AZD5335, a folate receptor alpha (FR α)-targeting ADC, in patients with platinum-resistant recurrent ovarian cancer.
 - PETRANHA Phase I/II trial of saruparib plus androgen receptor pathway inhibitors in patients with metastatic prostate cancer.

Gastrointestinal cancers

We have a broad and robust portfolio and development programme for the treatment of gastrointestinal cancers in many stages and disease types across multiple approved and potential new medicines.

- *Imfinzi* was approved in the US, and has been recommended for approval in the EU, for patients with early-stage gastric and gastroesophageal junction (GEJ) cancers based on the MATTERHORN Phase III trial. Results showed perioperative treatment with *Imfinzi* in combination with SoC FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival in patients with early-stage and locally advanced (Stages II, III, IVA) gastric and GEJ cancers.
- Positive results from the DESTINY-Gastric04 Phase III trial demonstrated statistically significant and clinically meaningful improvement in OS as a

2nd-line treatment for patients with HER2-positive metastatic gastric cancer.

- Data from our promising bispecifics pipeline was presented at ASCO, including the GEMINI-Hepatobiliary Phase II trial which showed rilvegostomig plus chemotherapy demonstrated promising efficacy with a manageable safety profile and sustained target engagement in advanced biliary tract cancer.

Blood cancers

In haematology, we are unleashing the potential of *Calquence*, the current SoC in multiple forms of blood cancer, while pushing the boundaries of science to redefine care through ambitious clinical development, deep clinical insights and a focus on improving the patient experience.

- *Calquence* plus chemoimmunotherapy was approved in several markets including the US, the EU and Japan for the 1st-line treatment of MCL based on the ECHO Phase III trial.
- A fixed-duration regimen of *Calquence* in combination with venetoclax, with or without obinutuzumab, was approved in the EU and several markets based on the AMPLIFY Phase III trial.
- In China, *Calquence* was approved as a monotherapy for the treatment of CLL/SLL based on the ChangE Phase III trial.
- Early data from our novel CD19xCD3 bispecific T-cell engager, surovatamig, in follicular lymphoma and diffuse large B-cell lymphoma showed promising clinical efficacy and safety.

Early detection is changing lives, but breast cancer remains the number one cause of female cancer deaths worldwide, with more than 665,000 deaths each year.



Therapy Area Review

Transforming care for billions

BioPharmaceuticals

Our ambition is to transform care for billions of people living with chronic diseases and deliver long-lasting immunity. We are working to intervene earlier to protect vital organs, slow or reverse disease progression, and achieve remission for often degenerative, debilitating and life-threatening conditions, so many more people can live better, healthier lives.

Cardiovascular, Renal & Metabolism

Total Revenue

\$12,861m

up 3% (2% at CER)

2024: \$12,517m

2023: \$10,628m

Our ambition is to enhance care and to improve outcomes for the millions of people who are living with the complexities of cardiovascular, renal and metabolic diseases; to intervene early to protect vital organs; and to reverse, slow or stop disease progression of these often debilitating, progressive and life-threatening conditions.

2025 overview

- Delivered strong financial performance driven by the global rollout of *Wainua*, continued growth of *Lokelma* and sustained demand for *Farxiga*, reaching about 77 million patients globally. We saw increased generic competition for *Farxiga* and other established products.
- Advanced late-stage portfolio, with two positive Phase III trial results for baxdrostat in hypertension and the launch of the laroprovstat Phase III programme in patients with elevated low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD) or at risk of a first ASCVD event. Early-stage portfolio progress includes positive Phase IIb laroprovstat results in LDL-C.
- Advanced Phase IIb trials in obesity (AZD5004 VISTA, AZD6234 APRICUS, AZD9550+AZD6234 ASCEND) and in T2D (AZD5004 SOLSTICE, AZD6234 ARAY).

Respiratory & Immunology

Total Revenue

\$8,866m

up 13% (12% at CER)

2024: \$7,876m

2023: \$6,404m

We have a bold ambition to transform respiratory and immunology care for patients – moving beyond symptom control to disease modification, remission and, one day, cure.

2025 overview

- Achieved double-digit growth driven by key launch brands (*Breztri*, *Fasenra*, *Tezspire*, *Saphnelo*, *Airsupra*). *Breztri* secured blockbuster status with Total Revenue of \$1.2 billion.
- Progressed late-stage portfolio with new life-cycle management indications, including four major market approvals and six Phase III programme readouts.
- Clinical progression for early portfolio, including four Phase I and II trial starts, including in systemic lupus erythematosus (SLE), asthma and chronic obstructive pulmonary disease (COPD).
- Received a world and industry-first approval in the UK for *Trixeo Aerosphere*, our triple-combination therapy for COPD for use with the next-generation propellant (NGP) with near-zero Global Warming Potential (GWP).

Vaccines & Immune Therapies

Total Revenue

\$1,268m

down 13% (14% at CER)

2024: \$1,462m

2023: \$1,357m

Our ambition is to tackle serious viral and bacterial infectious diseases with a high burden of disease to address some of the leading threats to global public health.

2025 overview

- FluMist* Home Administration launched in the US in August ahead of the 2025-2026 flu season, the first and only seasonal flu vaccine approved for self-administration for adults aged 18-49 or by caregivers for children aged 2-17.
- Beyfortus* is now approved in over 60 countries as the first respiratory syncytial virus (RSV) lower respiratory tract disease preventative option for a broad infant population.

Unmet medical need and world market

50%

of deaths worldwide are predicted to be caused by CVRM-related diseases by 2040.

1.4 billion

people across the globe are affected by hypertension.

Unmet medical need and world market

~540 million

people worldwide have chronic respiratory and immune-mediated diseases.

\$4.3 trillion

is the estimated global burden of COPD by 2050, a leading cause of hospital admissions and the world's third leading cause of death.¹

¹ Excluding COVID-19.

Unmet medical need and world market

One billion

cases of seasonal influenza annually.

~3.6 million

young children hospitalised each year due to RSV according to the World Health Organization.

Therapy Area Review | BioPharmaceuticals *continued*

Key marketed products

Product	Disease	Total Revenue	Commentary
Cardiovascular, Renal & Metabolism (CVRM)			
Farxiga/Forxiga (dapagliflozin)	Type 2 diabetes (T2D) Heart failure (HF) Chronic kidney disease (CKD)	↑ \$8,492m, up 10% (9% at CER)	Retained its position as the number one SGLT2 inhibitor worldwide by volume, driven by broad guideline support and continued uptake across HF and CKD. Approved in 126 countries, with sustained global growth supported by expanding use across the cardio-renal-metabolic spectrum.
Crestor (rosuvastatin calcium)	Dyslipidaemia Hyper-cholesterolaemia	↑ \$1,218m, up 5% (6% at CER)	Continued to serve as a widely used therapy in lipid management, with demand supported by its broad global footprint and ongoing need for effective LDL-C lowering. Approved in 91 countries.
Brilinta/Brilique (ticagrelor)	Acute coronary syndromes (ACS)	↓ \$823m, down 38% (38% at CER)	Delivered steady performance in the prevention of atherothrombotic events in adult patients with ACS, supported by ongoing adoption of guideline-directed therapies. Approved in more than 124 countries. Continues to play a wider role in secondary prevention of cardiovascular (CV) events.
Lokelma (sodium zirconium cyclosilicate)	Hyperkalaemia (HK)	↑ \$698m, up 29% (28% at CER)	Delivered strong growth driven by consistently robust demand across all regions, underpinned by rising recognition of HK as a barrier to optimised guideline-directed treatments in CKD and HF. Approved in 67 markets, with increasing patient adoption.
Seloken/Toprol-XL (metoprolol succinate)	Hypertension HF Angina	↔ \$608m, stable (up 2% at CER)	Maintained its position as a beta-blocker for CV disease management across major markets. Performance reflects stable use in hypertension and HF. Approved in 61 countries.
Roxadustat	Anaemia of CKD	↓ \$276m, down 18% (18% at CER)	Continued to support adult patients requiring treatment for CKD-related anaemia. Performance reflects targeted use in regulated markets.
Wainua/Wainzua (eplontersen)	Polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN)	↑ \$212m, up 148% (147% at CER)	Approved for the treatment of adult patients with stage one or two ATTRv-PN in 20 countries, including in the US.
Respiratory & Immunology (R&I)			
Symbicort (budesonide/formoterol)	Asthma COPD	↔ \$2,885m, stable (stable at CER)	Approved in mild asthma as an anti-inflammatory reliever in 47 countries.
Fasenra (benralizumab)	Severe eosinophilic asthma (SEA) Eosinophilic granulomatosis with polyangiitis (EGPA)	↑ \$1,981m, up 17% (16% at CER)	Approved as an add-on maintenance treatment for SEA in 83 countries. Approved for EGPA in more than 70 countries.
Breztri/Trixeo (budesonide/glycopyrrolate/formoterol)	COPD	↑ \$1,199m, up 23% (22% at CER)	Approved in more than 80 countries for the treatment of COPD. Approved for use with the NGP in the UK and in transition in EU countries based on a positive CHMP opinion.
Tezspire (tezepelumab)	Severe asthma	↑ \$1,131m, up 65% (64% at CER)	Approved in more than 70 countries. In 2025, <i>Tezspire</i> was approved for chronic rhinosinusitis with nasal polyps in the US and EU.
Saphnelo (anifrolumab)	SLE	↑ \$686m, up 45% (44% at CER)	Approved for the treatment of SLE in more than 70 countries. In 2025, <i>Saphnelo</i> was approved for subcutaneous (self-administration) in the EU.
Pulmicort (budesonide)	Asthma COPD Croup	↓ \$518m, down 24% (24% at CER)	Approved in more than 115 countries.
Airsupra (albuterol/budesonide)	Asthma	↑ \$166m, up 150% (150% at CER)	Approved in asthma for the treatment of symptoms and prevention of exacerbations in the US and six other countries.
Vaccines & Immune Therapies (V&I)			
Beyfortus (nirsevimab)	RSV	↓ \$703m, down 3% (3% at CER)	Commercialised in collaboration with Sanofi in all territories except the US where Sanofi has full commercial control. Approved in more than 60 countries.
Synagis (palivizumab)	RSV	↓ \$292m, down 35% (34% at CER)	Available in more than 100 countries outside the US. Sobi holds the US rights.
FluMist (live attenuated influenza vaccine)	Influenza	↑ \$272m, up 6% (3% at CER)	Approved in the US, EU and other countries. Approved for self-administration in the US. Daiichi Sankyo holds rights to <i>FluMist</i> in Japan.

Full details are given in the Development Pipeline and Patent Expiries of Key Marketed Products Supplements on our website, www.astrazeneca.com/annualreport2025.

Cardiovascular, Renal & Metabolism

Our strategy in CVRM

Our ambition is to improve outcomes for the millions of people who are living with cardiovascular, renal and metabolic diseases by enhancing care, intervening early to protect vital organs and reversing, slowing or stopping disease progression.


2025 review – strategy in action Cardiovascular

We are advancing science across CV disease by targeting the core risk factors that drive stroke, heart disease and HF.

- Hypertension: we are focused on addressing the significant global burden of hypertension, with around half of those affected not achieving recommended blood pressure control.
- Dyslipidaemia and ASCVD: we continue to address elevated LDL-C as a central CV risk factor, with ~70% of patients globally not at LDL-C goal despite statin therapy.
- HF and amyloidosis: we aim to prevent end-stage HF by enabling earlier diagnosis and treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). ATTR-CM is an underdiagnosed disease, with an estimated global prevalence of 300,000-500,000 patients, and an average mortality of 2-5 years.

Our CV portfolio continues to deliver important clinical and regulatory milestones.

- Baxdrostat, an aldosterone synthase inhibitor, delivered positive Phase III results in treatment-resistant and uncontrolled hypertension, with robust blood pressure reductions in both the BaxHTN and Bax24 trials. Findings were presented at the European Society of Cardiology and American Heart Association Scientific Sessions. Baxdrostat, alone and in combination, is being studied in seven trials and four indications, reflecting our confidence in its potential in hypertension, primary aldosteronism, CKD and hypertension, and prevention of HF.
- In March 2025, together with Ionis, we received EU approval for *Wainzua* for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage one or two polyneuropathy. This follows the US FDA approval in 2023 and Fast Track designation in ATTR-CM in 2024.
- Balcinrenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), is being evaluated in combination with dapagliflozin to address the unmet medical need in patients with chronic HF and impaired kidney function. The Phase III BalanceD-HF trial is underway and aims to deliver the cardiorenal benefits of MRAs while potentially reducing the risk of HK.



Nearly 64 million people worldwide live with heart failure. Advancing early detection, diagnosis and effective management can improve patient outcomes.

- In dyslipidaemia, laroprovstat (formerly AZD0780) achieved positive Phase IIb results in the PURSUIT trial, demonstrating robust LDL-C lowering with no food or fasting requirements and supporting its potential as an oral adjunct to existing lipid-lowering therapies. Findings were presented at the American College of Cardiology Scientific Session & Expo, with simultaneous publication in the Journal of the American College of Cardiology. Laroprovstat is being investigated in a Phase III clinical programme focused on LDL-C lowering in high-risk patient populations (AZURE-LDL, AZURE-HeFH, and AZURE-Outcomes).
- AZD5462, currently in Phase IIb, is the first and only small molecule in clinical trials mimicking the biology of the natural pregnancy hormone relaxin to improve cardiac function in patients with chronic HF.

Renal

We are driving renal disease innovation by addressing early dysfunction, high-risk markers and overlapping factors that accelerate progression.

- CKD: we focus on preventing or slowing kidney failure across the disease spectrum, which affects millions globally (30 million HF, >50 million high proteinuria, 600 million hypertension).

Our renal portfolio continues to deliver important clinical and regulatory milestones.

- Zibotentan/dapagliflozin is being evaluated in patients with CKD and proteinuria in the ongoing Phase III ZENITH-CKD clinical trial.
- Baxdrostat delivered positive Phase II results in the FightN trial for patients with CKD and hypertension. Findings were presented at the American Heart Association Hypertension Scientific Session, with simultaneous publication in the Journal of the American Society of Nephrology. Baxdrostat is being studied in combination with dapagliflozin in patients with CKD (BaxDuo-Arctic, BaxDuo-Pacific).

- Balcinrenone/dapagliflozin delivered positive Phase IIb results in the MIRO-CKD trial for patients with CKD at a high risk of disease progression. Findings were shared in a late-breaking presentation at the American Society of Nephrology's Kidney Week and simultaneously published in The Lancet.
- AZD2373, developed in collaboration with Ionis, has the potential to be the first precision medicine in our renal pipeline for treatment of APOL1-mediated kidney disease. Phase I data has demonstrated safety, tolerability and proof of mechanism in healthy participants.

Metabolism

We are expanding our work across metabolic disease by targeting the drivers of adiposity, insulin resistance and inflammation that heighten cardiometabolic risk.

- Obesity, weight management and diabetes: we aim to reduce or reverse weight-related comorbidities and advance organ protection for the 2.5 billion people living with obesity or overweight, most of whom have at least one co-morbidity.

Our metabolism portfolio continues to deliver important clinical and regulatory milestones.

- We have advanced the Phase IIb trials in obesity (AZD5004 VISTA, AZD6234 APRICUS, AZD9550+AZD6234 ASCEND) as well as in T2D (AZD5004 SOLSTICE, AZD6234 ARAY).
- We are progressing an innovative pipeline in metabolic dysfunction-associated steatohepatitis and advanced liver disease to target the main disease drivers. This includes AZD2389 (small molecule FAP inhibitor) targeting advanced liver fibrosis currently in Phase II studies.
- We acquired SixPeaks Bio, strengthening our existing obesity and weight management pipeline with the lead asset, a next-generation monoclonal antibody (mAb) that targets Activin Receptor Type 2A/B, with the potential to combine and conjugate with peptides targeting complementary mechanisms.

Therapy Area Review | BioPharmaceuticals *continued*

Respiratory & Immunology

Our strategy in R&I

We are committed to transforming care for some of the most debilitating and complex respiratory and immune-mediated diseases. Our portfolio of inhaled and biologic medicines, and our pipeline for the future, seek to address the challenges and vast unmet medical needs patients face today.

We are leading the way in reducing the environmental burden of care by driving improvements in patient outcomes as well as transitioning to pressurised metered-dose inhaled (pMDI) respiratory medicines with a propellant that has near-zero GWP.

2025 review – strategy in action COPD

We are working to eliminate COPD as a leading cause of death, transforming care through our broad portfolio by driving timely diagnosis, optimising therapeutic intervention and reducing mortality by addressing cardiopulmonary risk. We are advancing innovative medicines with different mechanisms of action, including next-generation biologics and novel orals to reduce exacerbations and elevate the standard of care across the disease severity spectrum.

- *Breztri* remains the fastest-growing triple inhaled therapy within the fixed-dose combination triple class¹ across major markets. *Breztri* has demonstrated a

reduction in mortality that has been recognised in the 2026 Report published by the Global Initiative for Lung Disease (GOLD). We are advancing evidence of *Breztri*'s ability to reduce the risk of exacerbations and all-cause mortality versus dual-therapy. The ORATOS clinical trial to study the effect of *Breztri* on heart and lung function enrolled its first patient subject in 2025. In 2025, we received a world and industry-first approval in the UK for *Trixeo Aerosphere* (marketed as *Breztri* in the rest of the world), our triple-combination therapy for COPD for use with the NGP with near-zero GWP. This was followed by a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, endorsing it for use in the EU. Regulatory applications are also currently under review in the US, China and additional countries.

- We have a robust late-stage biologics programme in COPD, including tozorakimab (Phase III LUNA programme), which has a unique dual mechanism of action targeting IL-33, with high-level results expected in 2026. Plus, indication expansion opportunities with *Tezspire* (Phase III JOURNEY and EMBARK trials started in 2025). In 2025, *Fasenra*'s Phase III RESOLUTE trial for COPD demonstrated numerical improvements, but did not meet the primary endpoint of reducing COPD exacerbations.
- Our innovative early pipeline in COPD is aimed at reaching patients who may not have access to biologics but no longer respond to inhaled therapy. AZD6793 is an oral small molecule IRAK4 inhibitor targeting key COPD disease drivers


triggered by bacterial and viral infections, smoke and other environmental factors. Data from the AZD6793 Phase I clinical trial were presented at the 2025 annual European Respiratory Society Congress. The Phase IIb PRESTO clinical trial is underway.

Asthma

We strive to eliminate asthma attacks and achieve clinical remission by reinforcing our inhaled portfolio as the backbone of care, driving towards clinical remission with systemic biologics and introducing novel oral and inhaled medicines to address patients who are not controlled on SoC inhaled therapy.

- *Symbicort* maintained its position as the leading inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) globally by volume and value. Performance has been driven by strong growth in Emerging Markets, and resilient performance in the US offset by generic erosion in the EU and Japan.
- *Airsupra* has had strong uptake in the US as the first and only FDA-approved anti-inflammatory rescue therapy that treats symptoms and prevents exacerbations. In 2025, the US FDA updated the *Airsupra* label to include results from the BATURA Phase III clinical trial for patients with intermittent, mild or persistent asthma.
- In 2025, we reported results on the *Breztri* Phase III KALOS and LOGOS trials in patients with uncontrolled asthma. The results showed clinically meaningful and statistically significant improvement in lung function compared with dual-combination inhaled (ICS/LABA) medicines.
- *Tezspire* continues to gain market share, achieve labels for a broad population of severe asthma patients, and secure reimbursement globally.
- In 2025, China regulatory authorities approved the paediatric indication for *Fasenra* 30mg for SEA, in patients as young as six years old. In 2025, we announced the positive high-level results from the *Fasenra* NATRON Phase III clinical trial for patients with hypereosinophilic syndrome, a rare disease characterised by elevated eosinophils in the blood and fatigue, rash and organ failure.
- Our early pipeline is exploring innovative compounds including new modalities, aimed at targeting key disease mechanisms. AZD8630, an inhaled fragment antibody (inhaled biologic) in Phase II in co-development with Amgen Inc., targets thymic stromal lymphopoietin and tozorakimab is in Phase IIb for uncontrolled asthma.

Some 391 million people are now living with COPD globally and up to 80% are undiagnosed. Early screening, diagnosis and optimal treatment can slow its progression and improve lives.



¹ Global triple therapy market definition: *Breztri*, *Enerzair*, *Trelegy*, *Trimbow*.

Other Respiratory

We are moving beyond asthma and COPD to address other respiratory diseases with significant unmet medical need, including severe viral lower respiratory tract disease (svLRTD), non-cystic fibrosis bronchiectasis, interstitial lung disease and idiopathic pulmonary fibrosis.

- The TILIA Phase III trial of tozorakimab in svLRTD is ongoing.
- We also announced *Tezspire* was approved for the treatment of chronic rhinosinusitis with nasal polyps in the US and EU.
- In our early portfolio, we continue exploring new mechanisms to address unmet medical needs in interstitial lung disease and idiopathic pulmonary fibrosis.

Immunology

We aim to become a leader in immunology, redefining treatment paradigms in areas of high unmet medical need, moving to clinical remission and eventually cure.

- *Saphnelo* continues its rapid growth in SLE. In 2025, we announced the positive high-level results from the Phase III TULIP-SC clinical trial studying subcutaneous administration of *Saphnelo* in SLE, which demonstrated clinically meaningful and statistically significant reduction in disease activity. *Saphnelo* subcutaneous administration was subsequently approved in the EU for adult patients with SLE who are receiving standard therapy and it is under regulatory review in several other countries around the world, including the US and Japan.
- In 2025, the US FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for *Saphnelo* for subcutaneous administration in SLE. We have provided the information requested by the FDA and anticipate a decision in the first half of 2026.
- *Saphnelo*'s Phase III AZALEA study for SLE patients in China also reported positive results in 2025. Additionally, updated treatment guidelines from the American College of Rheumatology in 2025 recognised remission and oral corticosteroid sparing as key treatment goals in SLE.
- Ongoing Phase III trials exploring the potential of *Saphnelo* in relevant rheumatologic diseases include IRIS (lupus nephritis), LAVENDER (cutaneous lupus erythematosus), JASMINE (myositis) and DAISY (systemic sclerosis).

Our early pipeline in lupus and related diseases includes novel and next-generation therapies with the potential for transformational efficacy:

- Two T-cell engager complex biologics progressed into Phase I: AZD5492 (CD20/CD8) in SLE as well as other autoimmune indications, and surovatamig (CD19/CD3) in SLE as well as rheumatoid arthritis (RA).

We're expanding our presence in rheumatology in other areas of high unmet medical need:

- *Fasenra* is now approved for the treatment of EGPA, a disease characterised by inflammation of the blood vessels that causes organ damage, including the lungs and gastrointestinal tract, in more than 70 countries including the US, EU and Japan, based on positive results from the MANDARA Phase III trial.
- AZD1163, a PAD2/4 inhibitor moved into Phase IIb in RA in patients who are partial and inadequate responders to other medicines (TNFs). Positive Phase I results were presented at the American College of Rheumatology annual meeting in 2025, supporting that PAD2/4 enzymes drive the autoimmune response leading to inflammation and tissue damage in RA.

In gastroenterology, compounds in clinical development include:

- *Tezspire* is being investigated in eosinophilic esophagitis, a chronic inflammatory disease of the gastrointestinal tract, with the Phase III high-level results anticipated in 2026 (CROSSING trial).
- A Phase II trial is ongoing exploring AZD7798, a mAb that targets CCR9 positive cells for depletion in small bowel Crohn's disease.

Vaccines & Immune Therapies

Our strategy in V&I

Through next-generation vaccines and long-acting antibodies, we aim to prevent viral respiratory diseases as a key cause of morbidity, hospitalisation and death and deliver new solutions in the fight against serious bacterial and chronic viral infections.

We are advancing platforms such as virus-like particle vaccine technology, bioconjugate vaccines, half-life extended antibodies and new antibody formats such as bispecifics to accelerate development and deliver tailored immune protection against previously hard-to-target or rapidly evolving pathogens.

2025 review – strategy in action

- In August 2025, we launched *FluMist* Home Administration in the US, the first seasonal flu vaccine approved for self- or caregiver administration at home. *FluMist* received approvals in 10 additional countries in 2025, including in the Southern Hemisphere enabling first launches in the region in 2026.
- mAbs targeting *Clostridium difficile*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus* bacterial pathogens advanced into Phase II trials and a pandemic influenza mRNA vaccine candidate entered Phase I/II development.

For more information on Site F-gas management, including pMDI inhalers, Scope 1 and 2 decarbonisation levers, Scope 3 decarbonisation levers and Transition risk and opportunities, see Climate change from page 42 of the Business Review.

Therapy Area Review

Pioneering new possibilities

Rare Disease

We continue to advance a diversified pipeline across disease areas with significant unmet medical need, where scientific progress has been absent or limited, advancing first- and/or best-in-class medicines and new modalities, while expanding our global geographic footprint for the rare disease community.

Total Revenue

\$9,126m

up 4% (4% at CER)
2024: \$8,768m
2023: \$7,764m

2025 overview

- Delivering robust and sustainable growth since acquisition of Alexion.
- Performance driven by durable growth across indications as well as market expansion.
- Advancing next wave of innovative therapies with a focus on first- and/or best-in-class medicines and new modalities with curative potential.
- A continued focus on launching in new countries globally and addressing underserved rare populations.
- Working with health systems, governments and advocates to improve health equity for people living with rare diseases.

Unmet medical need and world market

400 million <10%
people around the world are living with a rare disease. of rare diseases have approved treatment options.

Key marketed products

Product	Disease	Total Revenue	Commentary
Ultomiris¹ (ravulizumab)	Paroxysmal nocturnal haemoglobinuria (PNH) Atypical haemolytic uremic syndrome (aHUS) Generalised myasthenia gravis (gMG) Neuromyelitis optica spectrum disorder (NMOSD)	↑ \$4,718m, up 20% (19% at CER)	Approved in 73 countries for the treatment of certain adult and paediatric patients with PNH and patients with aHUS, including the US, EU, Japan and China. Approved in 73 countries for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive (Ab+), including the US, EU, Japan and China. Approved in 73 countries for the treatment of adult patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody-positive (Ab+), including the US, EU, Japan and China.
Soliris (eculizumab)	PNH aHUS gMG NMOSD	↓ \$1,837m, down 29% (28% at CER)	Approved in 60 countries for the treatment of patients with PNH and patients with aHUS, including the US, EU, Japan and China. Approved in 51 countries for the treatment of patients with gMG who are AChR-Ab+ including the US, EU, Japan and China. Approved in 53 countries for the treatment of adult patients with NMOSD who are AQP4-Ab+, including the US, EU, Japan and China.
Strensiq (asfotase alfa)	Hypophosphatasia (HPP)	↑ \$1,678m, up 19% (18% at CER)	Approved in 64 countries for the treatment of certain patients with HPP, including the US, EU and Japan.
Koselugo (selumetinib)	Neurofibromatosis type 1 (NF1) Plexiform neurofibromas (PN)	↑ \$662m, up 5% (3% at CER)	Approved in 76 countries for the treatment of certain paediatric patients with NF1 PN, including the US, EU, Japan and China, and in 41 countries for the treatment of certain adult patients with NF1 PN, including the US, EU and Japan.

¹ Ultomiris Total Revenue includes revenue of Voydeya which commenced in 2024.

Full details are given in the Development Pipeline and Patent Expiries of Key Marketed Products Supplements on our website, www.astrazeneca.com/annualreport2025.

Therapy Area Review | Rare Disease *continued*

Our strategy in Rare Disease

We are pioneering new possibilities for the rare disease community to help improve outcomes for more people impacted by rare disease around the globe through:

- Continued leadership in complement inhibition.
- Diversifying our pipeline across disease areas with significant unmet medical need, using an array of innovative modalities.
- Advancing an industry-leading suite of next-generation potential therapies, including biologics, genomic medicines, small molecules, and cell therapies.
- Bringing transformative treatments to more rare disease patients in more countries around the globe.
- Raising awareness of rare diseases, while shaping policies and ecosystems needed to advance access to innovation.

2025 review – strategy in action

Pioneering leadership in complement

In 2025, we saw growth in our C5 franchise, driven particularly by *Ultomiris* and demand across indications, including competitive gMG and PNH markets. Additionally, we continue to see successful conversion from *Soliris* to *Ultomiris* across indications.

Rare neurology

Data presented at scientific congresses throughout the year, including at the annual meetings of the American Academy of Neurology, the European Academy of Neurology, and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) reinforce the long-term safety and efficacy profiles of *Ultomiris* and *Soliris*, and demonstrates how these medicines can transform outcomes for rare neurological diseases, including gMG and NMOSD.

Generalised myasthenia gravis

gMG is a rare autoimmune disorder characterised by loss of muscle function and severe muscle weakness. We advanced our pioneering leadership in complement inhibition with positive high-level results from the PREVAIL Phase III clinical trial of gefurulumab in adults with AChR-Ab+ gMG. Gefurulumab, an investigational complement C5 inhibitor, is a novel dual-binding nanobody optimised for subcutaneous self-administration.

Data presented from the PREVAIL Phase III clinical trial at the Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in San Francisco, California showed that gefurulumab met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living at week 26

with clinically meaningful improvement seen as early as week one in adults with AChR-Ab+ gMG. PREVAIL also met all secondary endpoints, including change from baseline in Quantitative Myasthenia Gravis total score at week four and week 26.

Neuromyelitis optica spectrum disorder

NMOSD is a rare and debilitating autoimmune disease characterised by unpredictable relapses that can lead to permanent disability. Data presented at ECTRIMS demonstrated zero adjudicated on-trial relapses in adults with AQP4-Ab+ NMOSD treated with *Ultomiris* through the median follow-up of 170.3 weeks in the CHAMPION-NMOSD Phase III trial.

Rare haematology, nephrology and transplant

Rare nephrology

Phase III trials of *Ultomiris* in immunoglobulin A (IgA) nephropathy, cardiac surgery-associated acute kidney injury, and delayed graft function are also ongoing.

IgAN is a rare CKD that begins when the body develops abnormal IgA proteins that result in the build-up of immune complexes in the kidneys, causing damage. This can impact the ability of the kidneys to function properly, resulting in CKD that can progress to end-stage kidney disease. Approximately 25-30% of people with IgAN will progress to end-stage kidney disease, or kidney failure.

Haematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

Ultomiris is also being investigated in disease areas in which the complement pathway is thought to play a role. We conducted the largest global Phase III programme across a broad population of patients with HSCT-TMA, a severe and potentially life-threatening complication that can occur following HSCT. Initial results from the Phase III open-label trial of *Ultomiris* in paediatric patients with TMA after HSCT demonstrated clinically meaningful OS at 26 weeks. Our Phase III trial evaluating *Ultomiris* in adults and adolescents with HSCT-TMA is ongoing.

Diversified pipeline across diseases with significant unmet medical need

We advanced a diverse pipeline across additional disease areas with significant unmet medical need.

Amyloidosis and rare cardiology

Amyloidosis is a group of complex rare diseases caused by abnormal proteins that misfold and clump together to form amyloid that deposits in tissues or organs, including the heart, which can result in significant organ damage and organ failure. Across the enterprise, we are advancing a fast-growing, industry-leading pipeline across a broad range of modalities, and in Rare Disease

are positioned to address the most prevalent types of cardiac amyloidosis.

Amyloid light-chain (AL) amyloidosis

AL amyloidosis occurs when defective plasma cells in bone marrow produce abnormal proteins which aggregate to form amyloid fibril deposits. Amyloid fibril accumulation in tissues or organs, particularly in the heart and kidneys, may cause systemic and progressive damage and high mortality rates caused most often from cardiac failure.

Anselamimab is an investigational, potentially first-in-class anti-fibril mAb designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients living with AL amyloidosis. While high-level results from the CARES Phase III clinical programme did not achieve statistical significance for the primary endpoint in patients with Mayo stages IIIa and IIIb AL amyloidosis, compared to placebo, anselamimab showed highly clinically meaningful improvement in time to all-cause mortality and frequency of CV hospitalisation in a prespecified subgroup of patients with AL-kappa amyloidosis, compared to placebo.

Transthyretin amyloidosis (ATTR)

ATTR-CM is a systemic, progressive, debilitating condition that can lead to HF. Median survival in patients with advanced cardiomyopathy is between one to two years from diagnosis. There are frequent misdiagnoses and ATTR-CM can often go undetected for many years.


Clirimitug (ALXN2220) is an investigational mAb designed to selectively bind to and remove ATTR amyloid fibrils, with the potential to transform the course of disease by depleting ATTR build-up. A Phase III trial is underway and fully enrolled evaluating clirimitug as an add-on treatment to SoC in patients with ATTR-CM.

We hold an exclusive licence from BridgeBio to develop and commercialise *Beyontra* (acoramidis), a next-generation, orally-administered, highly-potent, small-molecule stabiliser of TTR, in Japan. In March 2025, *Beyontra* was approved in Japan for the treatment of adults with ATTR-CM.

Rare bone, metabolic and endocrine disorders

Hypophosphatasia

HPP is a rare, inherited and progressive metabolic disease characterised by defective mineralisation (the process that hardens and strengthens bones and teeth), impaired calcium and phosphate regulation, and non-skeletal manifestations such as muscle weakness, generalised fatigue and pain. HPP is caused by deficient activity of an enzyme known as alkaline phosphatase (ALP).



It can take more than five years for a rare disease patient to get the right diagnosis. Advances in newborn genomic sequencing and AI diagnostics are accelerating rare disease diagnosis and improving health equity.

Efzimotase alfa is an investigational enzyme replacement therapy designed to replace the deficient ALP enzyme activity as a self-administered, subcutaneous treatment optimised for dosing every two weeks to help address the current treatment burden and reach more patients living with HPP. Results from three Phase III studies HICKORY, CHESTNUT and MULBERRY, are expected in the first half of 2026. Together these trials cover patients across paediatric, adolescent and adult HPP populations.

Hypoparathyroidism (HypoPT)

HypoPT is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) and characterised by impaired regulation of calcium and phosphate levels in the blood. Eneboparatide, an investigational PTH receptor 1 agonist, met the primary endpoint of normalising serum calcium in adults with HypoPT at 24 weeks in the CALYPSO Phase III trial. Analysis of the 52-week results from the CALYPSO trial, to further characterise eneboparatide, are ongoing. We will continue monitoring these patients in the open-label extension.

Rare tumours

Neurofibromatosis type 1 plexiform neurofibromas

NF1 is a rare, progressive and genetic condition usually diagnosed in early childhood, but often progressing into adulthood, that can impact every organ system. Up to 50% of people living with NF1 may develop non-malignant tumours called PN that may affect the brain, spinal cord and nerves. PN may appear later in a person's life and can grow and become large, leading to pain, disfigurement and muscle weakness, among other debilitating symptoms.

Koselugo (selumetinib) is a kinase inhibitor that blocks specific enzymes that are overactive in people with NF1, causing tumour cells to grow. By blocking these enzymes, *Koselugo* slows down the growth of tumour cells and, therefore, the PN growth.

In 2025, we expanded the reach of *Koselugo* beyond certain paediatric patients with NF1 PN with its approval in Japan, the EU, the US and other countries for the treatment of adult patients with NF1 who have symptomatic, inoperable PN based on data from the KOMET Phase III trial, the largest and only placebo-controlled global Phase III trial in this patient population. In addition, a granular formulation of *Koselugo* was approved in Japan, the EU, the US and other countries, providing an option for young patients who may have difficulty swallowing a capsule. Additional regulatory reviews are ongoing.

Rare cancers

Rare cancers account for approximately a quarter of cancer deaths and have a lower five-year survival rate than most common cancers, representing a significant unmet medical need. We are partnering with colleagues across AstraZeneca to follow the science and identify opportunities where we intend to leverage our expertise and infrastructure to deliver transformative outcomes for patients.

Next wave innovation

We are partnering across therapy areas to advance an industry-leading suite of genomic medicines, cell therapies, small molecules, and next-generation biologics, with the objective to match innovative modalities to meet specific needs of patients with rare disease.

We initiated a Phase I/II clinical trial to evaluate ALXN2350, a potentially first-in-class gene therapy, in adults with BAG3-associated DCM (Bcl-2-associated athanogene 3- dilated cardiomyopathy), a rare cardiomyopathy.

In addition, the Phase Ib/II study of AZD0120, a CAR-T cell therapy targeting CD19 and BCMA, was initiated in patients with relapsed or refractory AL amyloidosis, expanding the reach of this asset into rare disease.

We continue to build a diversified pipeline by targeting new pathways and leveraging an array of innovative modalities. We are pioneering the next wave of innovation in complement inhibition in early-stage clinical trials, including ALXN1920, a kidney-targeted factor H fusion protein in primary membranous nephropathy, and ALXN2030, a siRNA targeting the complement C3 protein, in antibody mediated rejection, both in Phase II clinical trials. In addition, we initiated Phase II clinical trials evaluating tarperprumig, a complement factor P (properdin) inhibitor, in anti-neutrophil cytoplasmic antibody-associated vasculitis and ALXN2420, a growth hormone receptor antagonist in acromegaly, respectively.

In addition, we are collaborating to advance AI medical devices for early, accurate detection of rare diseases, including early detection of HPP in adults through an AI clinical decision support system, and FDA-cleared for cardiac amyloidosis detection during routine echocardiography assessment.

A commitment to health equity in rare disease

Being born with a rare disease is inherently inequitable. Further, the economic impact of rare diseases includes not only costs incurred by patients and healthcare systems but also the reduced earnings, productivity, or career opportunities of people living with a rare disease and their caregivers. We are committed to action to overcome societal and policy barriers and to advance health equity for people living with rare diseases. Together with health systems, governments and advocates, we are shaping the policy and care landscape the rare disease community needs.

Business Review

Delivering our strategic priorities sustainably, supporting scientific innovation and promoting commercial excellence.

Our business is organised to deliver our Growth Through Innovation strategy. The success of our functions is built on recruiting, retaining and developing talented people.



Science and Innovation

We are focused on science and innovation, from discovery through to development and life-cycle management, and on transforming care and outcomes for patients. We have three therapy area-focused R&D organisations – Oncology, BioPharmaceuticals, and Rare Disease.

Key topics covered

Summary and performance indicators
Research & Development
Sustainable innovation
Development pipeline overview
Patient safety and product quality

Our key topics covered include material sustainability topics, which have been identified through our double materiality assessment, see page 40 for more information.



Growth and Therapy Area Leadership

We are focused on launching medicines that deliver sustainable growth and realising the potential of our pipeline. Our Commercial regions align product strategy and commercial delivery while our Operations function manufactures and delivers our medicines.

Key topics covered

Summary and performance indicators
Our regions
Operations
Business conduct
Digital technologies
Cybersecurity and data privacy
Business development




People and Sustainability

We are committed to our people, ensuring that AstraZeneca remains a great place to work. We promote health equity and resilient healthcare, and play an active role in addressing the climate crisis. We operate in a responsible and sustainable way to build a healthy future for people, society and the planet.

Key topics covered

Summary and performance indicators
People
Sustainability
Accessible and affordable healthcare
Climate change
Nature

Global reach and presence



Strategic R&D centres

We have six strategic R&D centres including a growing presence in China with the opening of our Beijing R&D centre in 2025, advancing our effort to deliver life-changing medicines globally.

16,100

R&D employees across our global sites (2024: 15,200)

Global hubs

Our network of 10 global hubs is focused on translating our cutting-edge science into real-world impact.

47,400

Commercial employees (2024: 47,200)

Operations

Manufacturing supports business growth and pipeline development, maintaining excellence in product launch, quality and supply.

16,900

employees across our manufacturing sites (2024: 16,300)

217

successful on-time market launches (2024: 202)

People

We have a global commitment to inclusion and diversity.

96,100

employees (2024: 94,300)

43

countries of origin represented in executive levels (2024: 44)

Business Review *continued*



Science and Innovation

Summary and performance indicators

We are using our scientific capabilities and focusing on transformative science to accelerate the delivery of high-quality, life-changing medicines.

Our performance in 2025

- Invested \$14.2 billion in our R&D.
- One NME first approval, taking us to nine NMEs delivered against our Ambition 2030.
- 97 regulatory events and 38 pipeline progressions.
- 197 pipeline projects, of which 176 are in the clinical phase of development.


- Published 718 manuscripts with 135 in 'high-impact' journals.
- Since 2019, the number of R&D employees in China has grown significantly from over 300 to more than 1,200.

Performance indicators

Our performance indicators include the measurement of Phase II and III pipeline progressions, which are critical for ensuring both near- and long-term delivery. The initiation of Phase II NMEs is essential for maintaining the robustness and stability of our pipeline. Meanwhile, investments in Phase III are focused on delivering near-term value. Additionally, our submission and approval metrics serve as indicators of our advancement in four major markets: the US, EU, China and Japan.


NME Phase II starts/progressions

16




NME and major LCM submissions

54




NME and major LCM pivotal Phase II/III investment decisions

22



NME and major LCM approvals

43



Research & Development

In 2025, we continued to progress our science and pipeline, committed to early diagnosis and treatment, improving our understanding of disease biology and advancing our scientific modalities across disease areas.

Enhancing our understanding of disease biology

Advancing our understanding of disease biology is helping uncover novel drivers for the diseases we aim to prevent, treat and even cure. Selecting the right target remains the most important decision in drug discovery.

2025 developments:

- Achieved 40% representation of individuals with non-European genetic ancestries in our human genomic datasets, driving several high-impact publications that demonstrate the importance of diversity in genetic research.
- Delivered industry-leading genomic insights while remaining sustainable, redesigning algorithms that cut CO₂ emissions and compute time by 99.8% compared to global standards.
- Launched partnership with Illumina and industry partners to generate a 1-billion cell atlas, accelerating novel target discovery and expanding AI training data 1,000-fold through improved disease understanding.
- Established landmark 10-year partnership with the University of Gothenburg, Knut and Alice Wallenberg Foundation, and Region Västra Götaland to tackle obesity and metabolic diseases including a new Gothenburg-based research professorship launching in 2026.


Creating the next generation of therapeutics

We continue to advance our intentionally diverse portfolio of therapeutic modalities across disease areas, including cutting-edge platform technologies for innovative small molecules, biologics and genomic medicines.

2025 developments:

- Advanced our proprietary antibody drug conjugates (ADCs) with Phase I clinical data for torvu-sam (FRα) in ovarian cancer presented at ESMO and first subject in for the pivotal BLUESTAR-Endometrial01 trial with puxi-sam (B7-H4)s.
- Data published in Nature Communications describes our novel platform for enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumour biopsies.
- Expanded AZD0120 (BCMAxCD19 dual targeting) autologous CAR T-cell therapy programme across oncology, immunology and rare diseases with clinical data presented at The American Society for Hematology (ASH) Annual Meeting from our first US trial demonstrating high complete response rates in multiple myeloma and an encouraging safety profile. AZD0120 expansion continued in systemic lupus erythematosus with Phase I starts and Investigator Initiated data presented at the European Alliance of Associations for Rheumatology and the American College of Rheumatology, as well as Phase I starts in multiple sclerosis,

Research & Development spend



a basket study in rheumatoid arthritis, systemic sclerosis and idiopathic inflammatory myopathies, and rare diseases including amyloid light-chain amyloidosis.

- Advanced pipeline of CD8+ guided modalities, designed for more selective tumour-targeting with multiple disclosures including AZD9793 (GPC3 T-cell engager) and AZD6750 (CD8+ IL-2 immunocytokine).
- Acquired EsoBiotec to accelerate our in vivo cell therapy build through their ENABL platform capabilities.
- Entered into an agreement with Jacobio Pharma for JAB-23E73, a clinical-stage oral small molecule pan-KRAS inhibitor, with potential in pancreatic, colorectal and non-small cell lung cancers.
- Advancing genomic medicines into the clinic: gene therapy for BAG-3-related dilated cardiomyopathy and first siRNA therapy targeting complement C3 for antibody-mediated rejection after kidney transplantation, alongside expanded collaboration with JCR Pharmaceuticals and investment in Yoltech Therapeutics.
- Progressed several novel molecular entities within CVRM into Phase I clinical trials, including AZD1613 (PAPPA-1) for autosomal dominant polycystic kidney disease, AZD3974 (anti-inflammatory and anti-fibrotic mechanism) for cirrhosis, AZD4248 (NNMT) for cardiorenal disease, AZD4954 (Lp(a)) for dyslipidemia, and AZD4063 (PLN) for PLN R14del dilated cardiomyopathy, the first cardiac-targeted siRNA to reach clinical trials.
- Entered the acute kidney injury space with AZD4144 (NLRP3), which has completed Phase I and is now advancing to Phase II.
- Strengthened weight management portfolio through the acquisition of SixPeaks Bio, including early-stage assets that aim

to preserve lean mass, modulate body composition and improve metabolic function by targeting activin signalling pathways.

Better predicting clinical success of our candidate drug molecules

We are adopting a range of cutting-edge technologies, generating data that are more relevant to patients than previous methods, to help us predict the clinical effectiveness of our candidate drug molecules.

2025 developments:

- Established three-year collaboration with Sahlgrenska University to further our current adipose tissue research capabilities to support healthy weight loss programmes aiming to address adipose tissue dysfunction.
- In collaboration with Roche Tissue Diagnostics and Daiichi Sankyo, received FDA Breakthrough Device Designation (BDD) for the VENTANA TROP2 Rx Dx Computational Solution which incorporates Quantitative Continuous Scoring, marking the first BDD for an AI-driven companion diagnostic.
- Accelerated covalent drug discovery through advanced technology and strategic collaborations, including with the Gygi Lab at Harvard Medical School, to target previously undruggable proteins across multiple therapeutic areas.
- Established strategic AI collaborations with Tempus and Pathos to develop the largest multimodal oncology foundation model. We acquired Modella AI to advance foundation models across oncology clinical development, in addition to advancing existing and new collaborations with ImmunAI, Syneron Bio, Stanford Medicine and Algen Biotechnologies – to complement

our robust internal AI capabilities and enhance drug discovery and the probability of clinical success.

- Accelerated the identification of novel small molecules, oligonucleotides and biologics by applying AI technologies to predict molecular properties before synthesis so we can prioritise those most likely to deliver patient benefit.

Pioneering new approaches to engagement in the clinic

We are at the forefront of clinical innovation, designing and delivering patient-centric clinical trials that improve the patient and site team experience while optimising the use of data, digital technologies and AI.

2025 developments:

- Advanced AI medical devices for early, accurate detection of rare diseases, including hypophosphatasia in adults and FDA-cleared AI for cardiac amyloidosis, through collaborations with Pangaea Data and InVision.
- Transformed clinical trial operations across therapy areas through enhancing AI-driven patient data collection and digital consent, reducing consent form length by 35%, migrating 19 studies to new systems, and cutting processing time from 10 weeks to two.

For more information on deals, see Business development on page 37, and for how AI is transforming the way we work, see Digital technologies on page 36.

We are committed to early diagnosis and treatment, improving our understanding of disease biology and advancing our therapeutic modalities across diseases.



Business Review *continued*

Science and Innovation

Sustainable innovation

Our ambition is to transform the lives of patients with improved outcomes and a better quality of life, through more effective treatment and prevention, ultimately working towards a cure for some of the world's most complex diseases.

For more information, see:

Our Strategy and Key Performance Indicators, including the number of approved NMEs, regulatory events and pipeline progression events, pages 10 and 11.

Therapy Area Review, including key actions in 2025, pages 13, 17 and 23.

For more information on our policies, see pages 217 and 219.

For more information regarding key products in our pipeline in China, the EU, Japan and the US, see the Patent Expiries of Key Marketed Products Supplement on our website: www.astrazeneca.com/annualreport2025. For more information on IP, see our website: www.astrazeneca.com/sustainability/resources.html.

Our Code of Ethics highlights our commitment to science and innovation. We conduct innovative research, development and manufacturing to high standards of ethics and integrity everywhere we operate, following the laws, regulations, codes, guidelines and good practice standards related to safety, quality, research and bioethics. Our drug discovery and development is informed by our Product to Patient Governance Pathway, which details a rigorous scientific and strategic framework for portfolio decision making and development from Candidate Drug Investment Decision to Health Authority approval.

Sustainable innovation

We strive to deliver new treatments that address unmet medical needs while navigating potential setbacks or delays in bringing therapies to market. We are focused on accelerating the delivery of life-changing medicines that create enduring value, pushing the boundaries of science to discover innovations that transform and sustain health.

Intellectual property

Intellectual property rights are essential to sustaining the incentives our industry needs to invest in R&D that leads to new medicines. Drug development is inherently long, uncertain and costly, particularly when accounting for the high rate of failure. Early in R&D, thousands, and in some areas millions, of compounds may be screened to identify the few with the potential to become safe, effective therapies and ultimately secure regulatory approval. A robust system for obtaining, maintaining and enforcing patents is a critical pillar of a sustainable innovation ecosystem.

We provide transparency about where our patents are filed and enforced. Where we maintain patent protection for assets which may have relevance to Access to Medicine Index diseases, we provide patent identity and expiry information.

Development pipeline overview

2025 was another remarkable year. We achieved 97 regulatory events, either submissions or approvals for our medicines in major markets, including one NME first approval.





This success is supported by a robust pipeline of promising medicines. We had 38 significant pipeline progression events, including NME Phase II starts and pivotal Phase II/III investment decisions, showcasing our potential for sustainable growth.

Our pipeline comprises 197 projects, with 176 in the clinical phase of development. We have 20 NME projects in pivotal trials or under regulatory review, up from 19 at the end of 2024. In 2025, 35 NMEs progressed to their next development phase, while 20 projects were discontinued: 11 due to safety or efficacy, eight due to strategic shifts and one due to regulatory reasons.

Accelerating our pipeline

We are prioritising our investment in specific programmes, focusing on scientific innovation, patient benefit and return on investment. This has led to receiving twelve Regulatory Designations for Breakthrough Therapy,

Priority Review, Accelerated or Fast Track for 10 new medicines which offer potential to address unmet medical need in certain diseases. We also secured Orphan Drug Designation for the development of three medicines to treat rare diseases.



For more information, see Therapy Area Review from page 12.

¹ Includes NMEs and additional indications if the lead is not yet launched.

² Only includes major LCM projects.

Patient safety and product quality

Our business model requires the supply of safe and high-quality medicines, which are constantly and carefully monitored during their entire life-cycle. We are dedicated to patient safety and base our behaviours and decisions on our belief that everyone deserves to have confidence in the safety, quality and efficacy of our medicines.

10

product recalls

63

inspections from all health authorities relating to GMP and GDP

Zero

critical findings from health authorities relating to GMP and GDP

We ensure that the development, licensing, manufacturing, distribution and monitoring of active pharmaceutical ingredients (APIs), medicinal products and devices comply with international codes, Good Pharmaceutical Practices (GxP) including GMP (Good Manufacturing Practice), GDP (Good Distribution Practice) and Good Pharmacovigilance Practices, and our own Good Regulatory Practice. We continuously monitor the safety, quality and efficacy of our medicines throughout their life-cycle to maintain product confidence.

We ensure patient safety through key policies and standards such as our Code of Ethics, Quality Policy, Quality Standards and GxP. We are also a member of the Biotechnology Innovation Organization, International Federation of Pharmaceutical Manufacturers and Associations, the European Federation of Pharmaceutical Industries and Associations, the Pharmaceutical Research and Manufacturers of America and the Association of the British Pharmaceutical Industry, and adhere to their industry codes.

Pharmacovigilance

Our comprehensive pharmacovigilance system constantly monitors all products throughout their life-cycle, following global regulatory requirements, GxP principles and quality management standards. Safety systems and processes are established for all medicines, both in development and on the market, to identify and assess potential adverse drug effects. Dedicated safety teams, including safety physicians and pharmacovigilance scientists, provide safety profile information to regulators, healthcare professionals and patients as appropriate.

Our dedicated website for reporting adverse events and requesting medical information is available to healthcare providers and patients. Personal data in adverse event reports is pseudonymised according to legal requirements, in compliance with our Privacy Policy on the handling of personal information during inquiries, complaints, or adverse event reports. Ongoing training supports our employees, contractors and contracted third parties to report adverse events related to our products or partner products, to comply with regulations and contractual requirements, and protect patients.

We enhanced our patient safety efforts in 2025 by implementing a unified global safety database for adverse event reporting associated with both marketed products and clinical trials. By sharing information on a harmonised basis across the industry and regulators, we can increase internal efficiency and enhance patient safety.

In addition, during 2025 we implemented drug/project-specific Toxicity Management Guides (TMGs) across clinical programmes to support investigators in recognising and managing toxicities during clinical trials. TMGs provide clear instructions for dose interruption, dose reduction and treatment discontinuation, with recommendations for ongoing monitoring and clinical management aiming to promote enhanced patient care and reinforce our commitment to patient safety.

Product quality

Our Operations Quality function oversees GMP and GDP compliance across clinical and commercial manufacturing, testing and distribution, including contract manufacturing organisations, ensuring product quality and regulatory adherence. The function drives continuous improvement of the quality management system through corrective actions, risk management, internal audits, and periodic quality management reviews to maintain accountability and align with operational responsibilities.

Product and process performance assessments, based on relevant data and customer feedback, are conducted to ensure our products meet quality standards for identity, durability, reliability, usability, safety, efficacy and performance throughout the product life-cycle. An issue management process is in place to investigate and take corrective actions or improvements to address quality concerns affecting patients, products, or processes in compliance with regulations and within the appropriate time.

We are dedicated to patient safety and base our behaviours and decisions on our belief that everyone deserves to have confidence in the safety, quality and efficacy of our medicines.



For more information on our policies, see pages 217 and 219.

Business Review *continued*

 Growth and Therapy Area Leadership

Summary and performance indicators

We grow our business and serve more patients globally by working ethically, maintaining excellence in manufacturing and supply, and through the use of AI and new technologies.

Our performance in 2025

- Total Revenue, comprising Product Sales, Alliance Revenue and Collaboration Revenue, increased by 9% (8% at CER) to \$58,739 million.
- Committed to high ethical standards: 434 employees and third parties were removed from their role as a result of a breach.
- Delivered 217 successful on-time market launches.

Performance indicators
Global Total Revenue by geography

US		Emerging Markets	
\$25,450m		\$15,303m	
2025	\$25,450m	2025	\$15,303m
2024	\$23,235m	2024	\$13,675m
2023	\$19,077m	2023	\$12,025m
Actual growth	CER growth	Actual growth	CER growth
2025 +10%	2025 +10%	2025 +12%	2025 +14%
2024 +22%	2024 +22%	2024 +14%	2024 +22%
2023 +6%	2023 +6%	2023 +2%	2023 +9%
Europe		Established RoW	
\$12,739m		\$5,247m	
2025	\$12,739m	2025	\$5,247m
2024	\$12,188m	2024	\$4,975m
2023	\$9,611m	2023	\$5,099m
Actual growth	CER growth	Actual growth	CER growth
2025 +5%	2025 +1%	2025 +5%	2025 +6%
2024 +27%	2024 +26%	2024 -2%	2024 +3%
2023 +10%	2023 +8%	2023 -14%	2023 -8%

Our regions

Our growth is delivered by our Commercial teams, which employed 47,400 people at the end of 2025.

Commercial context

We drive growth and profitability through commercial excellence in each of the three regions into which we are organised: the US, Europe-Canada and International (which comprises Australia, New Zealand and Emerging Markets including China). Japan reports separately. Our financial reporting regions are the US, Europe, Established Rest of World (RoW) and Emerging Markets, which are defined below.

We have an active presence in more than 80 countries and sell our products in more than 125 countries. In most markets, we sell our medicines through wholly-owned local marketing companies, as well as distributors and local representative offices.

Our products are primarily marketed to primary and specialist care physicians.

Healthcare in a Changing World on page 6 outlines the trends the pharmaceutical sector is facing. In response, governments are increasingly focused on strategic autonomy, driven by concern over national security, crisis preparedness, economic competitiveness and sovereignty in key sectors. There is also strong pressure to build resilient supply chains. During 2025, the pharmaceutical sector faced increased trade tensions and drug pricing policy changes in the US that have had global implications, including for other wealthy nations that spend a lower share of their GDP on innovative medicines than the US. The US spends a far larger share of its income on new innovative medicines than other high-income OECD countries, and measures are being taken by the US administration to ensure wealthy nations make equitable contributions to global biopharmaceutical R&D.

US

Total Revenue increased by 10% in 2025 to \$25,450 million, driven by the continued demand growth of our medicines.

The US healthcare system is complex. Multiple payers and intermediaries influence patient access to branded medicines through regulatory rebates in government programmes and voluntary rebates paid to private insurers for commercially insured patients. Significant pricing pressure is driven by payer consolidation, restrictive reimbursement policies and cost control tools which reduce patient access.

In October 2025, we announced an agreement with the US administration to lower the cost of prescription medicines in America. We voluntarily agreed to a range of measures that will enable the American healthcare system and patients to access medicines at prices that are equalised with those available in other wealthy countries. We also reached an agreement with the US Department of Commerce for a three-year exemption

of Section 232 tariffs on medicines imported to the US, enabling the Group to onshore medicines manufacturing so that substantially all of its medicines sold in the US are made in the US. For more information, see Global manufacturing capability below.

The Inflation Reduction Act (IRA) of 2022 was passed to address Medicare spending concerns. *Farxiga* was selected for the first round of Medicare price negotiations under the IRA. As the Maximum Fair Price for Medicare has now taken effect in 2026, coinciding in the same year as the expected US loss of market exclusivity that will also reduce *Farxiga*'s price, the overall impact is expected to be manageable.

Calquence was selected for the second round of price negotiations in 2025. Its Maximum Fair Price for Medicare will take effect in 2027. Our diversified product portfolio, providing a broad spectrum of treatments across therapy areas, well position us to mitigate business impact.

Operations

Our manufacturing and supply function continued to support business growth and pipeline development, maintaining excellence in product launch, quality and resilient supply, with focus on progressive, sustainable processes.

In 2025, we made strong progress against our Operations strategic goals, expanding capacity and new modality capability, while leveraging new technology and AI innovations to sustainably support the demands of the business.

- We delivered 217 successful on-time market launches across markets.
- We progressed our investments in manufacturing footprint, technology and AI innovations.
- Our Operations function achieved an 89% reduction in its Scope 1 and 2 GHG emissions, a 24% reduction in water use, and a 23% reduction in waste against a 2015 baseline.

Managing our supply chain

In a year marked by elevated geopolitical and macroeconomic turbulence and capacity shortages, the external environment tested supply chains globally. Drug shortages reached record levels, weather-related disruptions intensified, quality challenges persisted industry-wide, and geopolitical events now encompass

Emerging Markets

Total Revenue in Emerging Markets, predominantly comprising countries in Latin America, the Middle East, Africa and Asia, was \$15,303 million, up 12% (14% at CER). In 2025, Total Revenue for China increased by 4% (4% at CER) to \$6,654 million (2024: \$6,413 million). Ex-China Emerging Markets Total Revenue grew by 19% (22% at CER), with continued increases across all therapy areas.

Following the Russian invasion of Ukraine in February 2022, we continue to provide practical support to ensure the safety, health and wellbeing of our employees. As a healthcare business, we are doing everything possible to ensure medical supply chains continue to operate and that patients in both countries are able to access our medicines, while complying with sanctions imposed on Russia.

trade and tariff uncertainty, driving cost pressure and friction at borders. Simultaneously, conflicts and instability in key regions forced rapid route reconfiguration and heightened the need for robust business continuity planning. Against this backdrop, we have continued to meet our responsibilities to patients by executing with excellence. We sustained high customer service, protected supply, ensured quality, launched new products on time, and built capacity and resilience to secure sustainable growth.

Supply chain finance

Our supply chain finance programme supports the cash flow of our external supply base. The programme is managed by Taulia LLC (with funding provided by some of the Group's relationship banks) and provides suppliers with visibility of invoices and payment dates via a dedicated platform. Suppliers can access this platform free of charge and have flexibility to select individual invoices for early payment. For further details, see Note 20 to the Financial Statements, on page 159.

Global manufacturing capability

Our principal tablet and capsule formulation and packing sites are in the UK, Sweden, China, Puerto Rico and the US, with local supply sites in Egypt, Japan and Russia, and regional supply sites in Brazil, Indonesia and Mexico. We also have major formulation sites for the global supply of parenteral and/or inhalation products in the US, Sweden, France, Australia and the UK. Most of the manufacture of APIs is delivered through the efficient use of external sourcing that is

Europe

Total Revenue was \$12,739 million, up 5% (1% at CER), with continued growth in Oncology and BioPharmaceuticals.

Established RoW

Established RoW comprises Japan, Canada, Australia and New Zealand. In 2025, Total Revenue increased by 5% (6% at CER) to \$5,247 million, with sales in Japan up 6% (5% at CER) to \$3,768 million. Growth was driven by strong performance from Oncology and Respiratory & Immunology medicines.

complemented by expanding use of internal capabilities. For biologics, our principal commercial manufacturing facilities are in the US, Ireland, Sweden, the UK and the Netherlands. Our network contains capabilities in process development, drug substance and drug product manufacturing, and distribution.

In July 2025, we announced our intention to invest in a \$4.5 billion new manufacturing facility in Charlottesville, Virginia, US. The new facility will produce drug substances for AstraZeneca's weight management and metabolic portfolio, as well as our leading ADC cancer portfolio. The facility will be at the forefront of technological innovation, leveraging AI, automation and data analytics to optimise production. In November 2025, we announced a further \$2 billion expansion of our manufacturing footprint in Maryland, US. Our investment in our existing Frederick Biologics facility will double capacity. Additionally, we will build a new facility in Gaithersburg, US, to produce medicines for clinical supply.

In May 2025, manufacturing ceased at our tablet facility in Bangalore, India. The intent to exit was announced in November 2023.

At the end of 2025, we employed 16,900 people at 31 Operations sites¹ in 15 countries.

¹ Excluding clinical supply sites.

Business Review *continued*

Growth and Therapy Area Leadership

Business conduct

We seek to create positive societal impact beyond the direct benefit of our life-changing medicines. We embed ethical behaviour in all our business activities, markets and across our value chain. We promote ethical, transparent and inclusive policies, both internally and with our partners and suppliers.

Our Code of Ethics (the Code) and its supporting Standards are the foundation of our global compliance programme. They embody our Values, including expected behaviours, principles and policies. Following the Code and supporting requirements, we deliver lasting benefits to patients and other stakeholders.

AZ Ethics

The Code asks employees to report possible violations and provides information on how to do so. This includes via the AZ Ethics helpline and website, which are also available to third parties, as well as our Company intranet site and social media platform. This is also included in the annual Code of Ethics training.

We continue to foster a culture where employees can speak their minds, with strong first-line oversight (and related reporting) as well as targeted second-line monitoring to identify concerns early and use learnings to improve our programme. Our Pulse survey enables management and the Board to understand the views and sentiments of our employees, including the proportion of employees who feel comfortable speaking up at work. The resulting report also demonstrates how our Values and behaviours are embedded across the workforce, including a summary metric dashboard organised by category, with

remedial action taken on any concerns identified and discussed as necessary. We also see regular usage of reporting channels across markets, evidencing that individuals are aware of how to report concerns.

Reporting can be done anonymously, where permitted by local law, through our helpline or via line managers or relevant functions such as Compliance or HR, who will carry out an investigation. Issues raised via AZ Ethics are triaged and assigned accordingly for action, with cases tracked and monitored for completion. Anyone who raises a potential breach in good faith is fully supported by management in confidence (subject to disclosure obligations in local markets) and we do not tolerate retaliation. Any whistleblower can report violations inside and outside the organisation (to the designated authority or the media), with the same level of protection, regardless of the means of reporting. The most serious incident reports from whistleblowers – those implicating senior leaders or involving other allegations of serious misconduct (including alleged bribery or corruption) – are promptly, independently and objectively investigated by our Global Compliance Investigations (GCI) team, an above-market investigatory unit within the Global Compliance function. Investigators are part of Compliance or HR and are not associated with the reporters or the implicated parties. In the event that someone within the Compliance or HR function is the subject of an investigation, the matter is managed by someone not involved with the implicated party and in certain cases, a third party may be retained to conduct the investigation. AZ Ethics is compliant with Directive (EU) 2019/1937 of the European Parliament and of the Council.

There were 4,441 instances (instances can involve multiple people) of employee and third-party non-compliance with our Code of Ethics. A total of 434 employees and third parties were removed from their role as a result of a breach and 1,810 received warnings. Breaches primarily consist of low-impact incidents.

Anti-bribery and anti-corruption

Adhering to high standards of business conduct and anti-bribery and anti-corruption (ABAC) principles is critical for us to meet global regulatory requirements, preserve ethical integrity, and safeguard stakeholder trust. We do not tolerate bribery or any other form of corruption. Preventing bribery and corruption is a focus of our third-party risk management and due diligence processes, as well as our monitoring and audit programmes.

Our Anti-Bribery and Anti-Corruption Global Standard, which was updated in 2025, outlines our key ABAC principles and is complemented by additional Global Standards and local requirements. Through our Global Compliance programme and associated policies and other controls, we strive to comply with all applicable ABAC legislation, including the UK Bribery Act 2010, which is aligned with the United Nations Convention against Corruption.

Our annual Code of Ethics training includes content around ABAC. The 2025 Code of Ethics training module also included content relating specifically to fraud in alignment with the new Failure to Prevent Fraud Offence in the UK Economic Crime and Corporate Transparency Act. Additionally, there were enhancements made to the Code to emphasise the need to remain vigilant around potential fraud. In 2025, 100% of active employees, including the SET and at-risk functions, completed mandatory annual training on the Code.

Where risks of bribery and corruption are higher e.g. Commercial teams, the Group provides additional training and resources, see below.

Responsible sales and marketing

Responsible sales and marketing practices are essential for us to maintain compliance with stringent regulatory frameworks, protect patient safety, and foster trust with healthcare professionals and the public. By adhering to ethical standards and all relevant laws, we ensure that our products are promoted transparently and in line with global healthcare expectations. We emphasise transparency, integrity and accountability in our operations, ensuring that our marketing strategies accurately reflect the efficacy and safety of our products.

At AstraZeneca, responsible sales and marketing practices are embedded in our Code of Ethics, Global Standards on ABAC and Promoting our Products, and our patient-centric Values.

Our compliance professionals advise on, and monitor adherence to, our Code and policies, and work with local staff to ensure we meet our high ethical standards. Nominated signatories review product promotional materials and activities to ensure compliance with applicable regulations and codes of practice, and that information is accurate and balanced. Group Internal Audit (GIA) conducts risk-based audits of marketing companies and other business units.

 For information on reporting to the Board, see page 73.

For information on material government investigations or proceedings, including material investigations related to anti-bribery and anti-corruption, see Note 30 to the Financial Statements on pages 185 to 188.

For information on our Code of Ethics, Global Standards on ABAC and Promoting our Products, see page 219.

Our Code of Ethics training continues to have a pathway tailored for our customer-facing Sales and Marketing employees with scenarios relevant to the highest risks in their roles.

In 2025, we identified 10 confirmed external breaches across our Commercial business. Confirmed external breaches comprise cases where AstraZeneca has been found to violate a law, industry code, or regulation by an external authority.

Animals in research

The responsible use of animals is a vital part of biomedical research and product safety testing, where suitable alternatives are not available. At the centre of our commitment to quality science and animal welfare are the Replacement, Reduction and Refinement of animals in research (the 3Rs). All animal studies are undertaken in compliance with all relevant local and national laws and regulations, and with the principles of the

'Guide for the Care and Use of Laboratory Animals' (Institute for Laboratory Animal Research). Wherever possible, we work with third parties accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International.

Animals were needed for in-house studies 138,356 times in 2025 (2024: 141,947), and on our behalf in contract research studies 63,869 times (2024: 63,810). In total, over 97% were rodents or fish, with the majority being mice (85%). The remainder is made up of rabbits, camelids, ferrets, dogs, pigs, non-human primates, chickens and sheep. Dogs and non-human primates make up less than 1% of the total. We do not conduct research using wild-caught non-human primates or great ape species, and we have an animal welfare assurance programme that ensures research conducted by third parties meets our high standards. We are committed to transparency and are

signatories to the Concordat on Openness on Animal Research (UK), the Openness Agreement on Animal Research and Teaching (Australia/New Zealand) and the United States Animal Research Openness Agreement.

For information on material commercial litigation and government investigations or proceedings, including material matters related to responsible sales and marketing, see Note 30 to the Financial Statements on pages 185 to 188.

We promote ethical, transparent and inclusive policies, both internally and with our partners and suppliers.



Business Review *continued*

Growth and Therapy Area Leadership

Digital technologies

AI is a force multiplier for our strategy – accelerating innovation, improving outcomes, and driving productivity and efficiency – so we can do more of what matters, faster and with greater impact.

In December, we created a dedicated Enterprise AI unit to bring together AI expertise and accelerate the delivery of Ambition 2030. Partnering with the business, this team will advance a unified enterprise AI transformation, prioritise and scale high value initiatives, manage change effectively, and unlock synergies that amplify impact.

In R&D, we are developing an ecosystem of foundation models and AI agentic frameworks to accelerate our drug discovery end-to-end. This ecosystem will transform our clinical development, leveraging our key differentiator – our data. Examples include:

- REINVENT, our small molecule discovery platform now enables significant time savings by predicting molecular properties and optimising potential molecules before synthesis and further development.

Over 90% of our small molecule discovery pipeline is AI-enabled, with similar approaches actively applied to other areas, including biologics.

- MILTON, integrates de-identified health records with genetic and protein data to develop models that can predict the risk of more than 1,000 diseases, sometimes 10 to 15 years before they're clinically diagnosed.
- Computational pathology solutions achieved FDA Breakthrough Device Designation as part of an AI-driven companion diagnostic, and released multi-cancer, cross-target QCS models, and identified promising biomarkers in gastric cancer.

We are rapidly integrating AI into clinical workflows from study design to site and patient selection – enhancing scientific decision-making and enabling broader, diverse patient groups to participate without compromising research quality.

In Commercial, partnering with leading technology companies is enabling us to tackle healthcare challenges. In over 20 markets, more than six million AI-enabled chest x-rays support early screening for high-risk lung nodules, improving referral and diagnostic pathways for possible lung cancer. In precision diagnostics, we published an AI-driven

computational pathology validation study that used advanced image analysis and machine learning to evaluate HER2 in breast cancer tissue. We are also deploying AI to increase efficiency, optimise content creation and enhance the relevance of physicians' interactions.

In Operations, we are scaling AI to build an intelligent, autonomous, sustainable supply network that reduces lead times, drives productivity, and cuts waste. Our synthetic drug development timelines are shortened thanks to our agentic AI platform which integrates scientific knowledge and simulation models. Our award-winning Digital Changeover solution is deployed across 17 sites and over 95% of eligible packing lines. To ensure uninterrupted supply, we are engineering a resilient, self-healing supply chain using predictive sensing and autonomous planning.

Underpinning our Enterprise AI transformation is our risk-based AI Governance Framework based on global laws, regulations and standards for best practice, and ensuring responsible use. It includes policies, processes, and guardrails for building, buying, and using AI, to manage risks while maximising the value of AI. We continue to upskill our teams to advance a digital first mindset and optimise transformation at scale.

Cybersecurity and data privacy

Innovative technology platforms are transforming the way we work, and we have measures in place to address the related cybersecurity and data privacy risks, to the extent possible.

Zero

material
cybersecurity
incidents

Zero

material security
breaches involving
personal data

Significant disruption to our IT systems, including breaches of data security or cybersecurity or failure to comply with applicable laws or regulations, could harm our reputation and materially affect our financial condition or ability to manufacture and distribute medicines to patients. These disruptions could potentially also negatively affect our patients, employees and other stakeholders.

Cybersecurity

Recognising the important role our employees play in managing our cybersecurity risk, we provide cybersecurity training, conduct recurring phishing simulations and have a Cybersecurity Culture and Awareness programme including regular messaging via internal communications. The annual cybersecurity training is mandatory for all active employees and is designed to reduce risk and improve resilience. In 2025, new content included emerging AI scenarios and reinforced our new AI standards.

AstraZeneca launched a Disaster Recovery Programme in 2025, focused on strengthening the Company's recovery capabilities and response frameworks to support the resilience of critical business applications. Continued evolution is required to keep pace with

changing business demands and an increasingly dynamic technology landscape – ensuring recovery strategies, tooling, and response practices remain current, scalable, and consistently effective.

Data privacy

The Enterprise Data Office (EDO) has established data governance practices that are managed through a control framework sponsored by our Enterprise Data Council (EDC). The EDO strengthens and standardises data governance, by partnering with other data functions across the Company and acting as a central hub for data management and related regulatory compliance. This approach also ensures that our data policies and standards are streamlined, clear and effective.

In 2025, we released a new standard operating procedure for the management of personal data incidents and a revised standard for data retention management. These updates aim to reduce the likelihood of personal data incidents.

Key privacy compliance concerns are reported via the SET data governance boards, EDO, EDC and appointed senior leaders. Breaches and policy deviations can also be reported to AZ Ethics via the helpline or website.

 For information on how cybersecurity and data privacy are governed by our Code of Ethics as well as the IT Security Policy Framework and Data Privacy Standard respectively, see page 219.

Business development

Business development is an essential part of our strategy and portfolio prioritisation process, creating additional value and helping accelerate the delivery of new medicines that address unmet medical need.

We proactively pursue opportunities to harness leading science and innovation while securing access to cutting-edge technologies and products. This strengthens the quality, effectiveness and productivity of our R&D across therapy areas and expands our innovative pipeline. Partnerships with academic institutions, governments, peers and biotechnology companies are critical to keep us at the forefront of innovations applicable across our portfolio and, ultimately, inform patient treatment. They give us access to key innovations in AI, precision medicine, genomics, and digital technologies, informing the development of optimal treatments for patients.

Our global presence, balanced across regions and disease areas, is supported by more than 1,000 collaborations worldwide and we have completed several strategically important business development transactions in 2025, some of which are summarised on this page.

EsoBiotec

AstraZeneca completed the acquisition of EsoBiotec and their Engineered NanoBody Lentiviral (ENaBL) platform which delivers genetic instructions to specific immune cells, such as T-cells, to enable the recognition and destruction of tumour cells for cancer treatment, and to eliminate autoreactive cells for potential application in immune-mediated diseases. AstraZeneca acquired all outstanding equity of EsoBiotec for a total consideration of up to \$1 billion, on a cash- and debt-free basis, comprising of an initial payment of \$425 million at closing, and up to \$575 million in contingent consideration linked to development and regulatory milestones.

Strategic partnerships in China

A strategic collaboration has been established with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office including Harbour BioMed and Syneron Bio. We will invest \$2.5 billion to establish manufacturing capabilities and create our sixth global strategic R&D centre in Beijing, supported by major research and manufacturing agreements that advance life sciences in China, and follows our acquisition of FibroGen China. The new centre is located in the Beijing International Pharmaceutical Innovation Park, proximate to leading biotech, research hospitals and the

National Medical Products Administration with a focus on advancing early-stage research and clinical development. The centre will be enabled by a new state-of-the-art AI and data science laboratory.

CSPC

In January 2026, we announced a proposed strategic collaboration agreement in China with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.

Alteogen

AstraZeneca entered into a licence agreement with Alteogen Inc. for ALT-B4 a novel hyaluronidase utilising Hybrozyme™ platform technology to enable selected subcutaneous oncology formulations, offering significant time-saving benefits for patients and healthcare systems. Financial arrangements include milestone payments and royalties.

SixPeaks Bio

Following the Series A financing and collaboration agreement from 2024, AstraZeneca has acquired the remaining shares in SixPeaks Bio by using the buyout option. The company has developed an activin IIA/B receptor antibody for robust preservation of skeletal muscle mass, a next-generation obesity product.

We are maximising the use of AI and new technologies to transform patient care. We have the potential to empower patients to play an active role in their own treatment.

Business Review *continued*

 People and Sustainability

Summary and performance indicators

Recognising the strong connection between business growth and resilience, and the need to address the major health challenges of our time, we are focused on how we deliver sustainable impact and how we do business, underpinned by science. We are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.

Our performance in 2025
People

- Received 1.2 million applications and hired 19,000 employees (7,000 internal and 12,000 external).
- Over 5,800 employees participated in a development programme.
- 51.5% of our senior middle management roles and above are filled by women.

Sustainability

- Updated our health equity strategy, embedding health equity across science, healthcare delivery and community investment.
- Continued to decarbonise our value chain, including our own operations.

Performance indicators
People

This priority is built on being a great place to work, patient-oriented, advancing a culture of lifelong learning, and achieving inclusion and diversity goals.

Great place to work

86%

believe that AstraZeneca is a great place to work (2024: 84%)

Advance culture of lifelong learning

81%

feel they have the opportunity for personal development and growth (2024: 81%)

Enable an agile organisation

79%

believe AstraZeneca has been successful at improving IT tools and systems (2024: 75%)

Patient-oriented

88%

believe that AstraZeneca is patient-oriented (2024: 87%)

Achieve inclusion and diversity goals

87%

feel they can be themselves without worrying about being accepted (2024: 85%)

Performance indicators
Sustainability

Achieving a healthier, more sustainable future requires tackling the biggest challenges of our time – from climate change and nature loss to health equity and health system resilience – and doing so in a way that is ethical, transparent and inclusive.

Ambition Zero Carbon (Scope 1 and 2)¹

-88.1%

reduction of Scope 1 and 2 GHG emissions from 2015 baseline year.



People positively impacted²

320 million

¹ Figures reflect market-based accounting, and are inclusive of biomethane certificates. See page 212 for methodology and definitions.

² See page 218 for methodology and definitions.

People

We rely on our global workforce to uphold our Code of Ethics and behaviours in line with our Values, to deliver our Ambition 2030 strategic priorities and work to sustain and improve short- and long-term performance.

86%

believe that AstraZeneca is a great place to work

89%

believe that in the last 12 months, they have improved their existing skills, or learned new skills, or had a development opportunity

Enabling an agile organisation

In 2025, we continued to build talent internally by investing in our workforce. We:

- Maintained the focus on building capability in our global hubs. In 2025, 2,760 external hires were made in these locations.
- Continued to develop internal talent and made 5,100 promotions during 2025.
- Focused on AI upskilling to enable employees to leverage AI in their roles. We also provided access to an AI agent builder, empowering teams to gain hands-on experience in developing and deploying AI-driven tools.

Human Resources Standards

Our Global Human Resources Standards outline our position on key topics. We expect all our employees to align with these standards and do not tolerate any actions which are not aligned. As well as complying with all workplace diversity legislation and requiring the same of the third parties we work with, we provide mechanisms by which employees can confidently raise concerns, and we have processes which enable disciplinary action to be taken where necessary.

Listening to our workforce

Encouraging employees to provide continuous feedback through various mechanisms helps us to foster an inclusive culture and be a great place to work. We invest in developing coaching capability in our leaders and employees to help them bring a coaching approach to their quarterly check-ins and everyday performance conversations. We also collect feedback

through onboarding surveys, exit interviews and our global employee opinion survey, Pulse. We encourage managers to listen to the workforce by providing them with access to the aggregated results for their teams. Managers also have access to a reporting tool to further support engagement across their teams. To ensure we are transparent, we share our global results with the Board, the SET, line managers and employees.

We have a Global Employee Relations team, working in partnership with Legal, Compliance, HR and employee representative groups, such as the European Consultation Committee, Works Councils and, where applicable, our nationally recognised trade unions. Accountability for these processes is with the Chief Human Resources Officer and delegated to members of the leadership team. On a day-to-day basis, this is managed by senior leaders. We also hear the views from our Employee Resource Groups, which are voluntary, employee-led groups open to all employees.

Health and safety

We are committed to providing a work environment that is both physically and psychologically safe for everyone. Our Global Safety, Health and Environment (SHE) Standard describes our management of and accountability for SHE. We do this by embracing a culture of learning and continuous improvement. We strive to maintain or exceed compliance with all company, legal and regulatory requirements ensuring that we are welcome in the communities in which we operate.

Developing skills and capabilities

We develop strategic capabilities through development programmes and high potential talent initiatives, supporting employees ranging from early talent and individual contributors to enterprise leaders. All employees have access to our global learning platform. AI-adoption is a key aspect of achieving our strategic objectives by accelerating decision making and innovation. In 2025, more than 50,000 employees participated in our Thriving in the Age of AI programme. We also continue to embed coaching skills to enhance performance and increase engagement.

To support our Values and understanding of our material sustainability matters, employees complete mandatory training on topics including Code of Ethics, see page 34, and Cybersecurity, see page 36.

These trainings help everyone understand the responsibility to employ high ethical standards when carrying out all aspects of our business globally.

Inclusion and diversity

Our global commitment to inclusion and diversity is woven into what we do, and is reflected in our Values and the behaviours that underpin them. Women comprise 54% (approximately 52,000) of our global workforce and men 45% (approximately 43,300)¹. At the end of 2025, there were seven women on our Board (50% of the total). Five out of 10 SET members (50%) were women and five were men (50%). Directors of the Company's subsidiaries comprised of 209 women (45%) and 256 men (55%)².

Our Board of Directors and the SET conduct quarterly reviews of our workforce composition. This encompasses gender, ethnicity and age representation among other things.

We are committed to hiring and promoting talent ethically and in compliance with applicable laws. Our Code of Ethics and its supporting Standards are designed to help protect against unlawful discrimination on any relevant grounds. The Code covers recruitment and selection, performance management, career development and promotion, transfer, training, and reward. We embrace the cognitive differences of neurodivergent employees and support employees with both seen and unseen disabilities in line with their country-specific laws and regulations. Where risk assessments can be performed, we will consider accommodating adjustments to the working environment that support an inclusive and safe workplace.

Our Global Standard for Inclusion and Diversity sets out how we foster an inclusive and diverse workforce where everyone feels valued and respected because of their individual abilities and perspectives. In 2025, our inclusion and diversity efforts earned recognition externally. We were featured in:

- Forbes World's Top Companies for Women
- Forbes World's Best Employers
- Financial Times, Diversity Leaders 2026
- TIME World's Best Companies.

¹ Approximately 800 employees have not disclosed their gender, therefore are not included in these totals.

² For the purposes of section 414C(8)(c)(ii) of the Companies Act 2006, 'Senior Managers' are the SET, the Directors of all of the subsidiaries of the Company and other individuals holding named positions within those subsidiaries. Individuals on multiple boards are counted once.

Business Review *continued*

People and Sustainability

Sustainability

Recognising the interconnection between business growth and addressing the major health challenges of our time, we are focusing on how we make a positive impact for people, society and the planet, and how we do business.

 For further information on the basis of preparation of our sustainability reporting, our metrics, targets and policies, see the Sustainability Statement from page 204.

Overview

- **Our sustainability impact:** We are taking action on climate and nature, health equity and health systems resilience.
- **How we do business:** We are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.

Our approach to sustainability reporting

Our sustainability reporting is prepared in line with the UK Companies Act 2006, the EU Corporate Sustainability Reporting Directive (CSRD) and European Sustainability Reporting Standards (ESRS), EU Taxonomy on Sustainable Activities and the recommendations of the Task Force on Climate-related Financial Disclosures.

Sustainability is embedded in our Growth Through Innovation strategy, with material sustainability topics aligned to our three strategic pillars and disclosed within the Business Review. This year we introduced the Sustainability Statement section in the Annual Report, setting out general disclosures such as basis for preparation, an overview of the double materiality assessment process and management of impacts, risks and opportunities, with policies, targets and metrics for each material topic. We have cross-referenced where ESRS disclosures are met throughout this Annual Report.

Our material sustainability topics

In 2025, we updated our 2024 double materiality assessment, and our material topics are presented below. Disclosures relating to these topics can be found in the Business Review, from page 26 and the Sustainability Statement, from page 204.

Science and Innovation


- Sustainable innovation, see page 30.
- Patient safety and product quality, see page 31.

Growth and Therapy Area Leadership

- Business conduct, see pages 34 to 35.
- Cybersecurity and data privacy, see page 36.

People and Sustainability

- People, see page 39.
- Accessible and affordable healthcare, see page 41.
- Climate change, see pages 42 to 44.
- Nature, see page 45.



Through our health equity programme, we aim to close healthcare gaps and to give people everywhere the chance to be as healthy as possible.

Accessible and affordable healthcare

Our medicines impact more than 100 million patient lives annually, ranging from cancer and chronic diseases to rare diseases. We are closing healthcare gaps along the entire patient journey to improve access to screening, early detection, diagnosis and treatment, and innovating to deliver our life-changing medicines in a sustainable and equitable way.

320 million

people positively impacted since 2024, including:

156 million

from underserved groups

In May 2025, we updated our health equity strategy, embedding health equity across science (including genomics and clinical trials), healthcare delivery and community investment, with a 2030 ambition to positively impact one billion people, including 400 million from underserved communities. Details of our health equity strategy and supporting policies and programmes can be found on our website.

Through collaborations, partnerships and stakeholder coalitions we are working to ensure essential and innovative medicines become more widely available and affordable. Pricing for our medicines seeks to reflect the value they bring to patients, payers and society, and the significant investment required for targeted treatment options. Through our health equity approach, we also aim to ensure that more individuals can equitably benefit from our clinical trials, science and capabilities.

We have a global tiered pricing policy comprising of four tiers based on gross national income, with confidential, flexible pricing focused on affordability and brand application in support of patients across all tiers. This aims to address disparities in countries' ability to pay, enhancing equitable access while supporting financial viability.

In support of our targets, we engage in ongoing health equity initiatives enterprise-wide. We continue to implement innovative solutions to optimise affordability and accessibility, where necessary addressing barriers beyond price.

Affordability and pricing

We take a broad and collaborative approach across diverse global healthcare systems, working with payers and policymakers to promote widespread, sustainable access. Our tailored programmes address local health needs, strengthen health systems resilience, and enhance affordability by partnering with country-specific health systems to deliver medicines in a locally accessible way. In 2025, our key continuous initiatives included:

- **Health system strengthening:** To build resilient and sustainable health systems, we partner with health system stakeholders to transform care by providing evidence-based recommendations and co-creating solutions that help to reduce disease progression, hospital admissions and premature deaths, globally.
- **Customised solutions for out-of-pocket gaps:** Supporting patients' ability to stay on prescribed therapies.
- **Patient Assistance Programmes (PAPs):** Assisting those unable to pay and addressing funding gaps, enabling patients to fund part of their treatment in line with their affordability and means, and in a manner consistent with applicable laws.
- **Tailored payment models:** Leveraging tiered pricing and innovative solutions such as, value-based agreements, to maximise patient access.

Clinical trial representation

We aim to achieve more representative clinical trial populations to better reflect the patient communities we serve. In 2025, we extended our real-time dashboard for measuring representativeness of Phase III studies to Canada, building on previous launches in the US and Brazil in 2024. We actively participate in public-private partnerships including the Innovative Health Initiative's Research in Europe and Diversity Inclusion, ESMO, and the Cancer Drug Development Forum to enhance trial representativeness, while contributing to the scientific community through publications in the American Society of Clinical Oncology Educational Book series that outline methods for improving clinical trial representation. Additionally, we are partnering with community-focused organisations such as Acclinate and Black Health Matters, as well as not-for-profit organisations including the Sexual Gender Minority Alliance, National Medical Fellowship, and Women Health Access Matters, all aimed at improving representation across our clinical trials.

These initiatives reflect our sustained ambition to improving clinical trial representation on multiple fronts, both within the Company and across the wider research ecosystem.

Key early and post-trial access

We reaffirm our approach to early and post-clinical trial access to medicines, providing our therapies to those in need prior to regulatory approval in specific countries, in addition to our approach to continue treating patients after the termination of clinical trials, ensuring ongoing access and continuity of care. Patients who face serious or life-threatening illnesses, and have exhausted alternative treatment options, will have their requests for early access to investigational medicinal products carefully considered. This applies to those unable to participate in clinical trials, and is carried out through appropriate early access pathways in accordance with local laws and regulations. Where appropriate, our approach also includes supporting continued treatment after clinical trial participation (post-trial access), ensuring safe, ethical, timely and lawful patient support prior to product approval in their respective countries.

 For information regarding Intellectual property, see page 30.

Business Review *continued*

People and Sustainability

Climate change

In support of our Ambition 2030 strategy, we have set and are delivering action on our corporate climate targets. We are decarbonising our value chain including our own operations, and through global initiatives and collaboration with our peers, we are driving action to accelerate the delivery of net-zero healthcare. Failure to meet regulatory requirements, voluntary sustainability targets and stakeholder expectations could adversely affect the Company's reputation with key stakeholders.

73,903

gross Scope 1 and 2 GHG emissions
(Market-based) (tonnes CO₂e)

6,197,690

gross Scope 3 GHG emissions
(tonnes CO₂e)

1.26

Scope 1 and 2 GHG emissions intensity
(tonnes CO₂e per million of Total Revenue)

69%

share of primary activity data in Scope 3 reporting

Transition plan for climate change

In 2020, we launched our Ambition Zero Carbon strategy, through which we are pursuing decarbonisation targets compatible with the limiting of global warming to 1.5°C, and making progress towards achieving net zero by 2045. Our near- and long-term GHG emissions targets were verified under the Science Based Targets initiative (SBTi) Net-Zero Corporate Standard in 2021. We are targeting a 98% absolute reduction in Scope 1 and 2 by 2026 (2015 baseline), a 50% absolute reduction in total Scope 3 by 2030 and 90% by 2045 (2019 baseline), and net zero by 2045.

Delivering these targets requires whole value-chain decarbonisation across Scopes 1, 2 and 3, through levers which eliminate, reduce, substitute and then neutralise residual emissions to achieve net zero. Specific decarbonisation levers are described below.

We have a near-term target of 98% absolute reduction in Scope 1 and 2 GHG emissions by 2026 from a 2015 baseline. By the end of 2025, we have achieved 88.1%. We face localised challenges across our global operations with accessing sources of renewable energy to decarbonise site operations and to procure and operate electric vehicles, that present transition risks for delivering reductions to our Scope 1 and 2 GHG footprint against our 2026 target.

Over 95% of our total GHG emissions are in the upstream and downstream value chain. To support our longer-term target of 50% reduction in total Scope 3 GHG emissions by 2030 and 90% reduction by 2045, from a 2019 baseline, we are engaging with suppliers for them to set validated science-based targets (SBTs) to cover most of our supplier spend by the end of 2025. Achieving Scope 3 targets requires extensive global decarbonisation across our entire supply chain, including our product portfolio which represents a large portion of our GHG emissions. Pharmaceutical products have a long development cycle, which makes it critical to design and embed climate considerations at an early stage for future products now in development. In addition, to achieve our goals, we must tackle emissions from our existing commercial portfolio, which creates challenges with heavily regulated production processes and materials.

We are conducting a scheduled review of our SBTi-verified Net-Zero Corporate Standard targets in line with SBTi timelines, taking the opportunity to embed learnings from the past five years. This includes certain targets disclosed in previous years. We expect to communicate the outcomes in 2026.

Governance

Our executive-led SET Sustainability Governance Group is accountable for the delivery of Ambition Zero Carbon and its transition plan. Regular governance updates and proposals are provided to the Group, which in 2025 included our CEO, Chief Financial Officer (CFO), Chief Human Resources Officer, Chief Compliance Officer and General Counsel, and the EVP, Global Operations, IT & Chief Sustainability Officer. The Sustainability Committee monitors progress on Ambition Zero Carbon. Sustainability reporting is overseen by the

Audit Committee. The CEO's responsibilities to the Board include the development and performance of the Ambition Zero Carbon strategy and related risks and opportunities. The EVP, Global Operations, IT & Chief Sustainability Officer is responsible for the Ambition Zero Carbon strategy and its execution, and all SET members have responsibility for working with their teams to ensure alignment of the Ambition Zero Carbon strategy with business priorities and climate risks and opportunities.

Initiatives approved by the SET Sustainability Governance Group are included in the relevant management units' financial planning.

Scope 1 and 2 decarbonisation levers

To support the achievement of the Scope 1 and 2 GHG target, we are addressing direct and indirect emissions through focused operational improvements and energy transitions.

Road fleet electrification

At the end of 2025, we had transitioned over 80% of our total owned and leased road vehicle fleet to battery electric vehicles (over 18,000 vehicles) and purchased renewable electricity Energy Attribute Certificates equivalent to charging energy requirements. 37 markets have achieved a 100% electric vehicle transition to date. The global transition is being progressed while some markets are experiencing challenges with the supply of vehicles and the availability of charging infrastructure.

Site F-gas management

F-gases are released during the production process of current pMDI medicines. Through a process change involving purging empty canisters in a vacuum instead of using a propellant, we have significantly reduced F-gas emissions. A second reduction initiative of capturing F-gas emissions from the production process, using cryogenic technology that liquefies the gases, has been completed in 2025, enabling the storage and removal from site for either incineration or recycling. This is a near-term solution to mitigate GHG emissions from our existing pMDI medicines as we transition to a pMDI portfolio using next-generation propellant (NGP) as part of our Scope 3 decarbonisation strategy.

Fuel switching (clean heat)

In 2025, supply of biomethane commenced via long-term commercial agreements with Vanguard Renewables in the US and Future Biogas in the UK. When fully operational, these collaborations are expected to enable up to 330 GWh of biomethane to be used across our US and UK sites, equivalent to 70% of our total global gas consumption.

 For more information regarding how our approach to climate mitigation action is grounded in the principles of our Code of Ethics and the SHE Framework, see pages 211 and 219.

Scope 3 decarbonisation levers

Product manufacture

Product manufacture is a significant contributor to our Scope 3 footprint, outside of AstraZeneca's own operations, and decarbonising products is a key pillar of our strategy to achieve our Scope 3 targets. We continue to implement our Life-Cycle Assessment (LCA) programme, aligned with ISO 14040 and 14044 standards, and this now encompasses medicines which contribute to the majority of our Total Revenue. Using this and other sustainability inputs, we have established an internal Product Sustainability Index (PSI) to understand the environmental impacts of our launched products and inform sustainability improvement plans. The PSI programme is also being piloted on development projects, with an initial focus on carbon and supported by a simplified internal LCA tool to enable early identification and assessment of products in development that will be part of our future footprint.

Non-product supplier emissions

To address the Scope 3 footprint associated with purchased goods and services, we prioritise collaboration with suppliers. We continued to advocate for our suppliers to set SBTs, ensuring that our climate ambitions are shared across our value chain. Additionally, we facilitate access to renewable electricity through initiatives such as the

Energize programme, enabling more suppliers to transition to renewable energy sources. Our leadership of industry collaborations, including the Sustainable Markets Initiative Health Systems Task Force and Pharmaceutical Supply Chain Initiative, further help to align climate expectations and best practices across the pharmaceutical industry's shared supplier base.

Product use

As part of our efforts to provide patients with access to treatment with lower GHG emissions, we are transitioning our portfolio of inhaled respiratory medicines delivered by pMDIs to use a NGP with near-zero GWP. pMDIs deliver essential, life-saving medicines for millions of people living with respiratory diseases worldwide and are the most commonly used type of inhaler device globally. Our NGP has 99.9% less GWP than propellants used in our current pMDI portfolio, which makes the transition to the NGP a key product-related element of our Ambition Zero Carbon strategy. In 2025, we announced the world-first approval by the UK Medicines and Healthcare products Regulatory Agency and a Committee for Medicinal Products for Human Use positive opinion for *Trixeo Aerosphere* to be used with the NGP, endorsing it for use in the EU and marking the initiation of the transition of our full portfolio to the NGP, with submissions for transitioning *Breztri/Trixio* in other territories underway.

Transport – distribution and business travel

We continue to reduce emissions through our transport modal shift programme, transitioning key distribution routes from air to sea. Performance regarding primary distribution emissions is tracked on a quarterly basis. We are also evaluating alternative fuels, including sustainable aviation fuel, with the aim of quantifying whole life-cycle sustainability impacts. In parallel, we are enhancing our secondary distribution reporting methodologies to identify emissions hotspots and highlight decarbonisation opportunities. New ways of working have significantly reduced our business travel emissions. All teams operate within a centrally tracked carbon travel budget. In addition, engagement work is ongoing to promote more sustainable modes of travel, particularly on routes with good alternatives.

Climate performance

Our global GHG metrics cover Scope 1, Scope 2 on a market-based basis (with location-based shown for comparison), total Scope 3 across all 15 categories, and total energy use. Scope 1 reflects the application of biomethane certificates; biogenic emissions are reported outside Scopes 1 to 3.

Global GHG emissions data for the period 1 January 2025 to 31 December 2025¹

	Unit	2025	2024	2023	Baseline 2015
Scope 1	Tonnes CO ₂ e	62,587	125,386	180,898	298,498
Scope 2 (Market-based) ²	Tonnes CO ₂ e	11,316	14,210	19,940	322,319
Scope 2 (Location-based)	Tonnes CO ₂ e	241,023	217,026	183,332	266,372
Gross Scope 1 and 2 GHG emissions (Market-based) ²	Tonnes CO ₂ e	73,903	139,594	200,838	620,818
Scope 1 and Scope 2 (Market-based) intensity	Tonnes CO ₂ e per million of Total Revenue	1.26	2.58	4.38	22.73
Biogenic emissions (outside-of-scope emissions) ³	Tonnes CO ₂ e	105,850	75,978	29,201	2,822
Total energy consumption	Megawatt hours (MWh)	1,612,136	1,676,076	1,733,325	1,832,611
	Unit	2025	2024	2023	Baseline 2019
Gross Scope 3 emissions (all relevant categories) ^{4,5}	Tonnes CO ₂ e	6,197,690	5,716,211	5,591,071	5,025,169
Scope 3 intensity ⁵	Tonnes CO ₂ e per million of Total Revenue	105.5	105.7	122.0	171.1

¹ The table above presents all emission sources required under the UK Streamlined Energy and Carbon Reporting (SECR) requirements. The portion of total global energy and emissions originating from AstraZeneca's UK and offshore area footprint were as follows: energy use 236,850 MWh (15%); Scope 1 site energy, non-energy and fleet emissions 10,941 tCO₂e (17%); Scope 2 site-imported energy emissions using market-based accounting 0 tCO₂e (0%); and Scope 2 site-imported energy emissions using location-based accounting 20,494 tCO₂e (9%).

² 96% of Scope 2 market-based GHG emissions are associated with contractual instruments such as energy attribute certificates and power purchase agreements.

³ Biomethane certificates are applied in Scope 1 with a CO₂ factor of zero; non-CO₂ emissions are reported.

⁴ Scope 3 GHG emissions (excluding Category 9) was 6,070,258 tCO₂e.

⁵ Regular data review is carried out to enhance accuracy, consistency of measurement across periods and reflect major business change. Reviews in 2025 resulted in revisions to figures reported in previous years primarily arising from: i) Revision of spend data methodology for Scope 3 categories 1,4,6 and use of latest emission factors, and ii) Alignment of capital goods (category 2) data and classifications to financial reporting scope. These changes are applied consistently across all prior years, and resulted in a reduction to the 2019 baseline by 12%.

Business Review *continued*

People and Sustainability

Climate change *continued*

Climate change adaptation

Climate change is expected to increase the frequency of extreme weather and climate-related natural disasters. This may cause disruption to our own and third-party supplier sites and distribution routes due to increased exposure to climate hazards. Medicine shortages due to climate disasters could lead to delayed supply of critical medicines, impacting patients. To mitigate exposure and build resilience to the risks presented by climate change, we identify and integrate risks into site business continuity and mitigation plans and in supply chain design.

Our Business Continuity Standard outlines the principles for consistent business continuity process and governance, in order to support effective and sustainable business resilience across AstraZeneca.

Business continuity and mitigation plans

To mitigate exposure and increase resilience to acute extreme weather events and longer-term shifts in climate patterns, identified climate risks are integrated into sites' business continuity and mitigation plans. Examples of climate change adaptation solutions implemented in 2025 include improving emergency response plans in relation to climate hazards.

In 2025, three new material construction projects were assessed on their exposure to physical climate risks based on their location and activities, using a high-carbon scenario. The assessment included dependencies on local communities and adaptation measures have been integrated into the design where feasible to protect the construction and to secure delivery of medicines to patients.

Climate-related risks in the supply chain are covered by supply chain design (e.g. dual sourcing, strategic planning for safety stock) as part of product-level business continuity management.

Climate risk management

We follow the science to manage the risks presented by climate change and to build resilience against any such risks. The identification and assessment of climate risk forms part of our existing risk management processes. We conduct scenario analyses using a low/medium/high case scenario based on the Intergovernmental Panel on Climate Change scenarios, namely Shared Socioeconomic Pathways (SSPs) and Representative Concentration Pathways (RCPs).

Impacts on climate change

Based on our current business model and reduced GHG emissions footprint, contribution to climate change is not considered to be a material impact. However, we have identified a material impact related to climate change adaptation; see page 206.

Climate-related physical risks

We have developed a process to conduct deep dive risk assessments for AstraZeneca sites, taking a risk-based approach. We have conducted scenario analysis based on a broad range of climate scenarios (SSP1-RCP2.6, SSP2-RCP4.5 and SSP5-RCP8.5) taking into consideration the likelihood, magnitude and duration of the hazards. As a part of the physical climate risk assessments, the resilience of the sites is assessed factoring in downtime of supply and backup from dual sourcing. No material physical climate-related financial risks have been identified.

Our strategy for adaptation is aligned to a high-emission scenario. Where appropriate, the risk mitigation measures and interventions are escalated to site management and captured on the local risk register. Identified risks are addressed in local business continuity plans or by technical mitigations in site master plans. Short-, mid- and long-term financial planning includes required investments.

Climate-related transition risks

Climate-related transition risks and opportunities are assessed both at enterprise and product levels, including prioritised medicines where LCA data is available. Through scenario analysis, risks and opportunities were identified to cover medicines in the therapy areas of Oncology, CVRM and R&I to see how drivers such as regulations, access to renewable energy, technology shifts, market expectations and reputational aspects can impact our financial forecast. In addition, transition risks and opportunities have been identified at enterprise level for transportation, renewable energy, and raw materials represented by F-gases used in our inhaled respiratory portfolio.

Our climate strategy is designed to address transition risks and opportunities in a low-carbon scenario and a pathway aligned with our SBTs of limiting global warming to 1.5°C.

 For more information regarding our Business Continuity Standard, see page 211.

For more information regarding the scenario analysis conducted within the resilience analysis process, see page 214.

For more information regarding how the Group assesses its resilience against risks including climate-related risks through a viability assessment, see the Viability Statement on page 46.

Nature

As we work to enhance patient health outcomes through advances in medical treatments, we aim to manage our dependencies and impacts on nature by designing them out where we can, and addressing those that remain across our raw material sourcing, production, use and disposal of our medicines.

We strive to minimise the environmental impact of our products from discovery to disposal, in alignment with our Code of Ethics. This approach is embedded into key internal processes and procedures throughout the life-cycle of our medicines, such as the OneSHE Framework.

Use and sourcing of raw materials

The development, manufacture and testing of medicines requires a wide range of ingredients, including chemicals and excipients, many requiring complex inputs to manufacture. We rely on materials sourced from wild species, such as horseshoe crab blood. We aim to manage adverse impacts that drive nature loss such as land use change and deforestation, unsustainable use of freshwater, GHG emissions and pollution.

Assessing nature risks

As part of our double materiality assessment, we assessed our nature-related impacts based on current visibility of our interfaces with nature. As we gain understanding of connections to nature within our supply chain, we aim to identify and assess adverse impacts and risks, developing action plans for responsible supply chain management.

Reducing the reliance on horseshoe crabs

To ensure the patient safety of injectable medicines there are global regulatory requirements to test raw materials, water systems and products for the presence of endotoxins, a significant risk to patient safety. Until recently, the blood of horseshoe crabs has been the only ingredient suitable to make the reagents needed to perform these tests. We are advocating for harmonised regulations to simplify the transition for product testing from horseshoe crab blood to synthetics. In the interim, most of our labs have transitioned to more efficient methods for endotoxin testing of water systems and in 2025, have reduced this dependency further by transitioning to a synthetic alternative for this purpose.

Pharmaceuticals in the environment

Pharmaceutical residues entering the environment is currently an unavoidable result of the patient use of medicines. We recognise our most material water pollution impact as the APIs in our products. APIs are biologically active molecules and may interact with and impact wildlife in the environment.

We have ongoing programmes and processes across the value chain to understand and minimise the impact of pharmaceuticals in the environment (PiE), as part of our ambition to lower the environmental burden of healthcare, while improving health outcomes and reducing our exposure to environmental risks.

Environmental risk assessments

To understand the environmental impacts of APIs, we complete Environmental Risk Assessments (ERAs) before the approval of a new medicine and, using experimental data, identify target concentrations of our APIs considered to pose insignificant risk to the environment. These are also utilised to manage our own emissions from the manufacture of our products. The Safe API Discharge process sets and monitors target concentrations of API emissions from manufacturing to the aquatic environment that are not to be exceeded by AstraZeneca and relevant supplier sites. Our ERAs demonstrate that PiE resulting from use of our products pose a low or insignificant environmental risk and are unlikely to cause adverse impacts. The data meets the international standards set by regulators, and we publish summaries of the ERAs and underlying data on www.astrazeneca.com/sustainability/resources.html.

EcoPharmacoVigilance

Our EcoPharmacoVigilance (EPV) approach reviews emerging science and peer-reviewed literature to inform and improve the ERAs of our APIs. We monitor measurements of our products in water bodies across the world that are published in scientific journals and publish those results on our website, as well as our industry-leading EPV dashboard, where users can visualise this data. It shows that, where detection of our APIs has been reported in scientific literature, the measured concentrations pose low or insignificant environmental risk in over 99% of cases. There can be some location-specific environmental risks for particular pharmaceuticals, especially in regions where there may be inadequate sewage treatment and/or high populations discharging waste into rivers with low-dilution conditions.

PFAS restrictions

In the EU, the European Chemicals Agency (ECHA) is evaluating a proposed restriction of per- and polyfluoroalkyl substances (PFAS), employing a broad, structure-based definition of PFAS. The proposal potentially impacts a family of more than 10,000 chemicals which are used across many industries. In other jurisdictions, including the UK, the US and Canada, policymakers have signalled their intent to restrict, or have initiated reviews aimed at restricting, PFAS chemicals. Definitions of PFAS may vary by jurisdiction, and scopes and timelines for regulatory action differ.

Not all materials classified as PFAS, nor all uses of such materials, present equivalent environmental or human-health risks. Certain PFAS materials play important roles across the biopharmaceutical value chain, supporting process integrity and product quality; in certain applications, technically viable alternatives are not available, making complete substitution challenging.

We apply a science-based approach to our management of PFAS use, which includes ongoing evaluation and implementation of reductions or substitutions of PFAS materials wherever possible, while continuing to protect medicines for patients, including ensuring supply security, patient safety and regulatory compliance. Proposals for blanket bans of PFAS that do not account for essential uses could potentially affect development, manufacturing, packaging and drug delivery of medicines, raising a potential risk of shortages or the removal of therapeutic options, with significant impact for patients and public health.

In the EU and globally, we are working with relevant authorities and experts to ensure any new regulations regarding the use of PFAS meet patient, public health and environmental needs, and protect the supply of medicines to patients in the EU and globally. These activities include industry-wide engagements in public-private partnerships on PFAS exposure, emissions, and end-of-life management in the healthcare sector, as well as our contributions to the ECHA's public consultations on the PFAS Restriction Proposal.

 For more information on our policies, see page 211.

Section 172(1) Statement

The Board is required to promote the success of AstraZeneca for the shareholders and wider stakeholders who interact with and are impacted by our business.

Throughout the year the Directors have considered the factors set out in section 172(1)(a)-(f) of the UK Companies Act 2006, as well as other factors relevant to the decision being made. The Board acknowledges that not every decision made will necessarily result in a positive outcome

for all stakeholders. By considering our Purpose and Values, together with AstraZeneca's strategic priorities, the Board aims to ensure that the decisions made are consistent and intended to promote the Company's long-term success.

The Board and management engaged with key stakeholders throughout the year to understand the issues and factors that are significant for these stakeholders, and a number of actions were taken as a result of this engagement.

These interactions, and the outcomes and actions which resulted, are set out in the Connecting with our stakeholders section from page 74 and throughout the Strategic Report.

We are committed to being a great place to work for the global workforce.

Details on engagement with employees can be found on page 39 of the Business Review, on page 78 of the Corporate Governance Report, page 85 and 86 in the Audit Committee Report and page 109 of the Remuneration Committee Report.

We are committed to employing high ethical standards when carrying out all aspects of our business globally. Our Code of Ethics (the Code) is based on our Values, expected behaviours and key policy principles.

More information on the Code can be found on page 34.

We recognise patients as people first and put them at the heart of what we do.

Further information on the importance of patients to the business can be found on page 31 of the Business Review and page 74 of the Corporate Governance Report.

Principal Decisions are decisions and discussions which are material or strategic to the Group and also those that are significant to our key stakeholder groups.

The consideration and impact of the Group's operations on the environment and how the Group has considered other factors, such as communities and suppliers, can be found throughout the People and Sustainability section from page 38 of the Business Review.

Details of how the Board operates and matters considered by the Board are set out in the Corporate Governance Report from page 71.

Details on the Board and SET composition and gender diversity can be found on pages 39, 68, and 80. Examples of how Directors discharged their duties and considered stakeholders when making Principal Decisions during 2025 are set out on page 77.

Viability Statement

In accordance with provision 31 of the 2024 UK Corporate Governance Code, the Board has determined that a three-year period to 31 December 2028 constitutes an appropriate period over which to provide its viability statement.

The Board assesses the Company's prospects using a 10-year long-range projection. It notes the rich and varied portfolio of medicines in development across a range of therapy areas and the medicines currently commercialised in more than 100 markets, concluding that the Company's long-term prospects remain strong. The Board also considers annually and on a rolling basis, a three-year bottom-up detailed business plan and, given the inherent uncertainty involved, believes that the three-year statement presents readers of this Annual Report with a reasonable degree of assurance over the ongoing viability of the Company, while still providing a longer-term perspective.

The three-year detailed business plan captures risks to the sales and cost forecasts at market and SET functional levels. The plan is used to perform central net debt and headroom-profile analysis. The following scenarios have been applied to this analysis to create a severe but plausible downside combining a number of the Principal Risks detailed on pages 48 and 49.

- **Principal Risks:** Pricing, affordability, access, competitive pressures and failures or delays in the quality or execution of the Group's commercial strategies.
 - Scenario 1: Government action on pricing, higher than anticipated competition and other commercial headwinds result in lower than anticipated growth rates for our medicines.
 - Scenario 2: A significant incident leads to reputational damage in a key market resulting in an ongoing 10% reduction in revenue achieved in this market.
- **Principal Risk:** Failure or delay in the delivery of our pipeline or launch of new medicines.
 - Scenario 3: Assumes no launches of new products.
- **Principal Risk:** Failure to maintain supply of compliant, quality medicines.
 - Scenario 4: Major equipment failure or a significant regulatory observation at one

of our major manufacturing sites results in a 12-month loss of manufacturing capability for one of our key oncology products, leading to supply interruption.

- **Principal Risks:** Failure in information technology or cybersecurity, adverse outcome of litigation and/or government investigations.
 - Scenario 5: A cyber incident results in interruption to manufacturing and associated penalties.

In addition, the Board has considered more stressed scenarios, including restrictions on debt factoring and no access to capital markets to raise new debt. In each scenario (or combination of scenarios above), the Group is able to rely on its existing cash, cash equivalents and short-term fixed income investments, committed credit facilities, leverage its cost base, reduce capital expenditure and take other cash management measures to mitigate the impacts and still have residual capacity to absorb further shocks.

Based on the results of this analysis, the Directors have a reasonable expectation that the Company will be able to continue in operation and meet its liabilities, as they fall due, over the three-year period of their assessment.

Our Risk Overview can be found from page 47 to 49. Full details are given in the Risk Supplement on our website, www.astrazeneca.com/annualreport2025.

Risk Overview

“We take smart risks.”

Managing risk

Our approach to risk management is designed to encourage clear decision making on which risks we take and how we manage and mitigate these risks. We strive to embed sound risk management within our strategy, planning, budgeting and performance management processes. The Board defines the Group's risk appetite. This enables the Group, in both quantitative and qualitative terms, to judge the level of risk it is prepared to take in achieving its overall objectives.

The Senior Executive Team (SET) is required by the Board to oversee and monitor the effectiveness of the risk management system. Within each SET function, leadership teams discuss the risks the business faces. Quarterly, each SET function assesses changes to these risks, new and emerging, and mitigation plans. These are assimilated into a Group Risk Report for the Board, Audit Committee and SET.

Global Compliance, Finance and Group Internal Audit support management and the Board by providing assurance over our internal controls and risk management system. The Board believes that existing processes provide it with adequate information on the risks and uncertainties we face. The Board has carried out a robust assessment of the emerging and Principal Risks facing the Group. Our Principal Risks are those risks that are most likely to significantly impact delivery of our business strategy or future performance and are a subset of the total risk landscape facing the Group. The table on pages 48 and 49 provides insight into these Principal Risks.

Emerging risks

We monitor our business activities and external and internal environments for new, emerging and changing risks to ensure these are managed appropriately. Annually, we combine input from each SET function and external insight to scan the horizon for emerging risks and a summary is presented to the Audit Committee and the Board. Emerging risks continue to be monitored as part of the ongoing risk management processes outlined above.

Climate risk

The identification and assessment of climate risk forms part of our existing risk management processes. ‘Failure to meet our sustainability targets, regulatory requirements and stakeholder expectations with respect to the environment’ incorporates climate risk within its scope and is a component of the Group's risk landscape but is not currently considered to be a Principal Risk for the Group.

Cybersecurity risk

Our approach to identifying, assessing and managing cybersecurity risks (including those that result from the use of third parties in business processes and data management) is integrated within our Group-wide approach to managing risk. Mitigation includes a comprehensive cybersecurity programme comprising executive oversight, defined standards, prioritised investment, active defence operations, and technology optimisation. Cyber risks are monitored and mitigation effectiveness regularly reported in KPI dashboards provided to management and the Audit Committee. Incidents are managed and reported using the cybersecurity incident management framework which in turn is connected to the Group's crisis management framework.

Risk Overview *continued*

Strategy key

-  Science and Innovation
-  Growth and Therapy Area Leadership

-  People and Sustainability
-  Achieve Group Financial Targets

Trend key

-  Increasing risk
-  Decreasing risk
-  Unchanged

Principal Risks

Risk category and Principal Risks	Context/potential impact	Management actions	Trend
Product pipeline risks			
Failure or delay in the delivery of our pipeline or launch of new medicines	   The development of pharmaceutical product candidates is a complex, risky and lengthy process involving significant resources. A project may fail at any stage of the process due to a number of factors, which could adversely affect our reputation, future business and results of operations.	• Prioritise and accelerate our pipeline. • Strengthen pipeline through acquisitions, licensing and collaborations. • Focus on innovative science in our main therapy areas. • Improve R&D productivity.	
Failure to meet regulatory or ethical requirements for medicine development or approval	  We are subject to laws and regulations that control our ability to market our pharmaceutical products. Delays in regulatory approvals could delay our ability to market our products and may adversely affect our revenue.	• Quality management systems incorporating monitoring, training and assurance activities. • Collaborating with regulatory bodies and advocacy groups to monitor and respond to changes in the regulatory environment, including revised processes, timelines and guidance.	
Commercialisation risks			
Pricing, affordability, access and competitive pressures	   The pricing and market access environment is highly complex and subject to dynamic economic, political and social pressures. Deterioration in socio-economic conditions may affect customers' ability or willingness to purchase our medicines and may adversely affect our business and results of operations.	• Implementation of pricing, reimbursement and policy frameworks. • Focus on key products. • Demonstrate value of medicines/health economics. • Implement innovative value-based agreements focused on patient outcomes. • Global footprint. • Diversified portfolio.	
Failures or delays in the quality or execution of the Group's commercial strategies	   A failure to execute our commercial strategies or achieve the level of sales anticipated for a medicine could materially impact our business.	• Focus on key products. • Substantial investment in sales and marketing activities. • Accelerate execution of plans and risk sharing through business development and strategic collaborations and alliances.	
Supply chain and business execution risks			
Failure to maintain supply of compliant, quality medicines	   Supply chain difficulties may result in product shortages which could lead to lost product sales and materially affect our reputation and results of operations.	• Establishment of new manufacturing facilities, creating capacity and technical capability to support new product launches. • Contingency plans, including dual sourcing, multiple suppliers and close monitoring and maintenance of stock levels. • Business continuity and resilience initiatives, disaster and data recovery, and emergency response plans. • Quality management systems.	
Failure in information technology or cybersecurity	  Significant disruption to our IT systems, including cybersecurity breaches, or failure to comply with applicable laws or regulations could harm our reputation and materially affect our financial condition or results of operations.	• Penetration testing and targeted remediation. • Data and application access hardening. • Identity and network controls improvement to protect priority areas. • Compliance with emerging cybersecurity laws and regulations. • Defence operations capability upgrade. • Enhanced Cloud asset monitoring. • Strengthening user device authentication. • Regular cybersecurity and privacy training for employees.	
Failure to collect and manage data or AI in line with legal and regulatory requirements and strategic objectives	    There is an increasing range of legislative and regulatory requirements to manage data across all countries where we conduct business such as restricting the movement of data between countries or how we make use of new technological capabilities such as AI. Failure to protect data effectively or the inappropriate use of technologies such as AI may lead to competitive disadvantage and/or loss of trust from key stakeholders, including patients, and prevent us from reaching our strategic objectives. In addition, failure to identify, prioritise and scale the appropriate AI opportunities may limit our ability to realise the benefits of AI in support of our strategic objectives.	• Enterprise Data Council. • Enterprise AI Governance Framework and Standard. • Data Privacy Framework and privacy impact assessment process.	

Risk category and Principal Risks	Context/potential impact	Management actions	Trend
Legal, regulatory and compliance risks			
Safety and efficacy of marketed medicines is questioned	   Safety concerns relating to our products may lead to recalls, seizures, interruption of supply and loss of product approvals, which could adversely affect patient access, our reputation and our revenues. Significant product liability claims could also arise, which may be costly, divert management attention, reduce demand for our products and damage our reputation.	Robust processes and systems in place to manage patient safety and efficacy trends as well as externally reported risks through regulatory agencies and other parties. This includes a comprehensive pharmacovigilance programme supplemented by close monitoring and review of adverse events.	
Adverse outcome of litigation and/or governmental investigations	  Our business is subject to a wide range of laws and regulations around the world. Actual or perceived failure to comply may result in AstraZeneca and/or its employees being investigated by government agencies and authorities and/or in civil legal proceedings. Government investigations, litigations, and other legal proceedings, regardless of outcome, could be costly, divert management attention, or damage our reputation and demand for our products. Unfavourable resolutions to proceedings against us could subject us to criminal liability, fines, penalties or other monetary or non-monetary remedies, including enhanced damages, requiring us to make significant provisions in our accounts relating to legal proceedings, and could materially adversely affect our business or results of operations.	- Established compliance framework with strong ethical and compliance culture. - Combined internal and external counsel management.	
IP risks related to our products	   The pharmaceutical industry is experiencing pressure from governments and other payers to impose limits on IP protections to manage healthcare costs. If we are unable to obtain, defend and enforce our IP, we may experience accelerated and intensified competition.	Active management of IP rights and IP litigation.	
Failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery/anti-corruption, anti-fraud and scientific exchanges	   Any failure to comply with applicable laws, rules and regulations, including anti-bribery/anti-corruption and anti-fraud legislation, may result in civil and/or criminal legal proceedings and/or regulatory sanctions, fines or penalties, impacting financial results.	- Strong ethical and compliance culture. - Established compliance framework including annual Code of Ethics training for all employees. - Focus on due diligence and oversight of third-party engagements.	
Economic and financial risks			
Geopolitical and/or macro-economic volatility disrupts the operation of our global business	   With an active presence in more than 80 countries, we are subject to political, socio-economic and financial factors around the world. A sustained global economic downturn or significant changes to exchange rates may adversely impact our business. Geopolitical tensions may lead to the imposition, alteration or escalation of trade controls, tariffs, taxes or other restrictions to market access, which may increase our costs or reduce revenues.	- Focus on key products. - Demonstrate value of medicines/health economics. - Diversified portfolio. - Global manufacturing capability.	
Failure to achieve strategic plans or meet targets or expectations	   Failure to successfully implement our business strategy may frustrate the achievement of our targets and materially damage our brand, business, financial position or results of operations.	- Focus on key products and innovative science in our core therapy areas. - Strengthen pipeline through acquisitions, licensing and collaborations. - Appropriate capital structure and balance sheet. - Portfolio-driven decision-making process governed by senior executive-led committees.	

Financial Review



“AstraZeneca achieved Total Revenue of \$58.7 billion in 2025, driven predominantly by \$58.6 billion of Product Revenue, representing growth of 9% (CER: 8%).”

2025 delivered strong commercial performance, driven by business-wide growth and exceptional pipeline delivery.

As anticipated, 2025 was an unprecedented year in advancing the 2030 ambition. Financially, we continued to make strong progress towards our \$80 billion Total Revenue goal, while sustaining significant investment in the R&D that will drive growth well beyond 2030. Making well-informed capital allocation decisions across R&D, business development and Capex projects, while continuing to grow the underlying business and manage risk remains the highest priority.

Total Revenue growth

AstraZeneca achieved Total Revenue of \$58.7 billion in 2025, including \$58.6 billion of Product Revenue and \$0.1 billion of Collaboration Revenue, with growth of 9% (CER: 8%). In 2025, we delivered 16 blockbuster medicines in total, including *Tezspire*, *Enhertu* and *Beyfortus* which are medicines included in collaborations with alliance partners.

Product Sales grew by 9% (CER: 9%) to \$55.6 billion, with 13 blockbuster medicines. Demand growth for our Oncology and CVRM products and new launch indications in Oncology, delivered continued Product Sales growth, with Oncology achieving 17% (CER: 16%) and CVRM achieving 3% (CER: 2%). *Farxiga* (\$8.4 billion), *Tagrisso* (\$7.3 billion) and *Imfinzi* (\$6.1 billion) each delivering strong results once again, while *Calquence* also showed continued growth. Within Rare Disease, *Ultomiris* achieved Product Sales of \$4.7 billion, an increase of 20% (CER: 19%), due to increased demand and continued conversion from *Soliris*.

In the US, we had overall growth of 8%, with Product Sales of \$23.4 billion, reflecting continued momentum across the Oncology portfolio. Product Sales rose in Emerging Markets by 11% (CER: 13%) to \$15.1 billion and in Europe by 11% (CER: 7%) to \$12.0 billion, with Oncology and *Farxiga* driving the increases in both regions. In Established Rest of World markets, there was growth of 3% (CER: 3%) to \$5.1 billion due to growth in Oncology.

Alliance Revenue increased by 39% (CER: 38%) to \$3.1 billion, including \$1.8 billion from *Enhertu*, which has shown continued growth since achieving blockbuster status in 2023. Collaboration Revenue decreased by 89% (CER: 89%) to \$0.1 billion.

Profitability

Reported Earnings Per Share (EPS) was \$6.60 in the year (2024: \$4.54) and Core EPS was \$9.16 (2024: \$8.21) driven by improved Operating Margin from Total Revenue growth. Reported EPS benefited from a lower intangible impairment impact than in 2024.

Key milestones/approvals

Our continued investment in the pipeline yielded several significant approvals and milestones in the year, notably for *Saphnelo*, *Beyontra*, *Datroway* and *Enhertu*. In December 2025, *Saphnelo* was approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on top of standard therapy. In March 2025, *Beyontra* launched in Japan where Alexion holds the exclusive licence to develop and commercialise. In June 2025, *Datroway* was approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. In December 2025,

Enhertu, in combination with pertuzumab, was approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.

Harmonised listing structure


In November 2025, our shareholders voted 99.36% in favour of the Board's proposal to harmonise the Company's listing structure in London, Stockholm and New York. On 2 February 2026, AstraZeneca Ordinary Shares were directly listed on the New York Stock Exchange, replacing the US listing of AstraZeneca ADSs on Nasdaq. This new listing structure will offer flexibility to access the broadest available pool of capital, including in the US, and enable more shareholders to participate in AstraZeneca's exciting future.

2025 was a year of enormous change, and the pace of change is set to accelerate. AI presents opportunities for productivity and innovation but also requires us to invest in our data foundations, technology and people. I am incredibly proud of our commitment to continuous improvement and the growth and agility demonstrated by our leaders, teams, and entire organisation throughout the year. With this momentum, we enter 2026 with confidence and a relentless focus on delivering sustainable long-term growth.

Aradhana Sarin
Chief Financial Officer

Highlights

Financial performance

**Product Sales****\$55.6bn**9% growth
(CER: 9%)**Alliance Revenue****\$3.1bn**39% growth
(CER: 38%)**Collaboration Revenue****\$0.1bn**-89% decrease
(CER: -89%)**Operating profit – Reported****\$13.7bn**37% growth
(CER: 36%)**Operating profit – Core****\$18.5bn**9% growth
(CER: 9%)**EPS – Reported****\$6.60**45% growth
(CER: 43%)**EPS – Core****\$9.16**12% growth
(CER: 11%)

Total Revenue: Therapy Areas

Oncology

15%growth
(CER: 14%)

CVRM

3%growth
(CER: 2%)

R&I

13%growth
(CER: 12%)

V&I

-13%decrease
(CER: -14%)

Rare Disease

4%growth
(CER: 4%)

Other Medicines

-9%decrease
(CER: -8%)

Total Revenue: geographical areas

US

10%

growth

Emerging Markets

12%growth
(CER: 14%)

Europe

5%growth
(CER: 1%)

Established RoW

5%growth
(CER: 6%)

Summary performance in 2025

	Reported			CER			Core		
	2025 \$m	2024 \$m	% Actual change	CER growth ¹ \$m	Growth due to exchange effects \$m	% CER change	2025 \$m	2024 \$m	% Actual change
- Product Sales	55,573	50,938	9	4,459	176	9	55,573	50,938	9
- Alliance Revenue	3,067	2,212	39	845	10	38	3,067	2,212	39
Product Revenue ²	58,640	53,150	10	5,304	186	10	58,640	53,150	10
Collaboration Revenue	99	923	(89)	(826)	2	(89)	99	923	(89)
Total Revenue	58,739	54,073	9	4,478	188	8	58,739	54,073	9
Cost of sales	(10,633)	(10,207)	4	(527)	101	5	(10,709)	(9,601)	12
Gross profit	48,106	43,866	10	3,951	289	9	48,030	44,472	8
Operating expenses	(34,744)	(34,115)	2	(427)	(203)	1	(29,935)	(27,794)	8
Other operating income and expense	381	252	52	134	(4)	53	383	250	54
Operating profit	13,743	10,003	37	3,658	82	36	18,478	16,928	9
Net finance expense	(1,334)	(1,284)	4	(60)	10	5	(1,092)	(1,169)	(7)
Share of after tax losses of joint ventures and associates	(7)	(28)	(74)	22	(1)	(77)	(7)	(28)	(74)
Profit before tax	12,402	8,691	43	3,620	91	40	17,379	15,731	10
Taxation	(2,169)	(1,650)	31	(499)	(20)	29	(3,170)	(3,001)	6
Profit after tax	10,233	7,041	45	3,121	71	43	14,209	12,730	12
Basic earnings per share (\$)	6.60	4.54	45	2.01	0.05	43	9.16	8.21	12

¹ As detailed on page 53, CER growth is calculated using prior year actual results adjusted for certain exchange rate effects, including hedging.

² Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Statement of Comprehensive Income to include a new subtotal 'Product Revenue' representing the summation of Product Sales and Alliance Revenue. Product Revenue and Collaboration Revenue form Total Revenue. Product Sales and Alliance Revenue will continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue. The comparative period has been retrospectively adjusted to reflect the additional subtotal.

Financial Review *continued*

Business background and results overview

The business background is covered in the Healthcare in a Changing World section from page 6, the Therapy Area Review from page 12, and the Our Strategy and Key Performance Indicators section from page 10, which describe in detail the business developments of our products.

As described earlier in this Annual Report, sales of our products are directly influenced by medical need and are generally paid for by health insurance schemes or national healthcare budgets. Our operating results can be affected by a number of factors other than the delivery of operating plans and normal competition.

Over the longer term, the success of our R&D is crucial, and we devote substantial resources to this area. The benefits of this investment are expected to emerge over the long term and there is considerable inherent uncertainty as to the scale and timing of outcomes and their transition to saleable products.

Measuring performance

Reported and Core performance are referred to in this Financial Review when reporting on our performance in absolute terms, but more often in comparison with earlier years:

- Reported performance takes into account all the factors (including those which we cannot influence, such as currency exchange rates) that have affected the results of our business. The Consolidated Financial Statements have been prepared in accordance with UK-adopted IAS and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The Consolidated Financial Statements also comply fully with IFRS Accounting Standards as issued by the IASB and IAS as adopted by the EU.
- Core performance measures are adjusted to exclude certain significant items, using a set of established principles.

Use of non-GAAP performance measures

CER, Core performance measures, Gross Margin, Operating Margin, Earnings before interest, taxes, depreciation and amortisation (EBITDA) and Net debt are non-GAAP performance measures because they cannot be derived directly from the Financial Statements.

By disclosing non-GAAP performance and growth measures, in addition to our Reported financial information, we are enhancing investors' ability to evaluate and analyse the financial performance and trends of our ongoing business and the related key business drivers. The adjustments are made to our Reported financial information in order to show non-GAAP performance measures that illustrate clearly the impact on our performance of factors such as changes in revenues and expenses driven by volume, prices and cost levels relative to such prior years or periods. These non-GAAP performance measures are not a substitute for, or superior to, financial measures prepared in accordance with GAAP.

As shown in the 2025 Reconciliation of Reported results to Core results table on page 55, our reconciliation of Reported financial information to Core performance measures includes a breakdown of the items for which our Reported financial information is adjusted, and a further breakdown by specific line item, as such items are reflected in our Reported income statement. This illustrates the significant items that are excluded from Core performance measures and their impact on our Reported financial information, both as a whole and in respect of specific line items.

Management presents these results externally to meet investors' requirements for transparency and clarity. Core financial measures are also used internally in the management of our business performance, in our budgeting process and when determining compensation. As a result, Core performance measures allow investors to differentiate between different kinds of costs, but they should not be used in isolation.

Our determination of non-GAAP measures, and our presentation of them within this Financial Review, may differ from similarly titled non-GAAP measures of other companies.

The SET retains strategic management of the costs excluded from Reported financial information in arriving at Core financial measures, tracking their impact on Reported Operating profit and EPS, with operational management being delegated on a case-by-case basis to ensure clear accountability and consistency for each cost category.

We strongly encourage readers of this Annual Report not to rely on any single financial measure but to review our Financial Statements, including the Notes thereto, and our other publicly filed reports, carefully and in their entirety.

Further details of the risks faced by the business are given in Risk Overview from page 47 and in the Risk Supplement at www.astrazeneca.com/annualreport2025.

For a detailed definition of Core measures, see page 53.

Also refer to the Summary performance in 2025 table on page 51, the 2025 Reconciliation of Reported results to Core results, and the Excluded from Core results tables on page 55, for our discussion of comparative growth measures.

Non-GAAP measures: definitions

Revenue

Constant exchange rate (CER) growth rates

□ Reconciliation, see page 55.

Definition: Retranslation of the current year's performance at the previous year's average exchange rates, adjusted for other exchange effects, including hedging.

Why we use them: CER measures allow us to focus on the changes in revenues and expenses driven by volume, prices and cost levels relative to the prior period. Revenues and cost growth expressed in CER allow management to understand the true local movement in revenues and costs, in order to compare recent trends and relative return on investment. CER growth rates can be used to analyse revenues in a number of ways but, most often, we consider CER growth by products and groups of products, and by countries and regions.

CER revenue growth can be further analysed by revenue volumes and selling price. Similarly, CER cost growth helps us to focus on the real local change in costs so that we can manage the cost base effectively.

Limitations: CER measures are not always better indicators of performance. Where countries are subject to high inflation and currencies that depreciate persistently, adjusting out the effect of foreign exchange fluctuations could give an overly optimistic view of growth.

Profitability

Core performance measures

□ Reconciliation, see page 55.

Core performance measures are adjusted to exclude certain significant items. In determining the adjustments to arrive at the Core result, we use a set of established principles relating to the nature or materiality of individual items or groups of items, excluding, for example, events which are (i) outside the normal course of business, (ii) incurred in a pattern that is unrelated to the trends in the underlying financial performance of our ongoing business, or (iii) related to major acquisitions, to ensure that investors' ability to evaluate and analyse the underlying financial performance of our ongoing business is enhanced.

Our Core adjustments are summarised as:

Restructuring costs, including charges and provisions related to our global restructuring programmes on our capitalised manufacturing facilities and IT assets. These can take place over multiple reporting periods, given the long life-cycle of our business.

Why we use them: We adjust for these charges and provisions because they primarily reflect the financial impact of change to legacy arrangements, rather than the underlying performance of our ongoing business.

Intangible amortisation and impairments, including impairment reversals but excluding any charges relating to IT assets. Intangibles generally arise from business combinations and individual licence acquisitions.

Why we use them: We adjust for these charges because their pattern of recognition is largely uncorrelated with the underlying performance of the business.

Other specified items, principally comprise acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables, arising from intangible asset acquisitions, remeasurement adjustments relating to Other payables and debt items assumed from the Alexion acquisition and legal settlements.

Why we use them: We adjust for these items to enable a more meaningful comparison of the performance of acquired businesses and products to that of internally developed products, as well as removing charges whose pattern of recognition is largely uncorrelated to the underlying performance of the business.

It should be noted that some costs excluded from our Core results, such as intangible amortisation and finance charges related to contingent consideration, will recur in future years, and other excluded items such as impairments and legal settlement costs, along with other acquisition-related costs, may recur in the future.

Limitations: Core results exclude significant costs (such as restructuring, intangible amortisation and impairments, and other acquisition-related adjustments), but incorporate associated benefits, including Product Sales arising from business combinations, asset acquisitions and assets which have been amortised, as well as the benefits resulting from restructuring activities and, as such, they should not be regarded as a complete picture of the Group's financial performance, which is presented in its Reported results. The exclusion of the adjusting items may result in Core earnings being materially higher or lower than Reported earnings.

Financial Review *continued*

Non-GAAP measures: definitions *continued*

Profitability *continued*

Gross Margin¹  Reconciliation, see page 55.	Definition: Gross Margin is defined as Gross profit as a percentage of Total Revenue. Why we use it: This measure sets out gross profitability when taking account of only direct Cost of sales. It is a key performance measure of the contribution to fund operating costs and overall quality of the business.	Limitations: Gross Margin excludes operating expenses, like marketing and administrative costs, so it doesn't reflect overall profitability.
Operating Margin  Reconciliation, see page 55.	Definition: Operating profit as a percentage of Total Revenue. Why we use it: This measure sets out profitability derived from operating activities before the impact of finance costs and tax. It is a key performance measure of the overall quality of the operations of the business.	Limitations: Operating Margin excludes the impact of financing costs and therefore should not be regarded as a full picture of revenue performance.
EBITDA  Reconciliation, see page 59.	Definition: Reported Profit before tax after adding back Net finance expense, results from joint ventures and associates, and charges for Depreciation, amortisation and impairment.	Why we use it: EBITDA allows us to understand our baseline profitability, removing any 'non-operational' expenses and non-cash items that are not considered by management to be reflective of the underlying performance of the Group. Limitations: EBITDA does not take account of the cost of investment to generate revenues, hence is not always the best indicator of performance.
Cash flow and liquidity		
Net debt  Reconciliation, see page 61.	Definition: Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments and Net derivative financial instruments.	Why we use it: Net debt is a measure that provides valuable additional information regarding the Group's net financial liabilities and is a measure commonly used by investors and rating agencies. It facilitates the tracking of one of our key financial priorities: deleveraging.

¹ Effective 1 January 2025, the Group has replaced the measure 'Product Sales Gross Margin' with the measure 'Gross Margin'. Previously, the measure excluded margin related to Alliance Revenue and Collaboration Revenue. The new measure is calculated using Gross profit as a percentage of Total Revenue, thereby encompassing all revenue categories, and is intended to provide a more comprehensive measure of total performance.

2025 Reconciliation of Reported results to Core results

	2025 Reported \$m	Restructuring costs \$m	Intangible asset amortisation and impairments \$m	Other ¹ \$m	2025 Core ² \$m	Core 2025 compared with Core 2024 ²	
						Actual growth %	CER growth %
Gross profit	48,106	(138)	32	30	48,030	8	7
<i>Gross Margin³ %</i>	<i>82</i>				<i>82</i>	<i>–</i>	<i>-1pp</i>
Distribution expense	(579)	–	–	–	(579)	4	4
Research and development expense	(14,232)	171	236	3	(13,822)	13	12
Selling, general and administrative expense	(19,933)	209	4,059	131	(15,534)	3	3
Other operating income and expense	381	(5)	–	7	383	54	55
Operating profit	13,743	237	4,327	171	18,478	9	9
<i>Operating Margin %</i>	<i>23</i>				<i>31</i>	<i>–</i>	<i>–</i>
Net finance expense	(1,334)	–	–	242	(1,092)	(7)	(6)
Taxation	(2,169)	(68)	(825)	(108)	(3,170)	6	5
Basic earnings per share (\$)	6.60	0.11	2.26	0.19	9.16	12	11

2024 Reconciliation of Reported results to Core results

	2024 Reported \$m	Restructuring costs \$m	Intangible asset amortisation and impairments \$m	Other ¹ \$m	2024 Core ² \$m	Core 2024 compared with Core 2023 ²	
						Actual growth %	CER growth %
Gross profit	43,866	569	32	5	44,472	18	20
<i>Gross Margin³ %</i>	<i>81</i>				<i>82</i>	<i>–</i>	<i>–</i>
Distribution expense	(555)	–	–	–	(555)	3	5
Research and development expense	(13,583)	275	1,090	7	(12,211)	19	19
Selling, general and administrative expense	(19,977)	312	4,286	351	(15,028)	9	11
Other operating income and expense	252	(2)	–	–	250	(81)	(81)
Operating profit	10,003	1,154	5,408	363	16,928	16	22
<i>Operating Margin %</i>	<i>18</i>				<i>31</i>	<i>–</i>	<i>–</i>
Net finance expense	(1,284)	–	–	115	(1,169)	19	15
Taxation	(1,650)	(219)	(1,044)	(88)	(3,001)	31	38
Basic earnings per share (\$)	4.54	0.60	2.82	0.25	8.21	13	19

¹ See Excluded from Core results table below for further details of other adjustments.

² Each of the measures in the Core columns is a non-GAAP measure.

³ Refer to page 54 for details on the 'Gross Margin' measure which has replaced 'Product Sales Gross Margin' effective from 1 January 2025.

Excluded from Core results

Restructuring costs	Restructuring costs totalling \$237 million (2024: \$1,154 million) mainly comprise those incurred on the PAAGR of \$232 million (2024: \$1,115 million).
Intangible asset amortisation and impairments	Amortisation totalling \$4,109 million (2024: \$3,839 million) relating to intangible assets, except those related to IT. Intangible impairment charges were \$218 million (2024: \$1,569 million), excluding those related to IT and other intangibles. Further details relating to intangible asset amortisation and impairments are included in Note 11 to the Financial Statements from page 151.
Other	- Other adjustments, excluding taxation adjustments, amounted to \$413 million (2024: \$478 million). - Other adjustments to Reported Selling, general and administrative (SG&A) expense were \$131 million (2024: \$351 million), primarily \$223 million relating to legal costs and income from net fair value adjustments to contingent consideration balances of \$97 million (2024: expense of \$311 million). See Note 20 to the Financial Statements from page 160 for details on contingent consideration balances, and Note 30 from page 181 for information on legal proceedings ongoing as of 31 December 2025. - Other adjustments to Reported Net finance expense of \$242 million (2024: \$115 million) include discount unwind charges on liabilities arising from business combinations and on liabilities resulting from the <i>Enhertu</i> collaboration agreement. - Other adjustments to Reported Taxation amounted to \$108 million (2024: \$88 million).

Financial Review *continued*

Total Revenue

Total Revenue for 2025 was up 9% (CER: 8%) to \$58,739 million, comprising Product Sales of \$55,573 million, up 9% (CER: 9%), Alliance Revenue of \$3,067 million, an increase of 39% (CER: 38%), and Collaboration Revenue of \$99 million, a decrease of 89% (CER: 89%).

In 2025, we succeeded in delivering 16 blockbuster drugs. Our five largest selling products in the year were *Farxiga* (\$8,492 million), *Tagrisso* (\$7,254 million), *Imfinzi* (\$6,063 million), *Ultomiris* (\$4,718 million) and *Calquence* (\$3,518 million).

Product Sales

	2025 \$m	2024 \$m	Actual growth %	CER growth %	Commentary ¹
Product Sales by Therapy Area					
Oncology	23,698	20,275	17	16	+ <i>Tagrisso</i> sales increase by 10% (CER: 10%) reflecting strong demand growth across all indications and key regions. + <i>Imfinzi</i> Product Sales increased by 29% (CER: 28%) due to new launch indications in bladder cancer and lung cancer. + <i>Calquence</i> continued its growth with an increase of 12% (CER: 12%), driven by sustained leadership in front-line CLL. + <i>Lynparza</i> Product Sales increased by 7% (CER: 6%) due to sustained global PARP inhibitor market leadership across four tumour types.
CVRM	12,764	12,448	3	2	+ <i>Farxiga</i> sales increased by 10% (CER: 9%), driven by heart failure and CKD indications despite generic competition in some markets. - <i>Brilinta</i> sales decreased by 38% (CER: 38%) driven by generic entry in the US and Europe in the first half of 2025.
R&I	8,167	7,416	10	10	+ <i>Fasenra</i> increased by 17% (CER: 16%) due to expanded severe eosinophilic asthma market share, further fuelled by first wave market launches for EGPA indication.
V&I	846	1,058	(20)	(20)	- <i>Synagis</i> decreased by 35% (CER: 34%) due to competition from <i>Beyfortus</i> .
Rare Disease	9,126	8,668	5	5	+ <i>Ultomiris</i> increased by 20% (CER: 19%) due to increasing patient demand and further conversion from <i>Soliris</i> . + <i>Strensiq</i> increased by 19% (CER: 18%) due to continued patient demand and geographic expansion.
Other Medicines	972	1,073	(9)	(8)	
Total	55,573	50,938	9	9	

	2025 \$m	2024 \$m	Actual growth %	CER growth %	Commentary ¹
Product Sales by geographical area					
US	23,444	21,655	8	8	+ Continued growth of our Oncology medicines. + <i>Tagrisso</i> increased by 11% due to underlying demand growth. + <i>Imfinzi</i> increased 35% due to demand growth across all indications, particularly new launches.
Emerging Markets	15,056	13,535	11	13	+ Growth in Oncology and CVRM, driven by <i>Tagrisso</i> , up 12% (CER: 14%), and <i>Forxiga</i> , up 17% (CER: 18%). + Ex-China Emerging Markets grew by 18% (CER: 21%), with continued increases in Oncology and <i>Farxiga</i> .
Europe	12,021	10,848	11	7	+ Growth due to Oncology momentum, driven primarily by <i>Tagrisso</i> .
Established RoW	5,052	4,900	3	3	+ Sales increased across all regions driven by strong Oncology performance and <i>Ultomiris</i> growth due to continued conversion from <i>Soliris</i> and strong demand following new launches.
Total	55,573	50,938	9	9	

¹ In the commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a '+' symbol beside an Oncology comment indicates that the item resulted in an increase in the Oncology Product Sales relative to the prior year period.

Alliance Revenue

	2025 \$m	2024 \$m
<i>Enhertu</i>	1,798	1,437
<i>Tezspire</i>	673	436
<i>Beyfortus</i>	422	237
<i>Datroway</i>	77	–
Other royalty income	92	91
Other Alliance Revenue	5	11
Total Alliance Revenue	3,067	2,212

Collaboration Revenue

	2025 \$m	2024 \$m
<i>Farxiga</i> : sales milestones	87	56
<i>Lynparza</i> : sales milestone	–	600
<i>Beyfortus</i> : sales milestones	–	167
<i>Koselugo</i> : sales milestone	–	100
Other Collaboration Revenue	12	–
Total Collaboration Revenue	99	923

Alliance Revenue

Alliance Revenue, comprising our share of gross profits, share of revenues and royalties, increased in the year by 39% (CER: 38%), to \$3,067 million, including \$1,798 million from *Enhertu* and \$673 million from *Tezspire*, which achieved blockbuster status in 2024. Details of our significant business development transactions which give rise to Alliance Revenue are given below.

***Enhertu* and *Datroway* (Daiichi Sankyo)**

In March 2019, AstraZeneca entered into an alliance with Daiichi Sankyo to develop and commercialise *Enhertu* for multiple cancer types. In July 2020, AstraZeneca entered into an alliance with Daiichi Sankyo to develop and commercialise *Datroway*, a TROP2-directed ADC. In markets where Daiichi Sankyo is selling the products, AstraZeneca is entitled to receive a royalty (in Japan) or a share of costs and income (in other territories). Share of gross profits and royalty income from Daiichi Sankyo are recognised as Alliance Revenue. *Enhertu* launched in the US in December 2019. *Datroway* launched in Japan in March 2025.

***Tezspire* (Amgen)**

In 2012, AstraZeneca entered into a collaboration agreement with Amgen to co-develop and co-commercialise five development stage programmes. Of these, only *Tezspire* remains in the collaboration. A second active molecule (AZD8630) was added in 2021. Manufacturing will be undertaken by Amgen, while commercialisation activity will be undertaken either jointly, or by AstraZeneca or Amgen individually, dependent on the market and on the agreed terms. AstraZeneca recognises 100% of the sales as principal in all markets other than the US, as well as 100% of the associated cost of sales. In markets other than the US, where AstraZeneca is recognising sales, the share of gross margin payable to

Amgen is shown as additional cost of sales. In the US, where Amgen is recognising sales, AstraZeneca records its share of gross profit as Alliance Revenue.

***Beyfortus* (Sanofi)**

In March 2017, AstraZeneca entered into an alliance with Sanofi to develop and commercialise *Beyfortus* jointly. Under the terms of the global agreement, Sanofi made an upfront payment of €120 million and agreed to pay up to €495 million upon achievement of certain development and sales-related milestones. All costs and profits are shared equally. The US element of this collaboration was subject to a participation agreement with Sobi, effective from January 2019 until April 2023, at which point there was an update to the contractual relationships between AstraZeneca, Sobi and Sanofi relating to the future sales of *Beyfortus*. Alliance Revenue includes AstraZeneca's 50% share of gross profits on sales of *Beyfortus* in major markets outside the US.

Collaboration Revenue

Collaboration Revenue, consisting of upfront payments and event-triggered milestones, decreased in the year by 89% (CER: 89%) to \$99 million. Details of our significant business development transactions which give rise to Collaboration Revenue are given below.

***Lynparza*/*Koselugo* (MSD)**

In July 2017, the Group announced a global strategic oncology collaboration with Merck & Co., Inc., known as Merck in the US and Canada, and MSD in other territories (MSD), to co-develop and co-commercialise AstraZeneca's *Lynparza* for multiple cancer types and *Koselugo* for neurofibromatosis type 1. As part of the agreement, MSD agreed to pay AstraZeneca up to \$8.5 billion in total consideration, including \$1.6 billion upfront, \$750 million for certain licence options and

up to \$6.2 billion contingent upon successful achievement of future regulatory and sales-related milestones. Of the \$1.6 billion upfront payment, \$1.0 billion was recognised as Collaboration Revenue on deal completion in 2017, with the remaining \$0.6 billion deferred to the balance sheet, virtually all of which has been released to the Consolidated Statement of Comprehensive Income as at 31 December 2025. In August 2025, the contractual arrangements between AstraZeneca and MSD were updated and simplified relating to the global development and commercialisation of *Koselugo*, an oral, selective mitogen-activated protein kinase (MEK) inhibitor. Under the updated arrangements AstraZeneca will fully recognise the costs, revenues and profits of *Koselugo* globally. MSD received an upfront payment of \$150 million and will receive deferred payments totalling up to \$400 million. In addition, MSD is eligible to receive up to \$175 million in potential approval milestones and up to \$235 million in sales milestone payments, plus single-digit royalties based on sales. Prior to the updated arrangements, AstraZeneca fully recognised the revenues of *Koselugo* but shared equally pre-tax profits and losses of the product with MSD. AstraZeneca records all product sales for *Lynparza*, with the share of gross profits due to MSD under the collaboration being recorded under Cost of sales. Additionally, AstraZeneca recognises Collaboration Revenue relating to regulatory milestones and sales-related milestones.

- Prior to 2025, since the start of the agreement, we have recognised Collaboration Revenue totalling \$3,810 million, comprising \$750 million resulting from the exercise of options, \$2,100 million in respect of sales-related milestones and \$960 million in respect of regulatory milestones.

***Beyfortus* (Sanofi)**

Details of this business development transaction are summarised in the Alliance Revenue section on this page.

- Prior to 2025, since the start of the agreement, we have recognised Collaboration Revenue totalling \$451 million, comprising \$127 million (€120 million) of upfront consideration, \$130 million (€120 million) in respect of regulatory milestones, and \$194 million (€175 million) in respect of sales-related milestones.

Financial Review *continued*

Key elements of financial performance in 2025

	Reported \$m	Actual growth %	CER growth %	Core \$m	Actual growth %	CER growth %	Commentary ¹
Gross profit	48,106	10	9	48,030	8	7	+ Positive effects from geographic mix. - Negative product mix effects from rising contributions of products with share of gross profit arrangements. - Pricing adjustments, for example to sales reimbursed by the Medicare Part D programme in the US, diluted the Gross Margin. - Royalty buyout expenses of \$235 million, incurred in the fourth quarter of 2025.
<i>Gross Margin %</i>	<i>82</i>	<i>+1pp</i>	<i>+1pp</i>	<i>82</i>	<i>-</i>	<i>-1pp</i>	
Research and development expense	(14,232)	5	4	(13,822)	13	12	+ Positive data read-outs for high-value pipeline opportunities that have ungated large late-stage trials. + Investments in platforms, new technology and capabilities to enhance R&D capabilities. + Additions from business development. - Reported R&D expense impacted by intangible asset impairments of \$210 million (2024: \$1,065 million).
Selling, general and administrative expense	(19,933)	-	(1)	(15,534)	3	3	+ Market development activities for launches and to support continued growth in existing brands. - Prior year Reported SG&A expense included an impairment charge of \$504 million recorded against the <i>Andexxa</i> intangible asset.
Other operating income and expense	381	52	53	383	54	55	• Consists primarily of royalties and an upfront fee on a divestment.
Operating profit	13,743	37	36	18,478	9	9	+ Operating profit increase driven by factors discussed above, Reported Operating profit was negatively impacted in prior year by intangible asset impairments.
<i>Operating Margin %</i>	<i>23</i>	<i>+5pp</i>	<i>+5pp</i>	<i>31</i>	<i>-</i>	<i>-</i>	
Net finance expense	(1,334)	4	5	(1,092)	(7)	(6)	- Core Net finance expense decreased principally due to changes in interest on tax, with movements in borrowing expenses broadly offset by lower interest income on cash balances.
Profit before tax	12,402	43	40	17,379	10	10	• Core pre-tax adjustments amounted to \$4,977 million in 2025 (2024: \$7,040 million), comprising \$4,735 million adjustments to Reported Operating profit (2024: \$6,925 million) and \$242 million to Reported Net finance expense (2024: \$115 million).
Tax rate %	18			18			
Basic earnings per share (\$)	6.60	45	43	9.16	12	11	

¹ In the commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a '+' symbol beside an R&D expense comment indicates that the item resulted in an increase in the R&D expense relative to the prior year period.

Reconciliation of Reported Profit before tax to EBITDA

	2025 \$m	2024 \$m	Actual growth %	CER growth %
Reported Profit before tax	12,402	8,691	43	40
Net finance expense	1,334	1,284	4	5
Share of after tax losses of joint ventures and associates	7	28	(74)	(77)
Depreciation, amortisation and impairment	5,733	6,688	(14)	(15)
EBITDA	19,476	16,691	17	16

Taxation

The Reported and Core tax rates for the year were both 18%.

The income tax paid for the year was \$2,845 million (2024: \$2,750 million). This was \$676 million higher than the Reported tax charge for the year, which benefited from a net deferred tax credit of \$164 million (2024: \$795 million), related to updates to estimates of prior period tax liabilities, payment of prior period tax liabilities, and the timing differences for cash payments. Additional information on these items is contained in Note 5 to the Financial Statements from page 144.

We pay corporate income taxes, customs duties, excise taxes, stamp duties, employment, environmental and many other business taxes in all jurisdictions in which we operate. We also collect and pay employee taxes and other indirect taxes such as value-added tax in these jurisdictions.

Total comprehensive income

Total comprehensive income increased by \$6,695 million to \$12,936 million in 2025. Other comprehensive income, net of tax, was \$2,703 million, an increase of \$3,503 million. This income was primarily driven by foreign exchange gains arising on consolidation of \$2,387 million (2024: losses of \$957 million).

Restructuring**Post Alexion Acquisition Group Review (PAAGR)**

In conjunction with the acquisition of Alexion in 2021, the enlarged Group initiated a comprehensive review, aimed at integrating systems, structure and processes, optimising the global footprint and prioritising resource allocations and investments. Except as referenced below, these activities are expected to be substantially complete by the end of 2026.

During 2023, the Group identified all remaining activities and finalised the scope of the programme. During 2025, the Group undertook an assessment of the planned activities within the PAAGR programme, this resulted in a decrease of \$0.4 billion in expected one-time restructuring costs, bringing the total expected costs to \$4.0 billion, of which approximately \$2.8 billion are cash costs and \$1.2 billion are non-cash costs, and capital investments of approximately \$2.2 billion.

The PAAGR programme includes the commencement of work on the planned upgrade of the Group's Enterprise Resource Planning (ERP) IT systems (Axial Project), which is expected to be substantially complete by the end of 2030, resulting in capital investments for software assets of \$1.3 billion and one-time restructuring cash costs of \$0.5 billion, over the full course of the project.

Run-rate pre-tax benefits, before reinvestment, are now expected to be approximately \$2.2 billion by the end of 2026. In line with established practice, restructuring costs will be excluded from our Core (non-GAAP) financial measures.

In 2025, the Group has recorded restructuring charges of approximately \$0.2 billion in relation to the PAAGR (2024: \$1.1 billion), bringing the cumulative charges to date under this programme to \$3.4 billion.

As at 31 December 2025, the PAAGR has realised annual run-rate pre-tax benefits, before reinvestment, of \$1.9 billion.

Other programmes

Legacy programmes include the centralisation of our global R&D footprint. Net costs for legacy programmes in 2025 were \$6 million (2024: \$39 million).

The aggregate restructuring charge incurred in 2025 across all our restructuring programmes was \$237 million (2024: \$1,154 million). Final estimates for programme costs, benefits and headcount impact in all functions are subject to completion of the requisite consultation in the various areas.

Our priority, as we undertake these restructuring initiatives, is to work with our affected employees on the proposed changes, acting in accordance with relevant local consultation requirements and employment law.



For more information regarding the AstraZeneca tax policy, see our website, www.astrazeneca.com.

Financial Review *continued*

Cash flow and liquidity – for the year ended 31 December 2025

Net cash generated from operating activities was \$14,575 million (2024: \$11,861 million). This primarily reflects an underlying improvement in business performance.

Net investment cash outflows were \$7,225 million (2024: \$8,353 million).

Investment cash outflows for 2025 include:

- Payments of contingent consideration from business combinations of \$1,164 million (2024: \$1,008 million), including \$1,054 million paid to Bristol-Myers Squibb Company (BMS) in respect of a share of the diabetes alliance.
- \$3,095 million (2024: \$2,662 million) for the purchase of intangible assets, including \$388 million of sales-related milestones and \$300 million of regulatory milestones paid to Daiichi Sankyo in respect of *Enhertu*, \$501 million relating to the CinCor asset acquisition and \$425 million for the EsoBiotec asset acquisition.
- \$66 million (2024: \$2,771 million) for the acquisition of subsidiaries, net of cash acquired.

Investment cash inflows include:

- \$136 million (2024: \$123 million) from the sale of intangible assets.

Net cash distributions to shareholders were \$5,452 million (2024: \$4,672 million), including proceeds from the issue of share capital of \$40 million (2024: \$38 million) less dividends paid of \$4,971 million (2024: \$4,629 million) and own shares purchased by the Employee Benefit Trust of \$521 million (2024: \$81 million).

Summary cash flows

	2025 \$m	2024 \$m
Net debt brought forward at 1 January	(24,570)	(22,510)
Profit before tax	12,402	8,691
Sum of changes in interest, depreciation, amortisation, impairment and share of after tax losses on joint ventures and associates	7,074	8,000
Decrease in working capital and short-term provisions	(1,137)	(893)
Tax paid	(2,845)	(2,750)
Interest paid	(1,316)	(1,313)
Gains on disposal of intangible assets	(168)	(64)
Fair value movements on contingent consideration arising from business combinations	(97)	311
Non-cash and other movements	662	(121)
Net cash available from operating activities	14,575	11,861
Purchase of intangibles, net of disposals	(2,959)	(2,539)
Acquisition of subsidiaries, net of cash acquired	(66)	(2,771)
Share-based payments attributable to business combinations	–	(3)
Payment of contingent consideration from business combinations	(1,164)	(1,008)
Other capital expenditure (net)	(3,036)	(2,032)
Investments	(7,225)	(8,353)
Dividends	(4,971)	(4,629)
Own shares purchased by Employee Benefit Trust	(521)	(81)
Proceeds from the issue of share capital	40	38
Distributions	(5,452)	(4,672)
Repayment of obligations under leases	(372)	(316)
Payment of Acerta Pharma share purchase liability	–	(833)
Other movements	(330)	253
Net debt carried forward at 31 December	(23,374)	(24,570)

Bonds issued in 2025 and 2024

	Repayment dates	Face value of bond \$m	Net book value of bond at 31 December 2025 \$m
Bonds issued in 2024:			
4.8% USD bond	2027	1,250	1,248
4.85% USD bond	2029	1,250	1,247
3.121% EUR bond	2030	704	764
4.9% USD bond	2031	1,000	995
3.278% EUR bond	2033	813	870
5.0% USD bond	2034	1,500	1,490
Total 2024		6,517	6,614

Net debt reconciliation

	2025 \$m	2024 \$m
Cash and cash equivalents	5,711	5,488
Other investments ¹	30	166
Cash and investments	5,741	5,654
Overdraft and short-term borrowings	(644)	(330)
Lease liabilities	(1,803)	(1,452)
Current instalments of loans and borrowings	(2,460)	(2,007)
Loans due after one year	(24,715)	(26,506)
Loans and borrowings	(29,622)	(30,295)
Net derivative financial instruments	507	71
Net debt²	(23,374)	(24,570)

¹ Other investments exclude non-current investments, which are included within the balance of \$2,223 million (2024: \$1,632 million) in the Consolidated Statement of Financial Position on page 126.

² The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities', which excludes the amounts for cash and overdrafts, other investments and non-financing derivatives shown above.

Payments due by period

	Less than 1 year \$m	1-3 years \$m	3-5 years \$m	Over 5 years \$m	Total 2025 \$m	Total 2024 \$m
Bank loans and other borrowings ¹	4,164	7,881	7,266	16,906	36,217	38,184
Lease liabilities	382	657	334	430	1,803	1,452
Contracted capital expenditure	1,420	276	29	2	1,727	1,575
Total	5,966	8,814	7,629	17,338	39,747	41,211

¹ Bank loans and other borrowings include interest charges payable in the period, as detailed in Note 28 to the Financial Statements from page 171.

Bonds

No bonds were issued in 2025.

In November 2025, AstraZeneca repaid a 3.375% fixed rate bond of \$2,000 million.

In March 2024, AstraZeneca issued \$5,000 million of USD bonds and, in August 2024, AstraZeneca issued \$1,517 million of EUR bonds with a notional face value of €1,400 million.

In 2024, AstraZeneca repaid floating rate bank loans of \$2,000 million, which matured in July 2024 and a \$1,600 million USD bond, which matured in May 2024. \$1,026 million was also repaid in respect of a EUR bond, with a notional face value of €900 million, which was held in a cash flow hedge and matured in May 2024.

Net debt

Net debt at 31 December 2025 was \$23,374 million (2024: \$24,570 million). At 31 December 2025, gross debt (interest-bearing loans and borrowings) was \$29,622 million (2024: \$30,295 million). Of the gross debt outstanding, \$3,486 million is due within one year (2024: \$2,676 million).

At 31 December 2025, Cash and cash equivalents and Other investments totalled \$5,741 million (2024: \$5,654 million).

The Group maintains committed bank facilities to manage liquidity. At 31 December 2025, the Group held \$4,875 million of such facilities with a maturity date of April 2030. In January 2026, the maturity of these facilities was extended by one year to April 2031. These facilities contain no covenants and were undrawn at 31 December 2025. The Group regularly monitors the credit standing of the banks providing the facilities and currently does not anticipate any issue with drawing on the committed facilities should this be necessary. Advances under these facilities currently bear an interest rate per annum based on SOFR (Secured Overnight Financing Rate) plus a margin.

Financial Review *continued*

Financial position – 31 December 2025

All data in this section are on a Reported basis.

Acquisitions

In assessing whether an acquired set of assets and activities is a business or an asset, management will first elect whether to apply an optional concentration test to simplify the assessment. Where the concentration test is applied, the acquisition will be treated as the acquisition of an asset if substantially all of the fair value of the gross assets acquired (excluding cash and cash equivalents, deferred tax assets and related goodwill) is concentrated in a single asset or group of similar identifiable assets. Where the concentration test is not applied, or is not met, a further assessment of whether the acquired set of assets and activities is a business will be performed.

Acquisitions treated as business combinations

FibroGen China

In August 2025, AstraZeneca completed the acquisition of FibroGen International (Hong Kong) Limited (FibroGen China) and its subsidiaries. The purchase price allocation review has been completed. The total consideration fair value was \$221 million. Upon closing, in August 2025, AstraZeneca obtained all rights to roxadustat in China, including manufacturing in China.

Fusion

In June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc. (Fusion), a clinical-stage biopharmaceutical company developing next-generation radioconjugates. The purchase price allocation review has been completed. The total consideration fair value of \$2,195 million includes cash consideration of \$2,051 million and future regulatory milestone-based consideration of \$144 million. Intangible assets of \$1,326 million and goodwill of \$947 million were recognised in the acquisition balance sheet, as well as a net deferred tax liability of \$246 million. AstraZeneca acquired the cash and cash equivalents on Fusion's balance sheet, which totalled \$30 million at the close of the transaction. Immediately prior to the acquisition, AstraZeneca held an approximate 1% shareholding in Fusion with a fair value of \$24 million. Fusion's results have been consolidated into the Group's results from 4 June 2024.

In December 2024, the intangible asset relating to the product in development, FPI-2059, was fully impaired by \$165 million due to portfolio prioritisation decisions. Development of FPI-2265 and AZD2068 are still ongoing and continue to be a priority.

Gracell

In February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases. The purchase price allocation review has been completed. The total consideration fair value of \$1,037 million includes cash consideration of \$983 million and future regulatory milestone-based consideration of \$54 million. Intangible assets of \$1,038 million and goodwill of \$136 million were recognised in the acquisition balance sheet, as well as a net deferred tax liability of \$260 million. AstraZeneca acquired the cash and cash equivalents on Gracell's balance sheet, which totalled \$209 million at the close of the transaction. Gracell's results have been consolidated into the Group's results from 22 February 2024.

The acquisitions have been accounted for as business combinations using the acquisition method of accounting in accordance with IFRS 3 'Business Combinations'.

Acquisitions treated as asset acquisitions

SixPeaks Bio

In October 2025, AstraZeneca, by exercise of an option, completed the acquisition of the remaining share capital of SixPeaks Bio AG (SixPeaks), following an initial investment of \$15 million made in 2024. \$170 million was paid on closing, \$30 million to be paid after two years and up to a further \$100 million is payable on achievement of regulatory milestones. SixPeaks is investigating potential therapies for weight-management with the aim of preserving lean muscle mass.

EsoBiotec

In May 2025, AstraZeneca completed the acquisition of EsoBiotec SA (EsoBiotec), a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, with potential use in oncology and immune-mediated diseases. AstraZeneca has acquired all outstanding equity of EsoBiotec for a total consideration of up to \$978 million, on a cash and debt-free basis. This includes an initial payment of \$425 million, and up to \$575 million in contingent consideration based on development and regulatory milestones.

Amolyt

In July 2024, AstraZeneca completed the acquisition of Amolyt Pharma SAS (Amolyt), a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. AstraZeneca acquired all outstanding equity of Amolyt with consideration of \$857 million, principally relating to \$800 million of intangible assets and \$98 million of cash and cash equivalents. Contingent consideration of up to \$250 million could be paid on achievement of a regulatory milestone; this potential liability would be recorded when the relevant recognition event for a regulatory milestone is achieved.

Icosavax

In February 2024, AstraZeneca completed the acquisition of Icosavax, Inc. (Icosavax), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle platform. Consideration totalled \$841 million, principally relating to \$639 million of intangible assets, \$141 million of cash and cash equivalents and \$51 million of marketable securities. Contingent consideration of up to \$300 million could be paid on achievement of regulatory and sales milestones; these potential liabilities would be recorded when the relevant recognition event for a regulatory or sales milestone is achieved.

Commitments and contingencies

We have commitments and contingencies which are accounted for in line with Group Accounting Policies and are described in Note 30 to the Financial Statements from page 180.

We also have taxation contingencies. These are described in Note 30 to the Financial Statements from page 189.

Off balance sheet transactions and commitments

We have no off balance sheet arrangements and our derivative activities are non-speculative. The table on page 61 sets out our minimum contractual obligations at the year end.

Research and development collaboration payments

Details of future potential R&D collaboration payments are also included in Note 30 to the Financial Statements from page 180. As detailed in Note 30, payments to our partners may not become payable due to the inherent uncertainty in achieving the development and revenue milestones linked to the future payments. We may enter into further collaboration projects in the future that may include milestone payments and, as certain milestone payments fail to crystallise due to, for example, failure to obtain regulatory approval, unfavourable

For full details of acquisitions, see Note 27 to the Financial Statements from page 170.

For further information, see page 37 of the Business Review.

data from key studies, adverse reactions to the product candidate or indications of other safety concerns, they may be replaced by potential payments under new collaborations.

Investments, divestments and capital expenditure

We have completed more than 45 major or strategically important business development transactions over the past three years. Our most significant business development transactions include:

CSPC Pharmaceutical Group

In October 2024, AstraZeneca entered into an exclusive licence agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early-stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidaemia. This further strengthens the Group's cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular (CV) disease. Under the terms of the agreement, AstraZeneca will receive access to CSPC's preclinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid-lowering therapy with potential in a range of CV disease indications, alone or in combination, including with AstraZeneca's oral small molecule PCSK9 inhibitor, AZD0780. CSPC received an upfront payment of \$100 million and is eligible to receive up to \$1,920 million for further development, regulatory and commercialisation milestones, plus tiered royalties.

In June 2025, AstraZeneca entered a strategic research collaboration with CSPC to discover and develop preclinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a preclinical small molecule oral therapy for immunological diseases. CSPC's research will utilise its AI-driven, dual-engine efficient drug discovery platform. CSPC received an upfront payment of \$110 million, and is also eligible to receive up to \$1,620 million in potential development milestone payments and up to \$3,600 million in sales milestone payments, plus potential single-digit royalties based on annual net sales of the products. AstraZeneca will have rights to exercise options for exclusive licences to develop and commercialise worldwide candidates identified under this agreement.

US investment plans

For more information regarding the expansion of our US manufacturing footprint in Virginia and Maryland, see Operations on page 33.

Agreement with US Government

In October 2025, AstraZeneca announced an agreement with the US administration to lower the cost of prescription medicines for American patients, see Our regions on page 32 for further information.

Eccogene

In November 2023, AstraZeneca and Eccogene entered into an exclusive licence agreement for AZD5004, an investigational oral once-daily GLP-1RA for the treatment of obesity, type-2 diabetes and other cardiometabolic conditions. Preliminary results from the Phase I trial have shown a differentiating clinical profile for AZD5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo. Under the terms of the agreement, Eccogene received an initial upfront payment of \$185 million and is eligible to receive up to an additional \$1.8 billion in future clinical, regulatory, and commercial milestones and tiered royalties. AstraZeneca is granted exclusive global rights for the development and commercialisation of AZD5004 for any indication in all territories except China, where Eccogene has the right to co-develop and co-commercialise alongside AstraZeneca.

We determine these business development transactions to be significant using a range of factors. We look at the specific circumstances of the individual arrangement and apply several quantitative and qualitative criteria. As we consider business development transactions to be an extension of our R&D strategy, the expected total value of development payments under the transaction and its proportion of our annual R&D spend, both of which are proxies for overall R&D effort and cost, are important elements of the determination of the significance. Other quantitative criteria we apply include, without limitation, expected levels of future sales, the possible value of milestone payments and the resources used for commercialisation activities (for example, the number of staff). Qualitative factors we consider include, without limitation, new market developments, new territories, new areas of research and strategic implications.

Capitalisation and shareholder return

Capitalisation

The total number of shares in issue at 31 December 2025 was 1,551 million (2024: 1,551 million). Shareholders' equity increased by \$7,881 million to \$48,667 million at the year end. Non-controlling interests were \$52million (2024: \$85 million).

Dividend and share repurchases

The Board has recommended a second interim dividend of \$2.17 (159.5 pence, 19.49 SEK) to be paid on 23 March 2026. This brings the full-year dividend to \$3.20 (236.2 pence, 29.30 SEK). Against Reported EPS, the Group had a dividend cover ratio of 2.06:1 in 2025 (2024: 1.46:1). Against Core EPS, the Group had a dividend cover ratio of 2.86:1 in 2025 (2024: 2.65:1). This dividend is consistent with the progressive dividend policy, by which, the Board intends to maintain or grow the dividend each year.

The Board regularly reviews its distribution policy and its overall financial strategy to continue to strike a balance between the interests of the business, our financial creditors and our shareholders. Having regard for business investment, funding the progressive dividend policy and meeting our debt service obligations, the Board currently believes it is appropriate to continue the suspension of the share repurchase programme which was announced in 2012.

The Board reviews the level of distributable reserves of the Parent Company annually and aims to maintain distributable reserves that provide adequate cover for dividend payments. At 31 December 2025, all of the Profit and loss account reserve of \$14,461 million (2024: overwhelming majority of the Profit and loss account reserve of \$13,495 million) was available for distribution, subject to filing these Financial Statements with Companies House. When making a distribution to shareholders, the Directors determine profits available for distribution by reference to guidance on realised and distributable profits under the Companies Act 2006 issued by the Institute of Chartered Accountants in England and Wales and the Institute of Chartered Accountants of Scotland in April 2017.

The profits of the Parent Company have been received in the form of receivables due from subsidiaries. The availability of distributable reserves in the Parent Company is dependent on those receivables meeting the definition of qualifying consideration within the guidance, and in particular on the ability of subsidiaries to settle those receivables within a reasonable period of time. The Directors consider that, based on the nature of these receivables and the available cash resources of the Group and other accessible sources of funds, at 31 December 2025, the overwhelming majority (2024: the overwhelming majority) of the Company's profit and loss reserves were available for distribution.

For more information regarding Dividends, see Note 25 to the Financial Statements on page 169.

Financial Review *continued*

Future prospects

As outlined earlier in this Annual Report, our strategic priorities support delivery of our Growth Through Innovation strategy, detailed on page 10.

Full year 2026: additional commentary

Total Revenue is expected to increase by a mid-to-high single-digit percentage. Core EPS is expected to increase by a low double-digit percentage.

The Core tax rate is expected to be between 18-22%.

The Group is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statement regarding forward-looking statements on page 228.

Currency impact

If foreign exchange rates for February 2026 to December 2026 were to remain at the average rates seen in January 2026, it is anticipated that 2026 Total Revenue for the year would benefit from a low single-digit percentage positive impact compared to performance at CER, and Core EPS growth would be broadly similar to the growth at CER.

This commentary represents management's current estimates and is subject to change. See the Cautionary statement regarding forward-looking statements on page 228.

Financial risk management

Financial risk management policies

Our risk management processes are described in the Risk Overview from page 47. These processes enable us to identify risks that can be partly or entirely mitigated through the use of insurance. We focus our insurance resources on the most critical areas, or where there is a legal requirement, and where we can get the best value for money through captive, structured and traditional insurance placements.

Treasury

The principal financial risks to which we are exposed are those arising from liquidity, interest rates, foreign currency and credit. We have a centralised treasury function to manage these risks in accordance with Board-approved policies. Note 28 to the Financial Statements from page 171 sets out the relevant policies and the way we manage these risks and our capital management objectives, as well as a sensitivity analysis of the Group's exposure to exchange rate and interest rate movements.

Strategic Report

The following sections make up the Strategic Report, which has been prepared in accordance with the requirements of the Companies Act 2006:

- AstraZeneca at a Glance
- Chair's Statement
- Chief Executive Officer's Review
- Healthcare in a Changing World
- Our Purpose, Values and Business Model
- Our Strategy and Key Performance Indicators
- Therapy Area Review
- Business Review
- Section 172(1) Statement
- Viability Statement
- Risk Overview
- Financial Review
- Sustainability Statement

and has been approved and signed on behalf of the Board.

M S Bowden

Company Secretary
10 February 2026

For more information, see Our Strategy and Key Performance Indicators from page 10.

Corporate Governance

Contents

Chair's Introduction	66
Corporate Governance Overview	67
Board of Directors	68
Senior Executive Team (SET)	70
Corporate Governance Report	71
Nomination and Governance Committee Report	79
Science Committee Report	81
Sustainability Committee Report	82
Audit Committee Report	83
Directors' Remuneration Report	90



Chair's Introduction



“The Board of Directors has a crucial role to play in promoting the long-term success of any company and I am grateful to my fellow Directors for the part they have played in AstraZeneca’s continued growth and many achievements.”

The Board

The Board is responsible for setting our strategy and policies, overseeing risk and corporate governance, and monitoring progress towards meeting our objectives and annual plans. In 2025, our decisions included pipeline-strengthening transactions, as well as approving the Group’s capital allocation, including capital expenditures. This included investments in new and expanded manufacturing facilities in Virginia and Maryland, US that form part of our planned \$50 billion investment in the US by 2030.

Harmonised listing

The strength, diversity and breadth of experience of our Board was routinely demonstrated during our deliberations, none more so than in the discussion of our harmonised listing structure across the London, New York and Stockholm Stock Exchanges.

Factors we considered included the strategic rationale for the harmonisation and its alignment with our long-term strategy for sustainable growth, as well as the benefits of a global listing to widen the pool of investors in AstraZeneca, especially US domestic institutional and retail investors. We also wanted to ensure that we have the flexibility to access the broadest available pool of capital, including in the US. Finally, it was important to us that investors could trade AstraZeneca Ordinary Shares across the three exchanges, while the Company remains UK-listed, headquartered, and tax resident.

Board Committees

A sound governance and committee structure underpins the Board’s effectiveness, and I am grateful to the Chairs of the Board Committees for the important contribution they make to that effectiveness and the additional responsibilities they bear.

The Audit Committee has an important role to play in monitoring the integrity of financial and sustainability reporting, examining the effectiveness of internal controls, risk management and compliance. Key activities in 2025 included consideration as well as in-depth reviews related to our key risks, which involved close monitoring of the ongoing investigations by Chinese authorities previously reported. The Committee also paid particular attention to tariffs and pricing negotiations with the US Government, and the potential impact on the Group.

During the year, the Audit and Sustainability Committees worked together on developments in the reporting and regulatory environment in relation to sustainability-related disclosures, which are reflected in the content of this year’s Annual Report. The Sustainability Committee also continued its important work on the implementation and communication of our sustainability strategy.

The Science Committee works on assuring the quality of our science with a particular focus during the year on our strategic science capabilities, such as cell therapy and precision medicines.

The Remuneration Committee focuses on ensuring that our reward framework supports AstraZeneca’s long-term success and worked closely with other Board Committees to set transparent and stretching performance targets that are aligned with our strategy and in the best interest of our shareholders. Diana Layfield, who has been a Board member since 2020, joined the Remuneration Committee in May.

Non-Executive Directors

In addition to welcoming Rene Haas and Birgit Conix to the Board at the start of 2025, Karen Knudsen joined as a Non-Executive Director at the end of the AGM in April.

Karen is a globally-recognised cancer scientist with broad executive experience in oncology, and is well-positioned in respect of the Board’s work. Karen’s deep knowledge of the US healthcare industry and medical academic environment also makes her a great fit for AstraZeneca. At the same time as joining the Board, Karen also became a member of the Science and Sustainability Committees, reflecting the broad contribution she can make to AstraZeneca’s success.

At the same Meeting, we said goodbye to Deborah DiSanzo and Andreas Rummelt, who stood down as Non-Executive Directors. On behalf of the whole Board, I would like to thank them both for the significant contributions they made to our work, as well as the insights and experience they brought to bear as Committee members.

Shareholders and other stakeholders

One of the Board’s important activities is to engage with shareholders and consider the interests of other stakeholders. I find this to be a particularly valuable activity which, in 2025, included engagements and advocating for AstraZeneca at the World Economic Forum in Davos, Expo 2025 in Osaka and Global Health Week in Abu Dhabi. I am particularly energised by the passion, dedication and creativity that is evident whenever I meet AstraZeneca employees.

The Executive Directors and I also maintain regular dialogue with investors to communicate our strategy and our governance principles which is why, once again, I look forward to chairing our 2025 digitally-enabled AGM in April and engaging with as many of you as possible.

Michel Demaré
Chair

Corporate Governance Overview

The Directors are collectively responsible for the success of the Group. The Board maintains and periodically reviews a list of matters that can only be approved by the Board. Matters that have not been expressly reserved to the Board in this way are delegated to the CEO or one of the Board's five Committees. The diagram below illustrates this governance structure.

The Board's responsibilities include setting our strategy and policies, overseeing risk and corporate governance, and monitoring progress towards meeting our objectives and annual plans. It is accountable to our shareholders for the proper conduct of the business and our long-term success, and seeks to represent the interests of all stakeholders.

The CEO, CFO and the SET take the lead in developing our strategy; proposals are reviewed and constructively challenged by the Board, before the strategy is approved.

Governance structure

The Board has delegated some of its powers to the CEO and operates with the assistance of five Committees:



Attendance in 2025

Board Committee membership and meeting attendance in 2025

● Board/Committee Chair

Director	Appointment date ¹	Board ²	Audit Committee	Remuneration Committee	Nomination and Governance Committee	Science Committee	Sustainability Committee
Non-Executive Chair and Executive Directors							
Michel Demaré	01/09/2019	● 9/9		6/6	● 4/4		
Pascal Soriot	01/10/2012	9/9					
Aradhana Sarin	01/08/2021	9/9					
Non-Executive Directors							
Euan Ashley	01/10/2020	9/9			4/4	● 7/7	
Philip Broadley	27/04/2017	8/9	● 6/6	6/6	4/4		
Birgit Conix	01/02/2025	7/8	4/4				
Rene Haas	01/01/2025	8/8					
Karen Knudsen	11/04/2025	6/6				4/4	3/3
Diana Layfield	01/11/2020	9/9		4/4		6/7	
Anna Manz	01/09/2023	9/9	6/6				
Sheri McCoy	01/10/2017	8/9	6/6	● 6/6	4/4		3/3
Tony Mok	01/01/2019	9/9				7/7	
Nazneen Rahman	01/06/2017	9/9		6/6	4/4	7/7	● 3/3
Marcus Wallenberg	05/04/1999	8/9				4/7	2/3
Deborah DiSanzo – retired on 11 April 2025	01/12/2017	3/3	2/2				
Andreas Rummelt – retired on 11 April 2025	01/08/2021	3/3					

¹ Date of first appointment or election to the Board.

² Five Board meetings in 2025 were held by video conference and four were held in person in Cambridge and London, UK; Gaithersburg, US; and Abu Dhabi, UAE.


Board of Directors as at 10 February 2026

Board composition as at 10 February 2026

Gender split of Directors



Directors' nationalities



Length of tenure of Non-Executive Directors

0-3 years

4

Birgit Conix
Rene Haas
Karen Knudsen
Anna Manz

3-6 years

2

Euan Ashley
Diana Layfield

6 years plus

6

Philip Broadley
Michel Demaré
Sheri McCoy
Tony Mok
Nazneen Rahman
Marcus Wallenberg

Committee membership key

- Committee Chair
- A Audit
- R Remuneration
- NG Nomination and Governance
- Sc Science
- Su Sustainability

Deborah DiSanzo ● A
Formerly Non-Executive Director of the Board
(Retired in April 2025)

Andreas Rummelt ● Su
Formerly Non-Executive Director of the Board
(Retired in April 2025)



Michel Demaré ● NG ● R

Non-Executive Chair of the Board
Skills and experience: Michel was previously Vice-Chairman of UBS Group AG (2010-2019), Chairman of Syngenta and Syngenta Foundation for Sustainable Agriculture (2013-2017), Chairman of SwissHoldings (2013-2015) and Chairman of IMD Business School (2020-2025). Between 2005 and 2013, Michel was CFO of ABB Ltd and interim CEO during 2008. He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005. Prior to that, he spent 18 years at The Dow Chemical Company, serving as CFO of Dow's Global Polyolefins and Elastomers division between 1997 and 2002.

Other appointments: Michel is a Non-Executive Director of Vodafone Group plc and Louis Dreyfus Int'l Holding BV.



Pascal Soriot

Executive Director and CEO
Skills and experience: Pascal brings a passion for science and medicine, significant experience in established and emerging markets, strength of strategic thinking and execution, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as COO of Roche's pharmaceuticals division and, prior to that, as CEO of Genentech. Pascal has worked in senior management roles in several major companies in Australia, New Zealand, Japan, the US and Switzerland before joining AstraZeneca in the UK. He is a Doctor of Veterinary Medicine and holds an MBA from HEC Paris. In 2022, Pascal received a knighthood for services to life sciences and leadership in the global response to the COVID-19 pandemic.

Other appointments: Pascal is on the Board of Agilent Technologies Inc. and Sustainable Markets Initiative Limited.



Aradhana Sarin

Executive Director and CFO
Skills and experience: Before joining AstraZeneca, Aradhana was CFO for Alexion, responsible for driving strategic growth, financial performance and business development. She has operational experience in biopharma, plus more than 20 years of professional experience at global financial institutions and extensive knowledge of global healthcare systems. This includes tenures at Citi Global Banking, UBS, and JP Morgan. Aradhana trained as a medical doctor in India and spent two years practising in both India and Africa. She completed her medical training at the University of Delhi and received her MBA from Stanford Business School.

Other appointments: Aradhana is on the Board of Governors of the American Red Cross and is an Independent Director and Audit Committee member of Anheuser-Busch InBev.



Philip Broadley ● A ● NG ● R

Senior independent Non-Executive Director
Skills and experience: Philip was previously Group Finance Director of Prudential and Old Mutual and served as a Non-Executive Director of Legal & General Group. He has served as Chairman of the 100 Group of Finance Directors and as a member of the Takeover Panel. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Philip graduated in Philosophy, Politics and Economics from St. Edmund Hall, Oxford University where he is a St Edmund Fellow, and holds an MSc in Behavioural Science from LSE.

Other appointments: Philip is the Non-Executive Chair of Lancashire Holdings Limited.



Euan Ashley ● Sc ● NG

Non-Executive Director
Skills and experience: Euan studied physiology and medicine at Glasgow University, trained at Oxford University Hospitals NHS Trust, and gained a DPhil in cardiovascular cellular biology and molecular genetics at the University of Oxford. In 2002, Euan moved to Stanford University, where his research focuses on mechanisms of cardiovascular health and disease. His laboratory leverages AI, digital health tools, and biotechnology partnerships to advance clinical research. Euan has received honours from the White House for contributions to personalised medicine and the American Heart Association's Medal of Honor for precision medicine.

Other appointments: Euan is the Arthur L. Bloomfield Professor of Medicine, Genetics and Biomedical Data Science, Chair of the Department of Medicine at Stanford University, and a member of the Board of Directors at DexCom, Inc.



Birgit Conix ● A

Non-Executive Director
Skills and experience: Birgit served Sonova as Group CFO and a Management Board member from 2021 to 2025. Previously, she was Group CFO and Executive Board member at TUI from 2018 to 2021. Before TUI, she served as Group CFO of Telenet Group from 2013 to 2018. Prior to that, she held senior positions at Johnson & Johnson, Heineken, Tenneco and Reed Elsevier. Birgit holds an MBA from the Booth School of Business, University of Chicago, and a Master of Science in Business Economics from Tilburg University.

Other appointments: Birgit is a member of ASML's Supervisory Board, where she is Chair of the ESG Committee and a member of the Audit Committee. She also serves on Ricola's Board where she is Chair of the Audit Committee.



Rene Haas

Non-Executive Director

Skills and experience: Rene has been CEO of Arm and a Board member since February 2022, leading Arm's successful IPO in September 2023. He has extensive experience in technology, computing and AI from leadership roles in the semiconductor industry. Rene joined Arm in 2013 and previously served as President of Arm's IP Product Groups. Prior to Arm, Rene held roles at NVIDIA, Scintera Networks and Tensilica. Based in Silicon Valley, he frequently engages with technology hubs in the UK, Europe and Asia. Rene earned a Bachelor of Science in Electrical and Electronics Engineering from Clarkson University and completed the Stanford University Graduate School of Business Executive Program.

Other appointments: Rene is CEO of Arm and serves on the Boards of Arm China and of SoftBank Group (Arm's majority owner).



Karen Knudsen Sc Su

Non-Executive Director

Skills and experience: Karen served as Hilary Koprowski Endowed Professor and Chair of Cancer Biology at Thomas Jefferson University, Enterprise Director of the Sidney Kimmel Comprehensive Cancer Center and EVP of Oncology Services at Jefferson Health. Most recently, she served as CEO of the American Cancer Society. Previous leadership roles include serving on the NCI Board of Scientific Advisors and on the Board of the American Association for Cancer Research.

Other appointments: Karen is CEO of the Parker Institute for Cancer Immunotherapy, Professor Emerita of Thomas Jefferson University and the Sidney Kimmel Comprehensive Cancer Center, Board Member of 3T Biosciences, Independent Director of Exai Bio, Board Member of Research America and of Paradigm Health, and Board Advisor for ArteraAI.



Diana Layfield R Sc

Non-Executive Director

Skills and experience: Diana has broad global business experience across technology, life sciences and financial services. She has held senior leadership roles at Google, Standard Chartered Bank, as the CEO of a start-up technology company, and in Healthcare and Life Sciences at McKinsey & Co. Previously at Google, Diana was General Manager, Search International & Growth (including Product and Engineering) and President, EMEA Partnerships and Vice-President, 'Next Billion Users'. Until December 2020, Diana was a Non-Executive Director of Aggreko plc. She has a BA from Oxford University and an MA in International Economics and Public Administration from Harvard University.

Other appointments: Diana is the CEO of Monzo Group, Chair of British International Investment plc, and a Council Member of the London School of Hygiene & Tropical Medicine.



Anna Manz A

Non-Executive Director

Skills and experience: Anna was CFO and a member of the Board of Directors of London Stock Exchange Group plc until 2024. From 2016 to 2020, she was an Executive Director and the CFO of Johnson Matthey Plc and, before that, spent 17 years at Diageo plc in a number of senior finance and strategy roles. She brings extensive expertise in accounting, corporate finance and M&A, as well as experience of business diversification, transformation and strategy. Anna was previously a Non-Executive Director of ITV plc and served on its Audit Committee and Remuneration Committee during most of that period.

Other appointments: Anna is CFO of Nestlé S.A. and a member of Nestlé's Executive Board.



Sheri McCoy R A NG Su

Non-Executive Director

Skills and experience: Until February 2018, Sheri was CEO and a Director of Avon Products, Inc. and, prior to that, had a 30-year career at Johnson & Johnson (J&J), latterly serving as Vice-Chairman of the Executive Committee, responsible for the Pharmaceuticals and Consumer business segments. Sheri joined J&J as an R&D scientist and subsequently managed businesses in every major product sector. She holds a BSc in Textile Chemistry from the University of Massachusetts Dartmouth, an MSc in Chemical Engineering from Princeton University and an MBA from Rutgers University.

Other appointments: Sheri serves on the Boards of Stryker, Kimberly-Clark, Galderma and Sail Biomedicines. She is also an industrial adviser for EQT, and in connection serves as Chair of Parexel and Chair of Dechra.



Tony Mok Sc

Non-Executive Director

Skills and experience: Tony is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His work includes multiple aspects of lung cancer research, including biomarker and molecular targeted therapy in lung cancer. Tony is the Past President of the International Association for the Study of Lung Cancer and a past Board member of the American Society of Clinical Oncology. He has achieved numerous awards including the European Society for Medical Oncology (ESMO) Lifetime Achievement Award, Giant of Cancer Care, and the Bronze Bauhinia Star.

Other appointments: Tony is Non-Executive Director of HUTCHMED (China) Limited, member of the Scientific Advisory Board of Prenetics Global Limited and serves on the Board of Insighta.



Nazneen Rahman Su NG R Sc

Non-Executive Director

Skills and experience: Nazneen has significant experience in rare disease and cancer genomics and sustainable healthcare. She qualified in medicine from Oxford University, is an accredited specialist in medical genetics and has a PhD in molecular genetics. Nazneen was Professor of Genetics at the Institute of Cancer Research, Head of Cancer Genetics at the Royal Marsden NHS Foundation Trust, and founder and Director of the TGLclinical Genetic Testing Laboratory until 2018. In 2020, Nazneen founded YewMaker to build science-based sustainable healthcare solutions. Nazneen has a strong commitment to open science and has garnered numerous awards, including a CBE in recognition of her contribution to medical sciences.

Other appointments: Nazneen is CEO of YewMaker and Director of the Sustainable Medicines Partnership.



Marcus Wallenberg Sc Su

Non-Executive Director

Skills and experience: Marcus has international business experience across various industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999.

Other appointments: Marcus is Chair of Skandinaviska Enskilda Banken AB, Saab AB, Wallenberg Investments AB and FAM AB. He is Vice-Chair of Investor AB and Vice-Chair of EQT AB. Marcus is also Chair of the Royal Swedish Academy of Engineering Sciences and a Board member of the Knut and Alice Wallenberg Foundation.

Senior Executive Team (SET) at 10 February 2026

The SET is the body through which the CEO exercises the authority delegated to him by the Board. The CEO leads the SET and has executive responsibility for the management, development and performance of the business.

SET members who sit on the Board:

- Pascal Soriot, CEO
- Aradhana Sarin, CFO



Sharon Barr
Executive Vice-President,
BioPharmaceuticals R&D

Sharon was appointed as Executive Vice-President, BioPharmaceuticals R&D in August 2023. She is responsible for discovery through to late-stage development across CVRM and R&I. Previously, Sharon was SVP, Head of Research and Product Development of Alexion. Sharon undertook a PhD in molecular biology from NYU and a postdoctoral fellowship at Stanford University.



Pam Cheng
Executive Vice-President,
Global Operations, IT & Chief
Sustainability Officer

Pam was appointed Executive Vice-President, Operations & IT in June 2015 and took on the sustainability strategy in January 2023. Prior to AstraZeneca, she worked for Merck/MSD, Universal Oil Products, Union Carbide and GAF Chemicals. She holds Bachelor's and Master's degrees in chemical engineering from Stevens Institute of Technology and an MBA from Pace University.



Ruud Dobber
Executive Vice-President,
BioPharmaceuticals Business Unit

Ruud is responsible for the disease areas of CVRM, R&I and V&I. Ruud joined AstraZeneca in 1997 and held various executive roles externally before this. Ruud was previously a research scientist in immunology and ageing, holding a PhD in Immunology from the University of Leiden, the Netherlands.



Marc Dunoyer
CEO, Alexion and Chief Strategy
Officer, AstraZeneca

Marc served as AstraZeneca's Chief Financial Officer until 2021. Previously, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman of GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University.



David Fredrickson
Executive Vice-President, Oncology
Haematology Business Unit

Dave is responsible for driving growth and maximising commercial performance of the AstraZeneca global Oncology and Haematology portfolio. Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions. Dave is a graduate of Georgetown University in Washington DC.



Susan Galbraith
Executive Vice-President,
Oncology Haematology R&D

Susan has global accountability for Oncology and Haematology R&D from discovery through to late-stage development. Susan joined AstraZeneca in 2010, having previously worked at Bristol-Myers Squibb. She graduated in medicine from Cambridge University, has a PhD from the University of London and qualified as a Clinical Oncologist in 2001.



Jeff Pott
Chief Human Resources Officer,
Chief Compliance Officer and
General Counsel

Jeff is responsible for all aspects of AstraZeneca's People strategy and leads our HR, Compliance, Legal and IP functions. Jeff joined in 1995, before which he specialised in pharmaceutical product liability and antitrust litigation. He holds a Bachelor's degree from Wheaton College and a Juris Doctor Degree from Villanova University.



Iskra Reic
Executive Vice-President,
International

Iskra is responsible for overall strategy and driving sustainable growth across the International region, which includes China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia and New Zealand. Iskra has a PhD in Strategy and Leadership and an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia.

Further information on the SET members is available on our website, www.astrazeneca.com.

See Board of Directors biographies from page 68.

Corporate Governance Report | Compliance with the UK Corporate Governance Code

Statement of compliance

Our statement of compliance below describes how we applied the principles in the 2024 UK Corporate Governance Code (the Code) for the year ended 31 December 2025. Throughout the accounting period, we have complied with all the provisions of the Code. A copy of the Code can be found on the Financial Reporting Council's (FRC) website, www.frc.org.uk.

Additional information for Swedish shareholders

The Company is incorporated under the laws of England and Wales and its shares are listed on the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange (NYSE). In accordance with the Company's listing on the London Stock Exchange, it applies the principles set out in the Code. As a result of its listing on Nasdaq Stockholm and in accordance with Swedish regulations, the Company is required to disclose the material ways in which its corporate governance practices differ from those applied by Swedish companies following the Swedish Corporate Governance Code (the Swedish Code).

A summary of the material ways in which the corporate governance practices applied by the Company differ from the principles of the Swedish Code, and a general description of the main differences in minority shareholders' rights between the Company's place of domicile (the UK) and Sweden, are available on our website, www.astrazeneca.com/investor-relations/corporate-governance.html.

1. Board leadership and Company purpose

A. Role of the Board and resources and control

The Board's role is to promote the long-term sustainable success of the Company. The Directors' diverse range of skills, experience and industry knowledge, and ability to exercise independent and objective judgement, help the Board to operate effectively in its oversight of delivery of the Group's strategy, generation of shareholder value and contributions to wider society.

The Board's effective operation is underpinned by a sound governance structure, described on page 67. Through a programme of regular Board and Board Committee meetings, Directors receive information on AstraZeneca's financial performance, the R&D pipeline and critical business issues. The Board is accountable to our shareholders for the proper conduct of the business and our long-term success, and seeks to represent the interests of all stakeholders.

The Board ensures that the necessary resources, policies and practices are in place to help the Company meet its objectives and measure its performance against them. The Group Internal Audit (GIA) and Compliance functions provide quarterly reports to the Audit Committee on their activities and annual reviews of key themes, processes and systems (including arrangements for whistleblowing). The Board has full oversight of these matters by way of the Audit Committee Chair's reports to the Board after each Audit Committee meeting. Board members are also able to access the information provided to the Audit Committee.

B. Purpose, culture and strategy

The Board believes that our Purpose, to push the boundaries of science to deliver life-changing medicines, positions AstraZeneca for long-term sustainable success.

Our Code of Ethics and Values underpin how we work together and the behaviours that drive our success and support our culture.

The Board is responsible for setting our strategy and policies, overseeing risk and corporate governance, and monitoring progress towards meeting our objectives and annual plans. The Board conducts an annual review of the Group's overall strategy.

C. Board decisions and outcomes

The Board makes decisions in the context of the Company's strategy and objectives. Examples of such decisions and their outcomes can be found in the Connecting with our stakeholders section on pages 74 to 76 and the Principal Decisions section on page 77.

D. Stakeholder engagement

The Board aims to ensure a good dialogue is maintained with shareholders, so that their views are understood and considered. The Board also engages with and considers wider stakeholder groups, including the workforce, in its decision making.

E. Workforce policies and practices

Based on our Values, expected behaviours and key policy principles, our Code of Ethics, which applies to all employees, including the Board, empowers employees to make decisions in the best interests of the Group, the Company, society and the patients we serve. Employees are able to raise concerns anonymously via the AZ Ethics helpline.

2. Division of responsibilities

F. Chair of the Board

Michel Demaré, our Non-Executive Chair, is responsible for leading the Board and its overall effectiveness in directing the Company. Mr Demaré was first appointed to the Board in 2019 and was considered to be independent on his appointment as Chair in April 2023.

G. Board composition, independence and division of responsibilities

The composition of the Board is set out on pages 68 and 69, with the majority consisting of independent Non-Executive Directors.

Directors' independence is considered annually by the Board. In December 2025, the Board considered the independence of the Non-Executive Directors, other than the Chair of the Board, for the purposes of the Code, the US Nasdaq Listing Rules and (in anticipation of the harmonised listing structure becoming effective) the NYSE Listing Rules. Taking into account the recommendations set out in the Code, the Nasdaq Listing Rules and NYSE Listing Rules, the Board considers that all the Non-Executive Directors, except Marcus Wallenberg, are independent. Mr Wallenberg was appointed as a Director of Astra in May 1989 and subsequently became a Director of the Company in 1999. He is also a Non-Executive Director of Investor AB, which has a 3.33% interest in the issued share capital of the Company as at 31 January 2026. Due to his overall length of tenure and relationship with a significant shareholder, the Board does not believe that he can be determined independent.

As well as being a Non-Executive Director of AstraZeneca and Chair of the Board's Sustainability Committee, Nazneen Rahman is the Director of the Sustainable Medicines Partnership (SMP), a multi-stakeholder, not-for-profit collaboration with the aim of advancing the environmental sustainability of medicines. AstraZeneca is a strategic collaborator in the SMP. Dr Rahman has recused herself from acting as the lead contact for the SMP in its relationship with AstraZeneca, and this relationship, including project work and overall programme management, is handled by other members of the SMP team.

The Directors are collectively responsible for the success of the Group. The roles of the Board, Board Committees, Chair, Senior independent Non-Executive Director and CEO are documented, as are the Board's reserved powers and delegated authorities. The Board's responsibilities and the

For more information on:

Our Purpose, Values and Business Model, see pages 8 and 9.

Our Code of Ethics, see pages 34 and 35.

Stakeholder engagement, see pages 74 to 76 and throughout the Strategic Report. Our Section 172(1) Statement is set out on page 46.

Corporate Governance Report | Compliance with the UK Corporate Governance Code *continued*

governance structure by which it delegates authority are outlined in the Corporate Governance Overview on page 67.

The CEO can exercise all the powers of the Board, except for those matters that are reserved to, and can only be approved by, the Board or a Committee of the Board. From January 2026, the matters reserved for the Board include: the appointment, termination and remuneration of any Director; approval of the annual budget; approval of any item of fixed capital expenditure or any proposal for the acquisition of an investment or business which exceeds \$500 million; approval of any proposal for the disposal of an investment or business which exceeds \$300 million; the raising of capital or loans by the Company (subject to certain exceptions); the giving of any guarantee in respect of any borrowing of the Company; and allotting shares of the Company.

H. Non-Executive Directors' role and time commitment

The Non-Executive Directors exercise objective judgement in respect of Board decisions, providing scrutiny and challenge and holding management to account. Non-Executive Directors also offer strategic guidance and specialist advice based on their breadth of experience and knowledge. The Non-Executive Directors regularly meet without the Executive Directors or other management present.

Philip Broadley was appointed Senior independent Non-Executive Director on 1 March 2021 and serves as a sounding board for the Chair and as an intermediary for the other Directors when necessary. As Senior independent Non-Executive Director, he is also available to shareholders if they have concerns that contact through the normal channels of Chair or Executive Directors has failed to resolve, or for which such contact is inappropriate. During the year, no shareholders asked to meet with Mr Broadley formally in his role as Senior independent Non-Executive Director.

As well as their work in relation to formal Board and Board Committee meetings, Non-Executive Directors commit time throughout the year to meetings and telephone calls with various levels of executive management and other key stakeholders, visits to AstraZeneca's sites throughout the world (whether in person or virtually) and, for new Directors, induction sessions and site visits. The Chair and individual Board members ensure that Board

members' time commitment to the Company is sufficient to fulfil their duties as Directors and fully discharge their obligations to shareholders, particularly in the case of the Chairs of Board Committees. For the Chair of the Board, generally, as a basic commitment, it is expected that they would need to devote about 40% of their time or the equivalent of not less than 90 days per annum in the fulfilment of their duties.

When contemplating taking up additional appointments, Non-Executive Directors consult the Chair to ensure thought is given to any potential impact on their time commitment to AstraZeneca. Careful consideration is given to the nature of the potential appointment and the type of company involved (for example, whether the company is a public listed company or privately held), to help assess the likely time requirement. For significant additional appointments, the full Board would typically be involved in this process.

In 2025, Pascal Soriot was appointed as a Director of Agilent Technologies Inc. and, in 2026, Diana Layfield was appointed as CEO of Monzo Group. These appointments were considered and approved by the Board in advance on the basis that they would not prevent or reduce the ability of either Director to perform their roles for AstraZeneca to the required standard.

The Board recognises that Mr Wallenberg has a wide portfolio of other roles, but believes he has brought, and continues to bring, considerable business experience and makes a valuable contribution to the work of the Board, which his portfolio of other roles supports. The Board is also satisfied that he is able to devote sufficient time to discharge his responsibilities as a Director, as demonstrated by his attendance at Board meetings, as detailed on page 67.

The performance of the Non-Executive Directors is assessed annually as part of the Board's performance evaluation, as described on page 78.

Subject to specific Board approval, Executive Directors may accept external appointments as non-executive directors of other companies and retain any related fees paid to them, provided that such appointments are not considered by the Board to prevent or reduce the ability of the executive to perform his or her role within the Group to the required standard.

I. Company Secretary

The Company Secretary is responsible to the Chair for ensuring that all Board and Board Committee meetings are properly conducted, that the Directors receive appropriate information prior to meetings to enable them to make an effective contribution, and that governance requirements are considered and implemented. The 2025 Board performance evaluation set out on page 78 provides details of the effective operation of the Board.

3. Composition, succession and evaluation

J. Appointments and succession planning

The Nomination and Governance Committee and, where appropriate, the full Board, regularly review the composition of the Board and succession plans for both SET- and Board-level positions. Directors have regular contact with, and access to, succession candidates for SET positions.

There is a formal, rigorous and transparent procedure for appointments to the Board, which is based on merit and objective criteria and takes into account the importance of diversity, inclusion and equal opportunities when considering potential appointments. The Nomination and Governance Committee Report details the process for appointments approved during the year on pages 79 and 80.

All Directors retire at each AGM and may offer themselves for re-election by shareholders. The Notice of AGM will give details of those Directors seeking election or re-election.

K. Skills, experience and knowledge

When the Nomination and Governance Committee reviews the composition of the Board and its Committees, it uses a matrix that records the skills and experience of current Board members and compares this with the skills and experience it believes are appropriate to the Company's overall business and strategic needs, both now and in the future. The Committee is also mindful of Directors' lengths of tenure and the need to refresh Board membership over time.

L. Board evaluation

In 2025, the Board undertook an internal Board performance review. More information on the review process, including the results and actions taken, can be found on page 78.

 For more information on:

The work of the Nomination and Governance Committee, see pages 79 and 80.

4. Audit, risk and internal control

M. Internal and external audit

The Audit Committee is responsible for reviewing the relationship with, and independence of, our external auditor, PwC. The Committee maintains a policy for the pre-approval of all audit services and audit-related services undertaken by the external auditor, the principal purpose of which is to ensure that the independence of the external auditor is not impaired.

The Audit Committee also reviews the independence and effectiveness of GIA.

N. Fair, balanced and understandable assessment

The Board considers this Annual Report, taken as a whole, to be fair, balanced and understandable, and provides the information necessary for shareholders to assess AstraZeneca's position and performance, business model and strategy. The Board's assessment is described on page 86.

The Board and the Audit Committee review the Company's quarterly financial results announcements to ensure they present a fair, balanced and understandable assessment of the Company's position and prospects to shareholders.

O. Risk management

The Board is responsible for the Company's risk management system and internal controls, and their effectiveness. The Board delegates some responsibilities for risk management oversight to the Audit Committee, such as quarterly reviews of the Company's principal and key active risks. During 2025, the Directors continued to review the effectiveness of our system of controls, risk management (including a robust assessment of the emerging and Principal Risks) and high-level internal control processes. This included an annual Governance and Assurance Report to all Directors, which is considered in detail by the Audit Committee and reviewed by the Board.

Any areas of concern are highlighted in the Audit Committee Chair's update to Directors at the relevant Board meeting and discussed by the Board. The report is based on a full year-end review of the Company's risk and control processes (incorporating financial, operational and compliance controls) and findings from assurance processes.

The Directors believe that the Group maintains an effective, embedded system of risk management and internal controls and complies with the FRC's guidance.

5. Remuneration

P. Remuneration policies and practices

The Remuneration Committee is responsible for determining, approving and reviewing the Company's global remuneration principles and frameworks, to ensure that they support the strategy of the Company and are designed to promote long-term sustainable success.

Q. Developing executive remuneration policy

The Remuneration Committee routinely reviews the Directors' Remuneration Policy and executive remuneration arrangements to ensure they continue to promote the delivery of the long-term strategy and support the Company's ability to recruit and retain executive talent to deliver against that strategy. The Committee also considers remuneration arrangements in the context of corporate governance best practice and arrangements for the wider workforce, and regularly consults with its major investors on remuneration proposals. No Director is involved in determining their own remuneration arrangements or outcomes.

R. Remuneration outcomes and independent judgement

To ensure it maintains independent judgement when determining remuneration outcomes, the Remuneration Committee considers a range of data, including detailed business and individual performance information, and also consults with other Board Committees to utilise their expertise when determining performance outcomes.

Further information on risk management and controls

Global Compliance and GIA

Through our compliance programme and three lines of defence risk management framework (line management; Risk and Compliance functions; GIA), Global Compliance helps the Group achieve its priorities and do business the right way. It takes a global approach that addresses key risk areas, including those related to third parties and anti-bribery/anti-corruption. Its work helps us to reinforce compliant behaviours through our Code of Ethics, policies, training, advice and guidance. We also conduct risk assessment activities and foster a culture where individuals can raise concerns.

We take alleged compliance breaches and concerns seriously. We investigate and take appropriate disciplinary and remediation action to address and prevent reoccurrence through internal functions and external advisers. Depending on breach severity, the Group may need to disclose and/or report the incident to a regulatory or government authority.

Global Compliance provides assurance insights to the Audit Committee on compliance matters. GIA carries out a range of audits and periodically reviews the assurance activities of other Group functions.

The results from these activities are reported to the Audit Committee. Global Compliance and GIA share outcomes and coordinate reporting on compliance matters throughout the organisation. GIA is established by the Audit Committee on behalf of the Board and acts as an independent and objective assurance function guided by a philosophy of adding value to improve the operational control framework of the Group. The scope of GIA's responsibilities encompasses, but is not limited to, the examination and evaluation of the adequacy and effectiveness of the Group's governance, risk management and internal control processes in relation to the Group's defined goals and objectives.

Among others, internal control objectives considered by GIA include:

- Compliance with significant policies, plans, procedures, laws and regulations.
- Consistency of operations or programmes with established objectives and goals, and effective performance.
- Safeguarding of assets.

Based on its activity, GIA is responsible for reporting significant risk exposures and control issues identified to the Board and to senior management, including fraud risks, governance issues and other matters needed or requested by the Audit Committee. It may also evaluate specific operations at the request of the Audit Committee or management, as appropriate.

 For more information on:

The work of the Remuneration Committee, see from page 90.

Our resources and controls, see the Audit Committee Report from page 83.

External audit, see page 85 and Note 31 to the Financial Statements on page 191.


Internal Audit, see page 85.

Our Viability Statement, see page 46 and the Risk Overview from page 47.

Corporate Governance Report | Connecting with our stakeholders

Considering the interests of our stakeholders is fundamental to our Group's strategy. The following table identifies our most strategically significant stakeholders and summarises the engagement that has been undertaken by management during 2025.

	Patients and patient networks	Payers	Investor community
Overview Significance of the stakeholder to the business	Patients are at the heart of what we do. Our stakeholders include individual patients, caregivers and patient advocacy organisations. We listen to their experiences, embedding these insights into every aspect of our work, and partner with them to enable access to high-quality, resilient healthcare systems, ensuring that the medicines and services we develop have the greatest impact on their lives.	AstraZeneca works closely with payers, including governments and medical insurance companies among others, to understand the impact of pricing medicines on public and private budgets.	The Board and management maintain regular and constructive dialogue with investors to communicate our strategy. We provide objective information about performance to enable investors to put a fair value on the Company and ensure our continued access to capital.
Interests Issues and factors which are most important to the stakeholder group	- Gathering and incorporating diverse insights throughout the drug development process to minimise patient burden and measure outcomes they care about most. - Ensuring healthcare systems are designed and delivered with the patient in mind. - Providing transparent, accessible information. - Ensuring the safety, efficacy and affordable accessibility of our medicines.	- Sustainable access to safe and effective innovative medicines. - Pricing of medicines, including breakthrough therapies and impact on public budgets. - Containing reimbursement expenditure. - Attracting business investment. - Investing in research and scientific collaborations.	- Financial and commercial performance. - R&D strategy, resource allocation and pipeline development. - Culture, values and behaviours. - Exposure to geopolitical and macroeconomic risks. - Sustainability and governance matters.
Engagement Examples of engagement in 2025	- Increased number of diverse patient engagements throughout drug development. - Involved patients and caregivers in co-creation of multiple programmes. - Expanded patient support and affordability programmes. - Collaborated with patient advocacy organisations on key healthcare system transformation projects, enabling access to improved healthcare and medicines across the globe.	- Engaged governments and policymakers to increase understanding of the AstraZeneca business model, to support investment in life sciences and to improve access to new medicines. - Engaged in discussions on evolving the current reimbursement system for medicines in the US. - Hosted site visits and tours at our manufacturing and R&D facilities for international and local politicians.	- Ongoing communications with shareholders, including quarterly results calls, in-person and virtual meetings and roadshows. - Gave online presentations, including investor events at medical conferences, and a webinar on our sustainability progress. - Receptions hosted by the Chair of the Board.
Outcomes Actions which resulted	- Delivered impactful and actionable insight to drive patient-focused drug development. - Increased patient support programmes. - Drove global consensus and supported the community to strengthen national healthcare systems.	- Established working relationships with key government stakeholders. - Organised regular meetings and events to increase understanding of how governments can better support life sciences investment and improve patient access to new medicines.	- Maintained access to senior and next-level/operational management, including increased virtual engagement. - Continued to streamline external-facing materials to provide increased transparency, following discussion with shareholders. - Increased focus on sustainability matters within results announcements and shareholder engagements.



	Healthcare professionals	Academic and R&D partners	Commercial collaborators and partners
Overview Significance of the stakeholder to the business	Healthcare professionals (HCPs) are the interface with patients. They provide insights into clinical trial design, and prescribe and advise patients on administering medicines. They also provide safety reports, collaborate in clinical studies and assist with the ethical and transparent distribution of medicines.	We collaborate with academic institutions and non-profit R&D partners globally to access the best science, stimulate innovation and deliver life-changing medicines to patients.	Partnering is an increasingly important part of our business. By combining forces, AstraZeneca and our partners can accelerate innovative science to bring life-changing medicines to patients.
Interests Issues and factors which are most important to the stakeholder group	• Development of medicines for unmet medical need. • Education and information on advances in medical science. • Accurate and balanced information on licensed medicines, including up-to-date safety data. • Uninterrupted supply of quality medicines. • Ethical and transparent interactions with industry.	AstraZeneca had approximately 1,500 active academic collaborations during 2025: • To advance innovative technology and science. • To address key scientific challenges. • To access the next generation of science leaders.	• Sharing vision and values. • Developing innovative medicines and improving access to them. • Cultivating trust and transparency in research, disclosures and relationships with stakeholders. • Willingness to collaborate with industry peers to optimise outcomes for common stakeholders, e.g. patients, physicians, policymakers and healthcare systems.
Engagement Examples of engagement in 2025	• Engaged in HCP educational events, advisory boards and clinical trials. • Responded to more than 146,800 HCP enquiries and processed adverse event reports from HCPs which contribute to the understanding of the safety profile of our medicines.	• We support more than 1,000 early career positions in R&D globally, including apprentices, graduates, placement students, sponsored PhDs, postdoctoral researchers and clinical fellows. • Through our Open Innovation programme, we openly share molecules, data and scientific expertise with academic researchers and start-ups; we currently have multiple ongoing clinical trials, over 150 ongoing preclinical studies and collaborative research projects, and we are participating in more than 20 public-private partnership projects aimed at addressing key scientific challenges. • Held joint seminars, education sessions, science days and consortia with research institutions such as: Partners of Choice Network, Yale University, Stanford Medicine and Moffitt Cancer Center.	• Regular alliance governance meetings to ensure collaborative approach across organisations. • Joint responsibility for deliverables and outcomes across functions at all levels. • Multiple discussions with regulators, policymakers, patient groups and clinicians, to inform development and commercial strategy to best meet patient needs.
Outcomes Actions which resulted	• Advisory boards informed clinical research and product strategy. • Clinical studies have led to new products. • Exchange of information supported HCP clinical decision making.	• Enabled new technologies, new target identification and validation, and new biomarkers. • Scientific publications and knowledge sharing. • Hosting apprenticeship, studentship, postgraduate and postdoctoral programmes to facilitate scientific discovery.	• Optimisation of outcomes through combined skillsets and use of innovative technologies/platforms to support development of new medicines. • Multiple late-stage trials initiated across multiple disease/patient types. • Accelerated launch of new medicines in unique areas. • Greater collaboration and relationships with industry partners and stakeholders.

Corporate Governance Report | Connecting with our stakeholders *continued*

In addition to the principal stakeholders described on pages 74 and 75, the Board considers the following stakeholder groups important for the business operations and strategic direction of the Company.

Community

We believe that creating a positive impact for people, society and the planet requires meaningful investments in the communities where we live and work, with a focus on the underserved. Our community investment activities support non-profit organisations all over the world to advance health equity, increase access to care, drive scientific innovation and build healthy and resilient communities for all.

Workforce

We continue to build talent internally by developing critical skills across our workforce, ensuring we have the capabilities to achieve our Ambition 2030. Our employees are a key part of our strategy, and we are committed to being a great place to work.

Health authorities

We engage regulators globally about the manufacture, development, review, approval and marketing of our products.

Governments

AstraZeneca partners closely with governments around the world to promote health, support healthcare research and innovation, facilitate equitable access to innovative care solutions, and build resilient and sustainable healthcare systems.

Multilateral and non-governmental organisations

AstraZeneca partners with multilateral organisations and non-governmental organisations (NGOs) to improve health equity, strengthen health systems resilience and tackle climate change, all in support of the UN Sustainable Development Goals. In health equity, we focus on ensuring representation in our science, including clinical trials and genomics research, and improving healthcare delivery through equitable screening, diagnosis and treatment programmes. Our community investments help to prevent disease through youth health promotion and education, and support

urgent humanitarian needs, including disaster relief and product donations.

Media

An active and constructive relationship with the media is important to build trust with the Company's key stakeholders by transparently reporting on the Group's activities, including the results of key trials and business updates, as well as seeking to enhance and protect the reputation of the organisation.

Suppliers and third-party providers

We work with a broad range of third-party suppliers to provide the goods and services needed to deliver life-changing medicines to patients globally. Our Procurement function operates efficiently and effectively to drive collaboration with those third-parties, fostering innovative, ethical and sustainable ways of working across the entire supply chain.

How the Board engages with stakeholders

The stakeholder table on pages 74 and 75 sets out management's main interactions with certain key stakeholders. Feedback from these interactions is provided to the Board in a variety of ways, which allows the Board to understand the key interests of stakeholders and consider them in its decision-making process.

The Board undertakes additional direct engagement with stakeholders to better understand their interests and concerns, so these can be factored into its decision making.

Examples of the Board's engagement are set out in the following columns. Information on how stakeholders and other factors were considered in the Board's principal decisions in 2025 is set out on the following page.

Full Board/Other

- During 2025, a number of Directors, including the CEO, the CFO and the Chair, met investors at roadshows and in one-on-one and group meetings.
- The 2025 AGM and the November 2025 general meeting regarding the harmonised

listing structure were digitally-enabled and broadcast live, which allowed the Company's geographically diverse shareholder base to participate in the meeting and engage with the Board. The digitally-enabled format allowed Directors and shareholders to join from locations across the globe.

- Investor reports and financial analysts' consensus data are made available to the Board. Feedback is regularly provided to the Board by management on their interactions with investors.
- The CEO and the CFO, along with other members of management, met governmental agencies and regulators to discuss matters including the pricing of medicines and equitable access.
- The CEO and other members of management attended a number of scientific conferences in 2025, relevant to the Company's main areas of R&D and Commercial activity.
- During the 2025 World Economic Forum in Davos, Switzerland, the Chair and senior leaders met with more than 25 governments and participated in four speaking engagements, highlighting the need to advance the sustainable transformation of health systems.
- The Chair was elected to the Steering Committee of the European Round Table of Industry (ERT) in May 2025. Through ERT plenaries, as well as Steering Committee and other meetings, the Chair engaged high-level officials from the EU, Denmark, Italy and the UK on strengthening European economic competitiveness

and building more resilient and sustainable health systems.

- The CEO, CFO and the Chair, regularly engaged with employees through in-person and online events, including 'townhalls' and 'fireside chat' sessions. Employees had the opportunity to ask questions in advance or during sessions.
- As part of its scheduled meetings during the year:
 - In London, UK, the Board hosted select employees for a lunch.
 - In Cambridge, UK, the Board met employees, including scientists and commercial teams, and external stakeholders, including academics and scientists.
 - In Gaithersburg, US, the Board hosted select employees for lunch and hosted a 'townhall' meeting.
 - In Abu Dhabi, UAE, the Board hosted select employees for a dinner, hosted a 'townhall' meeting and met external stakeholders, including Abu Dhabi government officials, through a series of site visits and presentations.
- The Committees of the Board also engage with employees and other stakeholders on matters within their areas of responsibility. For further information on Board Committees' engagement activities, see:
 - Science Committee Report on page 81
 - Sustainability Committee Report on page 82
 - Audit Committee Report from page 83
 - Directors' Remuneration Report from page 90.

For more information on how management and the Board have considered modern slavery, see the Audit Committee Report from page 83, Human Rights on page 217 and AstraZeneca's Modern Slavery Act Statement, which is available on our website, www.astrazeneca.com.

Corporate Governance Report | Principal Decisions

Set out below are examples of how key stakeholders, Section 172(1) of the Companies Act 2006 duties and other matters were considered by the Board when making its Principal Decisions in 2025.

Principal Decisions in 2025

Pipeline strengthening transactions

During 2025, the Board approved the acquisition of EsoBiotec and the restructuring of the *Koselugo* collaboration as part of its commitment to strengthen the Group's pipeline and financial performance.

The Board considered: **I P L M**

How the Board had regard to these matters:

- Reviewed the strategic rationale for the transactions and confirmed alignment with long-term growth objectives and delivery of the Ambition 2030 goals.
- Considered the benefits to patients if the Group was able to accelerate the development of novel treatments, which could potentially deepen clinical responses and improve patient outcomes.
- Assessed the financial impact of the transactions on the Group's viability and capital allocation priorities, alongside the potential financial benefits from the transactions.

Appointment of Karen Knudsen as Non-Executive Director

In February 2025, the Board approved Karen Knudsen's proposal for election as a Non-Executive Director at the Company's AGM. Following shareholder approval at the AGM, Karen's appointment became effective on 11 April 2025. Karen joined the Science Committee and Sustainability Committee upon her appointment.

The Board considered: **I L M**

How the Board had regard to these matters:

- Considered the Board's diversity, time commitments of potential candidates and other relevant governance considerations, including UK Corporate Governance Code provisions, as well as Board and Board Committee skills requirements and succession planning considerations.
- Considered changes to the wider business environment, such as the increasing importance of technology and AI, and changes in modalities, and what skills the Board needed to ensure that it could provide appropriate oversight to help the Company continue to grow in such an environment.

- Assessed potential candidates' experience through review and meetings to confirm they possessed the expertise and skills necessary to contribute to the Company's long-term strategy, support management in delivering long-term shareholder value and life-changing medicines, and uphold the highest standards for business conduct.
- Considered the independence of potential candidates by assessing potential conflicts of interest and affiliations to maintain objectivity and unbiased judgement in Board deliberations.

Harmonised listing structure

In September 2025, the Board approved the harmonisation of the Company's listing structure, involving a direct listing of AstraZeneca Ordinary Shares on the New York Stock Exchange to replace the listing of American Depositary Shares on the Nasdaq in the US. Following shareholder approval of the adoption of new Articles of Association at a general meeting in November 2025, the harmonised listing structure became effective on 2 February 2026.

The Board considered: **I L**

How the Board had regard to these matters:

- Reviewed the strategic rationale for the harmonised listing structure and confirmed its alignment with the Company's long-term strategy for sustainable growth.
- Considered the benefits to the Company of a global listing structure to widen the pool of investors in AstraZeneca, especially US domestic institutional and retail investors, and ensuring that the Group has the flexibility to access the broadest available pool of capital, including in the US.
- Considered the benefits to investors of being able to trade their interests in AstraZeneca Ordinary Shares across the London, New York and Stockholm Stock Exchanges, with the Company remaining UK listed, headquartered and tax resident and continuing to be included in the FTSE 100 index and the OMX Stockholm 30 index.

Capital expenditure

In December 2025, the Board approved the Group's overall capital expenditure for 2026 which include investments by the Company in new and expanded manufacturing facilities in Virginia and Maryland, US which form part of the Company's planned \$50 billion investment in the US by 2030.

The Board considered: **E I P L**

How the Board had regard to these matters:

- Considered the Group's Purpose, to push the boundaries of science to deliver life-changing medicines to patients, and how the Company's capital investments would support this Purpose.
- Reviewed the alignment of the capital spend to strategic priorities, business needs and delivery of Ambition 2030.
- Evaluated how the Company's capital investments would support the robust pipeline of new modalities and growth ambitions and enhance competitive position.

Key

- E** Employees
- I** Investors
- P** Patients

L The long-term success of the Company

M Maintaining high standards of business conduct

□ For our Section 172(1) Statement, see page 46.

For more information, on:

Acquisitions and collaborations, see Business development on page 37 of the Business Review.

Committees' composition and succession planning, see the Nomination and Governance Committee Report, on pages 79 and 80.

Investments, divestments and capital expenditure, see US investment plans on page 63.

Corporate Governance Report | Engaging with our workforce

AstraZeneca is committed to being a great place to work. Engagement with our employees and wider workforce is an important element in ensuring an environment where everyone is respected, openness is valued, diversity is celebrated, and every voice is heard. Our global workforce plays a critical role in upholding our Values, delivering our strategic priorities, and sustaining both short- and long-term performance. For AstraZeneca, 'global workforce' includes full-time and part-time employees, fixed-term workers and external contractors working full- or part-time, anywhere in the world.

The Board believes that engagement with the workforce is a collective responsibility. Consequently, the Board has chosen not to implement any of the three methods set out in the Code. Instead, it utilises a range of established mechanisms and communication channels across the Group to ensure meaningful engagement with the global workforce. These include:

- In-person and virtual engagement with the workforce, including 'townhall' meetings, 'fireside chats', Q&A sessions and lunches when Board members visit our sites. In 2025, Directors, individually and jointly, visited various Group sites or hosted in-person 'townhall' meetings across the world, including in Belgium, Canada, China, Germany, India, Ireland, Italy, Mexico, Poland, Switzerland, the United Arab Emirates, the US and the UK. This approach maximises the reach of these engagements and ensures interactions across diverse roles and geographies, as well as facilitating understanding of business operations.
- The Board's review of key workforce data included the global workforce Pulse survey, the biannual Workforce Culture and Employee Engagement Report, and data relating to talent, development, inclusion and diversity initiatives. These reports help demonstrate how our Values and behaviours are embedded throughout the workforce. Where the Board has concerns that the culture does not reflect

our Values, the Board seeks assurances from management that remedial action has been taken and, where necessary, requests senior management's attendance at Board meetings to discuss corrective actions.

- The Remuneration Committee's evaluation of reward across the workforce (as described on page 109).

Where required, issues or concerns raised by the workforce are fed back to management and discussed by the Board.

The Board believes that these holistic approaches provide comprehensive access to the views of the workforce, regardless of location, and deliver meaningful insights to inform strategic decision making.

Corporate Governance Report | Board performance evaluation

As part of the Board performance evaluation, Directors were asked to consider the following areas:

- Board composition
- Stakeholder oversight
- Board dynamics
- Board Committees
- Strategic oversight
- Risk oversight
- Succession planning and people oversight
- Board materials and support
- Areas for future focus

2025 overview

During the year, the Board carried out its annual evaluation of overall performance, including that of its Committees and individual Directors. The 2025 evaluation was conducted internally, with support from Christopher Saul Associates (CSA), an independent, external corporate governance advisory firm. CSA has no other commercial relationship with the Company or any individual Directors.

The evaluation process involved an online questionnaire covering a broad range of topics. CSA summarised the key themes from the responses. The responses and CSA's summary were reviewed and discussed by the Board at its December

2025 meeting. Ahead of the full Board discussion, the Chair used the report to guide his annual individual discussions with each Director to reflect on their contributions to the Board and identify personal development needs. The Company's last externally facilitated Board evaluation took place in 2024.

2025 outcomes and actions against prior year recommendations

Key conclusions from the 2025 evaluation include:

- The Board continues to operate effectively and remains well-balanced in terms of expertise, geographic representation and gender diversity.
- All Committees continue to demonstrate strong performance and a high level of commitment to their roles.

The evaluation identified several priorities for 2026, including:

- Continued focus on: strategy and navigating macroeconomic, geographical and regulatory challenges; portfolio prioritisation and capital allocation.
- Board and executive succession planning; and new technologies, including AI.
- Continuing to bring significant issues to the Board in a timely fashion to facilitate effective discussion.

- Continuing to build and foster relationships among Board members and supporting the integration of newer Board members.

In response to recommendations from the 2025 evaluation, the following actions were taken:

- The Board received enhanced reporting from the Nomination and Governance Committee, including regular updates on Executive Director succession planning.
- The Board received briefings on geopolitical risk and the wider pharmaceutical landscape.
- The content of the Board's annual strategy review was enhanced to provide more in-depth focus on incremental or newer areas of the business and more competitive analysis and increased review of strategic trends.

Nomination and Governance Committee Report



“The Nomination and Governance Committee works on behalf of the full Board to review the composition of the Board and its Committees and carry out succession planning for all Board positions.”

Nomination and Governance Committee members

- Michel Demaré (Chair)
- Euan Ashley
- Philip Broadley
- Sheri McCoy
- Nazneen Rahman

Non-Executive Directors' experience, as at 31 December 2025

Skills and experience	Total
Business	
Finance	7
Experience in accounting, corporate finance, internal controls and associated risk management.	
Management	8
Experience working in senior management roles of major companies, business transformation and strategy.	
Sales and marketing	3
Understanding and experience in sales and marketing.	
Technology, digital and AI	5
Knowledge and experience in technology, biotechnology, AI and digital health tools.	
Sustainability	5
Experience in managing the issues and opportunities associated with business sustainability, including corporate social performance, stakeholder engagement, and science-based solutions.	
Geographic	
The regions where the Non-Executive Directors are primarily based.	
UK	3
US	4
Europe	4
Asia	1
Industry-specific	
Science	7
Practical knowledge and experience in scientific research, development and innovation.	
Pre-AstraZeneca pharma	6
Professional experience in the pharmaceutical industry prior to joining AstraZeneca.	
Medical doctor/physician	3
Clinically trained medical doctor and/or physician.	

On behalf of the Nomination and Governance Committee (the Committee), I am pleased to present the Committee's report on its activities during 2025.

Committee's role

The Committee works on behalf of the full Board to review the composition of the Board and its Committees and carry out succession planning for all Board positions, including taking the lead in the search for and recruitment of new Directors. The Committee ensures the Board has an appropriate balance of expertise, experience and diversity. A matrix that records the skills and experience of current Board members is one of the main tools used by the Committee to do this. The matrix is shown in the table above.

Decisions relating to the appointment of Directors are made by the entire Board based on the Committee's recommendations. These take into account the merits of the candidates and the relevance of their background and experience, measured against objective criteria, with care taken to ensure appointees have enough time to devote to the Board's business.

Board and Board Committee composition and succession planning

The Committee considers both planned and unplanned (unanticipated) succession scenarios. The Committee continued to spend considerable time in 2025 on succession planning for Non-Executive Directors, as a number of Board members approach nine-year terms. Having appointed Rene Haas and Birgit Conix as Non-Executive Directors with effect from 1 January 2025 and 1 February 2025 respectively, as reported in the 2024 Annual Report, the Committee successfully concluded the appointment of Karen Knudsen as Non-Executive Director. Karen's appointment took effect following shareholder approval at the AGM in April 2025, and Karen became a member of the Science Committee and the Sustainability Committee on appointment. The search process was led by the Committee and involved Karen meeting with multiple Directors. As a globally-recognised cancer scientist with broad executive experience in oncology, Karen brings to the Board significant knowledge and experience of oncology, the US healthcare industry and the medical academic environment.

At the AGM in April 2025, Andreas Rummelt and Deborah DiSanzo retired from the Board. On behalf of the Board, I would like to thank them for their service to AstraZeneca and valuable contributions to the Board's work.

 The full role of the Nomination and Governance Committee is set out in its terms of reference, available at www.astrazeneca.com.

 For more information on each Director's individual experience in these areas, see the Board biographies on pages 68 and 69.

Nomination and Governance Committee Report *continued*

The Committee continued routine succession planning work for the role of CEO, which, as in previous years, included desktop research relating to potential external candidates and continued monitoring of the development of potential internal candidates. The Committee also reviewed succession planning for the Senior Executive Team roles.

Board and Technology, Coulter Partners, Heidrick & Struggles and Korn Ferry assisted the Committee with its succession planning and non-executive search work this year. Board and Technology, Coulter Partners and Heidrick & Struggles undertake executive search assignments for the Company, and Korn Ferry undertakes executive search assignments and other recruitment-related activities for the Company. The four firms used for succession planning work during the year have no other connection with AstraZeneca or its individual Directors.

Inclusion and diversity

The Board views all aspects of diversity among Board members as important considerations when reviewing its composition. The Board aims to maintain a balance in terms of the range of experience and skills of individual Board members, which includes relevant international business, pharmaceutical industry, sustainability, and financial experience, and appropriate scientific and regulatory knowledge. The biographies of current Directors are set out on pages 68 and 69.

The Board's Inclusion and Diversity Policy (the Policy), which is applicable to the Board and its Committees, reinforces the Board's ongoing commitment to all aspects of diversity and to fostering an inclusive environment in which each Director feels valued and respected. Although the Board appoints candidates using objective criteria, primarily based on merit and relevant experience, it recognises that an effective Board requires diversity. To help recruit Directors from a broad, qualified group of candidates, the Policy requires the use of at least one professional search firm that has signed up to the 'Voluntary Code of Conduct for Executive Search Firms', which the Company has complied with in 2025.

The Board's approach to inclusion and diversity continues to yield successful results, as shown in the following tables.

Table 1. Reporting table on sex/gender representation as at 31 December 2025

	Number of Board members	Percentage of the Board	Number of senior positions on the Board ¹	Number in executive management ²	Percentage of executive management
Men	7	50%	3	6	55%
Women	7	50%	1	5	45%
Non-binary	–	–	–	–	–
Not specified/prefer not to say	–	–	–	–	–

Table 2. Reporting table on ethnicity representation as at 31 December 2025

	Number of Board members	Percentage of the Board	Number of senior positions on the Board ¹	Number in executive management ²	Percentage of executive management
White British or other White (including minority-white groups)	10	71%	3	9	82%
Mixed/multiple ethnic groups	1	7%	–	–	–
Asian/Asian British	3	22%	1	2	18%
Black/African/Caribbean/Black British	–	–	–	–	–
Other ethnic group, including Arab	–	–	–	–	–
Not specified/prefer not to say	–	–	–	–	–

¹ Chair, CEO, CFO and Senior independent Non-Executive Director.

² Executive management includes the SET and Company Secretary.

The information presented in the tables was collected on a self-reporting basis.

The Board, SET and Company Secretary were provided with the prescribed table, and asked to complete it based on how they identify. As at 31 December 2025, the Board is pleased that the Company met the updated diversity policy targets as specified in the FCA's April 2022 Policy Statement on 'Diversity and inclusion on company boards and executive management':

- 50% of the Board (and 50% of Non-Executive Directors) were women, above the target of at least 40%.
- The Company met the policy target that at least one of the Chair of the Board, Chief Executive Officer, Senior independent Non-Executive Director or Chief Financial Officer be a woman.
- 29% of the Board identified as from an ethnic minority, above the target of at least one Board member being from a non-white ethnic minority background.

Ongoing training and development

Following their appointments during 2025, Rene, Birgit and Karen were offered a tailored induction programme to provide an understanding of the Group, reflecting their expertise and any Committee memberships.

In addition to arranging comprehensive induction programmes when new Non-Executive Directors are appointed to the Board, the Committee recognises the importance of continuing development and training opportunities for all Directors. We are committed to developing a culture of lifelong learning throughout our organisation. Specific sessions with internal and external experts are periodically arranged for the full

Board, which for example have included sessions on geopolitical risk, the wider pharmaceutical landscape and investor perspectives on the Company and the pharmaceutical sector.

At least annually, I discuss with each Director their contribution to the work of the Board and personal development needs. Directors' training needs are met by: a combination of internal and external presentations and updates, as part of Board and Board Committee meetings; topic-specific training sessions, where required; and the opportunity for Directors to attend external courses at the Company's expense. Directors are also encouraged to visit Group sites, physically or virtually, to deepen their understanding of operations and engage with employees and stakeholders.

Corporate governance

The Committee advises the Board periodically on significant developments in corporate governance and the Company's compliance with the UK Corporate Governance Code (the Code). Further information on our corporate governance arrangements, including the Company's statement of compliance with the Code during the year, is set out from page 71.

Michel Demaré

Chair of the Nomination and Governance Committee

 The Board's Inclusion and Diversity Policy can be read in full on our website, www.astrazeneca.com.

 Information about our approach to diversity in the organisation below Board level can be found in People, on page 39 of the Business Review.

Science Committee Report



“The Science Committee’s core role is to provide assurance to the Board regarding the quality, competitiveness and integrity of the Group’s R&D activities.”

Science Committee members

- Euan Ashley (Chair)
- Karen Knudsen¹
- Diana Layfield
- Tony Mok
- Nazneen Rahman
- Marcus Wallenberg
- EVP, Oncology Haematology R&D²
- EVP, BioPharmaceuticals R&D²
- CEO, Alexion²

¹ Appointed as a member of the Committee on 11 April 2025.

² Co-opted member of the Committee.

Chair’s introduction

The Science Committee’s (the Committee) core role is to provide assurance to the Board regarding the quality, competitiveness and integrity of the Group’s R&D activities. We achieve this through dialogue with AstraZeneca’s R&D leaders and other scientist employees, as well as visits to our R&D sites throughout the world. Our role is to review and assess:

- The approaches we adopt in respect of our chosen therapy areas.
- The scientific technology and R&D capabilities we deploy.
- The scientific strategy for maintaining our pipeline and competitiveness.
- The decision-making processes for R&D projects and programmes.
- The quality of our scientists, their career opportunities and talent development.
- Benchmarking against industry and scientific best practice, where appropriate.

We also periodically review important bioethical issues and assist in the formulation of appropriate policies in relation to such issues, agreeing these on behalf of the Board. The Committee also considers future trends in medical science and technology, and reviews, on behalf of the Board, the R&D aspects of specific business development or acquisition proposals, advising the Board on its conclusions.

Activities during the year

The Committee met seven times during 2025, both virtually and face-to-face. This included a two-day meeting at the AstraZeneca site in Gaithersburg, US where the Committee members engaged with R&D employees over several different sessions. Committee members attended a poster session with scientists from AstraZeneca and Alexion, and held one-to-one meetings with global R&D leaders. The Committee also hosted a lunch with AstraZeneca scientists, including rising stars nominated by various functions, visited the new cell therapy manufacturing site in Rockville, US and completed a lab tour of the AstraZeneca cell therapy research facilities at One MedImmune Way in Gaithersburg, US.

Our key areas of focus during the year included:

- **Company strategy and strategic priorities for R&D:** including key prioritised science platforms across R&D (Oncology, BioPharmaceuticals and Rare Disease) and areas of focus for long-term success.
- **AstraZeneca R&D strategic science capabilities:** including the cell therapy strategy across therapy areas, and in-depth reviews of precision therapies (cellular therapies and viral and non-viral gene therapies) and targeted therapies (antibody drug conjugates and radioconjugates).
- **Business development strategy:** engagements with business development teams across all therapy areas to review strategic priorities, opportunities under evaluation and key insights.

Acquisitions and in-licensing

- **agreements:** review for the Board the scientific case for acquisition, collaboration and licensing opportunities, including:
 - Acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity.
 - A collaboration and licensing agreement with Harbour BioMed to discover multi-specific antibodies.
 - A collaboration and licensing agreement with Syneron Bio to develop macro-cyclic peptides.
- **Data science and AI:** sessions focused on multimodal foundation models for clinical development and enabling data access for AI as part of a comprehensive multi-meeting process focused on all potential impacts of AI on AstraZeneca R&D.
- **Corporate scorecard outturn and goal setting:** providing insight and feedback to the Remuneration Committee in support of 2025 achievements and 2026 goal setting relating to R&D.

Euan Ashley

Chair of the Science Committee

 The full role of the Science Committee is set out in its terms of reference, available at www.astrazeneca.com.

Sustainability Committee Report



“The Sustainability Committee continued its important work in 2025 to oversee the execution of the Company’s sustainability strategy.”

Sustainability Committee members

- Nazneen Rahman (Chair)
- Karen Knudsen¹
- Sheri McCoy
- Marcus Wallenberg

Standing attendees at Committee meetings during 2025 included the: EVP, Global Operations, IT and the Chief Sustainability Officer; and VP, Global Sustainability and SHE.

¹ Appointed as a member of the Committee on 11 April 2025.

Chair’s introduction

The Sustainability Committee (the Committee) continued its important work during 2025 to oversee the execution of the Company’s sustainability strategy. In addition to this important function, the Committee’s other roles are:

- Collaborating with the Audit Committee to review the Company’s regulatory disclosures relating to sustainability and providing information and advice to support the Board and Audit Committee as required.
- Overseeing communication of our sustainability activities with our stakeholders.
- Monitoring developments and best practice, and providing input to the Board and other Board Committees on sustainability matters as required.
- Advising the Remuneration Committee on the Company’s sustainability metrics and targets, and performance against these.

Activities during the year

Committee meetings and informal interactions with employees provide valuable opportunities for members to engage directly with those responsible for executing AstraZeneca’s sustainability strategy. These exchanges helped the Committee build a deeper understanding of the initiatives underway, their progress, and the individuals driving them – insights we share with the wider Board.

 The full role of the Sustainability Committee is set out in its terms of reference, available at www.astrazeneca.com.

For more information about sustainability at AstraZeneca, visit www.astrazeneca.com/sustainability.

In 2025, the Committee met formally twice and additionally held a dedicated strategy day with key employees leading our global sustainability agenda. These engagements provided valuable insights into the implementation of our strategy across the business and enabled deeper dialogue on emerging priorities. Direct input from colleagues working on the ground helped the Committee better understand both the opportunities and challenges in translating ambition into action.

The Committee’s discussions this year focused on several strategic areas:

- **Scope 3 strategy development:** including the transition to next-generation propellants, product decarbonisation, supplier engagement, compensation mechanisms, and target-setting.
- **Health equity:** exploring how our strategy supports access, affordability, and outcomes across diverse populations.
- **A strategic review of sustainability initiatives:** assessing alignment with our broader corporate objectives and impact potential.
- **Ambition Zero Carbon:** evaluating our strategy and targets against the Science Based Targets initiative (SBTi).
- **Communication of our sustainability strategy:** ensuring clarity and consistency in how we share our progress and priorities with stakeholders.
- **Supporting the Remuneration Committee** in its consideration of how the delivery of our sustainability targets is incentivised.

This year, we were pleased to welcome Karen Knudsen to the Committee following her appointment to the Board on 11 April 2025. Karen brings significant knowledge of the US healthcare sector and the medical academic landscape, and her insights have already proven valuable. I am grateful for her contributions to the Committee’s discussions and activities.

As Chair, I remain proud of the Committee’s contribution to AstraZeneca’s sustainability journey. We are committed to maintaining robust governance, fostering transparency, and supporting the Company in delivering meaningful impact for patients, communities, and the planet.

Nazneen Rahman

Chair of the Sustainability Committee

Audit Committee Report



“The Committee’s principal responsibilities include monitoring the integrity of financial and sustainability reporting, including formal announcements relating to financial performance, reviewing the effectiveness of internal controls, risk management, compliance systems and processes, overseeing the external and internal audit processes, and oversight of external sustainability reporting assurance.”

Audit Committee members

- Philip Broadley (Chair)
- Sheri McCoy
- Anna Manz
- Birgit Conix¹

¹ Appointed as a member of the Committee on 1 February 2025.

Chair’s introduction

On behalf of the Audit Committee (the Committee), I am pleased to present the Committee’s report on its activities and the significant matters it considered during 2025.

The Committee’s principal responsibilities include monitoring the integrity of financial and sustainability reporting, including formal announcements relating to financial performance, reviewing the effectiveness of internal controls, risk management, compliance systems and processes, overseeing the external and internal audit processes, and oversight of external sustainability reporting assurance.

The Committee believes that it has carried out its responsibilities effectively throughout the year, and to a high standard, providing independent oversight. It has had good support from AstraZeneca personnel and PwC, the Company’s auditors.

The Committee continues to apply appropriate challenge to the Company’s management, for example, the change in revenue presentation to include a new metric, Product Revenue, and the change in metric from Product Sales Gross Margin to Gross Margin as a percentage of Total Revenue, were subject to robust discussions and scrutiny from the Committee before it was satisfied with management’s approach. The Committee also discussed the implications of US tariffs on accessibility of medicines, including any accounting implications, and requested a review of the nature and accounting for sales incentives. In addition, the Committee challenged management on the extent and proportionality of disclosures relating to sustainability reporting in light of changing regulatory requirements.

The Committee’s agenda continues to be driven by the Company’s key active risks and key strategic programmes which are considered at every Committee meeting,

and also inform the Committee’s in-depth review sessions, which have included:

- Our business development processes.
- Sustainability-related regulations and the measures in place to ensure compliance with regulatory standards, proportionality and balanced reporting.
- The tariffs required by the US Government and the potential impact on the Group.
- The annual review of the Group’s risk management framework and approach.
- A review of major capital projects.
- The planned upgrade of the Group’s Enterprise Resource Planning IT systems (S4HANA Project Axial).
- Our Information Technology and Information Security (IT/IS) function, including management and mitigation of cybersecurity threats.
- Our Operations function, as we continue to evolve our supply chain capabilities.

These sessions allowed the Committee to explore specific areas of risk in a ‘real world’ business context and in direct dialogue with the business that have responsibility for managing these risks.

Last year we reported that, following a rigorous tender process, KPMG would be appointed as the Group’s external auditor for the financial year ending 31 December 2026. During the year, the Committee reviewed plans and activities undertaken by management related to the audit transition and assurance that independence would be in place by 1 May 2025. Further details are provided on page 87. On behalf of the Committee, I would like to thank PwC for their work as the Group’s external auditor since 2017.

The Committee also spent considerable time continuing to keep up to date on external developments in the reporting and regulatory environment, including changes to sustainability-related reporting

requirements in the EU encompassing the Corporate Sustainability Reporting Directive (CSRD) and EU Taxonomy. The Committee reviewed preparations for the new UK Failure to Prevent Fraud offence and upcoming changes to the UK Corporate Governance Code (the Code) in readiness to meet the additional disclosures over the effectiveness of material controls as required by Provision 29.

We continued our approach of a combination of in-person and virtual Committee meetings and interactions with colleagues from across the organisation, including in-person visits by Committee members to AstraZeneca’s sites in Germany and Poland, details of which are provided on pages 85 and 86. I also attended the Group Internal Audit (GIA) annual conference at our Alexion manufacturing site in Dublin, which allowed me to engage with the GIA team and gain strategic insight into their work. These interactions, along with the in-depth sessions I refer to above, have allowed Committee members to maximise our engagement with colleagues across the business, deepen our understanding of the priorities and challenges facing many different markets and business areas, and hear a wide range of employees’ views directly.

I was also pleased to welcome Birgit Conix as a member of the Committee in February 2025 and she has already brought a valuable contribution to the Committee’s discussions during the year.

We hope you find the Committee’s report useful and informative and, as ever, I welcome any feedback.

Philip Broadley
Chair of the Audit Committee

Audit Committee Report *continued*

Committee overview

Committee composition

In December 2025, the Board determined the Committee met the UK and US composition requirements by virtue of Philip Broadley, Anna Manz and Birgit Conix having recent and relevant financial experience for the purpose of the Code, having competence in accounting and/or auditing for the purpose of the Disclosure Guidance and Transparency Rules, and being financial experts for the purposes of the Sarbanes-Oxley Act. All Committee members are independent for the purposes of the Code, and all meet the SEC independence criteria. The Committee, as a whole, have competence relevant to the sector in which the Company operates, by virtue of their experience of working in science-driven, healthcare and/or pharmaceutical industries, or as a result of their tenure with AstraZeneca. The Committee members' qualifications, skills and experience are detailed in their biographies on pages 68 and 69 and meeting attendance is shown on page 67.

Role of the Committee

The Committee's responsibilities were updated in the year to include the review of, and reporting to the Board on, matters related to sustainability reporting and the relationship with the sustainability assurance provider. The Committee reports to the Board on the principal matters it considers and any significant concerns it has or that have been reported to it.

Attendance at Committee meetings

Routine attendees at Committee meetings include the CFO; the Chief Human Resources Officer, Chief Compliance Officer and General Counsel; the VP, Ethics & Transparency and Deputy Chief Compliance Officer; the Deputy General Counsel; the VP, Group Internal Audit; the SVP, Finance, Group Controller and Head of Global Finance Services; and the Company's external auditor. Diana Layfield attended Committee

meetings during the year when the Committee reviewed cybersecurity risks. KPMG attended Committee meetings from July 2025 as part of the audit transition post independence, as well as attending some sessions in their role as the sustainability assurance provider. The Committee, and separately the Committee Chair, also meet privately and on an individual basis with attendees which helps ensure the effective flow of material information between the Committee and management. The CEO and other members of the SET attend when required by the Committee.

Activities during the year Financial reporting

Effective internal controls, appropriate accounting practices and policies, and the exercise of experienced judgement by the Committee and the Board underpin AstraZeneca's financial reporting integrity.

The Committee's activities in this area in 2025 included:

- Reviewing key elements of the Financial Statements and the estimates and judgements contained in the Group's financial disclosures, as well as considering the appropriateness of management's and the external auditor's analysis and conclusions on judgemental accounting matters. The significant financial reporting issues considered are described in detail in the table on pages 88 and 89. Further information on the significant accounting matters considered is included within our Group Accounting Policies from page 129.
- Considering the completeness and accuracy of the Group's reported financial performance against its internal and external key performance indicators on a quarterly and annual basis.
- Reviewing the preparation of the Directors' Viability Statement and considering the adequacy of the analysis supporting the assurance provided by that statement, as well as the going concern assessment and adoption of the going concern basis in preparing this Annual Report and the Financial Statements.
- Reviewing quarterly updates from both management and PwC on the programme of activities relating to control over financial reporting and the effectiveness of testing that has been performed across the internal control environment.
- Considering the external auditor's reports on its audit of the Group Financial Statements, as well as reports from management, Global Compliance and the external auditor on the effectiveness of our system of internal controls and, in particular, our internal control over financial reporting. This included consideration of compliance with applicable provisions of the Sarbanes-Oxley Act, in particular, the status of compliance with the programme of internal

controls over financial reporting implemented pursuant to section 404 of that Act.

- Discussing financial reporting considerations in relation to significant transactions that occurred in the year including the acquisition of EsoBiotec and FibroGen China, the amortisation and impairment of intangible assets, restructuring programmes, the addition of the Product Revenue subtotal and the presentation of Alliance Revenue, Collaboration Revenue and Gross Margin metrics.
- Reviewing, with appropriate challenge, the outcomes from the Group's budgeting and forecasting process for the near term, including capital expenditure projections.

The Committee was pleased to receive a formal correspondence from the Financial Reporting Council (FRC), which informed us that the FRC had conducted both a limited scope review of our supplier finance arrangements disclosures in the 2024 Annual Report, as well as a separate review of our reporting against certain principles and provisions of the Code, and concluded with no questions or queries that required our attention. The Committee also noted that the Group received formal communication from the Council for Swedish Financial Reporting Supervision, which had reviewed our 2024 Annual Report and accordingly submitted questions. Following receipt of our responses to these questions, the Council had no further questions and satisfactorily closed the review.

Risk identification and management

The Committee received quarterly updates on the Company's risks, which informed the Committee's agenda and targeted deep-dive reviews. These activities were complemented by the Committee's review of the risk management framework (including principal and emerging risks), which enabled the Committee to review and challenge the effectiveness of the Company's risk management and internal control systems.

The Committee also reviewed the Viability Statement and considered, in detail, the validity of each scenario and also assessed whether proposed mitigations were viable.

Cybersecurity risk, digital security and information governance

The Committee noted that the approach to identifying, assessing and managing cybersecurity risk is integrated within our Group-wide approach to risk management, with failure in information technology and cybersecurity identified as a Principal Risk. The Committee conducted regular reviews of cybersecurity risks, the effectiveness of existing mitigations and the need for additional mitigations. These reviews are supported by senior management, GIA and other assurance providers.

 The full role of the Audit Committee is set out in its terms of reference, available at www.astrazeneca.com.

 For more information on:

The basis of preparation of the Financial Statements on a going concern basis, see page 224 and in the Financial Statements, see page 129.

The significant financial reporting issues considered, see the table set out on pages 88 and 89.

The Viability Statement, see page 46 and the Principal Risks faced by the Group, see Risk Overview from page 47.

Digital technologies, see page 36.

Sustainability reporting

The Committee is responsible for reviewing the approach, key elements and principal disclosures related to sustainability reporting in the Company's annual reports, Form 20-F filings and quarterly results announcements. The Committee's activities in this area included:

- Review of the Group's double materiality assessment, Task Force on Climate-related Financial Disclosures (TCFD) disclosures and the EU Taxonomy disclosures in this Annual Report. These statements, as well as the Sustainability Data Annex, are also reviewed by the Sustainability Committee to support the Committee's review.
- Reviewing quarterly updates by management on proposed and updated regulations by the EU, Sweden, the UK and the International Sustainability Standards Board on sustainability reporting and the Group's approach to ensure compliant and proportional disclosures in the 2025 Annual Report.
- Considering the sustainability assurance provider's quarterly reports covering assurance work carried out in the period, including any findings and recommendations.

The Committee oversaw the conduct and performance of the sustainability assurance provider, KPMG, through its review and challenge of the scoping and assurance plan, and monitoring performance against the plan. The Committee also reviewed the effectiveness of KPMG as the sustainability assurance provider and concluded that the sustainability assurance process was effective for the year ended 31 December 2025.

Legal and Compliance

The Committee's activities in this area included reviewing:

- Quarterly reports from the Legal function to monitor the status of significant litigation matters and governmental investigations.
- Quarterly reports from Global Compliance to provide oversight of key compliance incidents and the dispersion of incidents and related disciplinary actions across markets, business units and management hierarchy. The reports included insights from incidents, assurance activities and related corrective actions taken so that the Committee could assess the effectiveness of controls and monitor and ensure timely remediation.
- Reports at each Committee meeting allowing the Committee to continue its close monitoring of the ongoing investigations by Chinese authorities previously reported and described further in Note 30 on page 188.
- Reporting on compliance with AstraZeneca's Code of Ethics to ensure high ethical standards and that

AstraZeneca operates within the law in all countries where we operate.

- The monitoring, review, education and improvements made to support assurance that the risk of modern slavery and human trafficking is eliminated, to the fullest extent possible, from AstraZeneca's supply chain.
- Reports on external developments and enforcement trends and related risk mitigation measures across a variety of risks as well as specific updates from key markets and regions.

Internal Audit

The Committee reviewed GIA's activities, including:

- Reviewing quarterly reports of work carried out by GIA, including the status of follow-up actions with management. In 2025, GIA provided assurance over compliance with significant policies, plans, procedures, laws and regulations, as well as risk-based audits across a broad range of key business activities and continued its thematic reporting to the business. The 2025 audit plan was aligned to our key active risks and wider risk taxonomy. Separate meetings are arranged to discuss follow-up actions in more depth with specific teams, when required by the Committee.
- Carrying out the annual effectiveness review of GIA in late 2025 by considering its performance against the internal audit plan and key activities.
- Approving the 2026 internal audit plan, which is aligned to our key active risks and wider risk taxonomy.
- Considering the geographic presence, reach and capabilities of GIA and the appropriateness of the Group's resource allocation for this vital assurance function.

The Committee supports GIA's efforts to deploy its resources in line with the continuously evolving shape and size of the overall organisation and was satisfied with the quality, experience and expertise of the GIA function.

An independent External Quality Assessment of GIA is performed every five years and was last performed in 2021.

External audit

The Company's external auditor, PwC, provided quarterly reports to the Committee over key audit and accounting matters, and business processes, internal controls and IT systems.

The Committee oversaw the conduct, performance and quality of the external audit through its review and challenge of the coverage of the external auditor's audit plan and monitoring against it. The Committee maintained regular contact with PwC through formal and informal reporting and discussion throughout the year, with a continued focus on maintaining audit

efficiency and quality. The Committee also sought management's feedback on the conduct of the audit and considered the level of and extent to which the auditors challenged management's assumptions.

A number of interactions took place between Committee members and PwC during the year, outside of formal Committee meetings, to enhance the Committee's understanding of the audit process, including the Committee Chair attending and presenting at PwC's Account Planning Workshop in March 2025.

The Committee reviewed audit and non-audit fees of the external auditor during the year, including the objectivity and independence of the external auditor through the application of the Audit and Audit-Related Services Approval Policy, as described further on pages 86 and 87.

Engagement with employees and other stakeholders

The Committee regularly interacts with members of management below the SET and seeks wider engagement with the Group's employees and other stakeholders, during deep dive sessions at formal Committee meetings and as separate engagements.

Committee members undertook a mixture of in-person and virtual interactions with a wide range of teams from across the organisation. This included teams from IT/IS, Operations, Finance, International, Sustainability, and Business Development. Committee members visited AstraZeneca sites in Germany and Poland where they engaged with employees from across these markets, including through all-employee townhalls and Q&A sessions, and breakfasts and lunches with small groups of employees. They also received presentations which included introductions to AstraZeneca in these markets and business outlook, examples of AI use and innovation, and insights into different therapy areas and business areas. Philip Broadley also attended the GIA annual conference at the Alexion site in Ireland which provided the opportunity to engage with the wider GIA team.

The breadth of these interactions is crucial in enhancing the Committee's understanding of the business and provides valuable insights into the key issues and challenges relating to, and current and emerging risks associated with, our activities in these areas.

For more information on our Code of Ethics and on Anti-bribery and anti-corruption, see pages 34 and 35.

AstraZeneca's Modern Slavery Act Statement is available on our website, www.astrazeneca.com.

Audit Committee Report *continued*

The Committee welcomes the opportunity to engage directly with employees in these meetings which provide an opportunity to gauge employee sentiment and hear their views directly. The Committee also uses these interactions to communicate the importance it attaches to compliance and our 'speak up' culture.

Reporting and regulatory environment

The Committee has kept abreast of developments in the reporting and regulatory environment. This has included governance and audit reforms in the UK, changes to the UK Listing Rules, and developments in sustainability-related reporting requirements in a number of jurisdictions. The Committee focused considerable effort keeping abreast of proposed and enacted legislation over sustainability reporting, in particular the EU Omnibus 1 proposals simplifying the CSRD reporting requirements, among other changes. The Committee also reviewed the proposals to simplify EU Taxonomy disclosures requirements, as well as developments in the UK's Sustainability Reporting Standards and the IFRS Sustainability Reporting Standards.

Ensuring the quality of external financial and sustainability reporting to shareholders and other stakeholders is paramount to the Committee. This includes its assessment of the annual reports to ensure that, taken as a whole, they are fair, balanced and understandable (for which the process is described on this page). External validation of the Annual Report is an important indicator of the quality of our reporting.

Committee performance

The Committee conducted the annual evaluation of its own performance, referring to the Committee-specific results of the internal Board effectiveness review. The results were reported to, and discussed with, the Committee and the Board. The overall results of the review were positive, with the Committee described as being very effective. The review noted that the change in the Company's external auditor would continue to be a key focus area for the Committee over the coming year.

Fair, balanced and understandable assessment

At the Board's instruction, the Committee assessed this Annual Report to ensure that, taken as a whole, it is fair, balanced and understandable, and provides necessary information for shareholders to assess the Company's position and performance, business model and strategy. The Committee reviewed the governance structure and assurance mechanisms for the preparation of this Annual Report and the contributor and SET member verification process.

An early draft of this Annual Report was reviewed to assess proposed content and structural changes from the prior year, and to undertake a review of the reporting for the year, following which Committee members provided their individual and collective feedback. In line with its terms of reference, the Committee (alongside the Board) took an active part in reviewing the Company's quarterly results announcements and considered the Company's other public disclosures which are managed through its Disclosure Committee (the Committee was updated on matters considered by the Disclosure Committee regularly throughout the year). To aid its review further, the Committee also received a summary of the final Annual Report content, including AstraZeneca's successes and setbacks during the year and their placement within the document.

These processes allowed the Committee to provide assurance to the Board to assist it in making the required statement under the Code, as set out from page 71.

Internal controls

Information on the Company's internal controls is included in the Audit, risk and internal control section in the Corporate Governance Report on page 73. During the period covered by this Annual Report there was no change in our internal control over financial reporting that occurred that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

At the January 2026 Committee meeting, the CFO presented the conclusions of the evaluation by the CEO and CFO of the effectiveness of our disclosure controls and procedures that is required by Item 15(a) of Form 20-F as at 31 December 2025. Based on their evaluation, the CEO and the CFO concluded that, as at that date, the Company maintained an effective system of disclosure controls and procedures.

External auditor

PwC is the Company's external auditor. In April 2025, PwC was reappointed as the Company's auditor for the financial year ended 31 December 2025, its ninth consecutive year as auditor, having first been appointed for the financial year ended 31 December 2017, following a competitive tender carried out in 2015. Sarah Quinn continued as the lead audit partner at PwC for 2025 following her appointment in January 2022.

In February 2025, the Committee recommended, and the Board approved, the appointment of KPMG as the Company's auditor for the financial year ending 31 December 2026. Accordingly, a resolution to appoint KPMG as auditor will be put to shareholders at the Company's AGM in April 2026.

Audit, audit-related and other assurance services provided by the external auditor

The Committee maintains the Audit, Audit-Related and Sustainability Assurance Services Pre-Approval Policy (the Policy) for the pre-approval of all audit, audit-related and other assurance to ensure that the independence of the external auditor is not impaired.

Certain audit and audit-related services can be performed by the external auditor, subject to annual fee limits agreed with the Committee in advance. Pre-approved services below a trivial threshold (within the overall annual fee limit) require case-by-case approval by the SVP Finance, Group Controller and Head of Global Finance Services.

Pre-approved audit services include the annual financial statement audit (including quarterly and half-year reviews), Sarbanes-Oxley Act section 404 attestation, statutory audits for subsidiary entities, and other procedures which form an opinion on the Group's Consolidated Financial Statements. The pre-approved audit-related services, which the Committee believes reasonably related to the performance of the audit or review of the Company's Financial Statements, included certain services required by law or regulation, such as financial statement audits of employee benefit plans and capital market transactions. The Policy prohibits tax services, but allows for audit-related services like assurance on tax regulatory certificates.

The CFO (supported by the SVP Finance, Group Controller and Head of Global Finance Services), monitors all services provided by the external auditor. Authority for approving work exceeding the pre-agreed annual fee limits or the trivial threshold is delegated to the Committee Chair. Regular reports are provided to the Committee on the operation of the pre-approval procedures.

All services other than the pre-approved audit and audit-related services, require approval by the Committee on a case-by-case basis. In 2025, PwC provided audit-related services including interim reviews of the results of the Group for the period ended 30 June 2025 and other assurance services.

The increase to the statutory audit fee for 2025 is largely driven by scope changes and inflationary increases.

Fees for audit-related and other assurance services amounted to 6% of the fees payable to PwC for audit services in 2025 (2024: 10%). The Committee is mindful of the 70% non-audit services fee cap under EU regulation, together with the overall proportion of fees for audit and audit-related services in determining whether to pre-approve such services. Fees for audit-related and other assurance services payable to PwC in 2025 were 6% (2024: 11%) of average audit fees over 2022 to 2024 (2024: 2021 to 2023).

PwC were better placed than any alternative provider to provide these services in terms of their familiarity with the Company's business, skills, capability and efficiency with which they could deliver the relevant services. All such services were either within the scope of the pre-approved services set out in the Policy or were presented to Committee members for pre-approval and all such services were permitted by the FRC Ethical Standard.

Audit, audit-related and other assurance services

2025	\$33.8m
2024	\$31.8m

- Statutory audit fee
- Audit-related and other assurance services

Assessing external audit effectiveness

The Committee evaluated PwC's performance and its compliance with independence criteria under applicable statutory, regulatory, and ethical standards. PwC's effectiveness was assessed principally against four key factors: judgement; mindset and culture; skills, character and knowledge; and quality control. The assessment also took into account views of senior management within Finance and regular Committee attendees.

In evaluating audit quality, the Committee focused on PwC's effective use of experts and technology, and its appropriate challenge of management's judgements especially in relation to areas of significant financial reporting issues (as described in the table on pages 88 and 89). Areas reviewed by the Committee included PwC's extensive and detailed review of the

valuations and assumptions related to defined benefit pension valuations, assumptions and calculations over Gross to Net Product Sales, legal settlements in the year, intangible asset assumptions used in cash flow modelling, and the recognition and measurement of uncertain tax liabilities.

The Committee concluded that PwC's audit was effective for the year ended 31 December 2025.

External audit transition

Following a tender process in 2024, the Committee recommended, and the Board approved, that KPMG be appointed as the external auditor for the financial year ended 31 December 2026, subject to shareholder approval at the 2026 AGM.

To ensure a smooth transition from PwC to KPMG, the Committee has monitored the activities of the audit transition, which commenced on 1 May 2025. This included the review of, and the review of the delivery of, plans to ensure KPMG exited all services requiring a one-year 'cool-in' period ahead of 1 January 2026, and exited all prohibited services to be fully independent ahead of 1 May 2025. This involved completion of some KPMG engagements without renewal, moving existing KPMG engagements to alternative providers or in-housing other activities. In addition, the Committee considered, and received regular updates on, KPMG's audit transition plans. KPMG also attended selected Group meetings with management and PwC for the financial year ended 31 December 2025, and is scheduled to review PwC's 2025 audit files after completion of the audit.

The Committee also reviewed and approved updates to the Policy to require pre-approval of any services provided by KPMG outside of services related to their role as the sustainability assurance provider and incoming auditor during the transition period. From 1 May 2025, KPMG is subject to the same pre-approval process, with the SVP Finance, Group Controller and Head of Global Finance Services approving all such services below a trivial threshold, with any services above the threshold requiring Committee Chair approval.

All services approved for KPMG in the period are reported to the Audit Committee on a quarterly basis. All such services were either within the scope of the pre-approved services set out in the Policy or were presented to Committee members for pre-approval and all such services were permitted by the FRC Ethical Standard.

Fees for sustainability assurance of \$2.8m were payable to KPMG for the year ended 31 December 2025, in addition to fees of \$0.5m for the audit of subsidiaries and \$0.1m for other assurance services.

Regulation

The Committee considers that the Company has complied with the Competition and Markets Authority's Statutory Audit Services for Large Companies Market Investigation (Mandatory Use of Competitive Tender Processes and Audit Committee Responsibilities) Order 2014 and the FRC's Audit Committees and External Audit Minimum Standard in respect of its financial year commencing 1 January 2025. The Committee was also pleased to obtain notification from the FRC that our reporting on the audit tendering process in our 2024 Annual Report served as an example of good practice in accordance with the Code.

Further information about the audit and non-audit fees for 2025 is disclosed in Note 31 to the Financial Statements on page 191.

Audit Committee Report *continued*

Significant financial reporting issues considered by the Committee in 2025

Matter considered	Committee's conclusion and response	
Valuation of intangible assets See Financial Review from page 50 and Note 11 to the Financial Statements from page 151.	The Group carries significant intangible assets on its Consolidated Statement of Financial Position arising from the acquisition of businesses and intellectual property (IP) rights to medicines in development and on the market. Each quarter, the CFO reports on the carrying value of the Group's intangible assets as well as the specific assets identified as at risk of impairment. For at risk assets, the Committee receives information on the difference between the carrying value and management's current estimate of discounted future cash flows for these products (the headroom). Products will be identified as 'at risk' if the headroom is small or, for medicines in development, there is a significant potentially adverse event such as the publication of clinical trial results, which could significantly alter management's forecasts. The reviews also cover the impact on any related contingent consideration arising from previous business combinations.	The Committee considered the impairment reviews of the Group's intangible assets. Impairments of \$8 million arose in relation to launched products and \$210 million in relation to products in development. The Committee assured itself of the integrity of the Group's accounting policy and valuation models for its assessment and valuation of its intangible assets, including understanding the key assumptions and sensitivities within those models. The Committee also considered the internal and external estimates for the Group's cost of capital relative to the broader industry. The Committee was satisfied that the Group had appropriately accounted for the identified impairments.
Revenue recognition See Financial Review from page 50 and Note 2 to the Financial Statements from page 140.	The US is our largest single market and accounted for 43% of our Total Revenue in 2025. Revenue recognition, particularly in the US, is affected by rebates, chargebacks, returns, other revenue accruals and cash discounts.	The Committee pays attention to management's estimates of these items, its analysis of any unusual movements and their impact on revenue recognition. The Committee receives regular reports from management and the external auditor on this complex area. The US market remains highly competitive with diverse marketing and pricing strategies adopted by the Group and its peers. The Committee recognised the close monitoring and control by management of the overall gross-to-net deductions. The Committee reviewed management's proposal to update the presentation of Total Revenue reporting to add an additional subtotal on the face of the Statement of Comprehensive Income for 'Product Revenue' representing the summation of Product Sales and Alliance Revenue. The Committee concurred with management that the additional subtotal of revenue types with similar characteristics reflects the growing importance of Alliance Revenue.
Alternative performance measures (APMs) See Financial Review from page 50.	AstraZeneca reports APMs to provide helpful supplementary information to the IFRS measures to enable a better understanding of the Group's financial performance and position. In the current period, net restructuring charges of \$237 million were recorded within non-core items once the restructuring programmes were approved. Management carefully analyses the presentation of various items to ensure it is fair and balanced, and follows guidelines issued by the European Securities and Markets Authority and the SEC, as well as FRC thematic reviews.	The Committee carefully considered management's presentation of the non-core items and concurred with management's presentation. The Committee further considered management's assessment and recommendation to present the \$223 million legal provision costs as non-core items and concurred with management that the presentation was appropriate due to their significance and was consistent with classification in prior years. The Committee reviewed proposed disclosures for non-GAAP items in line with the various regulatory guidance and concurred with management that the presentation enabled additional helpful guidance.
Litigation and contingent liabilities See Note 30 to the Financial Statements from page 181.	AstraZeneca is involved in various legal proceedings considered typical to its business and the pharmaceutical industry as a whole, including litigation and investigations relating to product liability, commercial disputes, infringement of IP rights, the validity of certain patents, antitrust law, and sales and marketing practices. The Committee considers the Group's approach to disclosure of, and any liabilities for, relevant matters. In the current period, net legal provisions of \$223 million were recorded for two legal proceedings within non-core items once the criteria for recognising a provision were met.	Of the matters the Committee considered in 2025, the more significant included: the defence of the IP litigation for <i>Forxiga</i> and the commercial litigation relating to <i>Seroquel</i> XR and Syntimmune, Inc. The Committee carefully considered the progress of these legal proceedings and the timing of recognition of any provision and concurred with management's assessment. The Committee was satisfied that the Group was effectively managing its litigation risks including seeking appropriate remedies and continuing to defend its IP rights vigorously.

Matter considered

Committee's conclusion and response

Tax charges and liabilities

- See Note 5 to the Financial Statements from page 144.
- AstraZeneca's Approach to Taxation, which was published in December 2025 and covers its approach to governance, risk management and compliance, tax planning, dealing with tax authorities and the level of tax risk the Group is prepared to accept, can be found on our website, www.astrazeneca.com.

The Group has business activities around the world and incurs a substantial amount and variety of business taxes. AstraZeneca pays corporate income taxes, customs duties, excise taxes, stamp duties, employment and many other business taxes in all jurisdictions where due. In addition, we collect and pay employee taxes and indirect taxes such as value-added tax. The taxes the Group pays and collects represent a significant contribution to the countries and societies in which we operate. Tax risk can arise from unclear laws and regulations as well as differences in their interpretation.

The Committee reviews the Group's approach to tax, including governance, risk management and compliance, tax planning, dealings with tax authorities and the level of tax risk the Group is prepared to accept.

During 2025, the Committee considered the analysis provided by management in light of the emerging tariff situation and the potential impact to the Group and concurred with the presentation and reporting of these items.

The Committee was satisfied with the Group's practices regarding tax liabilities, including, most notably, its response to developments in the corporate income tax environment.

Segmental reporting

- See the Key Judgement within Note 7 to the Financial Statements from page 147.

Management has reviewed the developments in the year and determined the Group continues to operate as a single segment based on key decisions on resource allocation and performance monitoring being carried out at a Group level by the SET.

There were no significant changes in the Group's business during the year.

The Committee received reports from management regarding considerations for segmental reporting based on the current operations and management of the business.

The Committee considered the analysis provided by management and concurred with management that presenting AstraZeneca's performance under one segment was appropriate.

Retirement benefits

- See Financial Review from page 50 and Note 22 to the Financial Statements from page 161.

Accounting for defined benefit pension and other post-retirement benefits remains an important area of focus. The present value of these liabilities is sensitive to changes in long-term interest rates, future inflation and mortality expectations. The assumptions used to value the liabilities for the Group's main post-retirement benefit obligations are updated every quarter along with asset valuations.

The Group is cognisant of the regulatory environment and local requirements around funding levels and contributions. The Group monitors its defined benefit pension risks and provides input and support to local fiduciaries to ensure requirements are met.

The Committee monitors the funding level of the Group's defined benefit obligations on a quarterly basis, alongside key developments. The Committee was satisfied that the actuarial assumptions used to value liabilities were appropriate during the year.

The Committee was reassured by the Group's engaged and balanced approach to managing the risks associated with its defined benefit obligations including its contribution policy. The Committee reviewed and concurred with management's accounting and presentation of pension balances.

The Committee is aware of the need to adhere to local funding regulations and is satisfied that the Group is complying with requirements.

Directors' Remuneration Report



“We are committed to pay for performance, with stretching targets that align rewards to long-term shareholder value and our Ambition 2030.”

Remuneration Committee members

- Sheri McCoy (Chair)
- Philip Broadley
- Michel Demaré
- Diana Layfield¹
- Nazneen Rahman

¹ Appointed as a member of the Committee on 1 May 2025.

We aim to be clear and transparent in how we link the remuneration of our executives to the successful delivery of our strategy and shareholder returns.

The Directors' Remuneration Report contains the following sections:

- Chair's letter, page 90
- Remuneration at a glance, page 94
- How our performance measures for 2026 support the delivery of our strategy, page 95
- How the Remuneration Committee ensures targets are stretching, page 96
- Annual Report on Remuneration, page 97.

On behalf of the Board, I am pleased to present AstraZeneca's Directors' Remuneration Report for the year ending 31 December 2025.


We continued to advance our science, scale our global footprint and create long-term value for patients, society and shareholders. With Total Revenue of \$58.7 billion achieved for 2025 and the growth momentum seen across therapy areas and regions, strong

commercial execution has been matched with remarkable pipeline progress in new and existing modalities that we believe will redefine standards of care in the coming years.

Our strong performance over the last 10 years is reflected in our total shareholder return (TSR) which, at 307%, has significantly outperformed global and European pharma peer groups (197% and 65%, respectively).

How we have performed in 2025

Total shareholder return (TSR)



The role of the Remuneration Committee is set out in its terms of reference, available at www.astrazeneca.com.

More information on the TSR peer groups for PSP awards can be found on page 103.

Further detail of 2025 commercial and scientific performance can be found in the Strategic Report from page 10.

² Calculated using a three-month calendar average, from 1 October to 31 December, prior to the start and at the end of the relevant period.

Delivery against strategy – 2025 Group scorecard performance¹

	Target	2025 outcome
 Science and Innovation: Annual pipeline progression		
Pipeline progression events	29	36
Regulatory events	54	69
 Growth and Therapy Area Leadership²		
Total Revenue	\$58.2bn	\$59.0bn
 Achieve Group Financial Targets		
Cash flow ³	\$11.3bn	\$11.9bn
Core EPS ⁴	\$9.10	\$9.24

¹ For details of the Committee's consideration of Group scorecard outcomes and a description of performance measures, see from page 99.

² Total Revenue target and outcome are at 2025 budget rates of exchange.

³ The Cash flow measure is set and evaluated at the actual exchange rate and is evaluated by reference to net cash flow from operating activities less capital expenditure, adding back proceeds from disposal of intangible assets.

⁴ Core EPS target and outcome are at 2025 budget rates of exchange.

AstraZeneca's 2025 performance

Science and Innovation

2025 has seen continued strong scientific momentum in delivering our medicines to patients with the delivery of 97 regulatory events, with 69 contributing to the Group scorecard, which is 15 more than our target set at the beginning of the year. These included *Datroway* in China, *Calquence* and *Imfinzi* in Japan, and *Airsupra* in the US.

AstraZeneca's pipeline is in a catalyst-rich phase across all therapy areas, with 85% of programmes in the pipeline delivering positive news. These included studies under *Enhertu*, *Tagrisso*, *baxdrostat*, *laroprovstat* and *gefurulumab*.

Further details on the advancement of our medicines is provided in the Therapy Area Review from page 12 of the Annual Report.

Growth and Therapy Area Leadership

The Group has seen strong growth across all therapy areas, supported by a diverse and broad-based business. Total Revenue increased by 9% (8% at CER) to \$58,739 million, Oncology Total Revenue increased by 15% (14% at CER) to \$25,619 million, BioPharmaceuticals Total Revenue increased by 5% (5% at CER) to \$22,995 million and Total Revenue from Rare Disease medicines increased by 4% (4% at CER) to \$9,126 million.

This growth was powered by the Operations teams across the business collectively delivering 217 successful on-time market launches across the year.

Further details on the 2025 financial results can be found in this Annual Report from page 50.

People and Sustainability

We continue to focus on building a culture that attracts and retains diverse, world-class talent, and enables enterprise leadership and innovation at scale. We are investing in skills for the future, including AI and data capabilities, with more than 50,000 employees participating in our 'Thriving in the Age of AI' accreditation programme.

We continued to enhance succession planning and leadership depth across all therapy areas in support of our strategic commitments. Over 2025, more than 70% of changes within the executive cohort, which includes all employees at vice president level and above, were appointed from internal talent, reflecting the strength of our leadership pipeline and ongoing focus on developing and advancing colleagues.

Sustainability remains core to our strategy. We have continued to deliver against our Ambition Zero Carbon, with an 88.1% reduction in Scope 1 and 2 greenhouse gas (GHG) emissions since 2015. We are now focusing on Scope 3 emissions to deliver our ambition to achieve Science Based Net Zero by 2045. We have made good progress with our suppliers, with over 80% of eligible spend from suppliers committed to science-based targets. We have also announced the world-first approval for medicines containing a next-generation propellant (NGP) with near-zero global warming potential.

Further information on our progress in relation to our sustainability agenda can be found in the Annual Report in section People and Sustainability from page 40.

Directors' Remuneration Report *continued*

2025 Remuneration outcomes

Our remuneration decisions continue to be anchored in rigorous performance assessment. When approving annual bonus outcomes, we therefore considered the Group scorecard along with the business and individual performance over 2025 including other achievements across the enterprise such as advancing our People and Sustainability priorities. In that context, the Committee believes that the payments outlined below fairly reflect performance.

Annual bonus


When determining bonus outturns, the Committee considered the formulaic outcome from the Group scorecard along with wider business and individual impact and performance in 2025. This included consideration of Pascal's leadership of external strategy, investment, science momentum and sustainability; and Aradhana's success in ensuring financial resilience and operating leverage. The Committee determined to award an annual bonus equivalent to 184% of target (92% of maximum) to Mr Pascal Soriot and 162% of target (81% of maximum) to Dr Aradhana Sarin (equivalent to 276% and 162% of base pay respectively). Details of the factors considered to determine the bonuses are provided from page 99.

These outcomes align with the bonuses (as a percentage of maximum) paid to higher performing colleagues in the wider workforce.

Long-term incentives

Our long-term incentive (LTI) targets were set at a stretch level to incentivise and reward sustainable outperformance and as a result of three very strong years, our 2023 award will vest towards the upper end of the possible range. The three-year performance period for PSP awards granted to our senior leaders in 2023, ended on 31 December 2025. Awards for all participants will vest at 97% of maximum, as shown from page 102, and reflects continued strong performance.


2025 Annual bonus scorecard performance¹



	Achieved
Science and Innovation: Annual pipeline progression	85%
Growth and Therapy Area Leadership	72%
Achieve Group Financial Targets	66%

■ Achieved

2023 PSP performance



	Achieved
Science and Innovation: First approvals and NME volume over three years	100%
Growth and Therapy Area Leadership	100%
Net Cash flow	100%
Relative TSR	84%
Sustainability: Ambition Zero Carbon	100%

■ Achieved

¹ When determining bonus outturns, the Committee considered the formulaic outcome from the Group scorecard along with wider business and individual impact and performance in 2025, including sustainability achievements.

Implementation of the Remuneration Policy for 2026

Base pay for the CEO and CFO has been reviewed in line with our Remuneration Policy and will increase by 4%, in line with the average salary increases for the wider workforce in the UK. Our emphasis remains on delivering performance-related pay and setting stretching targets. Our short and long-term incentive structures remain unchanged, maintaining continuity and alignment with Ambition 2030.

We have made a minor adjustment to the Sustainability metric for the 2026 PSP. Our commitment to reducing value chain emissions remains unchanged, for the 2026 PSP we will be focussing in on the NGP transition, as set out in more detail on page 105.

There are no changes to executive remuneration arrangements relating to the harmonisation of our listing structure.

Annual General Meeting and shareholder engagement

The Committee was pleased that the 2024 Directors' Remuneration Report received support from 96.4% of shareholders at the Company's 2025 Annual General Meeting (AGM). We were also pleased to receive a 99.36% vote in support of the harmonisation of our global listing to provide access to the broadest available pool of capital to enable our next phase of growth.

Following the AGM, we have undertaken extensive engagement with shareholders and proxy advisors to discuss our executive remuneration arrangements. We reached shareholders representing over 44.5% of our issued share capital, through written communications and meetings with several of our top shareholders and proxy advisors. We are grateful for the time investors have spent with us and welcome their ongoing feedback.

Throughout this engagement we reiterated our commitment to the clear linkage between pay outcomes and performance delivered for investors, and used this year's consultation period as an early opportunity to gather shareholders' initial views on what we should be considering as we look ahead to reviewing our Remuneration Policy for approval in 2027.

During these discussions we highlighted a key challenge we face relating to pay compression. The Policy provides the overarching framework for reward across all AstraZeneca employees globally and is designed to enable us to attract and retain talent at all levels, countries and functions. The CEO's maximum variable opportunity sets an effective ceiling for reward, which presents challenges when recruiting and retaining senior executive roles below the CEO level.

Independent market data shows that LTI opportunities for global top R&D executives at the median and upper quartile are materially higher than UK market norms. Our track record of strong performance means our leaders are highly visible and regularly targeted by competitors, underscoring the importance of our Policy enabling competitive reward globally while managing pay compression risks below Executive Director level.

Given our size, complexity, global footprint, the pay compression dynamics outlined above, and the realities of our talent market, we consider global pharmaceutical peers as the most relevant peer group when benchmarking executive remuneration. External market data indicates that our CEO's target total direct compensation remains below the global median and we aspire to close this gap over time.

Our Policy will be due for renewal at the 2027 AGM. We look forward to continuing our engagement with shareholders over the course of next year as we evaluate how we can ensure that our Policy allows us to offer market competitive remuneration for our key talent at Board level and below, while maintaining our strong focus on pay for performance to incentivise the sustainable value creation for our shareholders over the long term.

Key Committee activities in 2025


In May 2025, the Committee welcomed Diana Layfield, a member of the Board and the Science Committee since 2020 to the Remuneration Committee.

AstraZeneca remains committed to equitable and market-competitive total reward for our global workforce. In 2025, the Committee continued to review information regarding the participation and design of long-term

Positioning of our CEO against our pharmaceutical peers

Target Total Direct Compensation (base pay, target annual bonus and target LTI)

(£m)



■ Global pharmaceuticals¹ ■ European pharmaceuticals²

¹ Global pharma peer group consists of: AbbVie Inc., Amgen Inc., BMS, Eli Lilly and Co, Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc. and Pfizer Inc.

² European pharma peer group consists of: Bayer Aktiengesellschaft, GSK plc, Merck KGaA, Novartis AG, Novo Nordisk A/S, Roche Holding AG and Sanofi.

Remuneration includes base pay, target annual bonus and the expected value of LTI awards. Benchmarking data has been provided by the Committee's independent adviser.

incentives across the organisation, including eligibility, vehicle mix and performance alignment. The Committee actively considers relevant data to ensure equitable pay decisions and incentive outcomes, and supports management's ongoing activities to embed bias-free reward decision making, strengthen manager capability and evolve tools that enable fair and consistent outcomes across geographies, job families and the entirety of our workforce.

We have sustained our commitment to setting performance targets that are aligned to our strategy, transparent, stretching and rigorously approved. We apply a comprehensive and robust process working in tandem with the Science, Sustainability and Audit Committees, along with our external advisors to set stretching targets and to assess outcomes in the context of our internal ambitions and market consensus. We believe our pay for performance approach has been an important factor in supporting AstraZeneca's success.

In addition to overseeing the individual reward arrangements for the Chair, Executive Directors, SET and Company Secretary, the Committee has spent time

reviewing the reward in place for our critical talent and individuals with potential to become SET members to ensure that we are utilising the Policy appropriately. This is particularly important given the pressures we face in demand for our talent on a global basis.

Next steps

We trust that this Remuneration Report provides a clear explanation of how the Policy has been implemented in 2025 and how remuneration outcomes reflect performance. We ask for your support for the Directors' Remuneration Report at the Company's AGM in April 2026, and we welcome your continued dialogue and feedback.


Sheri McCoy

Chair of the Remuneration Committee

Remuneration at a glance


What our Executive Directors earned

Executive Directors' realised pay 2025 outcomes



Fixed pay consists of base pay and benefits funding. Further information on Executive Directors' realised pay for 2025 is on page 97.

Formulaic outcome of 2025 Group scorecard and 2023 PSP




See from page 97 for further information on the annual bonus and PSP outcome. When determining bonus awards, the Committee considered the formulaic outcome from the Group scorecard along with wider business and individual impact and performance in 2025, including Sustainability achievements.

Looking ahead

Executive Directors' remuneration for 2026


	Fixed remuneration	Annual bonus	Long-term incentives	Shareholding requirement	Post-cessation shareholding requirement
Pascal Soriot (CEO)	Base pay: £1,606,887 Benefits fund Pension: £176,758 (equivalent to 11% of base pay)	Max: 300% base pay Target: 150% base pay Deferred: 50% for three years	Max: 850% base pay Performance period: three years Holding period: two years	Holding requirement: 1,150% base pay	Holding requirement: 1,150% base pay for two years post-cessation
Aradhana Sarin (CFO)	Base pay: £1,029,137 Benefits fund Pension: £113,205 (equivalent to 11% of base pay)	Max: 200% base pay Target: 100% base pay Deferred: 50% for three years	Max: 550% base pay Performance period: three years Holding period: two years	Holding requirement: 750% base pay	Holding requirement: 750% base pay for two years post-cessation

CEO fixed vs performance-linked (%)



Based on maximum payout scenarios for the CEO assuming maximum of 300% and 850% of base pay for annual bonus and PSP respectively.

CFO fixed vs performance-linked (%)



Based on maximum payout scenarios for the CFO assuming maximum of 200% and 550% of base pay for annual bonus and PSP respectively.

Executive Directors' variable pay

	'26	'27	'28	'29	'30
Annual bonus (halved) ¹					
PSP					

Performance period
 Deferral period
 Holding period

¹ Half of the annual bonus is deferred for three years.

See from page 99 for further details on plan design.

How our performance measures for 2026 support the delivery of our strategy

AstraZeneca aims to continue to deliver great medicines to patients while maintaining cost discipline and a flexible cost base, driving operating leverage and increased cash generation. To incentivise and reward delivery of great performance over the short and longer term, the Committee carefully considers the balance of science, financial and sustainability measures between the annual bonus and PSP.

Our focus on incentivising innovative science aligns with our patient-centric culture, as we strive to push the boundaries of science to deliver life-changing medicines to patients. The 2026 performance measures are closely aligned with our strategic priorities, as shown below.

For more information about our strategic priorities, see from page 10.

For more information about the 2026 performance measures, see from page 105.

Key

● Annual bonus ● PSP ○ KPI

Strategic pillar

Science and Innovation

Remuneration performance measures

Science indices ●●○

Our science measures incentivise the development of NMEs and the maximisation of the potential of existing medicines.

Bonus performance is assessed on pipeline progressions through Phase II and Phase III clinical trials. These reflect the outcome of nearer-term strategic investment decisions. As registrational Phase II trials become more common practice (for example in relation to cell therapy), pipeline progression events for bonus performance includes pivotal investment decisions for registrational Phase II and Phase III trials.

In contrast, PSP performance is assessed on the volume of NMEs in Phase III and the registration stage, which reflects the outcome of longer-term strategic investment decisions.

Additionally, we measure regulatory submissions and approvals for bonus, and regulatory approvals for PSP to drive the conversion of scientific progress into commercial revenue over the short term (bonus) and the longer term (PSP).

Together, these science measures incentivise innovation and sustainable success along the length and breadth of the pipeline, leading to commercial growth.

Strategic pillar

Growth and Therapy Area Leadership

Remuneration performance measures

Total Revenue ●●○

Our Total Revenue measure is included in the bonus and the PSP, reflecting the importance of incentivising sustainable growth in both the short and longer term.

Financial targets

Achieve Group Financial Targets

Remuneration performance measures

Cash flow ●●○

Ensures that we can sustain investment in our pipeline and therapy areas while at the same time meeting our capital allocation priorities. Cash flow is included in both the bonus and the PSP, ensuring a focus on both shorter- and longer-term cash flow generation and balance sheet strength.

Core EPS ●○

Incentivises operational efficiency and cost discipline and remains a key measure of our profitability and a focus for our investors.

Total Shareholder Return (TSR) ●

Assessed relative to our peer group of companies, the TSR measure rewards positive performance that our shareholders also directly benefit from. This measure incentivises outperformance versus our peer group and promotes the delivery of long-term sustainable returns for our shareholders.

Strategic pillar

People and Sustainability ●

We are committed to people and making a difference to society. Assessment of performance against this pillar is captured through our holistic review of each Executive Director's individual performance (detailed on pages 100 and 101) as part of the final determination of annual bonus, including consideration of our progress against our People and Sustainability aspirations:

- Deliver a great employee experience by promoting inclusion and diversity and fostering personal growth and enterprise leadership.
- Leading on climate, equity and resilience by accelerating Ambition Zero Carbon, leading in addressing the connection between climate and health, and driving health equity and system resilience.
- Enabling an agile organisation by developing and implementing Gen AI strategy, investing in site footprint and workplaces, and simplifying processes.

Value Chain Emissions ●

This measure supports our ambition to reducing our Scope 3 GHG emissions in our value chain and the 2026 PSP, focuses on emissions reductions due to the NGP transition, adopting a carbon intensity metric expressed as kilograms of CO₂ equivalent per pMDI device.

How the Remuneration Committee ensures targets are stretching

We set stretching targets that incentivise our leaders to deliver exceptional performance, and to drive sustainable results for our patients, our employees and our shareholders. For the 2026 targets:

- The Committee has reviewed the proposed targets against internal and external forecasts, including market consensus and peer group performance, and is comfortable that the level of stretch promotes truly exceptional performance in line with the delivery of the Ambition 2030.
- Financial performance goals under the 2026 Group scorecard and PSP would require achievement and growth in excess of the average expected of the industry, particularly when taking the significant capital investment expected to be made during the performance period.

Consistent with our approach in prior years, we undertake the following robust process when setting annual bonus and PSP targets and assessing outcomes:

Stage 1 – Target setting	Science targets are based on a cohort of scientific opportunities specified at the start of the performance period. Opportunities represent potential achievements through the pipeline, from an early stage where our scientists work to discover new molecules, through to ultimately obtaining approvals and getting new medicines to patients. Rewarding success at each stage recognises the importance of creating and maintaining a long-term sustainable pipeline. Stretch of proposed targets is reviewed by the Science Committee, taking into account factors such as the expected net present value of the pipeline and the anticipated financial contribution it will make, past performance, the external regulatory environment, and internal resourcing and efficiencies. Targets for realisation of these opportunities are ambitious. The outlook for the delivery of the pipeline is increasingly challenging given the rising proportion of new modalities and innovation, representing previously untested science. Proposed targets for the Sustainability measure are reviewed and endorsed by the Sustainability Committee and exceed the 1.5°C Paris Agreement glide path. Our decarbonisation ambitions are increasingly challenging to deliver in the context of broader enterprise growth, particularly the higher supply volumes required to fulfil demand for our medicines.	Financial target metrics align to the Board-approved Mid-Term Plan (MTP), which sets the financial framework over three years. The MTP process includes detailed business reviews to challenge plans and efficiencies. The Committee sets targets considering consensus expectations, independent analytics, and anticipated challenges and opportunities. Total Revenue and Core EPS are set and assessed at budget exchange rates to neutralise currency impacts; the Committee also compares targets to prior plans at constant exchange rates to ensure ambitious growth. Where consensus differs from internal forecasts, the Committee investigates drivers (as an example, capital expenditure assumptions). This range of data is used by the Committee to ensure the stretching nature of performance targets is robustly tested. Additionally, the PSP TSR measure is designed to reward strong performance relative to our peers.
Stage 2 – Committee review and approval of targets	The Committee thoroughly reviews and challenges targets proposed by management, working in partnership with the Science and Sustainability Committees to ensure targets are stretching and robust. The Committee is provided with considerable supporting material for each metric and receives briefings from senior leaders across AstraZeneca. The science measures are reviewed and endorsed by the Science Committee, with a focus on ensuring that the targets will result in long-term sustainable value creation, and the Committee reviews and approves the full cohort of opportunities. The sustainability metric within the PSP is aligned to our Ambition Zero Carbon goal and reflects the importance of decarbonisation, with a focus on value chain (Scope 3) GHG emissions.	The sustainability metric has been reviewed and endorsed by our Sustainability Committee. Committee members participate in the full Board discussions on the strategy, MTP and budget, which form the basis for the targets. The Committee considers how proposed financial targets align with the MTP and budget; prior years' outcomes (in absolute terms and against target); how the ambition has changed from the prior MTP and budget; external guidance the Company has provided or plans to give; consensus from external financial analysts and factors it may be impacted by; and the underlying assumptions. Statistical analysis conducted by the Committee's independent adviser is also used to assess the proposals. This includes an assessment of historical levels of performance volatility.
Stage 3 – Performance assessment	At the end of the period, final performance against each metric is assessed. Outcomes are calculated based on performance against each weighted metric. Each performance measure is assessed on a standalone basis, so that underperformance against one measure cannot be compensated for by overperformance against another. Data for the metrics is taken from the Group's financial reports which are reviewed by the Audit Committee and approved by the Board.	The Science Committee independently considers and informs the Committee whether science achievements represent a fair and balanced outcome, reflecting genuine achievements and pipeline progression. The sustainability metric within the PSP is validated by the Sustainability Committee. Apart from Cash flow, which is set at actual rates of exchange, financial metrics are set at budget rates of exchange and evaluated at those rates at year end, which means they are not directly comparable year-on-year. The Committee is, however, provided with data to allow it to conduct year-on-year analyses.
Stage 4 – Determination of Executive Directors' bonuses	For annual bonus, the fairness of the formulaic Group scorecard outcome is considered in the context of overall business performance and the experience of shareholders. Such considerations include TSR performance and each Executive Director's personal impact on the delivery of the strategy, wider Sustainability performance and other organisational achievements, such as the realisation of technology-based milestones. Each year, there are important individual deliverables beyond the scorecard metrics which are taken into account when determining individual bonuses.	Having considered the Group scorecard outcome, overall business performance, the experience of shareholders and individual performance, as detailed from page 100, the Committee carefully determines a final bonus outcome for each Executive Director that is considered fair and appropriate for the year's performance, and is in the best interests of shareholders.

Annual Report on Remuneration

Key:

Audited information

Content contained within the Audited panel indicates that all the information within has been subject to audit.

Audited

Planned implementation for 2026

Content contained within a grey box indicates planned implementation for 2026.

The elements within the Executive Directors' realised pay are colour coded:

- Fixed remuneration has a light blue border and is found on page 98.
- Annual bonus has a yellow border and can be found on pages 98 to 102.
- Long-term incentives (LTIs) has a magenta border and can be found on pages 102 to 105.

Executive Directors' remuneration

This section of the Directors' Remuneration Report sets out the Executive Directors' remuneration for the year ended 31 December 2025, alongside the remuneration that will be paid to Executive Directors during 2026.

Executive Directors' realised pay for 2025 (single total figure of remuneration)

Audited

The table below sets out all elements of realised pay receivable by the Executive Directors in respect of the year ended 31 December 2025, alongside comparator figures for 2024. This includes the vesting of PSP awards from 2023 following the three-year performance period. These shares are subject to a further two-year holding period. The increase in AstraZeneca's share price over the period of grant to vest has provided the Executive Directors with a significant increase in value of the equity components of their reward. £1,981,570 of Mr Soriot's and £878,592 of Dr Sarin's 2025 realised pay is attributable to share price increases. The benefit of the increased share price has also been experienced by shareholders.

The Committee did not exercise any discretion in relation to the LTI outcomes or the formulaic outcome of the Group scorecard.

£'000		Base pay	Taxable benefits	Pension	Other	Total fixed	Annual bonus	Long-term incentives ¹	Total variable	Single total figure	Share price appreciation as % of single total figure
Pascal Soriot	2025	1,545	143	170	–	1,858	4,259	11,579	15,838	17,696	11%
	2024	1,486	138	163	–	1,787	3,499	11,345	14,844	16,631	9%
Aradhana Sarin	2025	990	10	109	–	1,109	1,603	5,134	6,737	7,846	11%
	2024	951	14	105	–	1,070	1,494	5,030	6,524	7,594	9%

¹ Long-term incentive values disclosed in 2024 have been recalculated using the average closing share price for the three months ended 31 December 2025. See page 102.

The following sections provide further detail on the figures in the above table, including the underlying calculations and assumptions and the Committee's performance assessments for variable remuneration.

The Annual bonus section is set out from page 98 to 102 and the Long-term incentives section from page 102 to 105. Information about the Executive Directors' remuneration arrangements for the coming year, ending 31 December 2026, is highlighted in grey boxes.

Annual Report on Remuneration *continued*

Fixed remuneration

Base pay

When awarding base pay increases, the Committee considers, among other factors, base pay increases applied across the UK employee population. The increase to the current Executive Directors' base pay for 2026 will be in line with the UK all-employee base pay budget at 4%.

£'000	2025		2026	
	Change from 2024	Base pay	Change from 2025	Base pay
Pascal Soriot	4%	1,545	4%	1,607
Aradhana Sarin	4%	990	4%	1,029

Audited

Taxable benefits

The totals within taxable benefits include the CEO's allowance under AstraZeneca's UK Flexible Benefits Programme, under which he can select benefits or take his allowance, or any proportion remaining after the selection of benefits, in cash (£120,231 taken as cash). In 2025, benefits included additional healthcare/death in service insurance, as well as personal tax advice. The value of this personal tax advice provided to each Executive Director in 2025 was £17,891 and £8,656 for the CEO and CFO respectively.

£'000	2025	2026
	Total taxable benefits	Taxable benefits
Pascal Soriot	143	In line with 2025
Aradhana Sarin	10	In line with 2025

Audited

Pension

The Executive Directors receive a pension allowance of 11% of base pay, in line with the wider UK workforce. During 2025, the Executive Directors took their pension allowance as a cash alternative to participation in a defined contribution pension scheme. Neither of the Executive Directors has a prospective entitlement to a defined benefit pension by reason of qualifying service.

£'000	2025			2026
	Pensionable base pay	Pension allowance	Cash in lieu of pension	Pension allowance
Pascal Soriot	1,545	11% of base pay	170	11% of base pay
Aradhana Sarin	990	11% of base pay	109	11% of base pay

Audited

Annual bonus

2025 Annual bonus

Annual bonuses earned in respect of performance during 2025 are included in the realised pay table.

Detailed information on the Committee's approach to target setting and assessment of performance is set out from page 96.

Half of the Executive Directors' pre-tax bonus is compulsorily deferred into Ordinary Shares which are released three years from the date of deferral. Bonuses are not pensionable.

£'000	Annual bonus in respect of performance during 2025				
	Bonus potential as % of base pay		Bonus payable in cash	Bonus deferred into shares	Total bonus awarded
	Target	Maximum			
Pascal Soriot	150%	300%	2,129.5	2,129.5	4,259 92% max
Aradhana Sarin	100%	200%	801.5	801.5	1,603 81% max

Audited

Annual bonus *continued***Audited****2025 Group scorecard assessment**

Performance against the 2025 Group scorecard is set out below.

The Group scorecard is used in the determination of bonus payouts for all AstraZeneca employees. Each metric within the scorecard is assessed on a standalone basis and has a defined payout range.

Performance below the specified threshold level for a metric will result in 0% payout for that metric. 100% of target bonus will pay out for on-target performance, and 200% of target bonus will pay out for performance at or above maximum. Performance between threshold and maximum is assessed on a pro rata basis. Maximum bonus payouts for the CEO and CFO for 2025 were capped at 300% and 200% of base pay respectively. The payout range for each metric is capped in line with each Executive Director's maximum bonus opportunity to ensure underperformance against one metric cannot be compensated for by overachievement against another. The table below shows the scorecard formulaic outcomes for the CEO and CFO as a percentage of target bonus.

2025 Group scorecard performance measures and metrics	Weighting	Threshold (0% payout)	Target (100% payout)	Maximum (200% payout)	Outcome	Formulaic outcome (% of target bonus)
Science and Innovation measures						
 Science and Innovation: Annual pipeline progression						
☐ Pipeline progression events	15%	15	29	44	36	22%
☐ Regulatory events	15%	38	54	70	69	29%
Subtotal – Science and Innovation measures	30%					51%
Financial measures						
 Growth and Therapy Area Leadership						
☐ Total Revenue (\$bn)	30%	56.5	58.2	60.0	59.0	43%
 Achieve Group Financial Targets						
☐ Cash flow (\$bn)	20%	9.6	11.3	13.0	11.9	27%
☐ Core EPS (\$)	20%	8.65	9.10	9.56	9.24	26%
Subtotal – Financial measures	70%					96%
Total	100%					147%

Key: ■ Bar charts are indicative of 2025 performance; scales do not start from zero.

Due to rounding, the total formulaic outcome differs from the arithmetic total of the individual metric outcomes disclosed above.

Pipeline progression events include Phase II starts and progressions, and NME and life-cycle management (LCM) positive pivotal trial investment decisions. Regulatory events include NME and major LCM regional submissions and approvals. Further detail on our Science and Innovation strategic priority and these events is included from page 10 of this Annual Report.

In 2025, the Growth and Therapy Area Leadership measure was based on Total Revenue. The Total Revenue and Core EPS measures are both set and evaluated at budget exchange rates at the beginning of the year and evaluated at those rates at the end of the performance period, so that any beneficial or adverse movements in currency, which are outside the Company's control, do not impact reward outcomes. The Cash flow measure is set and evaluated at the actual exchange rate and is evaluated by reference to net cash flow from operating activities less capital expenditure, adding back proceeds from disposal of intangible assets, to be fully transparent with all elements easily derived from the Group IFRS Cash Flow Statement.

Annual Report on Remuneration *continued*

Annual bonus *continued*

Audited

Overall assessment

During 2025, the Executive Directors' individual performance was assessed in the following key areas which align with the Company's objectives.

Pascal Soriot

In a year marked by significant geopolitical uncertainty, Mr Soriot successfully led AstraZeneca to deliver exceptional growth and another set of strong results, advancing AstraZeneca towards Ambition 2030 and helping to reshape the future of healthcare. Key achievements considered by the Committee are set out below.

Growth and Therapy Area Leadership

Over 2025, Mr Soriot has fostered collaboration and shaped groundbreaking agreements with governments and policy makers which have supported the strategic business and policy priorities, enabling future growth for AstraZeneca. These included an industry leading agreement with the US government providing greater clarity over pricing and lowering the prices of medicines for many patients in the US, engagements with the Chinese government and science leaders reinforcing AstraZeneca's long-term commitment to China, and announcements of some of the largest R&D and manufacturing investments in AstraZeneca's history at a number of strategic locations globally.

Under Mr Soriot's leadership, AstraZeneca delivered more medicines to patients around the world in 2025 than ever before, reflected in Total Revenue for the year increasing by 9% to \$58.7 billion.

Science and Innovation

Under Mr Soriot's leadership in 2025, significant progress has been made with transformative modalities which will drive Ambition 2030. This included capitalising on new pipeline opportunities in weight management, radioconjugates and next generation immunology bispecifics. The Company also expanded efforts in genomic medicine and cell therapy including the highly competitive acquisition of EsoBiotec.

Mr Soriot has continued to bring his judgement to bear in relation to investments in the pipeline which has resulted in industry-leading momentum across all therapy areas. 2025 saw an unprecedented proportion of programmes in the pipeline delivering positive news, including 16 Phase III positive clinical readouts. Results to highlight include the delivery of strong clinical data on surovatamig (which has the potential to become a backbone standard of care across six haematologic malignancies) and the acceleration of baxdrostat from Phase II acquisition to delivery of Phase III data and regulatory filing in two years. Other notable studies with positive readouts included *Enhertu*, *Tagrisso*, *laroprovstat* and *gefurilumab*.

2025 also saw the approval of *Beyontra*, the ninth of the 20 new medicines AstraZeneca hopes to deliver by 2030.

People and Sustainability

Mr Soriot has continued to champion a culture of learning and growth across the enterprise, sponsoring a range of learning and development offerings that enable employees and leaders to perform, grow, adapt and belong. In 2025, key investments have been made to build on team members' strengths and accelerate the ability to deliver the 2030 Ambition. Programmes include "Leading Ambition 2030" targeted at senior leaders, "Thriving in the Age of AI", with over 102,000 certificates awarded across the levels of accreditation in 2025, and "Manager in Action" in which over 1,800 line managers have participated so far.

With AI reshaping the pace of science and business, Mr Soriot announced the creation of a dedicated Enterprise AI unit which will rapidly advance enterprise AI transformation. This unit will deliver a single data foundation and accelerate high value AI initiatives that will enable the delivery of Ambition 2030.

Externally, AstraZeneca retained the EcoVadis Gold Medal ranking; was recognised for bold sustainability leadership as one of the top 20 Times Most Sustainable Companies, ranking in the 2025 FT Europe Climate Leaders List, inclusion in TIME World's Best Companies 2025, along with rankings in the Forbes World's Top Companies for Women, Forbes World's Best Employers, TIME World's Best Companies and the Financial Times Diversity Leaders 2026.

Internally, Mr Soriot has ensured focus remains on industry-leading progress for Ambition Zero Carbon with Scope 1 and Scope 2 Greenhouse Gas (GHG) reductions being ahead of the target for the end of 2025. 2025 also saw the first regulatory approvals for the transition of the portfolio of inhaled medicines to the innovative next-generation propellant with near-zero Global Warming Potential, progressing AstraZeneca's Scope 3 GHG decarbonisation strategy.

Annual bonus *continued***Aradhana Sarin****Audited**

Key achievements considered by the Committee in relation to Dr Sarin's performance are set out below.

Performance delivery	Under Dr Sarin's leadership, the Finance function enabled the delivery of another year of robust results. She steered the Company through headwinds including the impact of the Inflation Reduction Act in the US, provided guidance on multiple business development transactions, capital allocation decisions on Capex projects, and post-acquisition integration and risk management. Dr Sarin successfully led teams focusing on the automation of controls and testing of AI projects for invoice matching and journal entry which will be scaled through the enterprise. Over 2025, Dr Sarin took on leadership roles in a number of significant projects including US listing harmonisation, US Tariff analysis and mitigation plans, Most Favoured Nation pricing analysis, and negotiations for investments in the US and China, all of which pave a path for future growth and innovation.
Building a Finance Function of the Future	In a year where it has become more important than ever to invest in data foundations and technology, under Dr Sarin's leadership, Global Business Services (GBS) has continued to deliver for the enterprise, delivering annual savings of \$40 million and freeing up resources. GBS has successfully evolved from a scaled functional service provider into a transformation engine. The enterprise-wide deployment of ServiceNow across 60+ services has unified service management into a single, cohesive framework and the completion of the comprehensive process documentation has created a foundation for process re-engineering and AI-readiness at scale, yielding over 70 optimisation initiatives, directly contributing to a 9% increase in organisational productivity. Dr Sarin has continued to oversee the Axial programme, in which the enterprise is adopting the S4HANA platform. Significant progress has been made over 2025 in this transformation programme, encompassing an expanded scope to more sites and associated projects.
Great Place to Work	Dr Sarin continues to sponsor the Company's global Network of Women employee resource group. As a recognition of her support for women in STEM, healthcare and leadership, Dr Sarin was recognised by the Healthcare Businesswomen's Association (HBA) as the 2026 Woman of the Year. Over 2025, she continued to host the webcast "In conversation with" featuring highly accomplished women discussing issues relevant to the workplace which now attracts thousands of listeners across the Company as well as externally.

Final determination of Executive Directors' bonuses**Audited**

In determining the annual bonus outturn for Executive Directors, the Committee considers the formulaic Group scorecard outcome, as well as the overall business performance, shareholder experience and the personal contribution of the individual Executive Director. A description of the Executive Directors' personal achievements is detailed above.

Given the contributions made by both Mr Soriot and Dr Sarin in 2025 as outlined above, the Committee determined the bonus outturns for the Executive Directors should be 184% of target (or 92% of maximum) to Mr Pascal Soriot and 162% of target (or 81% of maximum) to Dr Aradhana Sarin.

Deferred Bonus Plan

Half of each Executive Director's pre-tax annual bonus is ordinarily deferred under the Deferred Bonus Plan (DBP). In respect of the bonus deferred, the Executive Director is granted a conditional award over shares. No further conditions apply to DBP shares. One half of the bonus earned in respect of performance during 2024 was deferred and details of the consequent DBP awards granted in 2025 are shown below. One half of the Executive Directors' bonus earned in respect of performance during 2025 will be deferred and the consequent DBP awards are expected to be granted in March 2026.

	2025 Grant¹				2026 Grant
	Ordinary Shares granted	Grant date	Grant price (pence per share) ²	Face value £'000	2025 Bonus deferred £'000
Pascal Soriot	14,623	4 March 2025	11963	1,749	2,129.5
Aradhana Sarin	6,243	4 March 2025	11963	747	801.5

¹ One half of the bonus earned in respect of performance during 2024 was deferred into shares, with the consequent DBP awards granted in 2025.

² The grant price is the average closing share price over the three dealing days preceding grant.

Annual Report on Remuneration *continued*

Annual bonus *continued*

2026 Group scorecard performance measures and metrics				
	Measure weighting	Underlying metrics (if applicable)	Metric weighting	2026 target
 Science and Innovation: Annual pipeline progression	30%	Pipeline progression events	15%	↑ c
		Regulatory events	15%	↑ c
 Growth and Therapy Area Leadership	30%	Total Revenue	30%	↑ c
 Achieve Group Financial Targets	40%	Cash flow	20%	↓ c
		Core EPS	20%	↑ c

Key: ↑ Target increased vs 2025 target ↓ Target decreased vs 2025 target ↔ Target constant c Commercially sensitive

We intend to disclose the 2026 Group scorecard outcome and details of the performance hurdles and targets in the 2026 Directors' Remuneration Report following the end of the performance period. The performance targets are currently considered to be commercially sensitive as prospective disclosure may prejudice the Company's commercial interests. Executive Directors' individual contribution will be assessed by reference to individual goals in line with the Company's objectives for the year.

Long-term incentives

Long-term incentives included in the Executive Directors' realised pay for 2025 figure: 2023 PSP

Audited

The Executive Directors' realised pay for 2025 includes the value of PSP awards with a performance period that ended 31 December 2025. These shares and dividend equivalents will not be released to the Executive Directors until the awards vest at the end of the holding period.

The value of the shares due to vest has been calculated using the average closing share price over the three-month period ended 31 December 2025 (13202 pence). The table below provides a breakdown showing the face value of these shares at the time they were granted, the value that is attributable to share price appreciation since grant, and the value of dividend equivalents accrued on these shares over the relevant performance period. Further information about the individual awards and performance assessments follows the table.

Audited

Long-term incentive awards with performance periods ended 31 December 2025							
				Value of shares due to vest			
		Ordinary Shares granted	Performance outcome	Face value at time of grant ¹ £'000	Value due to share price appreciation ² £'000	Dividend equivalent accrued over performance period £'000	Long-term incentives total £'000
Pascal Soriot	2023 PSP	85,808	97%	9,006	1,982	591	11,579
Aradhana Sarin	2023 PSP	38,046	97%	3,993	879	262	5,134

¹ Calculated using the grant price of 10821 pence, being the average closing share price over the three dealing days preceding the grant of the 2023 PSP awards.

² Calculated using the difference between the grant price and the average closing share price over the three-month period ended 31 December 2025. The average closing share price over the three-month period ended 31 December 2025 was 13202 pence.

The 2023 PSP awards granted to Mr Soriot and Dr Sarin on 4 March 2023, are due to vest and be released on 4 March 2028 on completion of a further two-year holding period. Performance over the period from 1 January 2023 to 31 December 2025 will result in 97% of the awards vesting, based on the following assessment of performance.

Long-term incentives *continued*

The Growth and Therapy Area Leadership target (measuring Total Revenue) is set at budget exchange rates at the beginning of the performance period and evaluated at those rates at the end of the performance period, so that any beneficial or adverse movements in currency, which are outside the Company's control, do not impact reward outcomes.

The Cash flow measure is assessed using cumulative net cash flow from operating activities less capital expenditure, adding back proceeds from the disposal of intangible assets.

The 2023 PSP sustainability metric focused on reduction in Scope 1 and Scope 2 GHG emissions glide path (Ambition Zero Carbon). For more information about the Company's sustainability initiatives, including Ambition Zero Carbon see Climate change from page 42.

AstraZeneca ranked sixth within the TSR peer group. The TSR peer group for the 2023 PSP consisted of AbbVie, Amgen, Astellas, BMS, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck KGaA, Moderna, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi and Takeda.

PSP awards granted during 2025

During 2025, conditional awards of shares were granted to the Executive Directors with face values equivalent to 850% of base pay for Mr Soriot and 550% of base pay for Dr Sarin under the PSP. Face value is calculated using the grant price, being the average closing share price over the three dealing days preceding grant.

Performance will be assessed over the period from 1 January 2025 to 31 December 2027 against the measures outlined below to determine the proportion of the award that vests. A further two-year holding period will then apply before vesting, which is scheduled to occur on the fifth anniversary of grant.

	Ordinary Shares granted	Grant date	Grant price (pence per share)	Face value £'000	End of performance period	End of holding period
Pascal Soriot	109,781	4 March 2025	11963	13,133	31 December 2027	4 March 2030
Aradhana Sarin	45,494	4 March 2025	11963	5,442	31 December 2027	4 March 2030

The 2025 PSP performance measures focus on scientific, ESG, commercial and financial performance over the three-year performance period. The five performance metrics attached to the 2025 PSP awards are detailed below. Twenty per cent of the award will vest if the threshold level of performance is achieved; the maximum level of performance must be achieved under each measure for 100% of the award to vest.

Relative total shareholder return (TSR) (20% of award)

TSR performance is assessed against a predetermined peer group of global pharmaceutical companies and consists of AbbVie, Amgen, Astellas, BMS, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck KGaA, Moderna, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi and Takeda. The rank which the Company's TSR achieves over the performance period will determine how many shares will vest under this measure.

TSR ranking of the Company	% of award that vests
Median	20% (threshold for payout)
Between median and upper quartile	Pro rata
Upper quartile	100%

Audited

2023 PSP performance measures and metrics	Weighting	Threshold (20% vesting)	Maximum (100% vesting)	Outcome	Payout
 Science and Innovation: First approvals and NME volume over three years					
NME Phase III/registrational volume	12%	10	20	20	12%
Regulatory events	18%	13	26	30	18%
Subtotal – Science and Innovation ¹	30%				30%
 Growth and Therapy Area Leadership (\$bn)	20%	43	50.5	59	20%
 Cash flow (\$bn)	20%	22	31	31.5	20%
Total shareholder return	20%	Median	UQ ²	6th	17%
 Ambition Zero Carbon	10%	142 ktCO ₂ e	91 ktCO ₂ e	73ktCO ₂ e	10%
Total¹	100%				97%

Key: ■ Bar charts are indicative of 2023 PSP performance; scales do not start from zero.

Due to rounding, the total outcome differs from the arithmetic total of the individual metric outcomes disclosed above.

¹ The subtotal and total reflect the weightings of the individual metrics.

² UQ = Upper Quartile.

Annual Report on Remuneration *continued*

Long-term incentives *continued*

Audited

Net Cash flow (20% of award)

The Cash flow measure is assessed using cumulative net cash flow from operating activities less capital expenditure adding back proceeds from the disposal of intangible assets. The level of vesting under this measure is based on a scale between a threshold target and an upper target.

Cash flow	% of award that vests
\$27.5bn	20% (threshold for payout)
Between \$27.5bn and \$31.5bn	Pro rata
\$31.5bn	75%
Between \$31.5bn and \$35.5bn	Pro rata
\$35.5bn and above	100%

Growth and Therapy Area Leadership (20% of award)

For PSP awards granted in 2025, the Growth and Therapy Area Leadership metric is Total Revenue. Disclosing the threshold and maximum hurdles for this measure could be construed to constitute financial guidance, which is not the Company's intention. The Growth and Therapy Area Leadership (Total Revenue) measure is thus considered to be commercially sensitive and will be disclosed following the end of the performance period, in the 2027 Directors' Remuneration Report. This measure is evaluated by reference to budget exchange rates.

Science and Innovation: First approvals and NME volume over three years (30% of award)

Performance is assessed using dual indices which measure NME Phase III/registrational volume and regulatory events, allowing disclosure of targets at the beginning of the performance period.

NME Phase III/registrational volume (12% of award)	% of award that vests	Regulatory events (18% of award)	% of award that vests
14	20% (threshold for payout)	18	20% (threshold for payout)
Between 14 and 21	Pro rata	Between 18 and 26	Pro rata
21	75%	26	75%
Between 21 and 28	Pro rata	Between 26 and 35	Pro rata
28	100%	35	100%

Ambition Zero Carbon (10% of award)

For the 2025 PSP, this measure encompasses aspects of our value chain (Scope 3) GHG emissions and for the 2025 PSP comprises the aggregate reductions from the NGP transition, primary distribution and business travel.

Emissions	% of award that vests
1,846 ktCO ₂ e split as: NGP transition: 1,553 ktCO ₂ e (which equates to a carbon intensity of 16.7 kgCO ₂ e per device) Business travel and primary distribution: 293 ktCO ₂ e	20% (threshold for payout)
1,632 ktCO ₂ e split as: NGP transition: 1,356 ktCO ₂ e (which equates to a carbon intensity of 14.6 kgCO ₂ e per device) Business travel and primary distribution: 276 ktCO ₂ e	75%
1,434 ktCO ₂ e split as: NGP transition: 1,172 ktCO ₂ e (which equates to a carbon intensity of 12.9 kgCO ₂ e per device) Business travel and primary distribution: 262 ktCO ₂ e	100%

Long-term incentives *continued*

PSP performance measures for 2026 grant

The sustainability measure with the 2026 PSP has been updated as set out below. All other measures remain unchanged from the 2025 PSP award.

PSP performance measure	Measure weighting	Underlying metrics (if applicable)	Metric weighting	Threshold (20% vesting)	Maximum (100% vesting)
 Science and Innovation: First approvals and NME volume over three years	30%	NME Phase III/registrational volume	12%	11	22
		Regulatory events	18%	18	36
 Growth and Therapy Area Leadership	20%	Total Revenue		Commercially sensitive until end of performance period	
 Cash flow	20%			\$28bn	\$36.5bn
 Relative TSR	20%			Median	Upper Quartile
 Sustainability	10%	Value Chain emissions intensity in kgCO ₂ e per pMDI device (Scope 3)		13.4 kgCO ₂ e	10.1 kgCO ₂ e

Regulatory events measure NME and major LCM approvals (taking into account the first approval over the performance period). NME Phase III/registrational volume measures the total NME pipeline volume at the end of the performance period. These two items ensure that management is assessed on both R&D late-stage delivery (approvals) and also future pipeline sustainability (volume).

Disclosing the threshold and maximum hurdles for the Growth and Therapy Area Leadership (Total Revenue) measure could be construed to constitute financial guidance, which is not the Company's intention. The Total Revenue measure is thus considered to be commercially sensitive and will be disclosed following the end of the performance period.

The Total Revenue measure is evaluated by reference to budget exchange rates such that beneficial or adverse movements in currency, which are outside the Company's control, do not impact reward outcomes. The companies in the TSR comparator group are shown on page 103.

The Cash flow measure is assessed using cumulative net cash flow from operating activities less capital expenditure adding back proceeds from the disposal of intangible assets. Capital expenditure is expected to increase materially during the performance period reflecting continued investments in new modalities, and the build-out of capability and capacity to support the 2030 Ambition, including previously announced investments in the US, Singapore and China. In addition, cash flow is expected to be temporarily affected by specific factors which will impact near-term phasing of working capital.

We remain committed to Ambition Zero Carbon and the reduction of value chain emissions. The 2026 PSP builds on the approach to Scope 3 emissions reduction introduced in the 2025 PSP, with the Sustainability metric for the 2026 PSP focusing on the NGP transition. This reflects the NGP's material impact on Scope 3 carbon emissions (26% of total emissions in 2025) and its status as the largest device transition in AstraZeneca's history. To ensure the measure supports both enterprise performance and the successful delivery of clinical milestones and device transition across markets, we will adopt a carbon intensity metric expressed as kilograms of CO₂ equivalent per pMDI device (kgCO₂e/device). This approach is intended to align executive incentives with our objective to deliver near-zero carbon intensity from our pMDI portfolio by 2030 while increasing the number of patients served.

As described on page 96, the Committee takes into account a wide range of data to ensure that the stretching nature of PSP hurdles is robustly tested and that financial targets are aligned with the Company's Mid-Term Plan. The Committee takes consensus and exchange rates into account when determining the appropriate level of stretch relative to prior plans and performance outturns.

PSP awards are expected to be granted to the Executive Directors in March 2026. The PSP award to be granted to Mr Soriot will be equivalent to 850% of base pay. The PSP award to be granted to Dr Sarin will be equivalent to 550% of base pay.

 For more information about How our performance measures for 2026 support the delivery of our strategy, and How the Remuneration Committee ensures targets are stretching, see pages 95 and 96, respectively.

Annual Report on Remuneration *continued*

Non-Executive Directors' remuneration

Non-Executive Directors' realised pay for 2025 (single total figure of remuneration)

Audited

The table sets out all elements of remuneration receivable by the Non-Executive Directors in respect of the year ended 31 December 2025, alongside comparative figures for the prior year.

	2025 Fees £'000	2024 Fees £'000	2025 Other £'000	2024 Other £'000	2025 Total £'000	2024 Total £'000
Michel Demaré ¹	890	800	63	–	953	800
Euan Ashley	188	160	–	–	188	160
Philip Broadley	268	233	–	–	268	233
Birgit Conix ²	135	–	–	–	135	–
Rene Haas ³	120	–	–	–	120	–
Karen Knudsen ⁴	121	–	–	–	121	–
Diana Layfield	162	135	–	–	162	135
Anna Manz	148	140	–	–	148	140
Sheri McCoy	238	205	–	–	238	205
Tony Mok	145	135	–	–	145	135
Nazneen Rahman	233	200	–	–	233	200
Marcus Wallenberg	168	155	–	–	168	155
Former Non-Executive Directors						
Deborah DiSanzo ⁵	41	140	–	–	41	140
Andreas Rummelt ⁵	40	135	–	–	40	135
Total	2,897	2,438	63	–	2,960	2,438

¹ Michel Demaré single figure includes office costs (invoiced in Swiss franc) of £62,900 for the year ended 31 December 2025.

² Birgit Conix was appointed with effect from 1 February 2025.

³ Rene Haas was appointed with effect from 1 January 2025.

⁴ Karen Knudsen was appointed with effect from 11 April 2025.

⁵ Deborah DiSanzo and Andreas Rummelt retired from the Board with effect from 11 April 2025.

Non-Executive Directors' fee structure

The Non-Executive Directors' fees effective from January 2026 are set out in the table below, alongside the fees applicable during 2025. Fees for the Non-Executive Directors (other than the Chair of the Board) were determined by the Chair of the Board and the Executive Directors. Changes to the Chair of the Board's fee were determined by the Remuneration Committee, excluding the Chair of the Board. No Board member participated in any decisions relating to their own fees.

The Non-Executive Directors' fees, including the Chair, are typically reviewed annually. In the latest review, the size and complexity of the AstraZeneca Group was considered, together with the continuing increase in workload, responsibilities, and time commitment for non-executive directors of global, publicly listed companies, in part driven by changes in the corporate governance and regulatory landscape in multiple jurisdictions. Independent market data from FTSE 10 companies was also reviewed to ensure that AstraZeneca's fees do not hinder the recruitment of Directors of the right experience and calibre for a Group of our scale in a global market.

With effect from January 2026, the Chair's fee has been increased from £890,000 to £925,600 and the Chair's office costs reimbursed by the Company has been increased from £75,000 to £78,000 per annum. Other increases have been made to certain fees as set out in the table below.

Non-Executive Director fees	2025 £'000	2026 £'000
Chair of the Board ¹	890	925.6
Basic Non-Executive Director	120	125
Senior independent Non-Executive Director	50	50
Chair of the Audit Committee ²	55	55
Member of the Audit Committee	27.5	27.5
Chair of the Remuneration Committee ²	50	55
Member of the Remuneration Committee	25	27.5
Chair of the Sustainability Committee ²	45	45
Member of the Sustainability Committee	22.5	22.5
Chair of the Science Committee ²	50	55
Member of the Science Committee	25	27.5
Chair of the Nomination and Governance Committee	–	–
Member of the Nomination and Governance Committee	17.5	17.5

¹ The Chair of the Board does not receive any additional fees for chairing, or being a member of a Committee.

² The Committee Chairs do not receive additional fees for being a member of the Committee.

Directors' shareholdings

Minimum shareholding requirements

Audited


The CEO and CFO are each required to build a shareholding to satisfy their respective minimum shareholding requirements (MSR), each within five years of their dates of appointment or, if the MSR is increased at any time, within five years of that increase. Following approval of the Remuneration Policy (the Policy) at the 2024 AGM on 11 April 2024, the minimum shareholder requirements for the Executive Directors were increased to match their variable pay opportunity, being 1,150% of base pay for Mr Soriot (increased from 650%), and 750% of base pay for Dr Sarin (increased from 450%). The Executive Directors have until 11 April 2029, to meet this requirement.

Shares that count towards the MSR are shares beneficially held by the Executive Director and their connected persons and share awards that are not subject to further performance conditions. Share awards included are DBP shares in deferral periods, and PSP shares in holding periods, on a net-of-tax basis. The value is calculated using the closing share price on 31 December 2025.

As at 31 December 2025, Dr Sarin exceeded her increased minimum shareholder requirement and Mr Soriot's holding was slightly below the increased MSR, but above the previous MSR of 650%. 50% of Mr Soriot's 2025 annual bonus will be deferred into shares and 97% of Mr Soriot's 2023 PSP will move into a two-year holding period, following completion of the performance period on 31 December 2025. These shares will count towards Mr Soriot's MSR in 2026.

A further post-employment shareholding requirement applies to Executive Directors. For two years following cessation of employment, Executive Directors are required to hold shares to the value of the shareholding requirement that applied at the cessation of their employment; or, in cases where the individual has not had sufficient time to build up shares to meet their guideline, the actual level of shareholding at cessation. The post-cessation requirement will be maintained through self-certification, with the Committee keeping this approach under review.

Position against the 2025 minimum shareholding requirement (MSR) as a percentage of base pay

	Beneficially owned shares and shares in a holding period ¹	Shares in deferral period ²	Shares subject to performance conditions	Value of shares counted towards MSR as a % of base pay ³	
Pascal Soriot	192,455	43,152	320,854	1,051%	CEO 
Aradhana Sarin	120,535	20,860	135,451	1,454%	
					CFO 

Key: ■ 2025 MSR ■ Shares counted towards MSR

¹ Holding period shares included are those which are not subject to continued employment.

² Shares in deferral periods which are not subject to continued employment.

³ Holding as at 31 December 2025. Shares subject to deferral and holding periods calculated net of a theoretical 50% tax rate. Shares subject to performance conditions are not included in the value of shares counted towards the MSR.

Non-Executive Directors are encouraged to build up, over a period of three years, a shareholding in the Company with a value approximately equivalent to the basic annual fee for a Non-Executive Director (which was increased to £120,000 during 2025) or, in the case of the Chair, approximately equivalent to his basic annual fee (£890,000 during 2025). The majority of Non-Executive Directors who had served for a period of three years or more as at 31 December 2025 met this expectation, based on the three-month average closing share price for the period ended 31 December 2025 (13202 pence).

Directors' interests as at 31 December 2025

The following table shows the beneficial interests of the Directors (including the interests of their connected persons) in Ordinary Shares as at 31 December 2025.

	Beneficial interest in Ordinary Shares as at 31 December 2025 ¹	Beneficial interest in Ordinary Shares as at 31 December 2024 ¹
Executive Directors		
Pascal Soriot	235,607	269,861
Aradhana Sarin	141,395	117,364
Non-Executive Directors		
Michel Demaré	10,000	10,000
Euan Ashley	1,545	1,545
Philip Broadley	8,025	8,025
Birgit Conix ²	1,080	–
Deborah DiSanzo ³	1,000	1,000
Rene Haas ²	–	–
Karen Knudsen ²	718	–
Diana Layfield	1,400	1,400
Anna Manz	487	487
Sheri McCoy	1,736	1,736
Tony Mok	3,500	3,500
Nazneen Rahman	720	1,017
Andreas Rummelt ³	27,205	27,205
Marcus Wallenberg	60,028	60,028

¹ For the Executive Directors, beneficial interests include shares in holding periods and deferral periods which are not subject to performance measures or continued employment.

Shares in a holding or deferral period are included on a gross basis.

² Birgit Conix was appointed to the Board on 1 February 2025, Rene Haas was appointed 1 January 2025 and Karen Knudsen was appointed on 11 April 2025.

³ Deborah DiSanzo and Andreas Rummelt retired from the Board on 11 April 2025.

Annual Report on Remuneration *continued*

Directors' shareholdings *continued*

Audited

Executive Directors' share plan interests

The following tables set out the Executive Directors' interests in Ordinary Shares under the Company's share plans.

Pascal Soriot

Share scheme interests	Grant date	Shares outstanding at 1 January 2025	Grant price (pence)	Shares granted in year	Shares released in year	Shares lapsed in year	Shares outstanding at 31 December 2025		Performance period end	Vesting and release date
							Shares subject to performance	Shares in deferral/holding period ¹		
DBP	04/03/2022	17,216	9154	–	17,216	–	n/a	–	n/a	04/03/2025 ^{2,3}
	04/03/2023	14,448	10821	–	–	–	n/a	14,448	n/a	04/03/2026
	04/03/2024	14,081	10081	–	–	–	n/a	14,081	n/a	04/03/2027
	04/03/2025	–	11963	14,623	–	–	n/a	14,623	n/a	04/03/2028 ⁴
PSP	06/03/2020	84,725	7376	–	84,725	–	–	–	31/12/2022	06/03/2025 ^{5,6}
	21/05/2020	8,471	7376	–	8,471	–	–	–	31/12/2022	21/05/2025 ^{7,8}
	05/03/2021	93,856	6844	–	–	–	–	93,856	31/12/2023	05/03/2026
	14/05/2021	17,064	6844	–	–	–	–	17,064	31/12/2023	14/05/2025
	04/03/2022	97,066	9154	–	–	(15,531)	–	81,535	31/12/2024	04/03/2027 ⁹
	04/03/2023	85,808	10821	–	–	–	85,808	–	31/12/2025	04/03/2028
	04/03/2024	95,791	10081	–	–	–	95,791	–	31/12/2026	04/03/2029
	13/05/2024	29,474	10081	–	–	–	29,474	–	31/12/2026	13/05/2029
	04/03/2025	–	11963	109,781	–	–	109,781	–	31/12/2027	04/03/2030 ¹⁰
Total		558,000		124,404	110,412	(15,531)	320,854	235,607		

¹ Shares in deferral/holding period are not subject to performance conditions.

² Market price on 4 March 2025, the actual date of release, was 12064 pence.

³ An additional 1,129 Ordinary Shares were released as a result of the reinvestment of dividend equivalents accrued during the deferral period.

⁴ Award granted following deferral of one half of the annual bonus earned in respect of performance during 2024, see page 101 for further detail.

⁵ Market price on 6 March 2025, the actual date of release, was 12028 pence.

⁶ An additional 8,679 Ordinary Shares were released as a result of the reinvestment of dividend equivalents accrued during the performance and holding period.

⁷ An additional 871 Ordinary Shares were released as a result of the reinvestment of dividend equivalents accrued during the performance and holding period.

⁸ Market price on 21 May 2025, the actual date of release, was 10492 pence.

⁹ 84% of the shares entered the holding period, following assessment of performance over the period to 31 December 2023. The remaining shares lapsed.

¹⁰ Details of PSP awards granted during 2025 are shown on page 103.

Aradhana Sarin

Share scheme interests	Grant date	Shares outstanding at 1 January 2025	Grant price (pence)	Shares granted in year	Shares released in year	Shares lapsed in year	Shares outstanding at 31 December 2025		Performance period end	Vesting and release date
							Shares subject to performance	Shares in deferral/holding period ¹		
DBP	04/03/2022	3,249	9154	–	3,249	–	n/a	–	n/a	04/03/2025 ^{2,3}
	04/03/2023	7,403	10821	–	–	–	n/a	7,403	n/a	04/03/2026
	04/03/2024	7,214	10081	–	–	–	n/a	7,214	n/a	04/03/2027
	04/03/2025	–	11963	6,243	–	–	n/a	6,243	n/a	04/03/2028 ⁴
PSP	13/08/2021	17,084	8209	–	–	–	–	17,084	31/12/2023	13/08/2026
	04/03/2022	43,038	9154	–	–	(6,887)	–	36,151	31/12/2024	04/03/2027 ⁵
	04/03/2023	38,046	10821	–	–	–	38,046	–	31/12/2025	04/03/2028
	04/03/2024	51,911	10081	–	–	–	51,911	–	31/12/2026	04/03/2029
	04/03/2025	–	11963	45,494	–	–	45,494	–	31/12/2027	04/03/2030 ⁶
Total		167,945		51,737	3,249	(6,887)	135,451	74,095		

¹ Shares in deferral/holding period are not subject to performance conditions.

² An additional 210 Ordinary Shares were released as a result of the reinvestment of dividend equivalents accrued during the deferral period.

³ Market price on 4 March 2025, the actual date of release, was 12064 pence.

⁴ Award granted following deferral of one half of the annual bonus earned in respect of performance during 2024, see page 101 for further detail.

⁵ 84% of the shares entered the holding period, following assessment of performance over the period to 31 December 2024. The remaining shares lapsed.

⁶ Details of PSP awards granted during 2025 are shown on page 103.

No Director or senior executive beneficially owns, or has options over, 1% or more of the issued share capital of the Company, nor do they have different voting rights from other shareholders. None of the Directors has a beneficial interest in the shares of any of the Company's subsidiaries. Between 31 December 2025 and 9 February 2026, there was no change in the interests in Ordinary Shares for current Directors shown in the table above.

Payments to former Directors

Audited

During 2025, no payments were made to former Directors.

Payments for loss of office

During 2025, no payments were made to Directors for loss of office.

Remuneration in the wider context

In our Corporate Governance Report on page 78, we outline how the Board has chosen to engage with AstraZeneca's workforce, and why this is critical to being a great place to work and delivering outstanding performance. The Directors believe that the Board as a whole should continue to take responsibility for gathering the views of the workforce. Consequently, instead of implementing one of the three methods for workforce engagement prescribed in the 2024 UK Corporate Governance Code, the Board chose to enhance and develop the long-standing existing channels of engagement to capture the global workforce's perspectives on a variety of topics, including remuneration.

The Committee engages with employees through site visits, virtual meetings and discussions with high-potential talent, communicating on remuneration matters where appropriate. Committee members review comprehensive data on reward, workforce trends and culture and receive regular reports on pay, benefits, incentives, performance management approach and broader talent policies to ensure well-informed executive pay decisions. Outcomes such as the annual Group scorecard are communicated internally and via the Directors' Remuneration Report, with additional materials published on the internal communication platform. Where significant changes are proposed, employee representative groups provide feedback to assess impact upon the broader workforce.

When reviewing executive remuneration, the Committee considers our global workforce, looking to ensure the total reward offering is competitive, compelling and aligned to our business performance, promoting a culture where everyone feels valued and included, as outlined in the table below. People and Sustainability remain one of our three strategic priorities, and our Business Review from page 26 explains the role that reward plays in developing an inclusive and diverse culture that encourages and rewards innovation, entrepreneurship and performance. In carrying out its responsibilities and when setting the Policy, the Committee also applies the principles and considers the provisions of the UK Corporate Governance Code.

Element	Policy features for the wider workforce	Comparison with Executive Director and Senior Executive Team
Base pay	Our base pay is the basis for a competitive total reward package for all employees, and we review base pay annually. This review takes account of country budget, relevant market comparators, the skills, capabilities, knowledge and experience of each individual relative to peers within the Company, and individual contribution. In setting the budget each year, we consider affordability as well as assessing how employee base pay is currently positioned relative to inflation, market rates, forecasts of any further market increases, and turnover.	The base pay of our Executive Directors and the SET forms the basis of their total remuneration, and we review their base pay annually. The primary purpose of the review is to ensure base pay remains competitive and reflects the contribution each individual makes to the organisation.
Pensions and benefits	We offer market-aligned wellbeing benefit packages reflecting market practice in each country in which we operate. Where appropriate, we offer elements of personal benefit choice to our employees.	The benefit packages of our Executive Directors and the SET are broadly aligned with the wider workforce of the country in which they are employed. Pension allowances for current UK Executive Directors are in line with the wider UK workforce.
Annual bonus	With the exception of our sales representatives receiving sales-related incentives, our global workforce participates in the same annual cash bonus plan as the Executive Directors and the SET, with the same Group scorecard performance measures outlined on page 99. Achievement against the scorecard creates a bonus pool from which all awards are made. For employees within our commercial organisation, the country-level share of the global bonus pool also takes into account country performance against KPIs. Individual outcomes are based on manager assessment of contribution against individual objectives and peers. Awards are based on a 0-200% target range.	The ranges for Executive Directors and the SET align with the wider workforce at 0-200% of target. Half of any award to an Executive Director under the plan is subject to deferral into shares subject to a three-year holding period. One sixth of any award to the SET under the plan is deferred into shares and is subject to a three-year holding period.
Long-term incentives	The PSP is operated with a three-year performance period for employees at Vice-President and Senior Vice-President level, with the same performance measures that apply to PSP awards made to the Executive Directors and the SET (outlined from page 102). A proportion of our workforce below this level is eligible to be considered for other LTI awards, such as restricted stock awards. Thirty-five per cent of our global employee population are eligible to receive an award under our LTI plans.	PSP awards to Executive Directors and the SET are granted under the same plan as PSP awards granted to Vice-Presidents and Senior Vice-Presidents. PSP awards to Executive Directors and the SET are subject to a two-year holding period following the three-year performance period.

Annual Report on Remuneration *continued*

Change in Director remuneration compared to other employees

In the table below, as per the requirements of the Companies (Directors' Remuneration Policy and Directors' Remuneration Report) Regulations 2019, changes to the base pay (or fees), taxable benefits and annual bonus of Directors are compared to employees for the previous financial year. The regulations require comparison between the remuneration of each Director and that of all employees of the parent company on a full-time equivalent basis. As AstraZeneca PLC has no direct employees, and in line with our disclosure approach in prior years to changes in employee remuneration, the selected comparator group is comprised of employees in the UK, US and Sweden who represent approximately 37% of our total employee population. We consider that this group is representative of the Group's major science, business and enabling units. These employee populations are also well balanced in terms of seniority and demographics.

	Change in 2025 against 2024 (%)			Change in 2024 against 2023 (%)			Change in 2023 against 2022 (%)			Change in 2022 against 2021 (%)			Change in 2021 against 2020 (%)		
	Base pay/ fees	Benefits	Annual bonus	Base pay/ fees	Benefits	Annual bonus	Base pay/ fees	Benefits	Annual bonus	Base pay/ fees	Benefits	Annual bonus	Base pay/ fees	Benefits	Annual bonus
Executive Directors															
Pascal Soriot	4.0	3.6	21.7	4.0	-0.9	23.2	4.5	3.1	-9.2	3.0	10.5	-0.8	3.0	1.1	35.9
Aradhana Sarin	4.0	-23.0	7.3	4.0	-70.4	2.7	4.5	-71.6	-9.2	147.2	2,753.2	169.3	–	–	–
Non-Executive Directors															
Michel Demaré ¹	11.2	100.0	–	37.0	–	–	268.9	–	–	7.0	–	–	18.7	–	–
Euan Ashley	17.2	–	–	34.7	–	–	8.0	–	–	6.8	–	–	300.0	–	–
Philip Broadley	14.8	–	–	16.5	–	–	0.0	–	–	15.6	–	–	16.9	–	–
Birgit Conix ²	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Deborah DiSanzo ³	-70.7	–	–	16.7	–	–	0.0	–	–	11.1	–	–	0.0	–	–
Rene Haas ⁴	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Karen Knudsen ⁵	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Diana Layfield	20.0	–	–	22.7	–	–	0.0	–	–	19.9	–	–	525.6	–	–
Anna Manz ⁶	5.4	–	–	250.0	–	–	–	–	–	–	–	–	–	–	–
Sheri McCoy	15.9	–	–	17.1	–	–	11.7	–	–	23.6	–	–	3.0	–	–
Tony Mok	7.4	–	–	22.7	–	–	0.0	–	–	6.8	–	–	0.0	–	–
Nazneen Rahman	16.2	–	–	25.3	–	–	3.0	–	–	18.2	–	–	11.0	–	–
Andreas Rummelt ³	-70.4	–	–	22.7	–	–	0.0	–	–	172.2	–	–	–	–	–
Marcus Wallenberg	8.4	–	–	24.0	–	–	0.0	–	–	17.1	–	–	3.6	–	–
Employees	5.7	5.7	0.4	5.8	5.8	7.7	7.0	7.0	3.2	6.0	6.0	19.3	4.9	4.9	44.4

¹ Michel Demaré was appointed Chair of the Board on 27 April 2023. Benefits for Michel Demaré are office costs introduced in January 2025.

² Birgit Conix was appointed on 1 February 2025.

³ Deborah DiSanzo and Andreas Rummelt retired from the Board on 11 April 2025.

⁴ Rene Haas was appointed on 1 January 2025.

⁵ Karen Knudsen was appointed on 11 April 2025.

⁶ Anna Manz was appointed on 1 September 2023.

CEO and employee pay ratios

The table below sets out the ratios of the CEO's realised pay to the equivalent pay for the lower quartile, median and upper quartile of UK employees (calculated on a full-time equivalent basis). The ratios have been calculated in accordance with the Companies (Miscellaneous Reporting) Regulations 2018 (the Regulations).

Year	Method	25th percentile pay ratio	50th percentile pay ratio	75th percentile pay ratio
2025	Option A	261:1	176:1	118:1
2024	Option A	231:1	153:1	102:1
2023	Option A	271:1	182:1	121:1
2022	Option A	230:1	159:1	107:1
2021	Option A	240:1	162:1	106:1
2020	Option A	284:1	197:1	130:1
2019	Option A	280:1	190:1	123:1
2018	Option A	230:1	160:1	103:1

The comparison with UK employees is specified by the Regulations. This group represents approximately 10% of our total employee population. The Regulations provide flexibility to adopt one of three methods of calculation; we continue to use Option A which is a calculation based on all UK employees on a full-time equivalent basis as we consider this to be the most appropriate method of comparison and in line with the calculation of the CEO's realised pay (shown on page 97 for 2025). The ratios are based on total pay, which includes base pay, benefits, bonus and LTI awards with all elements adjusted on a full-time equivalent basis if required. Our calculations are in line with the single figure methodology for UK employees where possible, with quartile data determined as at 31 December 2025. Calculations for UK employees are based on actual base pay and benefits data for the year, with estimates only used for annual bonus outcomes and LTI dividend equivalents. These estimates are based on the 2025 bonus budget and projected payouts, and anticipated dividends on LTI awards, respectively. No elements of pay have been excluded from the calculation, which has been determined following the approach of previous years.

Pay data (£'000) ¹	CEO		UK employees			
	Base pay	Total pay	25th percentile		50th percentile	
			Base pay	Total pay	Base pay	Total pay
2025	1,545	17,696	50	68	73	100
2024	1,486	14,728	50	64	70	96
2023	1,429	16,853	46	62	65	92
2022	1,367	15,323	48	67	67	96
2021	1,327	13,858	43	58	61	86
2020	1,289	15,447	41	54	60	78
2019	1,289	14,330	38	51	53	75
2018	1,251	11,356	36	49	50	71

¹ The prior years' figures have not been restated for subsequent share price changes (as shown in the CEO's realised pay for 2025 table on page 97).

The pay ratios at each quartile were higher in 2025 when compared to last year, due to realised bonus and LTI awards for the CEO in 2025.

Given the Committee's focus on ensuring CEO pay is performance-driven (and as demonstrated again this year), the majority of the single figure is comprised of variable pay and therefore may vary significantly year-on-year due to annual bonus and PSP outcomes, as well as share price movements. The Committee therefore also considers the CEO pay ratio without the LTI impact. When excluding LTI, the pay ratio of the CEO compared to the median UK employee is 63:1.

	2018	2019	2020	2021	2022	2023	2024	2025
50th percentile ratio excluding LTI	51:1	51:1	53:1	57:1	51:1	52:1	57:1	63:1

The Committee remains mindful of the debate on executive pay and seeks to ensure that when determining the remuneration of the CEO it finds the right balance when rewarding performance in a highly competitive global executive talent market. It believes the median ratio is consistent with the pay and progression policies for UK employees, which ensures our total reward offering is competitive and compelling, and aligned to individual and business performance as set out on page 109.

Relative importance of spend on pay

The table below shows the remuneration paid to all employees in the Group, including the Executive Directors, and expenditure on shareholder distributions through dividends. The figures have been calculated in accordance with the Group Accounting Policies and drawn from either the Group's Consolidated Statement of Comprehensive Income on page 125, or its Consolidated Statement of Cash Flows on page 128. Further information on the Group Accounting Policies can be found from page 129.

	2025 \$m	2024 \$m	Difference in spend between years \$m	Difference in spend between years %
Total employee remuneration	14,548	13,709	839	6
Distributions to shareholders: dividends paid	4,971	4,629	342	7


Total shareholder return

The graph on page 112 compares the TSR performance of the Company over the past 10 years with the TSR of the FTSE 100 Index and our global pharmaceutical peers. This graph is re-based to 100 at the start of the relevant period. These indices represent appropriate reference points for AstraZeneca reflecting our primary listing as a constituent of the FTSE 100 and a comparison against our global pharmaceutical peers. The pharmaceutical comparator group is also used to assess relative TSR performance for PSP awards to be granted in 2026 and consists of AbbVie, Amgen, Astellas, BMS, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck KGaA, Moderna, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi and Takeda. CEO remuneration over the same 10-year period is shown after the TSR graph.

Annual Report on Remuneration *continued*

Remuneration in the wider context *continued*

TSR over a 10-year period



CEO total remuneration table

Year	CEO	CEO realised pay £'000	Annual bonus payout against maximum opportunity %	LTI vesting rates against maximum opportunity %
2025	Pascal Soriot	17,696 ¹	92	97
2024	Pascal Soriot	14,728 ²	78.5	84
2023	Pascal Soriot	17,371	79.5	88
2022	Pascal Soriot	15,085	92	97
2021	Pascal Soriot	15,740	95	95
2020	Pascal Soriot	15,934	90	99
2019	Pascal Soriot	15,307	83	90
2018	Pascal Soriot	12,868	83	79
2017	Pascal Soriot	10,429	87	81
2016	Pascal Soriot	14,342 ³	54	95

¹ The 2025 realised pay is shown on page 97.

² This figure has been revised using the average closing share price over the three-month period to 31 December 2025, as explained on page 102.

³ This figure includes shares awarded to Mr Soriot in 2013 under the AZIP to compensate him for LTI awards from previous employment forfeited on his recruitment as the Company's CEO.

Governance

Committee membership

The Committee members as at 31 December 2025 were Sheri McCoy (Chair of the Committee), Philip Broadley, Michel Demaré, Diana Layfield and Nazneen Rahman. Diana Layfield was appointed to the Committee with effect from 1 May 2025. A Deputy Company Secretary acts as secretary to the Committee. The Committee met six times in 2025 and members' attendance records are set out on page 67. During the year, the Committee was materially assisted, except in relation to their own remuneration, by the CEO; the CFO; the SVP, Finance, Group Controller and Head of Global Finance Services; the SVP, Group Planning and Finance Business Partnering; the SVP, Global Portfolio/Project Management, Strategic Planning, BDO and Deal Finance; the VP, Global Sustainability and SHE; the Chief Human Resources Officer, Chief Compliance Officer and General Counsel; the SVP, Reward; the Senior Director Executive Reward; the Company Secretary; a Deputy Company Secretary; and the Non-Executive Directors forming the Science and Sustainability Committees. The assistance provided by these individuals fell within the ordinary course of their employment and/or services with AstraZeneca and they were not paid separately for it. The Committee's independent adviser attended all Committee meetings.

Independent adviser to the Committee

The Committee reappointed Willis Towers Watson (WTW) as its independent adviser. WTW were first appointed in September 2018, following a tender process undertaken in 2018. The tender process involved submission of written proposals, followed by shortlisted candidates being interviewed by both Committee members and members of the Company's management. WTW's service to the Committee during 2025 was provided on a time spent basis at a cost to the Company of £252,322, excluding VAT. During 2025, WTW also provided pensions advice and administration, and advice and support to management including market data to assist in the annual employee pay review, global pay survey data and employee benefits review. WTW have no other connection with the Company or individual Directors. The Committee reviewed the potential for conflicts of interest related to WTW and judged that there were no conflicts. WTW is a member of the Remuneration Consultants Group, which is responsible for the stewardship and development of the voluntary code of conduct in relation to executive remuneration consulting in the UK. The principles on which the code is based are transparency, integrity, objectivity, competence, due care and confidentiality. WTW adheres to the code.

Malus and clawback

The Committee regularly reviews the Company's approach to malus and clawback and market practice in this area, and our Global Standard on Malus and Clawback sets out the trigger events and the time periods these provisions may apply to. As a condition of annual bonus and PSP awards, the Committee seeks active acceptance of the malus and clawback terms applicable each year before any payment or grant is made to an individual. This allows the Committee to:

- Reduce the amount of bonus or PSP payable, or clawback some or all of any award in the circumstances and periods as set out within our Global Standard on Malus and Clawback.
- Cancel bonus eligibility.
- Prevent vesting of the PSP and/or DBP awards by holding the shares in AstraZeneca's LTI nominee platform to prevent transactions.

The triggers whereby the Committee has the discretion to apply malus and/or clawback include:

- Serious misconduct;
- Material misstatement or restatement of the audited results of the Group; or
- AstraZeneca suffering:
 - significant reputational damage;
 - a material adverse effect on its financial position; or
 - a material adverse effect on its business opportunities and prospects for sustained performance or profitability.

The Committee selected the malus and clawback periods to run for two years from a particular date, typically the date of payment, grant, or vesting as appropriate considering the arrangement under which the remuneration was due and the type of eligible employees participating in that arrangement. The Committee confirms that malus and clawback provisions were not exercised during the year.

Shareholder voting at the AGM

At the Company's AGM on 11 April 2025, shareholders voted in favour of a resolution to approve the Annual Statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024. The Directors' Remuneration Policy was approved by shareholders at the Company's AGM on 11 April 2024. The Policy can be found on the Company's website, www.astrazeneca.com/annualreport2025.

Resolution	Votes for	% for	Votes against	% against	Total votes cast	% of issued share capital voted	Withheld votes
Ordinary Resolution to approve the Annual Statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024 (2025 AGM)	1,152,784,239	96.4	43,097,131	3.6	1,195,881,370	77.12	2,041,421
Ordinary Resolution to approve the Directors' Remuneration Policy (2024 AGM)	761,702,826	64.43	420,514,520	35.57	1,182,217,346	76.26	34,645,873

Directors' service contracts and letters of appointment

The notice periods and unexpired terms of Executive Directors' service contracts at 31 December 2025 are shown in the table below.

Executive Director	Effective date of service contract	Notice period
Pascal Soriot	15 December 2016	12 months
Aradhana Sarin	1 August 2021	12 months

None of the Non-Executive Directors have a service contract but each has a letter of appointment. In accordance with the Company's Articles of Association, following their appointment, all Directors must retire at each AGM and may present themselves for re-election. All of the Non-Executive Directors, including the Chair of the Board, may terminate their appointment at any time, on three months' notice. None of the Non-Executive Directors has any provision in their letters of appointment giving them a right to compensation upon early termination of appointment.

Basis of preparation of this Directors' Remuneration Report

This Directors' Remuneration Report has been prepared in accordance with the Large and Medium-sized Companies and Groups (Accounts and Reports) (Amendment) Regulations 2013 (as amended) (the 2013 Regulations). A resolution to receive and approve the Directors' Remuneration Report will be proposed at the AGM on 9 April 2026.

On behalf of the Board


M S Bowden

Company Secretary
10 February 2026

Financial Statements

Contents

Preparation of the Financial Statements and Directors' Responsibilities	115
Directors' Annual Report on Internal Controls over Financial Reporting	115
Independent Auditors' Report	116
Consolidated Statements	125
Group Accounting Policies	129
Notes to the Group Financial Statements	137
Group Subsidiaries and Holdings	192
Company Statements	197
Company Accounting Policies	199
Notes to the Company Financial Statements	201



Preparation of the Financial Statements and Directors' Responsibilities

The Directors are responsible for preparing this Annual Report and Form 20-F Information and the Group and Parent Company Financial Statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare Financial Statements for each financial year. Under that law, the Directors have prepared the Group Financial Statements in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006, as applicable to companies reporting under those standards and Parent Company Financial Statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 101 'Reduced Disclosure Framework', and applicable law). In preparing the Group Financial Statements, the Directors have also elected to comply with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and International Accounting Standards as adopted by the European Union.

Under company law, the Directors must not approve the Financial Statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Parent Company and of their profit or loss for that period. In preparing each of the Group and Parent Company Financial Statements, the Directors are required to:

- Select suitable accounting policies and then apply them consistently.
- Make judgements and estimates that are reasonable and prudent.
- For the Group Financial Statements, state whether they have been prepared in accordance with UK-adopted international accounting standards.
- For the Parent Company Financial Statements, state whether FRS 101 has been followed, subject to any material departures disclosed and explained in the Parent Company Financial Statements.
- Prepare the Financial Statements on a going concern basis unless it is inappropriate to presume that the Group and the Parent Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Parent Company's transactions and disclose with reasonable accuracy at any time the financial position of the Parent Company. This enables them to ensure that the Financial Statements comply with the Companies Act 2006. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Group and to prevent and detect fraud and other irregularities.

Under applicable law and regulations, the Directors are also responsible for preparing a Directors' Report, Strategic Report, Directors' Remuneration Report, Corporate

Governance Report and Audit Committee Report that comply with that law and those regulations.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on our website. Legislation in the UK governing the preparation and dissemination of Financial Statements may differ from legislation in other jurisdictions.

Directors' responsibility statement pursuant to DTR 4

The Directors confirm that to the best of our knowledge:

- The Financial Statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole.
- The Directors' Report includes a fair review of the development and performance of the business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face.

On behalf of the Board of Directors
on 10 February 2026.

Pascal Soriot
Director

Directors' Annual Report on Internal Controls over Financial Reporting

As a consequence of our US listing, we are required to comply with certain US laws and regulations. Section 404 of the Sarbanes-Oxley Act is applicable to AstraZeneca as a foreign private issuer and requires us to annually assess and make public statements about the effectiveness of our internal control over financial reporting. Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The following report is provided by the Directors in connection with the Company's internal control over financial reporting:

- The Directors are responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
- The Directors conducted an evaluation of the effectiveness of internal control over financial reporting based on the Committee of Sponsoring Organizations (COSO) 2013 framework.

- The Directors concluded that our internal control over financial reporting was effective as at 31 December 2025.
- PricewaterhouseCoopers LLP, the independent registered public accounting firm that audited our financial statements as at 31 December 2025, has audited the effectiveness of internal control over financial reporting as at 31 December 2025 and has issued an unqualified report thereon.
- During the period covered by this Annual Report, there were no changes in internal control over financial reporting that have materially affected or are reasonably likely to materially affect the effectiveness of our internal control over financial reporting.

Independent auditors' report to the members of AstraZeneca PLC

Report on the audit of the financial statements

Opinion

In our opinion:

- AstraZeneca PLC's Group financial statements and Company financial statements (the "financial statements") give a true and fair view of the state of the Group's and of the Company's affairs as at 31 December 2025 and of the Group's profit and the Group's cash flows for the year then ended;
- the Group financial statements have been properly prepared in accordance with UK-adopted international accounting standards as applied in accordance with the provisions of the Companies Act 2006;
- the Company financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 101 "Reduced Disclosure Framework", and applicable law); and
- the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual Report and Form 20-F Information 2025 (the "Annual Report"), which comprise: the Consolidated Statement of Financial Position and the Company Balance Sheet as at 31 December 2025; the Consolidated Statement of Comprehensive Income, the Consolidated Statement of Cash Flows, and the Consolidated and Company Statements of Changes in Equity for the year then ended; the Group and Company Accounting Policies; and the Notes to the Group and Company Financial Statements.

Our opinion is consistent with our reporting to the Audit Committee.

Separate opinion in relation to International Accounting Standards as adopted by the European Union

As explained in the Group Accounting Policies to the financial statements, the Group, in addition to applying UK-adopted international accounting standards, has also applied International Accounting Standards as adopted by the European Union.

In our opinion, the Group financial statements have been properly prepared in accordance with International Accounting Standards as adopted by the European Union.

Separate opinion in relation to IFRS Accounting Standards as issued by the IASB

As explained in the Group Accounting Policies to the financial statements, the Group, in addition to applying UK-adopted international accounting standards, has also applied IFRS Accounting Standards as issued by the International Accounting Standards Board ("IASB").

In our opinion, the Group financial statements have been properly prepared in accordance with IFRS Accounting Standards as issued by the IASB.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard, as applicable to listed public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

To the best of our knowledge and belief, we declare that non-audit services prohibited by the FRC's Ethical Standard were not provided.

Other than those disclosed in Note 31, we have provided no non-audit services to the Company or its controlled undertakings in the period under audit.

Our audit approach

Overview

Audit scope

- Our audit included full scope audit, audit of specific significant line item(s) or specified procedures at each of the Group's 22 in-scope components.
- Taken together, the components at which audit work was performed accounted for 71% of the Group's revenue. Our scoping provided sufficient coverage over each significant financial statement line item ("FSLI") of the Group financial statements and provided us with the evidence we needed for our opinion on the Group financial statements taken as a whole.

Key audit matters

- Recognition and measurement of accruals for Managed Care, Medicaid and Medicare Part D rebates on US Product Sales (excluding Rare Diseases) (Group)
- Impairment assessment of the product, marketing and distribution rights and other intangibles (Group)
- Recognition and measurement of legal provisions and disclosure of contingent liabilities (Group)
- Valuation of defined benefit obligations in the United Kingdom ("UK") (Group)
- Distributable reserves (Company)

Materiality

- Overall Group materiality: \$620m (2024: \$500m) based on approximately 5% of profit before tax after adding back intangible asset impairment charges (Note 11), fair value movements and discount unwind on contingent consideration (Note 20) and the discount unwind on certain other payables arising from intangible asset acquisitions (Note 4).
- Overall Company materiality: \$200m (2024: \$155m) based on 0.4% of net assets as constrained by the allocation of overall Group materiality.
- Performance materiality: \$465m (2024: \$375m) (Group) and \$150m (2024: \$116.25m) (Company).

The scope of our audit

As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements.

Key audit matters

Key audit matters are those matters that, in the auditors' professional judgement, were of most significance in the audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) identified by the auditors, including those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters, and any comments we make on the results of our procedures thereon, were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

This is not a complete list of all risks identified by our audit.

Recognition, measurement and disclosure of tax liabilities for uncertain tax treatments, which was a key audit matter last year, is no longer included because of reduced risk following settlements with tax authorities during the year. Otherwise, the key audit matters below are consistent with last year.

Recognition and measurement of accruals for Managed Care, Medicaid and Medicare Part D rebates on US Product Sales (excluding Rare Diseases) (Group)

Impacted FSLIs	2025	2024
US Rebates, chargebacks, returns and other revenue accruals liability (excluding Rare Diseases) (which principally consists of rebates related to Managed Care, Medicaid and Medicare Part D)	\$5,605m	\$4,738m
In the US the Group recognises revenue on Product Sales under various commercial and government mandated contracts and reimbursement arrangements that include rebates, of which the most significant are Managed Care, Medicaid and Medicare Part D relating to US Product Sales. Rebates provided to customers under these arrangements are accounted for as variable consideration and recognised as a reduction to revenue, for which unsettled amounts are accrued. At the time Product Sales are invoiced, rebates and deductions that the Group expects to pay, are estimated. There is significant management estimation in determining the accruals in the US. Assumptions used to estimate the rebates are monitored and adjusted regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions.		
Discussions with the Audit Committee	How our audit addressed the Key Audit Matter	
Our discussions with and reporting to the Audit Committee included: • Our approach to the audit of rebates including details of planned substantive procedures and the extent of our controls reliance; • For the recorded accruals, whether the Group's estimate is comparable to our independently developed estimates; and • Our views of management's assessment over the accuracy of the accruals.	We evaluated the design and tested the operating effectiveness of controls relating to the recognition and measurement of the accruals for the Managed Care, Medicaid and Medicare Part D, including controls over significant assumptions. We determined that we could rely on these controls for the purposes of our audit. We: i) tested completeness and accuracy of data provided by management; ii) developed an independent estimate of the Managed Care, Medicaid and Medicare Part D accruals using the terms of the specific rebate programmes and/or contracts with customers; historical revenue data; market demand and market conditions in the US; third party information on inventory held by direct and indirect customers; and the historical trend of actual rebate claims paid; iii) compared our independent estimates to the accruals recorded by management; iv) evaluated the effect of any adjustments to prior years' accruals in the current year's results; v) tested actual payments made and rebate claims processed by the Group, and evaluated those claims for consistency with the contractual and mandated terms of the Group's arrangements; and vi) used professionals with specialised skill and knowledge to assist in assessing the compliance of the Group's Medicaid rebate policies against the regulatory requirements. We evaluated the appropriateness of the disclosures in Notes 2 and 20 of the Group financial statements.	

Relevant references in the Annual Report

Refer to the Audit Committee Report, Group Accounting Policies and Notes 2 and 20 in the Group financial statements.

Independent auditors' report to the members of AstraZeneca PLC *continued*

Impairment assessment of the product, marketing and distribution rights and other intangibles (Group)

Impacted FSLIs	2025	2024
Product, marketing and distribution rights and other intangibles (hereafter referred to as the intangible assets)	\$36,752m	\$36,505m
Net impairment charges	\$230m	\$1,572m

The recoverability of the carrying value of cash generating units (to which the intangible assets belong) depends on future cash flows and/or the outcome of research and development ("R&D") activities including decisions by the Group to terminate development. The determination of the recoverable amounts include significant estimates, which are highly sensitive and depend upon key assumptions including the outcome of R&D activities, probability of technical and regulatory success, market volume, share and pricing (to derive peak year sales), the amount and timing of projected future cash flows and sales erosion curves following patent expiry. Changes in these assumptions could have an impact on the recoverable amount of the Group's intangible assets.

During 2025, \$230m (2024: \$1,572m) of net impairment charges were recorded (of which \$218m (2024: \$1,569m) was recorded relating to Product, marketing and distribution rights and \$12m (2024: \$3m) relating to other intangibles).

Discussions with the Audit Committee

Our discussions with and reporting to the Audit Committee included:

- Our approach to audit the impairment assessment of the carrying value of cash generating units (to which the intangible assets belong) including details of planned substantive procedures and the extent of our controls reliance;
- The methodologies and significant assumptions used to determine the recoverable values of the intangible assets; and
- The evaluation of the reasonableness of the probability of technical and regulatory success with the assistance of our professionals with specialised skill and knowledge.

How our audit addressed the Key Audit Matter

We evaluated the design and tested the operating effectiveness of controls relating to management's intangible asset impairment assessment, controls over the identification of triggering events and the valuation of the recoverable amounts of the intangible assets, including controls over the significant assumptions. We determined that we could rely on these controls for the purposes of our audit.

For those intangible assets in the scope of our audit we: i) tested management's process for identifying indicators of impairment and the process for developing the recoverable amounts; ii) evaluated the appropriateness of the methodology used by management to estimate the recoverable amounts; iii) tested the completeness and accuracy of the underlying data used in the models; and iv) evaluated the significant assumptions used by management related to the probability of technical and regulatory success, with the assistance of professionals with specialised skill and knowledge; market volume, share and pricing (to derive peak year sales); and sales erosion curves following patent expiry.

In evaluating management's significant assumptions we: i) compared significant assumptions to external market and industry data, and benchmarks; ii) performed comparisons of current and past long term forecasts; and iii) performed comparisons of management's probability of technical and regulatory success benchmarks to actual trial and regulatory success rates for the past three years.

We evaluated the appropriateness of the disclosures in Note 11 of the Group financial statements.

Relevant references in the Annual Report

Refer to the Audit Committee Report, Group Accounting Policies and Note 11 in the Group financial statements.

Recognition and measurement of legal provisions and disclosure of contingent liabilities (Group)

Impacted FSLIs	2025	2024
Provisions in respect of legal claims and settlements (together, legal provisions)	\$376m	\$859m
Financial statements disclosure: Contingent liabilities disclosure in respect of legal proceedings	Note 30	Note 30

The Group is involved in various legal proceedings considered typical to its business, including actual or threatened litigation and actual or potential government investigations relating to employment matters, product liability, commercial disputes, pricing, sales and marketing practices, infringement of IP rights and the validity of certain patents and competition laws.

Most of the claims involve highly complex issues. Provisions are recognised when there is a legal or constructive present obligation as a result of a past event, it is probable that an outflow of economic resources will be required to settle the obligation and a reasonable estimate can be made of the amount of the obligation. Management's assessment as to whether or not to recognise provisions or assets, and of the amounts concerned, usually involves a series of complex judgements about future events and can rely heavily on estimates and assumptions. Determining the timing of recognition of when an adverse outcome is probable is considered a key judgement.

Discussions with the Audit Committee

Our discussions with and reporting to the Audit Committee included:

- Our approach to audit the assessment of the ongoing litigations and claims including details of planned substantive procedures and the extent of our controls reliance;
- The assessment of management's judgement in the outcome of the Group's legal matters;
- Consideration of any potential impacts on the financial statements in respect of the China personal information infringement, illegal trade and medical insurance fraud matters, as disclosed in Note 30; and
- Our conclusions on the appropriateness of the in-year movements in the legal provisions.

How our audit addressed the Key Audit Matter

We evaluated the design and tested the operating effectiveness of controls relating to management's evaluation of the liability of legal claims, including controls over determining the probability of a loss and whether the amount of loss can be reasonably estimated, and related financial statement disclosures. We determined that we could rely on these controls for the purposes of our audit.

We obtained and evaluated letters of audit enquiry with the Group's internal and external legal counsel for significant litigation. We tested the completeness of management's assessment of both the identification of legal proceedings and possible outcomes of each significant legal matter. We evaluated the reasonableness of management's assessment regarding whether an adverse outcome is probable and estimated reliably. We inspected certain external legal documents. We evaluated the Group's legal provisions within Note 21 and management's judgement regarding the proceedings set out as contingent liabilities within Note 30. Where appropriate, we considered the scope, preliminary findings and conclusions of investigations with the assistance of professionals with specialised skill and knowledge.

We evaluated the appropriateness of the disclosures in Notes 21 and 30 of the Group financial statements.

Relevant references in the Annual Report

Refer to the Audit Committee Report, Group Accounting Policies, Notes 21 and 30 in the Group financial statements.

Independent auditors' report to the members of AstraZeneca PLC *continued*

Valuation of defined benefit obligations in the United Kingdom ("UK") (Group)

Impacted FSLIs	2025	2024
Defined benefit obligations in the UK	\$4,767m	\$4,592m
The Group's most significant scheme is in the UK. The valuation of pension plan obligations requires significant estimation in determining appropriate assumptions such as the mortality, discount, and inflation rates.	Movements in these assumptions can have a material impact on the determination of the defined benefit obligations. Management engaged with qualified independent actuaries to assist in determining these assumptions.	
Discussions with the Audit Committee	How our audit addressed the Key Audit Matter	
Our discussions with and reporting to the Audit Committee included: • Our approach to the audit of the valuation of the defined benefit obligations in the UK including details of planned substantive procedures and the extent of our controls reliance; and • For the significant assumptions used by management, whether and where the Group's assumptions lay within our reasonable range.	We evaluated the design and tested the operating effectiveness of controls relating to the valuation of the defined benefit obligations, including controls over the significant assumptions. We determined that we could rely on these controls for the purposes of our audit. We tested completeness and accuracy of the data provided by management. We involved professionals with specialised skill and knowledge to assist in evaluating the reasonableness of management's estimate by i) developing an independent estimate of the defined benefit obligations for the UK; and ii) comparing the independent estimate to management's estimate. Developing the independent estimate involved independently determining mortality, inflation and discount rate assumptions by evaluating the specifics of the plan and, where applicable, considering national information, and consistency with external market and industry data. We evaluated the appropriateness of the disclosures in Note 22 of the Group financial statements.	
Relevant references in the Annual Report Refer to the Audit Committee Report, Group Accounting Policies and Note 22 in the Group financial statements.		

Distributable reserves (Company)

Impacted FSLIs	2025	2024
The Company's Profit and loss account	\$14,461m	\$13,495m
The directors review and disclose the level of distributable reserves of the Company annually and aim to maintain distributable reserves that provide adequate cover for dividend payments. At 31 December 2025, all of the Profit and loss account reserve of \$14,461m (31 December 2024: the overwhelming majority of \$13,495m) was available for distribution, subject to filing the Company financial statements with Companies House.	There is judgement when determining the profits available for distribution by reference to guidance on realised and distributable profits in accordance with Companies Act 2006 issued by the Institute of Chartered Accountants in England and Wales and the Institute of Chartered Accountants of Scotland in April 2017. The profits of the Company have been received in the form of receivables due from subsidiaries. The availability of distributable reserves in the Company is dependent on those receivables meeting the definition of qualifying consideration within the guidance, and in particular on the ability of subsidiaries to settle those receivables within a reasonable period of time.	
Discussions with the Audit Committee	How our audit addressed the Key Audit Matter	
Our discussions with and reporting to the Audit Committee included: - Our approach to audit the assessment of the distributable reserves in the Company including involvement of our professionals with specialised skill and knowledge; and - Evaluation of the appropriateness of management's judgements with the assistance of our professionals with specialised skill and knowledge.	We obtained and audited the analysis of distributable reserves, which included testing the completeness and accuracy of the underlying data used in the distributable reserve determination. We involved our professionals with specialised skill and knowledge to assess whether judgements made by management were appropriate and the analysis was aligned with the relevant technical guidance on the determination of realised profits under the Companies Act 2006. In determining whether the Profit and loss account reserve is distributable we evaluated whether there is qualifying consideration in a form of receivables due from subsidiaries, and in particular on the ability of subsidiaries to settle those receivables within a reasonable period of time.	
Relevant references in the Annual Report Refer to the Company Statement of Changes in Equity in the Company financial statements.	We evaluated the appropriateness of the disclosure related to the profits available for distribution within the Company Statement of Changes in Equity.	

How we tailored the audit scope

We tailored the scope of our audit to ensure that we performed enough work to be able to give an opinion on the financial statements as a whole, taking into account the structure of the Group and the Company, the accounting processes and controls, and the industry in which they operate.

The Group operates in over 100 countries and the size of operations within each territory varies. We identify a component by defining each distinct legal or reporting entity and each Shared Service Centre ("SSC") as a component. Each component subsequently reports to the Group through an integrated consolidation system.

In selecting the components that are in scope each year and establishing the overall approach to the Group audit, we determined the type of work that needed to be performed by us, as the Group engagement team, or component auditors within PwC UK and other PwC network firms operating under our instruction, to ensure that we had sufficient coverage from our audit work over each significant line of the Group financial statements. Where the work was performed by component auditors, we determined the level of involvement we needed to have in the audit work in these territories to be able to conclude whether sufficient appropriate audit evidence had been obtained as a basis for our opinion on the Group financial statements as a whole.

As a result of our risk assessment procedures and the detailed scoping exercise performed at the planning stage of our audit, we identified 22 components across 14 countries at which we determined that we need to perform audit work. Taken together, these components accounted for 71% of the Group's revenue. The in-scope components were audited by the Group engagement team and 15 component teams.

- Out of the 22 components, we identified four reporting components which required a full scope audit of their complete financial information, either due to their size or risk characteristics. These components are the principal operating units in the US (one component) and China (two components), as well as the Company (over which we audited all significant FSLIs using the Company materiality).
- For nine out of the remaining 18 components, we performed audit procedures on a specific line item or line items within that component that we considered had the potential for the greatest impact on the significant accounts in the financial statements because of the size of these accounts. The table opposite illustrates the work covered in these nine components:

FSLI	Locations in specific scope
Revenue	UK, Sweden, US, Japan, Germany, Spain, China and Canada
Cost of sales	UK, Sweden, US and Ireland
Research and development expense	UK, Sweden and US
Selling, general and administrative expense	UK, Sweden, US and Ireland
Taxation	Sweden and US
Property, plant and equipment	UK, Sweden and Ireland
Non-current other receivables	UK
Inventories	UK, Sweden and Ireland
Trade and other receivables	UK, Sweden and US
Trade and other payables	UK and Sweden
Retirement benefit obligations	UK and Sweden
Non-current other payables	UK and Sweden

Note that, based on the structure of the Group, work on some parts or the entirety of some of these line items was performed centrally, including by our SSC component teams.

- SSC components represented five out of the remaining nine components and were located in Poland, Malaysia, India, Costa Rica and Romania. Our teams auditing the SSC components performed audit procedures over certain controls and transactions.
- Two out of the remaining four components, which represent US tax reporting entities, were scoped in for taxation line items in the financial statements because of the size or risk.
- The final two components are treasury components for which we centrally audited specific FSLIs.
- Additionally, for non-full scope components which were not considered inconsequential components, we performed targeted risk assessments procedures.
- Audit procedures were performed centrally at the Group level in relation to various balances and activities accounted for and managed centrally including: goodwill, intangible assets (excluding software), financial instruments, taxation, other investments and litigation matters as well as the consolidation.

In March 2025, we held a meeting with the partners and senior staff from the key PwC member firms involved in the audit. At this meeting we considered developments specific to the Group, key audit matters and discussed our approach to the Group audit including the work performed at shared service centre locations. We heard from key members of management and the Chair of the Audit Committee.

As part of our cycle of in person oversight we visited China and the US (covering both components in each country). In addition, we were in regular contact with our UK component team in Cambridge. We also visited the SSCs in Poland and India. In addition to these on-site visits, regular virtual meetings with the component auditors were held, whereby we performed reviews of the component auditors' planned response to significant risks and reviewed the component auditors' working papers. Alongside our team oversight we attended meetings with local management.

The impact of climate risk on our audit

In planning and executing our audit, we considered the potential impact of climate change on the Group's business and the financial statements. The Group has set out its intention – as part of the Ambition Zero Carbon programme – to achieve net zero greenhouse gas emissions by maximising energy efficiency, shifting to renewable energy sources and investing in nature-based removals to compensate for any residual GHG footprint.

As a part of our audit we made enquiries of management to understand the extent of the potential impact of the physical and transitional climate change risk on the financial statements. We also discussed the climate change initiatives and commitments from Ambition Zero Carbon and other initiatives to reduce CO₂ emissions, and the impact these have on the Group including on future cash flow forecasts.

Management considers that the impact of climate change does not give rise to a material financial statement impact. We evaluated management's risk assessment and understood the Group's governance processes including the Sustainability Committee. We performed an audit risk assessment of how the impact of the Group's commitments in respect of

Independent auditors' report to the members of AstraZeneca PLC *continued*

climate change including Ambition Zero Carbon may affect the financial statements and our audit.

We challenged the extent to which climate change considerations including the expected cash flows from the initiatives and commitments had been reflected, where appropriate, in management's impairment assessment process, going concern assessment and viability assessment.

We found that climate change impacts are included within management's forecasts although the initiatives and commitments did not have a material impact including on our key audit matters. We assessed the consistency of other information disclosed in the Annual Report with the financial statements, and with our knowledge obtained from the audit.

Materiality

The scope of our audit was influenced by our application of materiality. We set certain

quantitative thresholds for materiality. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures on the individual FSLIs and disclosures and in evaluating the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

Based on our professional judgement, we determined materiality for the financial statements as a whole as follows:

	Financial statements – Group	Financial statements – Company
Overall materiality	\$620m (2024: \$500m).	\$200m (2024: \$155m).
How we determined it	Approximately 5% of profit before tax after adding back intangible asset impairment charges (Note 11), fair value movements and discount unwind on contingent consideration (Note 20), and the discount unwind on certain other payables arising from intangible asset acquisitions (Note 4).	0.4% of net assets as constrained by the allocation of overall Group materiality.
Rationale for benchmark applied	The reported profit of the Group can fluctuate due to intangible asset impairment charges, fair value and discount unwind movements on contingent consideration, and the discount unwind on certain other payables arising from intangible asset acquisitions. These amounts are prone to year on year volatility and are not necessarily reflective of the operating performance of the Group and as such they have been excluded from the benchmark amount. Our approach is consistent with the prior year.	We have considered the nature of the business of AstraZeneca PLC (being a holding company for investment activities) and have determined that net assets are an appropriate basis for the calculation of the overall materiality level.

For each component in the scope of our Group audit, we allocated a materiality that is less than our overall Group materiality. The range of materiality allocated across components was between \$62m and \$450m.

We use performance materiality to reduce to an appropriately low level the probability that the aggregate of uncorrected and undetected misstatements exceeds overall materiality. Specifically, we use performance materiality in determining the scope of our audit and the nature and extent of our testing of account balances, classes of transactions and disclosures, for example in determining sample sizes. Our performance materiality was 75% (2024: 75%) of overall materiality, amounting to \$465m (2024: \$375m) for the Group financial statements and \$150m (2024: \$116.25m) for the Company financial statements.

In determining the performance materiality, we considered a number of factors – the history of misstatements, risk assessment and aggregation risk and the effectiveness of controls – and concluded that an amount at the upper end of our normal range was appropriate.

We agreed with the Audit Committee that we would report to them misstatements identified during our audit above \$62m (Group audit) (2024: \$50m) and \$62m (Company audit) (2024: \$50m) as well as misstatements below those amounts that, in our view, warranted reporting for qualitative reasons.

Conclusions relating to going concern

Our evaluation of the directors' assessment of the Group's and the Company's ability to continue to adopt the going concern basis of accounting included:

- Agreeing the underlying cash flow projections to Board approved Group-level budgets and forecasts, assessing how these forecasts are compiled, and assessing the accuracy of management's forecasts;
- Evaluating the key assumptions within management's forecasts and ensuring that such assumptions are consistent with those modelled in relation to impairments;
- Considering liquidity and available financial resources;
- Assessing whether the stress testing performed by management appropriately considered the principal risks facing the business; and
- Evaluating the feasibility of management's mitigating actions in the stress testing scenarios and performing our own sensitivities.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's and the

Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the Group's and the Company's ability to continue as a going concern.

In relation to the directors' reporting on how they have applied the UK Corporate Governance Code (the "Code"), we have nothing material to add or draw attention to in relation to the directors' statement in the financial statements about whether the directors considered it appropriate to adopt the going concern basis of accounting.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Strategic Report and Directors' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

Strategic Report and Directors' Report

In our opinion, based on the work undertaken in the course of the audit, the information given in the Strategic Report and Directors' Report for the year ended 31 December 2025 is consistent with the financial statements and has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the Group and Company and their environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic Report and Directors' Report.

Directors' Remuneration

In our opinion, the part of the Directors' Remuneration Report to be audited has been properly prepared in accordance with the Companies Act 2006.

Corporate governance statement

The UK Listing Rules require us to review the directors' statements in relation to going concern, longer-term viability and that part of the corporate governance statement relating to

the Company's compliance with the provisions of the Code specified for our review. Our additional responsibilities with respect to the corporate governance statement as other information are described in the Reporting on other information section of this report.

Based on the work undertaken as part of our audit, we have concluded that each of the following elements of the corporate governance statement, included within the Corporate Governance Overview, Corporate Governance Report, Nomination and Governance Committee Report, Science Committee Report, Sustainability Committee Report and Audit Committee Report is materially consistent with the financial statements and our knowledge obtained during the audit, and we have nothing material to add or draw attention to in relation to:

- The directors' confirmation that they have carried out a robust assessment of the emerging and principal risks;
- The disclosures in the Annual Report that describe those principal risks, what procedures are in place to identify emerging risks and an explanation of how these are being managed or mitigated;
- The directors' statement in the financial statements about whether they considered it appropriate to adopt the going concern basis of accounting in preparing them, and their identification of any material uncertainties to the Group's and Company's ability to continue to do so over a period of at least twelve months from the date of approval of the financial statements;
- The directors' explanation as to their assessment of the Group's and Company's prospects, the period this assessment covers and why the period is appropriate; and
- The directors' statement as to whether they have a reasonable expectation that the Company will be able to continue in operation and meet its liabilities as they fall due over the period of its assessment, including any related disclosures drawing attention to any necessary qualifications or assumptions.

Our review of the directors' statement regarding the longer-term viability of the Group and Company was substantially less in scope than an audit and only consisted of making inquiries and considering the directors' process supporting their statement; checking that the statement is in alignment with the relevant provisions of the Code; and considering whether the statement is consistent with the financial statements and our knowledge and understanding of the Group and Company and their environment obtained in the course of the audit.

In addition, based on the work undertaken as part of our audit, we have concluded that each of the following elements of the

corporate governance statement is materially consistent with the financial statements and our knowledge obtained during the audit:

- The directors' statement that they consider the Annual Report, taken as a whole, is fair, balanced and understandable, and provides the information necessary for the members to assess the Group's and Company's position, performance, business model and strategy;
- The section of the Annual Report that describes the review of effectiveness of risk management and internal control systems; and
- The section of the Annual Report describing the work of the Audit Committee.

We have nothing to report in respect of our responsibility to report when the directors' statement relating to the Company's compliance with the Code does not properly disclose a departure from a relevant provision of the Code specified under the UK Listing Rules for review by the auditors.

Responsibilities for the financial statements and the audit

Responsibilities of the directors for the financial statements

As explained more fully in the Preparation of the Financial Statements and Directors' Responsibilities, the directors are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The directors are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Group's and the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or the Company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are

Independent auditors' report to the members of AstraZeneca PLC *continued*

considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the Group and industry, we identified that the principal risks of non-compliance with laws and regulations related to patent protection, product safety (including but not limited to the US Food and Drug Administration regulation, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency, China Food and Drug Administration), data protection legislation, antibribery and competition law (including but not limited to the US Foreign Corrupt Practices Act, the UK Proceeds of Crime Act, the UK Economic Crime and Corporate Transparency Act and the provisions set out by the National Healthcare Security Administration in China), and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006, UK Listing Rules and tax legislation. We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to journal entries to manipulate financial results and potential management bias in accounting estimates. The Group engagement team shared this risk assessment with the component auditors so that they could include appropriate audit procedures in response to such risks in their work. Audit procedures performed by the Group engagement team and/or component auditors included:

- Evaluation and testing of the design and operating effectiveness of management's controls to prevent and detect irregularities;
- Discussions with VP Group Internal Audit, the Deputy Chief Compliance Officer, the Head of Global Investigations and the Group's General Counsel and Deputy General Counsels along with other members of Group legal and external counsel where applicable, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud;

- Assessment of matters reported on the Group's whistleblowing helpline;
- Assessment of the results of management's investigations, with the assistance of professionals with specialised skill and knowledge where appropriate;
- Challenging assumptions made by management in its significant accounting estimates; and
- Identifying and testing the validity of selected journal entries, including certain journal entries posted with unusual account combinations, and certain consolidation journals.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Our audit testing might include testing complete populations of certain transactions and balances, possibly using data auditing techniques. However, it typically involves selecting a limited number of items for testing, rather than testing complete populations. We will often seek to target particular items for testing based on their size or risk characteristics. In other cases, we will use audit sampling to enable us to draw a conclusion about the population from which the sample is selected.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Companies Act 2006 exception reporting

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- we have not obtained all the information and explanations we require for our audit; or
- adequate accounting records have not been kept by the Company, or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of directors' remuneration specified by law are not made; or
- the Company financial statements and the part of the Directors' Remuneration Report to be audited are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Appointment

We were first appointed by the company for the financial year ended 31 December 2017. Our uninterrupted engagement covers nine financial years.

Other matter

The company is required by the Financial Conduct Authority Disclosure Guidance and Transparency Rules to include these financial statements in an annual financial report prepared under the structured digital format required by DTR 4.1.15R – 4.1.18R and filed on the National Storage Mechanism of the Financial Conduct Authority. This auditors' report provides no assurance over whether the structured digital format annual financial report has been prepared in accordance with those requirements.

Sarah Quinn (Senior Statutory Auditor)

for and on behalf of
PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
London
10 February 2026

Consolidated Statement of Comprehensive Income

for the year ended 31 December

	Notes	2025 \$m	2024 \$m	2023 \$m
– Product Sales	2	55,573	50,938	43,789
– Alliance Revenue	2	3,067	2,212	1,428
Product Revenue		58,640	53,150	45,217
Collaboration Revenue	2	99	923	594
Total Revenue		58,739	54,073	45,811
Cost of sales		(10,633)	(10,207)	(8,268)
Gross profit		48,106	43,866	37,543
Distribution expense		(579)	(555)	(539)
Research and development expense	3	(14,232)	(13,583)	(10,935)
Selling, general and administrative expense	3	(19,933)	(19,977)	(19,216)
Other operating income and expense	3	381	252	1,340
Operating profit		13,743	10,003	8,193
Finance income	4	360	458	344
Finance expense	4	(1,694)	(1,742)	(1,626)
Share of after tax losses in associates and joint ventures	12	(7)	(28)	(12)
Profit before tax		12,402	8,691	6,899
Taxation	5	(2,169)	(1,650)	(938)
Profit for the period		10,233	7,041	5,961
Other comprehensive income:				
Items that will not be reclassified to profit and loss:				
Remeasurement of the defined benefit pension liability	22	290	80	(406)
Net gains on equity investments measured at fair value through Other comprehensive income		188	139	278
Fair value movements related to own credit risk on bonds designated as fair value through profit or loss		–	12	(6)
Tax (expense)/income on items that will not be reclassified to profit and loss	5	(94)	(43)	101
		384	188	(33)
Items that may be reclassified subsequently to profit and loss:				
Foreign exchange arising on consolidation	23	2,387	(957)	608
Foreign exchange arising on designated liabilities in net investment hedges	23	18	(122)	24
Fair value movements on cash flow hedges		263	(129)	266
Fair value movements on cash flow hedges transferred to profit and loss		(314)	177	(145)
Fair value movements on derivatives designated in net investment hedges	23	14	39	44
Gains/(costs) of hedging		1	(21)	(19)
Tax (expense)/income on items that may be reclassified subsequently to profit and loss	5	(50)	25	(12)
		2,319	(988)	766
Other comprehensive income/(expense) for the period, net of tax		2,703	(800)	733
Total comprehensive income for the period		12,936	6,241	6,694
Profit attributable to:				
Owners of the Parent		10,225	7,035	5,955
Non-controlling interests	26	8	6	6
Total comprehensive income attributable to:				
Owners of the Parent		12,920	6,236	6,688
Non-controlling interests	26	16	5	6
Basic earnings per \$0.25 Ordinary Share	6	\$6.60	\$4.54	\$3.84
Diluted earnings per \$0.25 Ordinary Share	6	\$6.54	\$4.50	\$3.81
Weighted average number of Ordinary Shares in issue (millions)	6	1,550	1,550	1,549
Diluted weighted average number of Ordinary Shares in issue (millions)	6	1,562	1,563	1,562
Dividends declared and paid in the period	25	4,846	4,602	4,487

All activities were in respect of continuing operations.

\$m means millions of US dollars.

Consolidated Statement of Financial Position

at 31 December

	Notes	2025 \$m	2024 \$m
Assets			
Non-current assets			
Property, plant and equipment	8	12,962	10,252
Right-of-use assets	9	1,741	1,395
Goodwill	10	21,242	21,025
Intangible assets	11	37,846	37,177
Investments in associates and joint ventures	12	302	268
Other investments	13	2,223	1,632
Derivative financial instruments	14	498	182
Other receivables	15	1,327	930
Income tax receivable	5	1,391	–
Deferred tax assets	5	5,819	5,347
		85,351	78,208
Current assets			
Inventories	16	6,557	5,288
Trade and other receivables	17	15,177	12,972
Other investments	13	30	166
Derivative financial instruments	14	90	54
Income tax receivable	5	1,158	1,859
Cash and cash equivalents	18	5,711	5,488
		28,723	25,827
Total assets		114,074	104,035
Liabilities			
Current liabilities			
Interest-bearing loans and borrowings	19	(3,104)	(2,337)
Lease liabilities	9	(382)	(339)
Trade and other payables	20	(25,280)	(22,465)
Derivative financial instruments	14	(81)	(50)
Provisions	21	(686)	(1,269)
Income tax payable	5	(1,084)	(1,406)
		(30,617)	(27,866)
Non-current liabilities			
Interest-bearing loans and borrowings	19	(24,715)	(26,506)
Lease liabilities	9	(1,421)	(1,113)
Derivative financial instruments	14	–	(115)
Deferred tax liabilities	5	(3,500)	(3,305)
Retirement benefit obligations	22	(1,105)	(1,330)
Provisions	21	(918)	(921)
Income tax payable	5	(700)	(238)
Other payables	20	(2,379)	(1,770)
		(34,738)	(35,298)
Total liabilities		(65,355)	(63,164)
Net assets		48,719	40,871
Equity			
Capital and reserves attributable to equity holders of the Company			
Share capital	24	388	388
Share premium account		35,266	35,226
Capital redemption reserve		153	153
Merger reserve		448	448
Other reserves	23	1,440	1,411
Retained earnings	23	10,972	3,160
		48,667	40,786
Non-controlling interests	26	52	85
Total equity		48,719	40,871

The Financial Statements from pages 125 to 196 were approved by the Board and were signed on its behalf by

Pascal Soriot
Director
10 February 2026

Aradhana Sarin
Director

Consolidated Statement of Changes in Equity

for the year ended 31 December

	Share capital \$m	Share premium account \$m	Capital redemption reserve \$m	Merger reserve \$m	Other reserves \$m	Retained earnings \$m	Total attributable to owners \$m	Non-controlling interests \$m	Total equity \$m
At 1 January 2023	387	35,155	153	448	1,468	(574)	37,037	21	37,058
Profit for the period	–	–	–	–	–	5,955	5,955	6	5,961
Other comprehensive income ¹	–	–	–	–	–	733	733	–	733
Transfer to Other reserves ²	–	–	–	–	(4)	4	–	–	–
Transactions with owners									
Dividends (Note 25)	–	–	–	–	–	(4,487)	(4,487)	–	(4,487)
Dividends paid to non-controlling interests (Note 25)	–	–	–	–	–	–	–	(4)	(4)
Issue of Ordinary Shares	1	33	–	–	–	–	34	–	34
Share-based payments charge for the period (Note 29)	–	–	–	–	–	579	579	–	579
Settlement of share plan awards	–	–	–	–	–	(708)	(708)	–	(708)
Net movement	1	33	–	–	(4)	2,076	2,106	2	2,108
At 31 December 2023	388	35,188	153	448	1,464	1,502	39,143	23	39,166
Profit for the period	–	–	–	–	–	7,035	7,035	6	7,041
Other comprehensive expense ¹	–	–	–	–	–	(799)	(799)	(1)	(800)
Transfer to Other reserves ²	–	–	–	–	15	(15)	–	–	–
Transactions with owners									
Dividends (Note 25)	–	–	–	–	–	(4,602)	(4,602)	–	(4,602)
Dividends paid to non-controlling interests (Note 25)	–	–	–	–	–	–	–	(4)	(4)
Issue of Ordinary Shares	–	38	–	–	–	–	38	–	38
Changes in non-controlling interests	–	–	–	–	–	–	–	61	61
Movement in shares held by Employee Benefit Trusts ²	–	–	–	–	(68)	–	(68)	–	(68)
Share-based payments charge for the period (Note 29)	–	–	–	–	–	660	660	–	660
Settlement of share plan awards	–	–	–	–	–	(621)	(621)	–	(621)
Net movement	–	38	–	–	(53)	1,658	1,643	62	1,705
At 31 December 2024	388	35,226	153	448	1,411	3,160	40,786	85	40,871
Profit for the period	–	–	–	–	–	10,225	10,225	8	10,233
Other comprehensive (expense)/income ¹	–	–	–	–	(61)	2,756	2,695	8	2,703
Transfer to Other reserves ²	–	–	–	–	47	(47)	–	–	–
Transactions with owners									
Dividends (Note 25)	–	–	–	–	–	(4,846)	(4,846)	–	(4,846)
Dividends paid to non-controlling interests (Note 25)	–	–	–	–	–	–	–	(6)	(6)
Issue of Ordinary Shares	–	40	–	–	–	–	40	–	40
Changes in non-controlling interests	–	–	–	–	–	(214)	(214)	(43)	(257)
Movement in shares held by Employee Benefit Trusts ²	–	–	–	–	43	–	43	–	43
Share-based payments charge for the period (Note 29)	–	–	–	–	–	719	719	–	719
Settlement of share plan awards	–	–	–	–	–	(781)	(781)	–	(781)
Net movement	–	40	–	–	29	7,812	7,881	(33)	7,848
At 31 December 2025	388	35,266	153	448	1,440	10,972	48,667	52	48,719

¹ Included within Other comprehensive income of \$2,703m (2024: expense of \$800m; 2023: income of \$733m) is a gain of \$1m (2024: charge of \$21m; 2023: charge of \$19m), relating to Gains/(costs) of hedging.

² Amounts charged or credited to Other reserves relate to exchange adjustments arising on goodwill and movements in shares held by Employee Benefit Trusts. Transfer to Other reserves includes \$70m (2024: \$nil; 2023: \$nil) in respect of the opening balance on the cash flow hedge reserve. The cash flow hedge reserve was previously disclosed within Retained earnings but from 2025 is disclosed within Other reserves.

Consolidated Statement of Cash Flows

for the year ended 31 December

	Notes	2025 \$m	2024 \$m	2023 \$m
Cash flows from operating activities				
Profit before tax		12,402	8,691	6,899
Finance income and expense	4	1,334	1,284	1,282
Share of after tax losses in associates and joint ventures	12	7	28	12
Depreciation, amortisation and impairment	3	5,733	6,688	5,387
Increase in trade and other receivables		(1,728)	(1,624)	(1,425)
Increase in inventories		(755)	(131)	(669)
Increase in trade and other payables and provisions		1,346	862	2,394
Gains on disposal of intangible assets	3	(168)	(64)	(251)
Fair value movements on contingent consideration arising from business combinations	20	(97)	311	549
Non-cash and other movements	18	662	(121)	(386)
Cash generated from operations		18,736	15,924	13,792
Interest paid		(1,316)	(1,313)	(1,081)
Tax paid		(2,845)	(2,750)	(2,366)
Net cash inflow from operating activities		14,575	11,861	10,345
Cash flows from investing activities				
Acquisition of subsidiaries, net of cash acquired	27	(66)	(2,771)	(189)
Payments upon vesting of employee share awards attributable to business combinations	27	–	(3)	(84)
Payment of contingent consideration from business combinations	20	(1,164)	(1,008)	(826)
Purchase of property, plant and equipment		(2,810)	(1,924)	(1,361)
Disposal of property, plant and equipment		13	55	132
Purchase of intangible assets		(3,095)	(2,662)	(2,417)
Disposal of intangible assets		136	123	291
Movement in profit-participation liability	3	–	–	190
Purchase of non-current asset investments		(229)	(96)	(136)
Disposal of non-current asset investments		–	78	32
Movement in short-term investments, fixed deposits and other investing instruments		131	30	97
Payments to associates and joint ventures	12	(10)	(158)	(80)
Disposal of investments in associates and joint ventures		–	13	–
Interest received		286	343	287
Net cash outflow from investing activities		(6,808)	(7,980)	(4,064)
Net cash inflow before financing activities		7,767	3,881	6,281
Cash flows from financing activities				
Proceeds from issue of share capital		40	38	33
Own shares purchased by Employee Benefit Trusts		(521)	(81)	–
Payments to acquire non-controlling interests		(183)	–	–
Issue of loans and borrowings		15	6,492	3,816
Repayment of loans and borrowings		(2,029)	(4,652)	(4,942)
Dividends paid	25	(4,971)	(4,629)	(4,481)
Hedge contracts relating to dividend payments	25	113	16	(19)
Repayment of obligations under leases		(372)	(316)	(268)
Movement in short-term borrowings		364	(31)	161
Payment of Acerta Pharma share purchase liability		–	(833)	(867)
Net cash outflow from financing activities		(7,544)	(3,996)	(6,567)
Net increase/(decrease) in Cash and cash equivalents in the period		223	(115)	(286)
Cash and cash equivalents at the beginning of the period		5,429	5,637	5,983
Exchange rate effects		46	(93)	(60)
Cash and cash equivalents at the end of the period	18	5,698	5,429	5,637

Group Accounting Policies

Basis of accounting and preparation of financial information

The Consolidated Financial Statements (or Group Financial Statements) have been prepared under the historical cost convention, modified to include revaluation to fair value of certain financial instruments and pension plan assets and liabilities as described below, in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards. The Consolidated Financial Statements also comply fully with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) and International Accounting Standards as adopted by the European Union.

The Consolidated Financial Statements are presented in US dollars, which is the Company's functional currency.

New accounting requirements

The following amendments have been issued and adopted:

- amendments to IAS 21 'The Effects of Changes in Foreign Exchange Rates', effective for periods beginning on or after 1 January 2025 - endorsed by the United Kingdom Endorsement Board (UKEB) on 15 July 2024.

The above amendments did not have a significant impact on the Group's net results, net assets or disclosures.

Product revenue subtotal

Effective 1 January 2025, the Group has updated the presentation of Total Revenue on the face of the Consolidated Statement of Comprehensive Income to include a new subtotal 'Product Revenue'. This represents the summation of Product Sales and Alliance Revenue on the basis of the similar characteristics of the underlying product sales curve profiles related to the end customer. Product Revenue and Collaboration Revenue form Total Revenue. Product Sales and Alliance Revenue continue to be presented separately, with the new subtotal providing additional aggregation of revenue types with similar characteristics, reflecting the growing importance of Alliance Revenue.

There are no changes to the Revenue accounting policy regarding the types of transactions recorded in each revenue category. The comparative years have been retrospectively adjusted to reflect the additional subtotal, resulting in total Product Revenue being reported for the year ended 31 December 2024 of \$53,150m and the year ended 31 December 2023 of \$45,217m.

Basis for preparation of Financial Statements on a going concern basis

The Group has considerable financial resources available. As at 31 December 2025, the Group has \$10.6bn in financial resources (cash and cash equivalent balances of \$5.7bn and undrawn committed bank facilities of \$4.9bn that are available until April 2030), with \$3.5bn of borrowings due within one year. These facilities contain no financial covenants, and in January 2026 their maturity was extended to April 2031.

The Group has assessed the prospects of the Group over a period longer than the required 12 months from the date of Board approval of these Consolidated Financial Statements, with no deterioration noted requiring a further extension of this review. The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively high level of resilience and predictability to cash inflows, although government price interventions in response to budgetary constraints are expected to continue to adversely affect revenues in some of our significant markets. The Group, however, anticipates new revenue streams from both recently launched medicines and those in development, and the Group has a wide diversity of customers and suppliers across different geographic areas.

Consequently, the Directors believe that, overall, the Group is well placed to manage its business risks successfully. Accordingly, they continue to adopt the going concern basis in preparing the Annual Report and Financial Statements.

Estimates and judgements

The preparation of the Financial Statements in conformity with generally accepted accounting principles requires management to make estimates and judgements that affect the reported amounts of assets and liabilities at the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The accounting policy descriptions set out the areas where judgements and estimates need exercising, the most significant of which include the following Key Judgements **KJ** and Significant Estimates **SE**:

- revenue recognition – see Revenue accounting policy on page 130 **KJ** and Note 2 on page 141 **SE**
- expensing of internal development expenses – see Research and development accounting policy on page 131 **KJ**
- impairment reviews of Intangible assets – see Note 11 on page 153 **SE**
- useful economic life of Intangible assets – see Research and development accounting policy on page 131 **KJ**

- business combinations and Goodwill – see Business combinations and goodwill accounting policy on page 134 **KJ**
- litigation liabilities – see Legal proceedings within Note 30 on page 181 **KJ**
- operating segments – see Note 7 on page 147 **KJ**
- employee benefits – see Note 22 on page 168 **SE**
- taxation – see Note 30 on page 190 **KJ**

The Group has assessed the impact of sustainability topics on its financial reporting. This includes an impact assessment on the valuation and useful lives of Intangible assets and the identification and measurement of provisions and contingent liabilities in response to climate and pollution risks.

Sustainability-related opportunities on innovation are integral to the Financial Statements with a key indicator of the Group's investment being Research and development (R&D) expense. Business conduct and patient safety are both considered as part of our recognition and measurement of provisions and contingent liabilities, noted within sections of Government investigations and proceedings and Product liability litigation as relevant, of Note 30. No material accounting impacts or changes to judgements or other required disclosures were noted.

KJ Key Judgements are those judgements made in applying the Group's accounting policies that have a material effect on the amounts of assets and liabilities recognised in the Financial Statements.

SE A Significant Estimate has a significant risk of material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Financial risk management policies are detailed in Note 28 to the Financial Statements from page 171.

AstraZeneca's management considers the following to be the material accounting policies in the context of the Group's operations.

Revenue

Revenue comprises Product Sales, Alliance Revenue and Collaboration Revenue.

Revenue excludes inter-company revenues and value-added taxes.

Group Accounting Policies *continued*

Product Sales

Product Sales represent net invoice value less estimated rebates, returns and chargebacks, which are considered to be variable consideration and include significant estimates. Sales are recognised when the control of the goods has been transferred to a third party. This is usually when title passes to the customer, either on shipment or on receipt of goods by the customer, depending on local trading terms. Revenue is not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur.

Rebates are amounts payable or credited to a customer, usually based on the quantity or value of Product Sales to the customer for specific products in a certain period. Product Sales rebates, which relate to Product Sales that occur over a period of time, are normally issued retrospectively.

At the time Product Sales are invoiced, rebates and deductions that the Group expects to pay are estimated based upon assumptions developed using contractual terms, historical experience and market-related information. The rebates and deductions are recognised as variable consideration and recorded as a reduction to revenue with an accrual recorded. These rebates typically arise from sales contracts with government payers, third-party managed care organisations, hospitals, long-term care facilities, group purchasing organisations and various state programmes.

In markets where returns are significant, estimates of the quantity and value of goods which may ultimately be returned are accounted for at the point revenue is recognised. Our returns accruals are based on actual experience over the preceding 12 months for established products together with market-related information such as estimated stock levels at wholesalers and competitor activity which we receive via third-party information services. For newly launched products, we use rates based on our experience with similar products or a predetermined percentage.

When a product faces generic competition, particular attention is given to the possible levels of returns and, in cases where the circumstances are such that the level of Product Sales are considered highly probable to reverse, revenues are only recognised when the right of return expires, which is generally on ultimate prescription of the product to patients.

The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Once the uncertainty associated with returns is resolved, revenue is adjusted accordingly.

Under certain collaboration agreements which include a profit sharing mechanism, our recognition of Product Sales depends on which party acts as principal in sales to the end customer. In the cases where AstraZeneca acts as principal, we record 100% of sales to the end customer. In the cases where AstraZeneca does not act as principal, we record the share of gross profits received within Alliance Revenue.

Certain arrangements include bill-and-hold arrangements under which the Group invoices a customer for a product but retains physical possession of the product until it is transferred to the customer at a point in time in the future. For these types of arrangements, an assessment is made to determine when the performance obligation has been satisfied, which is when control of the product is transferred to the customer. If the customer has obtained control of the product even though that product remains in the Group's physical possession, the performance obligation to transfer a product has been satisfied and Product Sales are recognised. Control is considered to have transferred when the reason for the bill-and-hold arrangement is substantive, the product can be identified separately as belonging to the customer, the product is ready for physical transfer to the customer and AstraZeneca is unable to use or sell the product to another customer.

Alliance Revenue

Alliance Revenue comprises income arising from the ongoing operation of collaborative arrangements related to sales made by collaboration partners, where AstraZeneca is entitled to a share of gross profits, a share of revenues or royalties, which are recurring in nature while the collaboration agreement remains in place. Alliance Revenue does not include Product Sales where AstraZeneca is leading commercialisation in a territory, or reimbursement for AstraZeneca-incurred expenses such as R&D or promotion costs, which arise from the license of intellectual property.

The Group periodically enters into transactions where it acquires part of the rights to a product intangible (either on-market or in-process R&D), but for commercial reasons does not act as principal in selling the product to the customer and therefore does not recognise income from the product in the form of Product Sales. This may occur where, for example, a collaboration partner retains the right to commercialise in a specific territory,

and has sufficient local control over that commercialisation to book Product Sales, while the Group instead receives a proportion of the value generated by those Product Sales, either in the form of a share of gross profits, a share of revenues or a royalty. This revenue is recognised when the Group's right to receive the share of the collaboration partner's income is established and can be reliably measured.

Where an out-licensing arrangement meets the definition of a licence agreement, sales royalties are recognised when achieved by applying the royalty exemption under IFRS 15 'Revenue from Contracts with Customers'. Where the arrangement meets the definition of a licence agreement, share of gross profits, share of revenues and sales royalties are recognised when achieved by applying the royalty exemption under IFRS 15. All other sales royalties are recognised when considered it is highly probable there will not be a significant reversal of cumulative income. The determination requires estimates to be made in relation to future Product Sales.

Collaboration Revenue

Collaboration Revenue includes income arising from entering into collaborative arrangements where the Group has out-licensed (sold) certain rights associated with products and where AstraZeneca retains a significant ongoing economic interest in the product. Significant interest can include ongoing supply of finished goods, profit sharing arrangements or being principal in the sales of medicines. These collaborations may include development, manufacturing and/or commercialisation arrangements with the collaborator. Income from out-licences may take the form of upfront fees and milestones.

KJ Timing of recognition of clinical and regulatory milestones is considered to be a Key Judgement. There can be significant uncertainty over whether it is highly probable that there would not be a significant reversal of cumulative revenue in respect of specific milestones if these are recognised before they are triggered due to them being subject to the actions of third parties. In general, where the triggering of a milestone is subject to the decisions of third parties (e.g. the acceptance or approval of a filing by a regulatory authority), the Group does not consider that the threshold for recognition is met until that decision is made.

Where Collaboration Revenue arises from the licensing of the Group's own intellectual property, the licences we grant are typically rights to use intellectual property which do not change during the period of the licence and therefore related non-conditional revenue is recognised at the point the licence is granted and variable consideration as soon as recognition criteria are met.

Other performance obligations in the contract might include the supply of product. These arrangements typically involve the receipt of an upfront payment, which the contract attributes to the license of the intangible assets, and ongoing receipts for supply, which the contract attributes to the sale of the product we manufacture. In cases where the transaction has two or more components, we account for the delivered item (for example, the transfer of title to the intangible asset) as a separate unit of account and record revenue on delivery of that component. Where practicable, consideration is allocated to performance obligations on the basis of the standalone selling price of each performance obligation. However, where there is a licence of intellectual property, it is not always possible to establish a reliable estimate of the standalone selling price of the licence as they are unique. Therefore, in these rare situations, the residual approach is used to determine the consideration attributable to the licence.

Where fixed amounts are payable over one year from the effective date of a contract, an assessment is made as to whether a significant financing component exists, and if so, the fair value of this component is deferred and recognised as financing income over the period to the expected date of receipt.

Where control of a right-to-use licence for an intangible asset passes at the outset of an arrangement, revenue is recognised at the point in time control is transferred. Where the substance of a licence arrangement is that of a right-to-access rights attributable to an intangible asset, revenue, in the form of an upfront fee, is recognised over time, normally on a straight-line basis over the life of the contract.

Where Collaboration Revenue is recorded and there is a related intangible asset that is licensed as part of the arrangement, an appropriate amount of that intangible asset is charged to Cost of sales based on an allocation of cost or value to the rights that have been licensed.

Cost of sales

Cost of sales are recognised as the associated revenue is recognised. Cost of sales include manufacturing costs, royalties payable on revenues recognised, movements in provisions for inventories, inventory write-offs and impairment charges in relation to manufacturing assets. Cost of sales also includes co-collaborator sharing of profit arising from collaborations, and foreign exchange gains and losses arising from business trading activities.

Research and development

Research expenditure is charged to profit and loss in the year in which it is incurred.

KJ Internal development expenditure is capitalised only if it meets the recognition criteria of IAS 38 'Intangible Assets'. This is considered a Key Judgement. Where regulatory and other uncertainties are such that the criteria are not met, the expenditure is charged to profit and loss and this is almost invariably the case prior to approval of the drug by the relevant regulatory authority. Where, however, recognition criteria are met, Intangible assets are capitalised and amortised on a straight-line basis over their useful economic lives from product launch. At 31 December 2025, no amounts have met the recognition criteria.

Payments to in-license products and compounds from third parties for new research and development projects (in process research and development) generally take the form of upfront payments, milestones and royalty payments. Where payments made to third parties represent consideration for future research and development activities, an evaluation is made as to the nature of the payments. Such payments are expensed if they represent compensation for sub-contracted research and development services not resulting in a transfer of intellectual property. By contrast, payments are capitalised if they represent compensation for the transfer of identifiable intellectual property developed at the risk of the third party. Such payments may be made once development or regulatory milestones are met and may also be made on the basis of sales volumes once a product is launched. Development and regulatory milestone payments are capitalised as the milestone is triggered. Sales-related payments are accrued and capitalised with reference to the latest Group sales forecasts for approved indications at the present value of expected future cash flows. Assets capitalised are amortised, on a straight-line basis, over their useful economic lives from product launch.

KJ The determination of useful economic life is considered to be a Key Judgement. On product launch, the Group makes a judgement as to the expected useful economic life with reference to the expiry of associated patents for the product, expectation around the competitive environment specific to the product and our detailed long-term risk-adjusted sales projections compiled annually across the Group and approved by the Board.

The useful economic life can extend beyond patent expiry dependent upon the nature of the product and the complexity of the development and manufacturing process. Significant sales can often be achieved post patent expiration.

Intangible assets

Intangible assets are stated at cost less accumulated amortisation and impairments. Intangible assets relating to products in development are subject to impairment testing at least annually. All Intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. The determination of the recoverable amounts includes key estimates which are highly sensitive to, and depend upon, key assumptions as detailed in Note 11 to the Financial Statements from page 151.

Impairment reviews have been carried out on all Intangible assets that are in development (and not being amortised), all major intangible assets acquired during the year and all other intangible assets that have had indicators of impairment during the year. Recoverable amount is determined as the higher of value in use or fair value less costs to sell using a discounted cash flow calculation, with the products' expected cash flows risk-adjusted over their estimated remaining useful economic life. Sales forecasts and specific allocated costs (which have both been subject to appropriate senior management review and approval) are risk-adjusted and discounted using appropriate rates based on our post-tax weighted average cost of capital or for fair value less costs to sell, a required rate of return for a market participant. Our weighted average cost of capital reflects factors such as our capital structure and our costs of debt and equity.

Any impairment losses are recognised immediately in Operating profit. Intangible assets relating to products which fail during development (or for which development ceases for other reasons) are also tested for impairment and are written down to their recoverable amount (which is usually nil).

If, subsequent to an impairment loss being recognised, development restarts or other facts and circumstances change indicating that the impairment is less or no longer exists, the value of the asset is re-estimated and its carrying value is increased to the recoverable amount, but not exceeding the original value, by recognising an impairment reversal in Operating profit.

Government grants

Government grants are recognised in the Consolidated Statement of Comprehensive Income so as to match with the related expenses that they are intended to compensate. Where grants are received in advance of the related expenses, they are initially recognised in the Consolidated Statement of Financial Position under Trade and other payables as deferred income and released to net off against the related expenditure when incurred.

Group Accounting Policies *continued*

Each contract is assessed to determine whether there are both grant elements and supply of product which need to be separated. In each case, the contracts set out the specified terms for the supply of the product and the provisions for funding for certain costs, primarily research and development associated with the intellectual property (IP). It is considered whether there are any conditions for the funding to be refunded. The consideration in the contract is allocated between the grant and supply elements. The standalone selling price for the supply of products is determined by reference to observed prices with other customers. The amount allocated as a government grant is determined by reference to the specific agreed costs and activities identified in the contract as not directly attributable to the supply of product. Government grants are recorded as an offset to the relevant expense in the Consolidated Statement of Comprehensive Income and are capped to match the relevant costs incurred.

Other operating income and expense

Other operating income and expense is generated from activities outside of the Group's normal course of business, which includes Other income from divestments of or full out-license of assets and businesses including royalties and milestones where the Group does not retain a significant continued interest. Where the arrangement meets the definition of a licence agreement, sales milestones and sales royalties are recognised when achieved by applying the royalty exemption under IFRS 15 'Revenue from Contracts with Customers'. All other milestones and sales royalties are recognised when it is considered highly probable that there will not be a significant reversal of cumulative income. The determination requires estimates to be made in relation to future Product Sales.

Joint arrangements and associates

The Group has arrangements over which it has joint control and which qualify as joint operations or joint ventures under IFRS 11 'Joint Arrangements'. For joint operations, the Group recognises its share of revenue that it earns from the joint operations and its share of expenses incurred. The Group also recognises the assets associated with the joint operations that it controls and the liabilities it incurs under the joint arrangement. For joint ventures and associates, the Group recognises its interest in the joint venture or associate as an investment and uses the equity method of accounting.

Employee benefits

The Group accounts for pensions and other employee benefits (principally healthcare) under IAS 19 'Employee Benefits'. In respect of defined benefit plans, obligations are determined using the projected unit credit method and are discounted to present value by reference to market yields on high-quality corporate bonds, while plan assets are measured at fair value. Given the extent of the assumptions used to determine the value of scheme assets and scheme liabilities, these are considered to be significant estimates. The operating and financing costs of such plans are recognised separately in profit and loss; current service costs are spread systematically over the working lives of employees and financing costs are recognised in full in the periods in which they arise. Remeasurements of the net defined benefit pension liability, including actuarial gains and losses, are recognised immediately in Other comprehensive income.

Where the calculation results in a surplus to the Group, the recognised asset is limited to the present value of any available future refunds from the plan or reductions in future contributions to the plan subject to consideration of the effect any minimum funding requirement for future service has on the benefit available as a reduction in future contributions.

Payments to defined contribution plans are recognised in profit and loss as they fall due.

Taxation

The current tax payable is based on taxable profit for the year. Taxable profit differs from reported profit because taxable profit excludes items that are either never taxable or tax deductible or items that are taxable or tax deductible in a different period. The Group's current tax assets and liabilities are calculated using tax rates that have been enacted or substantively enacted by the reporting date. Current tax includes the Group's charge for any Pillar Two income taxes.

Deferred tax is provided using the balance sheet liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognised unless they arise from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. Deferred tax liabilities are not recognised to the extent they arise from the initial recognition of non-tax deductible goodwill. Deferred tax assets are

recognised to the extent that there are future taxable temporary differences or it is probable that future taxable profit will be available against which the asset can be utilised. This requires judgements to be made in respect of the availability of future taxable income.

The Group applies the exception to recognising and disclosing information about deferred tax assets and liabilities related to Pillar Two income taxes, as provided in the amendments to IAS 12 'Income Taxes' issued in May 2023.

No deferred tax asset or liability is recognised in respect of temporary differences associated with investments in subsidiaries and branches where the Group is able to control the timing of reversal of the temporary differences and it is probable that the temporary differences will not reverse in the foreseeable future.

The Group's deferred tax assets and liabilities are calculated using tax rates that are expected to apply in the period when the liability is settled or the asset realised based on tax rates that have been enacted or substantively enacted by the reporting date. Deferred tax liabilities relating to assets recognised because of a business combination which may qualify for intellectual property incentives are measured at the relevant statutory tax rate. Deferred tax assets and liabilities are offset in the Consolidated Statement of Financial Position if, and only if, the taxable entity has a legally enforceable right to set off current tax assets and liabilities, and the Deferred tax assets and liabilities relate to taxes levied by the same taxation authority on the same taxable entity.

Liabilities for uncertain tax positions require management to make judgements of potential exposures in relation to tax audit issues based upon interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Tax benefits are recognised when it is probable the tax positions will be accepted by the tax authorities. When a position is not considered probable of being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable result. This is measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty.

Further details of the estimates and assumptions made in determining our recorded liability for transfer pricing contingencies and other tax contingencies are included in Note 30 to the Financial Statements from page 189.

Share-based payments

All plans have been classified as equity settled after assessment. The grant date fair value of the market-based performance elements of employee share plan awards is calculated using a modified Monte Carlo model, with other elements at market price. In accordance with IFRS 2 'Share-based Payment', the resulting cost is recognised in profit on a straight-line basis over the vesting period of the awards. The value of the charge is adjusted to reflect expected and actual levels of awards vesting, except where the failure to vest is as a result of not meeting a market condition. Cancellations of equity instruments are treated as an acceleration of the vesting period and any outstanding charge is recognised in profit immediately.

Cash outflows relating to the purchase of shares by consolidated Employee Benefit Trusts (EBTs) relating to the vesting of share plans are recognised within financing activities. Cash outflows relating to the employer and employee taxes paid on vesting of share plans are recognised in operating activities as they relate to employee remuneration. The cost of shares held by EBTs at the period end is deducted from equity. The cash flows relating to replacement awards issued to employees as part of the Alexion Pharmaceuticals, Inc. (Alexion) acquisition are classified within investing activities, as they are part of the aggregate cash flows arising from obtaining control of the subsidiary.

Property, plant and equipment

The Group's policy is to depreciate the difference between the cost of each item of Property, plant and equipment and its residual value over its estimated useful life on a straight-line basis. Assets under construction are not depreciated until the asset is available for use, at which point the asset is transferred into either Land and buildings or Plant and equipment, and depreciated over its estimated useful economic life.

Reviews are made annually of the estimated remaining lives and residual values of individual productive assets, taking account of commercial and technological obsolescence as well as normal wear and tear. It is impractical to calculate average asset lives exactly. However, the useful economic lives range from approximately 10 to 50 years for buildings, and three to 15 years for plant and equipment. All items of Property, plant and equipment are tested for impairment when there are indications that the carrying value may not be recoverable. Any impairment losses are recognised immediately in Operating profit.

Leases

The Group's lease arrangements are principally for property, most notably a portfolio of office premises and employee accommodation, and for a global car fleet, utilised primarily by our sales and marketing teams.

The lease liability and corresponding right-of-use asset arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

- fixed payments, less any lease incentives receivable
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date
- the exercise price of a purchase option if the Group is reasonably certain to exercise that option
- payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option, and
- amounts expected to be payable by the Group under residual value guarantees.

Right-of-use assets are measured at cost comprising the following:

- the amount of the initial measurement of lease liability
- any lease payments made at or before the commencement date less any lease incentives received
- any initial direct costs, and
- restoration costs.

Judgements made in calculating the lease liability include assessing whether arrangements contain a lease and determining the lease term. Extension and termination options have been considered when determining the lease term, along with all facts and circumstances that may create an economic incentive to exercise an extension option, or not exercise a termination option. Extension periods (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated).

The lease payments are discounted using incremental borrowing rates, as in the majority of leases held by the Group the interest rate implicit in the lease is not readily identifiable. Calculating the discount rate is an estimate made in calculating the lease liability. This rate is the rate that the Group would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. To determine the incremental borrowing rate, the Group uses a risk-free interest rate adjusted for credit risk, adjusting for terms specific to the lease including term, country and currency.

The Group is exposed to potential future increases in variable lease payments that are based on an index or rate, which are initially measured as at the commencement date, with any future changes in the index or rate excluded from the lease liability until they take effect. When adjustments to lease payments based on an index or rate take effect, the lease liability is reassessed and adjusted against the right-of-use asset.

Lease payments are allocated between principal and finance cost. The finance cost is charged to the Consolidated Statement of Comprehensive Income over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative standalone prices.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset's useful life. It is impractical to calculate average asset lives exactly. However, the total lives range from approximately 10 to 50 years for buildings, and three to 15 years for motor vehicles and other assets.

There are no material lease agreements under which the Group is a lessor.

Business combinations and goodwill

In assessing whether an acquired set of assets and activities is a business or an asset, management will first elect whether to apply an optional concentration test to simplify the assessment. Where the concentration test is applied, the acquisition will be treated as the acquisition of an asset if substantially all of the fair value of the gross assets acquired (excluding cash and cash equivalents, deferred tax assets, and related goodwill) is concentrated in a single asset or group of similar identifiable assets.

Where the concentration test is not applied, or is not met, a further assessment of whether the acquired set of assets and activities is a business will be performed.

Group Accounting Policies *continued*

KJ The determination of whether an acquired set of assets and activities is a business or an asset can be judgemental, particularly if the target is not producing outputs. Management uses a number of factors to make this determination, which are primarily focused on whether the acquired set of assets and activities include substantive processes that mean the set is capable of being managed for the purpose of providing a return. Key determining factors include the stage of development of any assets acquired, the readiness and ability of the acquired set to produce outputs and the presence of key experienced employees capable of conducting activities required to develop or manufacture the assets. Typically, the specialised nature of many pharmaceutical assets and processes is such that until assets are substantively ready for production and promotion, there are not the required processes for a set of assets and activities to meet the definition of a business in IFRS 3 'Business Combinations'.

On acquiring a business, fair values are assigned to identifiable assets and liabilities by the application of judgement. Contingent liabilities are recognised at fair value unless it cannot be measured reliably.

Where not all of the equity of a subsidiary is acquired, the non-controlling interest is recognised either at fair value or at the non-controlling interest's proportionate share of the net assets of the subsidiary, on a case-by-case basis.

The timing and amount of future contingent elements of consideration is an estimate. Contingent consideration, which may include development and launch milestones, revenue threshold milestones and revenue-based royalties, is fair valued at the date of acquisition using decision-tree analysis with key inputs including probability of success, consideration of potential delays and revenue projections based on the Group's internal forecasts. Unsettled amounts of consideration are held at fair value within payables with changes in fair value recognised immediately in profit.

Goodwill is the difference between the fair value of the consideration and the fair value of net assets acquired.

Goodwill arising on acquisitions is capitalised and subject to an impairment review, both annually and when there is an indication that the carrying value may not be recoverable.

Subsidiaries

A subsidiary is an entity controlled, directly or indirectly, by AstraZeneca PLC. Control is regarded as the exposure or rights to the variable returns of the entity when combined with the power to affect those returns. Control is normally evidenced by holding more than 50% of the share capital of the company, however other agreements may be in place that result in control where they give AstraZeneca finance decision-making authority over the relevant activities of the company.

The financial results of subsidiaries are consolidated from the date control is obtained until the date that control ceases.

Inventories

Inventories are stated at the lower of cost and net realisable value. The first in, first out or an average method of valuation is used. For finished goods and work in progress, cost includes directly attributable costs and certain overhead expenses (including depreciation). Selling expenses and certain other overhead expenses (principally central administration costs) are excluded. Net realisable value is determined as estimated selling price less all estimated costs of completion and costs to be incurred in selling and distribution.

Write-downs of inventory occur in the general course of business and are recognised in Cost of sales for launched or approved products and in Research and development expense for products in development.

Trade and other receivables

Financial assets included in Trade and other receivables are recognised initially at fair value. The Group holds the Trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method, less any impairment, based on expected credit losses.

Trade receivables that are subject to debt factoring arrangements are derecognised if they meet the conditions for derecognition detailed in IFRS 9 'Financial Instruments'.

Trade and other payables

Financial liabilities included in Trade and other payables are recognised initially at fair value. Subsequent to initial recognition they are measured at amortised cost using the effective interest method. Contingent consideration payables are held at fair value within Level 3 of the fair value hierarchy as defined in Note 13.

Financial instruments

The Group's financial instruments include Lease liabilities, Trade and other receivables and payables, liabilities for contingent consideration under business combinations, and rights and obligations under employee benefit plans which are dealt with in specific accounting policies.

The Group's other financial instruments include:

i) Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, current balances with banks and similar institutions, and highly liquid investments with maturities of three months or less when acquired. They are readily convertible into known amounts of cash and are held at amortised cost under the hold to collect classification, where they meet the hold to collect 'solely payments of principal and interest' test criteria under IFRS 9 'Financial Instruments'. Those not meeting these criteria are held at fair value through profit or loss. Cash and cash equivalents in the Consolidated Statement of Cash Flows include unsecured bank overdrafts at the balance sheet date where balances often fluctuate between a cash and overdraft position (such overdrafts are included within current Interest-bearing loans and borrowings in the Consolidated Statement of Financial Position).

ii) Fixed deposits

Fixed deposits, principally comprising funds held with banks and other financial institutions, are initially measured at fair value, plus direct transaction costs, and are subsequently measured at amortised cost using the effective interest method at each reporting date. Changes in carrying value are recognised in the Consolidated Statement of Comprehensive Income.

iii) Other investments

Investments are classified as fair value through profit or loss (FVPL), unless the Group makes an irrevocable election at initial recognition for certain non-current equity investments to present changes in Other comprehensive income (FVOCI). If this election is made, there is no subsequent reclassification of fair value gains and losses to profit and loss following the derecognition of the investment.

iv) Bank and other borrowings

The Group uses derivatives, principally interest rate swaps, to hedge the interest rate exposure inherent in a portion of its fixed interest rate debt. In such cases the Group will either designate the debt as FVPL when certain criteria are met or as the hedged item under a fair value hedge.

If the debt instrument is designated as FVPL, the debt is initially measured at fair value (with direct transaction costs being included in profit and loss as an expense) and is remeasured to fair value at each reporting date with changes in carrying value being recognised in profit and loss (along with changes in the fair value of the related derivative), with the exception of changes in the fair value of the debt instrument relating to own credit risk which are recorded in Other comprehensive income in accordance with IFRS 9 'Financial Instruments'. Such a designation has been made where this significantly reduces an accounting mismatch which would result from recognising gains and losses on different bases.

If the debt is designated as the hedged item under a fair value hedge, the debt is initially measured at fair value (with direct transaction costs being amortised over the life of the debt) and is remeasured for fair value changes in respect of the hedged risk at each reporting date with changes in carrying value being recognised in profit and loss (along with changes in the fair value of the related derivative).

If the debt is designated in a cash flow hedge, the debt is measured at amortised cost (with gains or losses taken to profit and loss and direct transaction costs being amortised over the life of the debt). The related derivative is remeasured for fair value changes at each reporting date with the portion of the gain or loss on the derivative that is determined to be an effective hedge recognised in Other comprehensive income. The amounts that have been recognised in Other comprehensive income are reclassified to profit and loss in the same period that the hedged forecast cash flows affect profit. The reclassification adjustment is included in Finance expense in the Consolidated Statement of Comprehensive Income.

Other interest-bearing loans are initially measured at fair value (with direct transaction costs being amortised over the life of the loan) and are subsequently measured at amortised cost using the effective interest method at each reporting date. Changes in carrying value are recognised in the Consolidated Statement of Comprehensive Income.

v) Derivatives

Derivatives are initially measured at fair value (with direct transaction costs being included in profit and loss as an expense) and are subsequently remeasured to fair value at each reporting date. Changes in carrying value of derivatives not designated in hedging relationships are recognised in profit and loss.

The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral, for the benefit of the other, equivalent to the market valuation of all of the derivative positions above a predetermined threshold. Cash collateral received from counterparties is included within current Interest-bearing loans and borrowings within the Consolidated Statement of Financial Position. Cash collateral pledged to counterparties is recognised as a financial asset and is included in current Other investments within the Consolidated Statement of Financial Position. Cash collateral received is included in Movement in short-term borrowings within financing activities in the Consolidated Statement of Cash Flows. Cash collateral paid is included in Movements in short-term investments within investing activities in the Consolidated Statement of Cash Flows. The cash flow presentation of cash paid and received follows the Consolidated Statement of Financial Position presentation of the financial asset and financial liability that is recognised from posting the collateral.

Foreign currencies

Foreign currency transactions, being transactions denominated in a currency other than an individual Group entity's functional currency, are translated into the relevant functional currencies of individual Group entities at average rates for the relevant monthly accounting periods, which approximate to actual rates.

Monetary assets and liabilities arising from foreign currency transactions are retranslated at exchange rates prevailing at the reporting date. Exchange gains and losses on loans and on short-term foreign currency borrowings and deposits are included within Finance expense. Exchange differences on all other foreign currency transactions are recognised in Operating profit in the individual Group entity's accounting records.

Non-monetary items arising from foreign currency transactions are not retranslated in the individual Group entity's accounting records.

In the Consolidated Financial Statements, income and expense items for Group entities with a functional currency other than US dollars are translated into US dollars at average exchange rates, which approximate to actual rates, for the relevant accounting periods. Assets and liabilities are translated at the US dollar exchange rates prevailing at the reporting date. Exchange differences arising on consolidation are recognised in Other comprehensive income.

If certain criteria are met, non-US dollar-denominated loans or derivatives are designated as net investment hedges of foreign operations. Exchange differences arising on retranslation of net investments, and of foreign currency loans which are designated in an effective net investment hedge relationship, are recognised in Other comprehensive income in the Consolidated Financial Statements. Foreign exchange derivatives hedging net investments in foreign operations are carried at fair value. Effective fair value movements are recognised in Other comprehensive income, with any ineffectiveness taken to profit. Gains and losses accumulated in the translation reserve will be recycled to profit and loss when the foreign operation is sold.

Provisions

Provisions are recognised when there is either a legal or constructive present obligation as a result of a past event, it is probable that an outflow of economic resources will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the effect of the time value of money is material, provisions are discounted at the relevant pre-tax discount rate. Where provisions are discounted, the increase in the provision resulting from the passage of time is recognised as a finance cost.

Litigation and environmental liabilities

AstraZeneca is involved in legal disputes, the settlement of which may involve cost to the Group. A provision is made where an adverse outcome is probable and associated costs, including related legal costs, can be estimated reliably. Determining the timing of recognition of when an adverse outcome is probable is considered a Key Judgement, refer to Note 30 to the Financial Statements on page 181.

Where it is considered that the Group is more likely than not to prevail, or in the extremely rare circumstances where the amount of the legal liability cannot be estimated reliably, legal costs involved in defending the claim are charged to the Consolidated Statement of Comprehensive Income as they are incurred.

Where it is considered that the Group has a valid contract which provides the right to reimbursement (from insurance or otherwise) of legal costs and/or all or part of any loss incurred or for which a provision has been established, the amount expected to be received is recognised as an asset only when it is virtually certain.

Group Accounting Policies *continued*

AstraZeneca is exposed to environmental liabilities relating to its past operations, principally in respect of soil and groundwater remediation costs. Provisions for these costs are made when there is a present obligation and where it is probable that expenditure on remedial work will be required and a reliable estimate can be made of the cost.

Restructuring

Restructuring costs are incurred in programmes that are planned and controlled by the Group which materially change either the scope of a business undertaken by the Group, or the manner in which that business is conducted.

A provision for restructuring costs is recognised when a detailed formal plan is in place and has either been announced to those affected or has started to be implemented. The general recognition criteria for provisions must also be met, as described in the Provisions policy.

Impairment

The carrying values of non-financial assets, other than Inventories and Deferred tax assets, are reviewed at least annually for indicators of impairment. For Goodwill, Intangible assets in development and any other assets where such indication exists, the asset's recoverable amount is estimated based on the greater of its value in use and its fair value less cost to sell. In assessing the recoverable amount, the estimated future cash flows, adjusted for the risks associated with the probability of success specific to each asset, as well as inflationary impacts, are discounted to their present value using a nominal discount rate that reflects current market assessments of the time value of money, the general risks affecting the pharmaceutical industry and other risks specific to each asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash flows of other assets. Impairment losses are recognised immediately in the Consolidated Statement of Comprehensive Income.

Applicable accounting standards and interpretations issued but not yet adopted

At the date of authorisation of these Financial Statements, certain new accounting standards and amendments were in issue relating to the following standards and interpretations but not yet adopted by the Group:

- IFRS 18 'Presentation and Disclosure in Financial Statements' is effective for accounting periods beginning on or after 1 January 2027 and will replace IAS 1 'Presentation of Financial Statements'. IFRS 18 sets out new presentation requirements for the Statement of Comprehensive Income, as well as more stringent and additional requirements on the aggregation, disaggregation and categorisation of income and expenses within the Statement of Comprehensive Income. Additionally, alternative performance measures included within the Annual Report which meet the definition of Management-defined Performance Measures are required to be disclosed within the Notes to the Financial Statements. IFRS 18 was endorsed by the UKEB on 10 December 2025.
- The Group continues to advance with the implementation of IFRS 18 and is well progressed with the adoption impact assessment. The Group is not seeking to early adopt this new standard. However, as a means of illustrating the impact of IFRS 18 on the presentation of the Group's results for the year ended 31 December 2025, the currently expected IFRS 18 adoption impacts for 2025 are shown in Note 1 to the Financial Statements. The Group continues to monitor IFRS 18 implementation guidance in advance of adoption for the accounting year beginning 1 January 2027.

In addition, the following amendments were issued but not yet adopted:

- amendments to IFRS 9 'Financial Instruments' and IFRS 7 'Financial Instruments: Disclosures', effective for periods beginning on or after 1 January 2026 – endorsed by the UKEB on 15 April 2025 and 23 July 2025.

Notes to the Group Financial Statements

1 IFRS 18 'Presentation and Disclosure in Financial Statements'

IFRS 18 'Presentation and Disclosure in Financial Statements' is effective for accounting periods beginning on or after 1 January 2027 and will replace IAS 1 'Presentation of Financial Statements'. There are also consequential amendments to IAS 7 'Cash Flows', IAS 8 'Accounting Policies, Changes in Accounting Estimates and Errors', IAS 33 'Earnings per Share' and IAS 34 'Interim Financial Reporting', also effective for accounting periods beginning on or after 1 January 2027. The Group is well progressed with the impact assessment of the adoption of this new standard, with the expected impact for the year ended 31 December 2025 detailed below.

The Group will apply IFRS 18 retrospectively, in accordance with IAS 8. The Group has not elected to utilise the option to change the measurement of eligible investments in associates and joint ventures from the equity method to fair value through profit or loss at the date of transition.

The new standard introduces new requirements for the presentation, classification and disclosure of financial statement line items. The requirements were introduced to help achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users. The key changes include the requirement to classify all income and expense into one of five categories; operating, investing, financing, taxation and discontinued operations, and introduces new mandated subtotals within the Consolidated Statement of Comprehensive Income, including Operating profit, Profit before financing and income tax and Profit for the period. In addition, details of management-defined performance measures ('MPMs') will now be disclosed as well as further detailed disclosure related to operating expense by nature. The new standard also offers enhanced guidance on aggregation and disaggregation of financial information.

Although the adoption of IFRS 18 will have no impact on the Group's Profit for the period or Total Revenue, the Group expects that grouping items of income and expense in the Consolidated Statement of Profit or Loss into the new categories will impact how Operating profit is reported.

The Group does not have a specified main business activity as defined in IFRS 18.

Reconciliation of the Consolidated Statement of Profit or Loss – Illustrative under IFRS 18 for the year ended 31 December 2025

IAS 1 presentation	Existing IAS 1 2025 \$m	Transition adjustments \$m	Adjusted for IFRS 18 2025 \$m	Expected IFRS 18 presentation
– Product Sales	55,573	–	55,573	– Product Sales
– Alliance Revenue	3,067	–	3,067	– Alliance Revenue
Product Revenue	58,640	–	58,640	Product Revenue
Collaboration Revenue	99	–	99	Collaboration Revenue
Total Revenue	58,739	–	58,739	Total Revenue
Cost of sales	(10,633)	9	(10,624)	Cost of sales
Gross profit	48,106	9	48,115	Gross profit
Distribution expense	(579)	–	(579)	Distribution expense
Research and development expense	(14,232)	–	(14,232)	Research and development expense
		(12,529)	(12,529)	Selling and marketing expense
Selling, general and administrative expense	(19,933)	12,529	(7,404)	General and administrative expense
Other operating income and expense	381	13	394	Other operating income and expense
Operating profit	13,743	22	13,765	Operating profit
		343	343	Investing income
		(7)	(7)	Share of after tax losses in associates and joint ventures
		14,101	14,101	Profit before financing and income tax
Finance income	360	(360)		
Finance expense	(1,694)	(5)	(1,699)	Finance expense
Share of after tax losses in associates and joint ventures	(7)	7		
Profit before tax	12,402	–	12,402	Profit before tax
Taxation	(2,169)	–	(2,169)	Taxation
Profit for the period	10,233	–	10,233	Profit for the period

Explanation of the adjustments due to IFRS 18

Share of after tax losses in associates and joint ventures will be presented within the investing category of the Consolidated Statement of Comprehensive Income, within the new subtotal of Profit or loss before financing and income tax which totals an expected \$14,101m in 2025.

Returns on deposits and equity securities, and interest income on tax balances, previously reported within Finance income will be reclassified under IFRS 18 to Investing income, totalling an expected \$360m in 2025.

Notes to the Group Financial Statements *continued*

1 IFRS 18 'Presentation and Disclosure in Financial Statements' *continued*

Foreign exchange differences on cash and short-term deposits, previously included within Finance income and Finance expense, will be classified within the investing category under IFRS 18, expected to result in a reduction to Finance expense and a decrease in Investing income of \$17m in 2025.

Gains and losses on certain designated hedges, previously included within Finance income and Finance expense, will be classified within the operating category under IFRS 18, resulting in an expected reduction to Finance expense and an increase in Other operating income and expense of \$13m in 2025.

Under IFRS 18, Selling, general and administrative expense (\$19,933m in 2025) will be disaggregated into Selling and marketing expense (\$12,529m in 2025) and General and administrative expense (\$7,404m in 2025).

Consolidated Statement of Cash Flows

The Consolidated Statement of Cash Flows under the amended IAS 7 requirements will start with Operating profit (\$13,765m for 2025 under IFRS 18), rather than the previous starting point of Profit before tax (\$12,402m in 2025 under IAS 1), removing the need to add back Finance income and expense (\$1,334m in 2025) and Share of after tax losses of associates and joint ventures (\$7m in 2025). In addition, Interest paid (\$1,316m in 2025) will be reclassified to Cash flows from financing activities under IFRS 18, previously classified within Cash flows from operating activities.

Operating expenses by nature

The Group currently presents expenses in the Consolidated Statement of Comprehensive Income by function. While IFRS 18 continues to permit this presentation, it introduces additional disclosure requirements in the Notes to the Financial Statements. The following table presents 2025 operating expenses split by nature according to the requirements of IFRS 18.

	Depreciation \$m	Amortisation \$m	Net impairment charges \$m	Employee benefits \$m	Net inventory write-downs \$m
Total amount related to:					
Cost of sales	404	86	3	1,633	314
Distribution expense	6	–	–	43	–
Research and development expense	456	47	214	4,879	–
Selling and marketing expense	210	9	–	6,346	–
General and administrative expense	205	4,064	26	1,759	–
Other operating income and expense	2	1	–	78	–
Total amount relating to operating category	1,283	4,207	243	14,738	314

The amounts disclosed are those expensed during the year, except for depreciation and employee benefits which include amounts capitalised to inventory and software development costs.

Management-defined performance measures (MPMs)

The Group has identified Core Gross profit (\$48,039m in 2025 under IFRS 18), Core Operating profit (\$18,500m in 2025 under IFRS 18) and Core Profit attributable to owners of the Parent (numerator of core basic earnings per share, \$14,201m in 2025 under IFRS 18) as MPMs used in its public communications to communicate management's view of an aspect of the operating performance of the Group as a whole. These measures are not specifically required to be presented or disclosed by IFRS, which means they may not be directly comparable with similarly labelled or described measures by other entities.

The reported IFRS results are adjusted to exclude certain significant items. In determining the adjustments to arrive at the Core result, we use a set of established principles relating to the nature or materiality of individual items or groups of items, excluding, for example, events which are (i) outside the normal course of business, (ii) incurred in a pattern that is unrelated to the trends in the underlying financial performance of our ongoing business, or (iii) related to major acquisitions, to ensure that investors' ability to evaluate and analyse the underlying financial performance of our ongoing business is enhanced. Group management believes that these adjusted measures offer a relevant alternative perspective on the Group's underlying operating performance by excluding the effects of the above mentioned items that are not indicative of the ongoing business activities. Group management considers this useful for understanding profitability trends and for evaluating the Group's ability to generate sustainable earnings from its core operations.

Our Core adjustments are summarised as:

Restructuring costs, including charges and provisions related to our global restructuring programmes on our capitalised manufacturing facilities and IT assets. These can take place over multiple reporting periods, given the long life-cycle of our business.

Why we use them: We adjust for these charges and provisions because they primarily reflect the financial impact of change to legacy arrangements, rather than the underlying performance of our ongoing business.

Intangible amortisation and impairments, including impairment reversals but excluding any charges relating to IT assets. Intangibles generally arise from business combinations and individual licence acquisitions.

Why we use them: We adjust for these charges because their pattern of recognition is largely uncorrelated with the underlying performance of the business.

Other specified items, principally comprise acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables arising from intangible asset acquisitions, remeasurement adjustments relating to Other payables and debt items assumed from the Alexion acquisition and legal settlements.

Why we use them: We adjust for these items to enable a more meaningful comparison of the performance of acquired businesses and products to that of internally developed products, as well as removing charges whose pattern of recognition is largely uncorrelated to the underlying performance of the business. It should be noted that some costs excluded from our Core results, such as intangible amortisation and finance charges related to contingent consideration, will recur in future years, and other excluded items such as impairments and legal settlement costs, along with other acquisition-related costs, may recur in the future.

Limitations: Core results exclude significant costs (such as restructuring, intangible amortisation and impairments, and other acquisition-related adjustments), but incorporate associated benefits, including Product Sales arising from business combinations, asset acquisitions and assets which have been amortised, as well as the benefits resulting from restructuring activities and, as such, they should not be regarded as a complete picture of the Group's financial performance, which is presented in its Reported results. The exclusion of the adjusting items may result in Core earnings being materially higher or lower than Reported earnings.

2025 Reconciliation of Expected Reported (IFRS 18) results to Expected Core (IFRS 18) results

	2025 Expected Reported (IFRS 18) \$m	Restructuring costs \$m	Intangible amortisation and impairments \$m	Other \$m	2025 Expected Core (IFRS 18) \$m
Gross profit	48,115	(138)	32	30	48,039
Income tax ¹		18	(3)	(5)	
Profit attributable to non-controlling interests		–	–	–	
Distribution expense	(579)	–	–	–	(579)
Research and development expense	(14,232)	171	236	3	(13,822)
Selling and marketing expense	(12,529)	40	–	1	(12,488)
General and administrative expense	(7,404)	169	4,059	130	(3,046)
Other operating income and expense	394	(5)	–	7	396
Operating profit	13,765	237	4,327	171	18,500
Income tax ¹		(68)	(825)	(58)	
Profit attributable to non-controlling interests		–	–	–	
Net investing	336	–	–	–	336
Profit before financing and income tax	14,101	237	4,327	171	18,836
Finance expense	(1,699)	–	–	242	(1,457)
Taxation	(2,169)	(68)	(825)	(108)	(3,170)
Profit for the period	10,233	169	3,502	305	14,209
Profit attributable to non-controlling interests	(8)	–	–	–	(8)
Profit attributable to owners of the Parent	10,225	169	3,502	305	14,201
Income tax ¹		(68)	(825)	(108)	
Profit attributable to non-controlling interests		–	–	–	
Basic earnings per \$0.25 Ordinary Share	\$6.60	\$0.11	\$2.26	\$0.19	\$9.16

¹ The income tax effect for each adjusting item is calculated at the statutory tax rate applicable to that item in the relevant jurisdiction.

Notes to the Group Financial Statements *continued*

2 Revenue Product Sales

	2025					2024					2023				
	US \$m	Emerging Markets \$m	Europe \$m	Rest of World \$m	Total \$m	US \$m	Emerging Markets \$m	Europe \$m	Rest of World \$m	Total \$m	US \$m	Emerging Markets \$m	Europe \$m	Rest of World \$m	Total \$m
Oncology:															
<i>Tagrisso</i>	3,064	1,971	1,423	796	7,254	2,763	1,755	1,301	761	6,580	2,276	1,621	1,120	782	5,799
<i>Imfinzi</i>	3,509	640	1,239	675	6,063	2,603	479	948	687	4,717	2,171	355	742	751	4,019
<i>Calquence</i>	2,339	233	784	162	3,518	2,190	153	656	130	3,129	1,815	98	493	108	2,514
<i>Lynparza</i>	1,434	669	914	262	3,279	1,332	655	832	253	3,072	1,254	542	734	281	2,811
<i>Enhertu</i>	–	668	207	102	977	–	350	126	69	545	–	169	60	32	261
<i>Zoladex</i>	19	842	157	88	1,106	16	795	148	99	1,058	14	687	133	118	952
<i>Truqap</i>	586	23	85	34	728	408	2	12	8	430	6	–	–	–	6
<i>Imjudo</i>	227	22	52	45	346	180	16	36	49	281	146	5	16	51	218
<i>Datroway</i>	–	2	–	–	2	–	–	–	–	–	–	–	–	–	–
<i>Others</i>	9	280	19	117	425	18	297	23	125	463	37	351	34	143	565
	11,187	5,350	4,880	2,281	23,698	9,510	4,502	4,082	2,181	20,275	7,719	3,828	3,332	2,266	17,145
Cardiovascular, Renal & Metabolism:															
<i>Farxiga</i>	1,730	3,324	2,941	405	8,400	1,750	2,853	2,634	419	7,656	1,451	2,211	1,881	420	5,963
<i>Crestor</i>	45	1,041	1	129	1,216	46	934	37	136	1,153	55	862	52	138	1,107
<i>Brilinta</i>	393	273	147	10	823	751	294	268	20	1,333	744	285	271	24	1,324
<i>Lokelma</i>	301	129	129	139	698	256	86	92	108	542	214	50	58	90	412
<i>Seloken</i>	–	586	18	3	607	–	589	13	3	605	1	621	11	7	640
<i>Roxadustat</i>	–	274	–	–	274	–	331	–	–	331	–	271	–	–	271
<i>Wainua</i>	204	4	4	–	212	85	–	–	–	85	–	–	–	–	–
<i>Others</i>	49	262	158	65	534	187	252	226	78	743	287	286	230	65	868
	2,722	5,893	3,398	751	12,764	3,075	5,339	3,270	764	12,448	2,752	4,586	2,503	744	10,585
Respiratory & Immunology:															
<i>Symbicort</i>	1,193	801	560	331	2,885	1,187	805	559	328	2,879	726	753	549	334	2,362
<i>Fasenra</i>	1,195	117	482	187	1,981	1,049	92	404	144	1,689	992	64	355	142	1,553
<i>Breztri</i>	614	298	191	96	1,199	516	245	143	74	978	383	161	81	52	677
<i>Tezspire</i>	–	40	297	121	458	–	11	156	81	248	–	1	48	37	86
<i>Saphnelo</i>	596	16	49	25	686	425	7	26	16	474	260	2	8	10	280
<i>Pulmicort</i>	5	414	63	36	518	6	568	71	37	682	28	575	68	42	713
<i>Airsupra</i>	162	4	–	–	166	66	–	–	–	66	2	–	–	–	2
<i>Others</i>	75	133	59	7	274	167	169	57	7	400	156	215	55	8	434
	3,840	1,823	1,701	803	8,167	3,416	1,897	1,416	687	7,416	2,547	1,771	1,164	625	6,107
Vaccines & Immune Therapies:															
<i>Beyfortus</i>	184	–	94	3	281	232	–	84	2	318	87	–	19	–	106
<i>Synagis</i>	(3)	214	50	31	292	(8)	210	116	129	447	(1)	195	175	177	546
<i>FluMist</i>	28	5	210	29	272	28	1	204	25	258	23	1	188	4	216
<i>Others</i>	–	1	–	–	1	28	2	5	–	35	–	16	14	114	144
	209	220	354	63	846	280	213	409	156	1,058	109	212	396	295	1,012
Rare Disease:															
<i>Ultomiris</i>	2,667	261	1,053	737	4,718	2,261	141	884	638	3,924	1,750	71	668	476	2,965
<i>Soliris</i>	1,092	405	200	140	1,837	1,523	443	416	206	2,588	1,734	424	670	317	3,145
<i>Strensiq</i>	1,332	104	123	119	1,678	1,167	54	99	96	1,416	937	40	89	86	1,152
<i>Koselugo</i>	219	228	161	54	662	212	177	103	39	531	195	59	53	24	331
<i>Others</i>	113	40	67	11	231	100	34	66	9	209	85	29	49	8	171
	5,423	1,038	1,604	1,061	9,126	5,263	849	1,568	988	8,668	4,701	623	1,529	911	7,764
Other:															
<i>Nexium</i>	67	611	50	88	816	96	591	60	120	867	115	578	53	199	945
<i>Others</i>	(4)	121	34	5	156	15	144	43	4	206	18	153	52	8	231
	63	732	84	93	972	111	735	103	124	1,073	133	731	105	207	1,176
Product Sales	23,444	15,056	12,021	5,052	55,573	21,655	13,535	10,848	4,900	50,938	17,961	11,751	9,029	5,048	43,789

SE Rebates and chargebacks in the US

The major market where estimates are seen as significant is the US. When invoicing Product Sales in the US, we estimate the rebates and chargebacks we expect to pay and we consider there to be a significant estimate associated with the rebates for Managed Care, Medicaid and Medicare Part D. The total adjustment in respect of prior year net US Product Sales in 2025 was 0.7% (2024: 0.6%; 2023: 1.0%); this represents the difference between our prior year estimates for rebates and chargebacks against actual amounts paid for the US business. The most significant of these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales in 2025 of 0.2% (2024: 0.1%; 2023: 0.3%) and Managed Care and Medicare of 0.4% (2024: 0.6%; 2023: 0.5%).

The adjustment in respect of the prior year net US Product Sales, excluding the Rare Disease therapy area in 2025, was 0.9% (2024: 0.8%; 2023: 1.4%), with Medicaid and state programmes of 0.2% (2024: 0.1%; 2023: 0.4%) and Managed Care and Medicare of 0.5% (2024: 0.7%; 2023: 0.7%).

These values demonstrate the level of sensitivity; further meaningful sensitivity is not able to be provided due to the large volume of variables that contribute to the overall rebates, chargebacks, returns and other revenue accruals. These variables include assumptions in respect of aggregate future sales levels, segment mix and customers' contractual performance, and in addition for Managed Care, US Medicaid and Medicare Part D, the channel inventory levels, and assumptions related to lag time. These assumptions are built up on a product-by-product and customer-by-customer basis, taking into account specific contract provisions coupled with expected performance, and are then aggregated into a weighted average rebate accrual rate for each of our products. Accrual rates are reviewed and adjusted on an as-needed basis. There may be further adjustments when actual rebates are invoiced based on utilisation information submitted to AstraZeneca (in the case of contractual rebates) and claims/invoices are received (in the case of regulatory rebates and chargebacks).

Alliance Revenue

	2025 \$m	2024 \$m	2023 \$m
<i>Enhertu</i>	1,798	1,437	1,022
<i>Tezspire</i>	673	436	259
<i>Beyfortus</i>	422	237	57
<i>Datroway</i>	77	–	–
Other royalty income	92	91	81
Other Alliance Revenue	5	11	9
	3,067	2,212	1,428

Collaboration Revenue

	2025 \$m	2024 \$m	2023 \$m
<i>Farxiga</i> : sales milestones	87	56	29
<i>Lynparza</i> : sales milestone	–	600	–
<i>Beyfortus</i> : sales milestones	–	167	27
<i>Koselugo</i> : sales milestone	–	100	–
<i>Lynparza</i> : regulatory milestones	–	–	245
COVID-19 mAbs: licence fees	–	–	180
<i>Beyfortus</i> : regulatory milestones	–	–	71
tralokinumab: sales milestones	–	–	20
Other Collaboration Revenue	12	–	22
	99	923	594

3 Operating profit

Operating profit includes the following significant items:

Cost of sales

In 2025, Cost of sales includes a charge of \$25m (2024: \$nil; 2023: \$114m) in relation to the release, in line with sales, of fair value uplift to inventory that was recognised under IFRS 3 'Business Combinations'.

Selling, general and administrative expense

In 2025, Selling, general and administrative expense includes a credit of \$44m (2024: charge of \$260m; 2023: charge of \$520m) resulting from changes in the fair value of contingent consideration arising from the acquisition of the diabetes alliance from Bristol-Myers Squibb Company (BMS). These adjustments reflect revised estimates for future sales performance for the products acquired and, as a result, revised estimates for future royalties payable.

In 2025, Selling, general and administrative expense also includes a charge of \$218m (2024: \$48m; 2023: \$1,013m) relating to a number of legal proceedings, including settlements in various jurisdictions in relation to several marketed products (see Note 30).

Research and development expense: Government grants

During the year \$nil (2024: \$nil; 2023: \$74m) of government grants were recognised within Research and development expense relating to *Vaxzevria*.

Notes to the Group Financial Statements *continued*

3 Operating profit *continued*

Depreciation, impairment, amortisation and provision charges

The following items have been included in Operating profit:

	2025 \$m	2024 \$m	2023 \$m
Depreciation of Property, plant and equipment (Note 8)	879	799	733
Impairment of Property, plant and equipment (Note 8)	13	42	8
Depreciation of Right-of-use assets (Note 9)	404	343	275
Impairment of Right-of-use assets (Note 9)	–	7	14
Amortisation of Intangible assets (Note 11)	4,207	3,923	3,926
Net impairment of Intangible assets (Note 11)	230	1,574	434
Net charges to Provisions, net of reversals (Note 21)	541	513	1,313

Other operating income and expense

	2025 \$m	2024 \$m	2023 \$m
Royalty income	160	103	107
Gains on disposal of Intangible assets	168	64	251
Net (losses)/gains on disposal of other non-current assets	(14)	(4)	41
Update to the contractual relationships for <i>Beyfortus</i>	–	–	712
Other income ¹	201	210	393
Other expense	(134)	(121)	(164)
Other operating income and expense	381	252	1,340

¹ Other income in 2025 includes \$nil of income from Allergan Plc. in respect of the development of brazikumab (2024: \$nil; 2023: \$75m).

Gains on disposal of intangible assets in 2023 includes \$241m on disposal of commercial rights to *Pulmicort* Flexhaler to Cheplapharm Arzneimittel GmbH in the US.

As part of the total consideration received in respect of the agreement to sell US rights to *Synagis* in 2019, \$400m in total was received related to the rights to participate in the future cash flows from the US profits or losses for *Beyfortus*, with \$190m cash inflows in 2023 primarily relating to a cash receipt from Swedish Orphan Biovitrum AB (Sobi) following achievement of a regulatory milestone. All associated cash flows have been presented within investing activities as the Group has received the cash in exchange for agreeing to transfer future cash flows relating to an intangible asset. In 2023, the contractual relationship between AstraZeneca and Sobi relating to future sales of *Beyfortus* in the US was replaced by a royalty relationship between Sanofi Pasteur, Inc. and Sobi. As a result, in 2023 the Profit Participation Liability was extinguished and derecognised from the Consolidated Statement of Financial Position, with a gain of \$712m recorded in Other operating income and expense.

Restructuring costs

In conjunction with the acquisition of Alexion in 2021, the enlarged Group initiated the Post Alexion Acquisition Group Review (PAAGR); a global restructuring programme aimed at integrating systems, structure and processes, optimising the global footprint and prioritising resource allocations and investments. During 2023, the Group identified all remaining activities and finalised the scope of the programme. During 2024, the Group undertook a further assessment of those planned activities. This included the commencement of work on the planned upgrade of the Group's Enterprise Resource Planning IT systems (Axial Project), which is expected to be substantially complete by the end of 2030. The Group has also continued to progress other legacy restructuring programmes.

During 2025, the Group has incurred \$237m of restructuring costs, of which \$232m resulted from activities that are part of the PAAGR, bringing the cumulative charges under this programme to \$3,414m. Costs in 2025 included a \$138m credit to Cost of sales primarily due to the reversal of inventory and related product provisions related to *Andexxa* following the decision to cease promotional activities, \$209m expense within Selling, general and administrative expense in relation to severance, HR, Finance, IT and other integration costs and \$171m expense within Research and development expense in relation to severance as well as the transformation of clinical, regulatory and other R&D data and systems.

Total restructuring costs in 2025 includes a net impairment reversal to Property, plant and equipment of \$3m (2024: charge of \$43m; 2023: charge of \$7m).

The tables below show the costs that have been charged in respect of restructuring programmes by cost category and type. Severance provisions are detailed in Note 21.

	2025 \$m	2024 \$m	2023 \$m
Cost of sales	(138)	569	109
Research and development expense	171	275	212
Selling, general and administrative expense	209	312	207
Other operating income and expense	(5)	(2)	(61)
Total charge	237	1,154	467

	2025 \$m	2024 \$m	2023 \$m
Severance costs	100	213	57
Accelerated depreciation and impairment charges	11	64	68
Other ¹	126	877	342
Total charge	237	1,154	467

¹ Other costs are those incurred in designing and implementing the Group's various restructuring initiatives. In 2024, Other costs included \$480m for inventory and related product provisions related to Andexxa following the decision to cease promotional activities which were partly reversed in 2025 following revised sales forecasts. In 2025, Other costs include the costs of integrating systems, structure and processes as part of the PAAGR, costs relating to the Alexion acquisition, internal project costs and external service fees.

Financial instruments

Included within Operating profit are the following net gains and losses on financial instruments:

	2025 \$m	2024 \$m	2023 \$m
Gains/(losses) on forward foreign exchange contracts	190	(81)	42
Losses on receivables and payables	(190)	(143)	(260)
Total	–	(224)	(218)

4 Finance income and expense

	2025 \$m	2024 \$m	2023 \$m
Finance income			
Returns on deposits and equity securities	280	339	291
Fair value gains on debt and interest rate swaps	–	113	43
Interest income on income tax balances	80	6	10
Total	360	458	344
Finance expense			
Interest on debt, leases and other financing costs	(1,335)	(1,391)	(1,132)
Net interest on post-employment defined benefit plan net liabilities (Note 22)	(51)	(50)	(38)
Net exchange losses	(31)	(42)	(34)
Discount unwind on contingent consideration arising from business combinations (Note 20)	(60)	(113)	(132)
Discount unwind on other long-term liabilities ¹	(138)	(116)	(200)
Fair value losses on debt and interest rate swaps	(49)	(18)	(3)
Interest expense on income tax balances	(30)	(12)	(87)
Total	(1,694)	(1,742)	(1,626)
Net finance expense	(1,334)	(1,284)	(1,282)

¹ Included within Discount unwind on other long-term liabilities is \$nil relating to the Acerta Pharma B.V. (Acerta Pharma) share purchase liability (2024: \$nil; 2023: \$55m) and the discount unwind of other payables of \$116m (2024: \$91m; 2023: \$100m) that have arisen from intangible asset additions, see Note 20 for further details.

There was no interest capitalised during the year.

Financial instruments

Included within Finance income and expense are the following net gains and losses on financial instruments:

	2025 \$m	2024 \$m	2023 \$m
Interest and fair value adjustments in respect of debt designated at fair value through profit or loss, net of derivatives	(46)	107	13
Interest and changes in carrying values of debt designated as hedged items in fair value hedges, net of derivatives	(76)	(38)	–
Interest and fair value changes on fixed and short-term deposits, equity securities, other derivatives and tax balances	314	306	177
Interest on debt, commercial paper, overdrafts and lease liabilities held at amortised cost	(1,177)	(1,251)	(1,004)

The Group held derivatives that economically hedged a debt instrument designated at fair value through profit or loss. Both the derivatives and debt instrument matured in 2023. The Interest and fair value adjustments in respect of debt designated at fair value through profit or loss, net of derivatives, includes the following amounts related to these matured instruments: derivatives \$nil (2024: \$nil; 2023: loss of \$1m) and debt \$nil (2024: \$nil; 2023: gain of \$7m).

Notes to the Group Financial Statements *continued*

5 Taxation

Taxation charge/(credit) recognised in the Consolidated Statement of Comprehensive Income is as follows:

	2025 \$m	2024 \$m	2023 \$m
Current tax			
Current year	2,199	2,314	2,417
Pillar Two income tax charge	194	238	–
Adjustment to prior years	(60)	(107)	28
Total	2,333	2,445	2,445
Deferred tax			
Origination and reversal of temporary differences	(117)	(818)	(1,473)
Adjustment to prior years	(47)	23	(34)
Total	(164)	(795)	(1,507)
Taxation charge recognised in the profit for the year	2,169	1,650	938

Taxation (charge)/credit recognised in Other comprehensive income is as follows:

	2025 \$m	2024 \$m	2023 \$m
Current and deferred tax			
Items that will not be reclassified to profit and loss:			
Remeasurement of the defined benefit liability	(69)	(23)	102
Equity investments measured at fair value through Other comprehensive income	(25)	(20)	(1)
Total	(94)	(43)	101
Items that may be reclassified subsequently to profit and loss:			
Foreign exchange arising on designated liabilities in net investment hedges	(66)	28	(24)
Fair value movement on cash flow hedges	16	(3)	12
Total	(50)	25	(12)
Taxation (charge)/credit recognised in Other comprehensive income	(144)	(18)	89

The reported tax rate in the year was 18%.

Taxation has been provided at current rates on the profits earned for the years covered by the Group Financial Statements.

Factors affecting future tax charges

As a group with worldwide operations, AstraZeneca is subject to several factors that may affect future tax charges, principally the levels and mix of profitability in different jurisdictions, transfer pricing regulations, tax rates imposed and tax regime reforms.

Tax reconciliation to UK statutory rate

The table below reconciles the UK statutory tax charge to the Group's total tax charge:

	2025 \$m	2024 \$m	2023 \$m
Profit before tax	12,402	8,691	6,899
Notional taxation charge at UK corporation tax rate of 25% (2024: 25%; 2023: 23.5%)	3,101	2,173	1,621
Differences in effective overseas tax rates	(168)	(60)	(224)
Deferred tax credit relating to change in tax rates ¹	(23)	(24)	(66)
Unrecognised deferred tax asset ²	86	104	341
Items not deductible for tax purposes	101	64	46
Intellectual Property incentive regimes ³	(655)	(561)	(367)
Pillar Two income taxes	194	238	–
Other items ⁴	(360)	(200)	(406)
Adjustments to prior periods	(107)	(84)	(7)
Total tax charge for the year	2,169	1,650	938

¹ The 2023 item relates to the impact of the difference in the UK current and deferred tax rates during 2023.

² This includes the non-recognition of deferred tax assets where it is not probable that there will be sufficient forecast future profits to utilise the assets.

³ The Group receives intellectual property incentives in certain jurisdictions.

⁴ Other items in 2025 includes the release of tax provisions due to updates to estimates of prior period tax liabilities following settlements with tax authorities and the expiry of the relevant statute of limitations, and the impact of internal transfers of assets. Other items in 2024 includes a net credit following internal transfers of assets. Other items in 2023 include a favourable adjustment of \$828m to deferred taxes arising from a UK company undertaking an intragroup purchase of certain intellectual property offset by a charge of \$422m mainly relating to updates to tax liabilities following progress of reviews by tax authorities, administrative appeal processes and adjustments arising on expiry of the relevant statute of limitations (see Note 30 for more details).

AstraZeneca is domiciled in the UK but operates in other countries where the tax rates and laws are different to those in the UK. The impact on differences in effective overseas tax rates on the Group's overall tax charge is noted above.

Current tax

Current income tax balances on the Statement of Financial Position as at 31 December are as follows:

	2025 \$m	2024 \$m
Non-current income tax receivable	1,391	–
Current income tax receivable	1,158	1,859
Total income tax receivable	2,549	1,859
Current income tax payable	(1,084)	(1,406)
Non-current income tax payable	(700)	(238)
Total income tax payable	(1,784)	(1,644)
Net income tax receivable	765	215

Management assesses at each balance sheet date whether income tax receivables and payables will be realisable within 12 months. Amounts expected to be realisable after 12 months are reflected as non-current income tax receivables and payables.

Deferred tax

The total movement in the net deferred tax balance in the year was \$277m. The movements are as follows:

	Intangibles, Property, plant and equipment \$m	Elimination of unrealised profit on inventory \$m	Untaxed reserves ¹ \$m	Losses and tax credits carried forward \$m	Accrued expenses \$m	Other \$m	Total \$m
Net deferred tax balance at 1 January 2024	(2,491)	2,386	(660)	1,106	889	644	1,874
Income statement	803	238	(186)	36	74	(170)	795
Other comprehensive income	34	–	–	–	–	(42)	(8)
Equity	–	–	–	–	–	(28)	(28)
Additions and disposals	(605)	–	–	127	2	(1)	(477)
Exchange	93	(152)	68	(70)	(40)	(13)	(114)
Net deferred tax balance at 31 December 2024	(2,166)	2,472	(778)	1,199	925	390	2,042
Income statement	33	45	(46)	87	52	(7)	164
Other comprehensive income	(32)	–	–	–	–	(59)	(91)
Equity	–	–	–	–	–	105	105
Exchange	(92)	162	(147)	105	46	25	99
Net deferred tax balance at 31 December 2025²	(2,257)³	2,679	(971)	1,391	1,023	454	2,319

¹ Untaxed reserves relate to taxable profits where the tax liability is deferred to later periods.

² The Group recognises deferred tax assets to the extent that there are either taxable temporary differences or that it is probable that sufficient future taxable profits will arise, against which these deductible temporary differences can be utilised. The US includes a net deferred tax asset of \$94m as at 31 December 2025 which includes tax losses and other deductible temporary differences. The Group has performed an assessment of recovery of deferred tax assets and the Group has forecasted future taxable profits for relevant entities and considers that it is probable that sufficient future taxable profits will arise against which these deductible temporary differences can be utilised within 10 years. In arriving at these forecasts, the Group has reviewed the Group-level budgets and forecasts and the ability of relevant entities to generate future income from developing and commercialising products. Assessing the availability of future taxable income to support recognition of deferred tax assets relies upon our Group forecasts and changes in these Group forecasts will impact the recoverability of deferred tax assets. To the extent that there are neither taxable temporary differences nor sufficient taxable profits, no deferred tax asset is recognised and details of unrecognised deferred tax assets are included in the table below.

³ Includes deferred tax assets of \$178m on liabilities in respect of intangibles and \$327m on lease liabilities in respect of right-of-use assets.

The net deferred tax balance, before the offset of balances within countries, consists of:

	Intangibles, Property, plant and equipment \$m	Elimination of unrealised profit on inventory \$m	Untaxed reserves \$m	Losses and tax credits carried forward \$m	Accrued expenses \$m	Other \$m	Total \$m
Deferred tax assets at 31 December 2024	1,781	2,472	–	1,221	1,039	688	7,201
Deferred tax liabilities at 31 December 2024	(3,947)	–	(778)	(22)	(114)	(298)	(5,159)
Net deferred tax balance at 31 December 2024	(2,166)	2,472	(778)	1,199	925	390	2,042
Deferred tax assets at 31 December 2025	2,020	2,679	3	1,424	1,201	672	7,999
Deferred tax liabilities at 31 December 2025	(4,277)	–	(974)	(33)	(178)	(218)	(5,680)
Net deferred tax balance at 31 December 2025	(2,257)	2,679	(971)	1,391	1,023	454	2,319

Analysed in the Consolidated Statement of Financial Position, after offset of balances within countries, as follows:

	2025 \$m	2024 \$m
Deferred tax assets	5,819	5,347
Deferred tax liabilities	(3,500)	(3,305)
Net deferred tax balance	2,319	2,042

Notes to the Group Financial Statements *continued*

5 Taxation *continued*

Unrecognised deferred tax assets

Deferred tax assets (DTA) of \$1,738m (2024: \$1,523m) have not been recognised in respect of deductible temporary differences because it is not probable that future taxable profit will be available against which the Group can utilise the benefits therefrom.

	2025 Temporary differences \$m	2025 Unrecognised DTA \$m	2024 Temporary differences \$m	2024 Unrecognised DTA \$m
Temporary differences expiring:				
Within 10 years	409	81	161	37
More than 10 years	152	32	217	46
Indefinite	4,460	885	3,883	816
	5,021	998	4,261	899
Tax credits and State tax losses expiring:				
Within 10 years		137		162
More than 10 years		386		373
Indefinite		217		89
		740		624
Total		1,738		1,523

To the extent that dividends remitted from overseas subsidiaries, joint ventures and associates are expected to result in additional taxes, appropriate amounts have been provided for. Unremitted earnings or differences in the carrying value and tax basis of investments may be liable to additional taxes if distributed as dividends or on a liquidation event. Deferred tax is provided for such differences in relation to Group entities where management is intending to remit earnings in the foreseeable future. The aggregate amount of gross temporary differences associated with investments in subsidiaries, partnerships and branches for which deferred tax liabilities have not been recognised totalled approximately \$8,460m at 31 December 2025, \$3,657m of which has a corresponding deductible temporary difference of the same gross value which is not recognised as it is not probable of reversing in the foreseeable future but on which different tax rates apply.

6 Earnings per \$0.25 Ordinary Share

	2025	2024	2023
Profit for the year attributable to equity holders (\$m)	10,225	7,035	5,955
Basic earnings per Ordinary Share	\$6.60	\$4.54	\$3.84
Diluted earnings per Ordinary Share	\$6.54	\$4.50	\$3.81
Weighted average number of Ordinary Shares in issue for basic earnings (millions)	1,550	1,550	1,549
Dilutive impact of share incentive awards outstanding (millions)	12	13	13
Diluted weighted average number of Ordinary Shares in issue (millions)	1,562	1,563	1,562

The earnings figures used in the calculations above are post-tax. The weighted average number of Ordinary Shares in issue is calculated by taking the number of Ordinary Shares outstanding each day weighted by the number of days that those shares were outstanding.

7 Segment information

The Group has reviewed its assessment of reportable segments under IFRS 8 'Operating Segments' and concluded that the Group continues to have one reportable segment.

KJ This determination is considered to be a Key Judgement and this judgement has been taken with reference to the following factors:

1 The level of integration across the different functions of the Group's pharmaceutical business:

AstraZeneca is engaged in a single business activity of pharmaceuticals and the Group does not have multiple operating segments. AstraZeneca's pharmaceuticals business consists of the discovery and development of new products, which are then manufactured, marketed and sold. All of these functional activities take place (and are managed) globally on a highly integrated basis. These individual functional areas are not managed separately.

2 The identification of the Chief Operating Decision Maker (CODM) and the nature and extent of the financial information reviewed by the CODM:

The SET, established and chaired by the CEO, is the vehicle through which the CEO exercises the authority delegated to him from the Board for the management, development and performance of AstraZeneca as a whole. It is considered that the SET is AstraZeneca's Chief Operating Decision Making body (as defined by IFRS 8). The operation of the SET is principally driven by the management of the Commercial operations, R&D, manufacturing and supply and enabling functions. All significant operating decisions are undertaken by the SET. While members of the SET have responsibility for implementation of decisions in their respective areas, operating decision making is at SET level as a whole. Where necessary, these are implemented through cross-functional sub-committees that consider the Group-wide impact of a new decision. For example, product launch decisions would be initially considered by the SET and, on approval, passed to an appropriate sub team for implementation. The ability of the enterprise to develop, produce, deliver and commercialise a wide range of pharmaceutical products are central to the SET decision-making process.

In assessing performance, the SET reviews financial information on an integrated basis for the Group as a whole, substantially in the form of, and on the same basis as, the Group's IFRS Financial Statements. The high upfront cost of discovering and developing new products, coupled with the relatively insignificant and stable unit cost of production, means that there is not the clear link that exists in many manufacturing businesses between the revenue generated on an individual product sale and the associated cost and hence margin generated on a product. Consequently, the profitability of individual drugs or classes of drugs is not considered a key measure of performance for the business and is not monitored by the SET. The focus of additional financial information reviewed is at brand sales and Gross Margin level within specific geographies. Expenditure analysis is completed for the science units, operations and enabling functions; there is no allocation of these centrally-managed Group costs to the individual product or brands. The bonus of SET members' continues to be derived from the Group scorecard outcome as discussed in our Directors' Remuneration Report.

3 How resources are allocated:

Resources are allocated on a Group-wide basis according to need. In particular, capital expenditure, in-licensing, and R&D resources are allocated between activities on merit, based on overall therapeutic considerations and strategy under the aegis of the Group's Early-Stage Product Committees and Late-Stage Product Committees.

Geographic areas

The following table shows information for Total Revenue by geographic area and material countries. Product Sales by geographic area are included in the country/region where the legal entity resides and from which those sales were made. The additional tables show the Operating profit and Profit before tax made by companies located in that area, together with Non-current assets, Total assets, Assets acquired, Net operating assets, and Property, plant and equipment owned by the same companies.

	Total Revenue		
	2025 \$m	2024 \$m	2023 \$m
UK	4,359	4,740	3,368
Rest of Europe			
France	1,408	1,283	1,152
Germany	2,890	2,524	2,099
Italy	1,078	949	813
Spain	1,136	994	847
Sweden	2,623	2,290	1,704
Others	4,320	3,663	3,110
	13,455	11,703	9,725
The Americas			
Canada	954	937	967
US	23,970	21,806	18,121
Others	2,633	2,246	1,683
	27,557	24,989	20,771
Asia, Africa & Australasia			
Australia	454	439	390
China	6,636	6,419	5,872
Japan	3,556	3,452	3,640
Others	2,722	2,331	2,045
	13,368	12,641	11,947
Total Revenue	58,739	54,073	45,811

Notes to the Group Financial Statements *continued*

7 Segment information *continued*

Total Revenue outside of the UK totalled \$54,380m for the year ended 31 December 2025 (2024: \$49,333m; 2023: \$42,443m).

	Operating profit			Profit/(loss) before tax		
	2025 \$m	2024 \$m	2023 \$m	2025 \$m	2024 \$m	2023 \$m
UK	7,066	2,680	665	6,152	1,349	(577)
Rest of Europe	5,233	5,924	4,885	5,468	6,057	4,999
The Americas	440	423	1,495	(213)	318	1,328
Asia, Africa & Australasia	1,004	976	1,148	995	967	1,149
Continuing operations	13,743	10,003	8,193	12,402	8,691	6,899

	Non-current assets ¹		Total assets	
	2025 \$m	2024 \$m	2025 \$m	2024 \$m
UK	10,328	8,699	21,983	20,139
Rest of Europe	31,974	30,654	41,596	37,884
The Americas	29,714	28,730	42,201	38,544
Asia, Africa & Australasia	2,409	2,181	8,294	7,468
Continuing operations	74,425	70,264	114,074	104,035

	Assets acquired ²		Net operating assets ³	
	2025 \$m	2024 \$m	2025 \$m	2024 \$m
UK	1,759	582	7,936	7,173
Rest of Europe	2,814	2,225	33,217	30,852
The Americas	1,877	3,925	26,374	24,501
Asia, Africa & Australasia	557	1,394	2,764	2,602
Continuing operations	7,007	8,126	70,291	65,128

¹ Non-current assets exclude Deferred tax assets, Income tax receivable, Derivative financial instruments, certain other financial assets and post-employment benefit assets.

² Included in Assets acquired are those assets that are expected to be used during more than one period (Property, plant and equipment, Goodwill and Intangible assets) and include those acquired through business combinations (Note 27).

³ Net operating assets exclude short-term investments, cash, short-term borrowings, loans, Derivative financial instruments, Retirement benefit obligations and non-operating receivables and payables.

	Property, plant and equipment	
	2025 \$m	2024 \$m
UK	3,138	2,847
Ireland	1,645	1,323
Sweden	2,282	1,692
US	3,558	2,856
Rest of the world	2,339	1,534
Continuing operations	12,962	10,252

Geographic markets

The table below shows Product Sales in each geographic market in which customers are located.

	2025 \$m	2024 \$m	2023 \$m
UK	1,111	1,314	978
Rest of Europe	12,412	10,686	8,201
The Americas	27,273	25,081	20,855
Asia, Africa & Australasia	14,777	13,857	13,755
Continuing operations	55,573	50,938	43,789

Product Sales are recognised when control of the goods has been transferred to a third party. A significant proportion of this is upon delivery of the products to wholesalers. Two wholesalers (2024: one; 2023: one) individually represented greater than 10% of Product Sales. The value of Product Sales to the two wholesalers was \$8,218m (2024: \$7,567m; 2023: \$6,513m) and \$5,957m (2024: \$4,468m; 2023: \$3,795m), respectively.

8 Property, plant and equipment

	Land and buildings \$m	Plant and equipment \$m	Assets in course of construction \$m	Total Property, plant and equipment \$m
Cost				
At 1 January 2024	6,469	8,704	2,045	17,218
Additions through business combinations (Note 27)	1	15	2	18
Capital expenditure	27	63	1,905	1,995
Transfer of assets into use	312	729	(1,041)	–
Disposals and other movements	(44)	(271)	(40)	(355)
Exchange adjustments	(185)	(386)	(82)	(653)
At 31 December 2024	6,580	8,854	2,789	18,223
Additions through business combinations (Note 27)	3	2	–	5
Capital expenditure	25	91	2,811	2,927
Transfer of assets into use	278	779	(1,057)	–
Disposals and other movements	(35)	(172)	1	(206)
Exchange adjustments	389	766	196	1,351
At 31 December 2025	7,240	10,320	4,740	22,300
Depreciation and impairment				
At 1 January 2024	2,765	5,051	–	7,816
Depreciation charge for the year	231	568	–	799
Impairment charge	–	(7)	49	42
Disposals and other movements	(39)	(252)	(49)	(340)
Exchange adjustments	(101)	(245)	–	(346)
At 31 December 2024	2,856	5,115	–	7,971
Depreciation charge for the year	249	630	–	879
Impairment charge	4	8	1	13
Disposals and other movements	(32)	(148)	(1)	(181)
Exchange adjustments	188	468	–	656
At 31 December 2025	3,265	6,073	–	9,338
Net book value				
At 31 December 2024	3,724	3,739	2,789	10,252
At 31 December 2025	3,975	4,247	4,740	12,962
			2025 \$m	2024 \$m
The net book value of land and buildings comprised:				
Freeholds			3,564	3,329
Leaseholds			411	395

Notes to the Group Financial Statements *continued*

9 Leases

Right-of-use assets

	Land and buildings \$m	Motor vehicles \$m	Other \$m	Total Right-of-use assets \$m
Cost				
At 1 January 2024	1,352	495	36	1,883
Additions through business combinations (Note 27)	20	–	–	20
Additions – separately acquired	332	342	18	692
Disposals and other movements	(73)	(140)	(5)	(218)
Exchange adjustments	(43)	(33)	(2)	(78)
At 31 December 2024	1,588	664	47	2,299
Additions through business combinations (Note 27)	1	–	–	1
Additions – separately acquired	362	215	10	587
Disposals and other movements	29	(91)	–	(62)
Exchange adjustments	68	48	4	120
At 31 December 2025	2,048	836	61	2,945
Depreciation and impairment				
At 1 January 2024	549	215	19	783
Depreciation charge for the year	183	151	9	343
Impairment charge	7	–	–	7
Disposals and other movements	(71)	(115)	(6)	(192)
Exchange adjustments	(22)	(14)	(1)	(37)
At 31 December 2024	646	237	21	904
Depreciation charge for the year	205	188	11	404
Disposals and other movements	(65)	(93)	2	(156)
Exchange adjustments	29	21	2	52
At 31 December 2025	815	353	36	1,204
Net book value				
At 31 December 2024	942	427	26	1,395
At 31 December 2025	1,233	483	25	1,741

Lease liabilities

	2025 \$m	2024 \$m
The present value of lease liabilities is as follows:		
Within one year	(382)	(339)
Later than one year and not later than five years	(991)	(825)
Later than five years	(430)	(288)
Total lease liabilities	(1,803)	(1,452)

The interest expense on lease liabilities included within Finance expense was \$80m (2024: \$61m; 2023: \$33m).

The total cash outflow for leases in 2025 was \$452m (2024: \$377m; 2023: \$301m).

The Group has entered into lease contracts that have not yet commenced. The nominal value of estimated future lease payments under these lease contracts approximates \$1,702m as of 31 December 2025. Of this value, \$1,348m relates to a property lease in the US which is expected to commence in 2026 with a lease term of 15 years.

10 Goodwill

	2025 \$m	2024 \$m
Cost		
At 1 January	21,335	20,361
Additions through business combinations (Note 27)	–	1,083
Exchange and other adjustments	223	(109)
At 31 December	21,558	21,335
Amortisation and impairment losses		
At 1 January	310	313
Exchange and other adjustments	6	(3)
At 31 December	316	310
Net book value		
At 31 December	21,242	21,025

Goodwill is tested for impairment at the operating segment level, this being the level at which goodwill is monitored for internal management purposes. As detailed in Note 7, the Group does not have multiple operating segments and is engaged in a single business activity of pharmaceuticals.

Recoverable amount is determined on a fair value less costs to sell basis using the market value of the Company's outstanding Ordinary Shares. Our market capitalisation is compared to the book value of the Group's net assets and this indicates a significant surplus at 31 December 2025 (and 31 December 2024). No goodwill impairment was identified.

11 Intangible assets

	Product, marketing and distribution rights \$m	Other intangibles \$m	Software development costs \$m	Total \$m
Cost				
At 1 January 2024	69,207	2,707	1,575	73,489
Additions through business combinations (Note 27)	2,308	56	–	2,364
Additions – separately acquired	2,226	150	290	2,666
Disposals	(294)	–	(285)	(579)
Exchange and other adjustments	(964)	(13)	(50)	(1,027)
At 31 December 2024	72,483	2,900	1,530	76,913
Additions through business combinations (Note 27)	50	–	–	50
Additions – separately acquired	3,392	170	463	4,025
Disposals	(312)	(128)	(8)	(448)
Exchange and other adjustments	2,151	131	118	2,400
At 31 December 2025	77,764	3,073	2,103	82,940
Amortisation and impairment losses				
At 1 January 2024	32,266	2,061	1,073	35,400
Amortisation for year	3,761	78	84	3,923
Impairment charges	1,577	3	2	1,582
Impairment reversals	(8)	–	–	(8)
Disposals	(286)	–	(283)	(569)
Exchange and other adjustments	(561)	(13)	(18)	(592)
At 31 December 2024	36,749	2,129	858	39,736
Amortisation for year	3,928	181	98	4,207
Impairment charges	218	12	–	230
Disposals	(312)	(128)	(8)	(448)
Exchange and other adjustments	1,247	61	61	1,369
At 31 December 2025	41,830	2,255	1,009	45,094
Net book value				
At 31 December 2024	35,734	771	672	37,177
At 31 December 2025	35,934	818	1,094	37,846

Other intangibles consist mainly of research and device technologies and the Alexion brand name. Included within Software development costs are assets currently in development that will commence amortisation when ready for use.

Included within Additions – separately acquired are amounts accrued in Other payables of \$1,624m (2024: \$365m), relating to deferred payments and other non-cash consideration for the acquisition of Product, marketing and distribution rights, which are not reflected in the current year Consolidated Statement of Cash Flows. Disposals include amounts related to fully amortised or impaired assets that are no longer in use by the Group.

Notes to the Group Financial Statements *continued*

11 Intangible assets *continued*

Amortisation charges are recognised in the Consolidated Statement of Comprehensive Income as follows:

	Product, marketing and distribution rights \$m	Other intangibles \$m	Software development costs \$m	Total \$m
Year ended 31 December 2023				
Cost of sales	32	–	–	32
Research and development expense	–	28	–	28
Selling, general and administrative expense	3,739	47	80	3,866
Total	3,771	75	80	3,926
Year ended 31 December 2024				
Cost of sales	32	1	–	33
Research and development expense	3	22	–	25
Selling, general and administrative expense	3,726	55	84	3,865
Total	3,761	78	84	3,923
Year ended 31 December 2025				
Cost of sales	32	–	54	86
Research and development expense	–	26	21	47
Selling, general and administrative expense	3,896	155	22	4,073
Other operating income and expense	–	–	1	1
Total	3,928	181	98	4,207

Net impairment charges are recognised in the Consolidated Statement of Comprehensive Income as follows:

	Product, marketing and distribution rights \$m	Other intangibles \$m	Software development costs \$m	Total \$m
Year ended 31 December 2023				
Research and development expense	417	–	–	417
Selling, general and administrative expense	17	–	–	17
Total	434	–	–	434
Year ended 31 December 2024				
Research and development expense	1,065	–	–	1,065
Selling, general and administrative expense	504	3	2	509
Total	1,569	3	2	1,574
Year ended 31 December 2025				
Research and development expense	210	–	–	210
Selling, general and administrative expense	8	12	–	20
Total	218	12	–	230

Impairment charges and reversals

We perform a rigorous impairment trigger assessment for all our intangible assets. Intangible assets under development and not available for use are tested annually for impairment and other intangible assets are tested when there is an indication of impairment loss or reversal. Where testing is required, the recoverable amount of the assets is estimated in order to determine the extent of the impairment loss or reversal. Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the Cash Generating Unit (CGU) to which it belongs. The Group considers that as the intangible assets are linked to individual products and that product cash flows are considered to be largely independent of other product cash flows, the CGU for intangibles is predominantly at the product level. Group-level budgets and forecasts include forecast capital investment and operational impacts related to sustainability projects, as well as inflationary impacts, and form the basis for the value in use models used for impairment testing.

An asset's recoverable amount is determined as the higher of an asset's or CGU's fair value less costs to sell or value in use, in both cases using discounted cash flow calculations where the asset's expected post-tax cash flows are risk-adjusted over their estimated remaining period of expected economic benefit. Where the value in use approach is used, the post-tax risk-adjusted cash flows are discounted using AstraZeneca's post-tax weighted average cost of capital (7.5% for 2025 and 7.5% for 2024) which is a nominal rate. There is no material difference in the approach taken to using pre-tax cash flows and a pre-tax rate compared to post-tax cash flows and a post-tax rate, as required by IAS 36 'Impairment of Assets'. Where fair value less costs to sell is used to determine recoverable value, the discount rate is assessed with reference to a market participant, this is not usually materially different to the AstraZeneca post-tax weighted average cost of capital of 7.5%. Intangible assets have been tested for impairment under the value in use basis at risk-adjusted post-tax discount rates ranging between 7.5% to 9.5%.

SE Key assumptions and significant estimates used in calculating the recoverable amounts are highly sensitive and specific to the nature of the Group's activities including:

- outcome of R&D activities
- probability of technical and regulatory success
- market volume, share and pricing (to derive peak year sales)
- amount and timing of projected future cash flows
- sales erosion curves following patent expiry.

Whilst the intangible assets portfolio is generally exposed to significant impairment risk within the next financial year, no sensitivities have been disclosed since no specific asset has been identified as having a significant risk of a material impairment arising from reasonably possible changes in key assumptions.

For assets held at fair value less costs to sell, we make appropriate adjustments to reflect market participant assessments.

In 2025, the Group recorded impairment charges of \$8m in respect of launched products. Impairment charges recorded against products in development totalled \$210m.

In 2024, the Group recorded impairment charges of \$504m in respect of launched products. Following a strategic review of our portfolio priorities, a business decision was made to cease promotional activity for *Andexxa* resulting in impairment charges of \$504m recorded against the *Andexxa* intangible asset under a value in use model applying a discount rate of 7.5% (revised carrying amount: \$nil). Impairment charges recorded against products in development totalled \$1,073m. This included full impairments of *vemircopan* (ALXN2050, \$753m, acquired as part of the Alexion business combination in 2021), following outcome of research activities, and *FPI-2059* (\$165m, acquired as part of the Fusion Pharmaceuticals, Inc. (Fusion) business combination in 2024) due to portfolio prioritisation decisions. The remaining impairments of \$155m relate to impairments of various products in development, due to either management's decision to discontinue development as part of Group-wide portfolio prioritisation decisions, or due to the outcome of research activities.

In 2023, the Group recorded impairment charges of \$17m in respect of launched products. Impairment charges recorded against products in development totalled \$417m, including \$244m related to *ALXN1840* which was fully impaired following the decision to discontinue development.

The Group has performed an assessment on assets which have had impairments recorded in previous periods to determine if any reversals of impairments were required. No impairment reversals were recorded in 2025. Impairment reversals of \$8m were recorded in 2024 against products in development. No impairment reversals were recorded in 2023.

When launched products are partially impaired, the carrying values of these assets in future periods are particularly sensitive to changes in forecast assumptions, including those assumptions set out above, as the asset is impaired down to its recoverable amount.

Significant assets

	Carrying value \$m	Remaining amortisation period
C5 franchise (<i>Soliris/Ultomiris</i>) intangible assets arising from the acquisition of Alexion	10,981	2 to 10 years
Intangible assets arising from the acquisition of Acerta Pharma	3,371	7 years
<i>Enhertu</i> intangible assets acquired from Daiichi Sankyo, Inc.	3,331	8 years
<i>Strensiq</i> , <i>Kanuma</i> intangible assets arising from the acquisition of Alexion	2,846	7 to 13 years
Intangible asset products in development arising from the acquisition of Alexion ¹	1,944	Not amortised
Intangible assets arising from the acquisition of ZS Pharma, Inc.	1,460	6 years
<i>Baxdrostat</i> intangible asset acquired from CinCor Pharma, Inc. ¹	1,291	Not amortised
Intangible asset products in development arising from the acquisition of Fusion ¹	1,182	Not amortised
<i>Datroway</i> intangible assets acquired from Daiichi Sankyo, Inc.	1,020	13 years
Intangible asset products in development arising from the acquisition of Gracell Biotechnologies, Inc. ¹	975	Not amortised
Intangible asset products in development arising from the acquisition of Amolyt Pharma SAS ¹	861	Not amortised
<i>Koselugo</i> intangible asset acquired from Merck & Co., Inc.	835	6 years
Intangible asset products in development arising from the acquisition of Icosavax, Inc. ¹	639	Not amortised
<i>Airsupra</i> intangible asset acquired from Bond Avillion 2 Development LP	526	9 years
ENaBL platform asset arising from the acquisition of EsoBiotec SA ¹	441	Not amortised

¹ Assets in development are not amortised but are tested annually for impairment.

In 2025, the *Koselugo* intangible asset was recognised on acquisition of the remaining 50% of global rights from Merck & Co., Inc. (MSD) following the amendment of an existing global development and commercialisation arrangement.

The Engineered NanoBody Lentiviral (ENaBL) platform intangible asset recognised on acquisition of EsoBiotec SA in 2025 was assessed under the optional concentration test in IFRS 3 'Business Combinations' and was determined to be an asset acquisition, as substantially all of the value of the gross assets acquired was concentrated in this single asset.

In 2024, the intangible assets recognised on acquisition of Amolyt Pharma SAS and Icosavax, Inc. were separately assessed under the optional concentration test in IFRS 3 and were individually determined to be asset acquisitions, as substantially all of the value of the gross assets acquired in each transaction was concentrated in these single assets.

Notes to the Group Financial Statements *continued*

12 Investments in associates and joint ventures

	2025 \$m	2024 \$m
At 1 January	268	147
Additions	14	158
Share of after tax losses	(7)	(28)
Exchange and other adjustments	27	(9)
At 31 December	302	268

On 22 May 2024, AstraZeneca entered into an agreement with Fuse Biosciences (Cayman) Limited to acquire equity. Under the terms of the agreement, AstraZeneca contributed \$11m in initial funds, holds 25% board representation, and holds an 18.75% interest in the associate entity.

On 1 November 2023, AstraZeneca entered into an agreement with Cellectis S.A., a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet medical need, including oncology, immunology and rare diseases. Under the terms of the agreement, AstraZeneca contributed \$80m in funds for a 22% interest in the associate entity. On 22 May 2024, a further contribution of \$140m was made for a further 22% interest. AstraZeneca holds a 44% interest in the associate entity.

On 1 December 2020, AstraZeneca and China International Capital Corporation (CICC) entered into an agreement to set up a Global Healthcare Industrial Fund to drive healthcare system innovation by leveraging local capital and accelerating China-related innovation incubation. The agreement resulted in the formation of a new entity, Wuxi AstraZeneca-CICC Venture Capital Partnership (Limited Partnership). AstraZeneca holds a 22% interest in the associate entity and has contributed \$74m in cumulative funds to date.

On 23 September 2021, AstraZeneca entered into an agreement with VaxEquity Limited (VaxEquity) to collaborate and develop self-amplifying RNA technology with the aim of generating treatments for target diseases. AstraZeneca contributed \$14m in initial funds and holds a 40% interest in the associate entity. On 21 April 2025, VaxEquity was dissolved.

All investments are accounted for using the equity method. At 31 December 2025, unrecognised losses in associates and joint ventures totalled \$209m (2024: \$177m) which have not been recognised due to the investment carrying value reaching \$nil value.

Aggregated summarised financial information for the associate and joint venture entities is set out below:

	2025 \$m	2024 \$m
Non-current assets	690	577
Current assets	756	508
Total liabilities	(553)	(516)
Net assets	893	569
Amount attributable to AstraZeneca	122	131
Goodwill	161	152
Exchange adjustments	19	(15)
Carrying value of investments in associates and joint ventures	302	268

Joint contractual arrangements were entered into between AstraZeneca and Daiichi Sankyo, Inc. (Daiichi Sankyo); in March 2019 for the co-development and co-commercialisation of *Enhertu* and in July 2020 for the co-development and co-commercialisation of *Datroway*. Each party shares global pre-tax net income from the collaboration on a 50:50 basis (with the exception of Japan where Daiichi Sankyo maintains exclusive rights and AstraZeneca receives a royalty). The joint operation is not structured through a separate legal entity, and it operates from AstraZeneca and Daiichi Sankyo's respective principal places of business.

13 Other investments

	2025 \$m	2024 \$m
Non-current investments		
Equity securities at fair value through Other comprehensive income	2,212	1,632
Equity securities at fair value through profit and loss	11	–
Total	2,223	1,632
Current investments		
Fixed income securities at fair value through profit or loss	8	37
Cash collateral pledged to counterparties	22	129
Total	30	166

Other investments held at FVOCI include equity securities which are not held for trading and which the Group has irrevocably elected at initial recognition to recognise in this category. Other investments held at FVPL comprise a mixture of equity securities and fixed income securities that the Group holds to sell.

The fair value of listed investments is based on year end quoted market prices. Fixed deposits and Cash collateral pledged to counterparties are held at amortised cost with carrying value being a reasonable approximation of fair value given their short-term nature.

Cash collateral pledged to counterparties relates to collateral pledged on derivatives entered into to hedge the Group's risk exposures.

Fair value hierarchy

The table below analyses equity securities and bonds, contained within Other investments and carried at fair value, by valuation method. The different levels have been defined as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices)
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	2025 FVPL \$m	2025 FVOCI \$m	2024 FVPL \$m	2024 FVOCI \$m
Level 1	8	1,765	37	1,279
Level 2	–	–	–	–
Level 3	11	447	–	353
Total	19	2,212	37	1,632

Assets are transferred in or out of each Level on the date of the event or change in circumstances that caused the transfer.

Equity securities that are analysed at Level 3 include investments in private biotech companies. In the absence of specific market data, these unlisted investments are held at fair value based on the cost of investment and adjusting as necessary for impairments and revaluations on new funding rounds, which approximates to fair value. Movements in Level 3 investments are detailed below:

	2025 FVPL \$m	2025 FVOCI \$m	2024 FVPL \$m	2024 FVOCI \$m
At 1 January	–	353	–	313
Additions	11	124	–	56
Revaluations	–	(50)	–	(9)
Impairments and exchange adjustments	–	20	–	(7)
At 31 December	11	447	–	353

14 Derivative financial instruments

	Non-current assets \$m	Current assets \$m	Current liabilities \$m	Non-current liabilities \$m	Total \$m
Cross-currency swaps designated in a net investment hedge	148	–	–	–	148
Cross-currency swaps designated in a cash flow hedge	34	–	–	(71)	(37)
Cross-currency swaps designated in a fair value hedge	–	–	–	(44)	(44)
Forward foreign exchange designated in a cash flow hedge ¹	–	5	(1)	–	4
Other derivatives	–	49	(49)	–	–
31 December 2024	182	54	(50)	(115)	71

	Non-current assets \$m	Current assets \$m	Current liabilities \$m	Non-current liabilities \$m	Total \$m
Cross-currency swaps designated in a net investment hedge	171	2	–	–	173
Cross-currency swaps designated in a cash flow hedge	203	–	–	–	203
Cross-currency swaps designated in a fair value hedge	124	–	–	–	124
Forward foreign exchange designated in a cash flow hedge ¹	–	8	(2)	–	6
Other derivatives	–	80	(79)	–	1
31 December 2025	498	90	(81)	–	507

¹ Forward foreign exchange (FX) designated in a cash flow hedge relates to contracts hedging anticipated CNY, EUR, GBP, JPY and SEK transactions occurring in the quarter immediately after the balance sheet date.

All derivatives at 31 December 2025 are held at fair value and fall within Level 2 of the fair value hierarchy as defined in Note 13. During 2024 the Group held an equity warrant classed as Level 3 in the fair value hierarchy, this warrant expired on 31 December 2024. No derivatives have been reclassified within the hierarchy during the year.

The fair value of interest rate swaps and cross-currency swaps is estimated using appropriate zero coupon curve valuation techniques to discount future contractual cash flows based on rates at the current year end.

The fair value of forward foreign exchange contracts and currency options are estimated by discounted cash flow models using appropriate yield curves based on market forward foreign exchange rates at the year end. The majority of forward foreign exchange contracts for existing transactions had maturities of less than one month from year end.

The interest rates used to discount future cash flows for fair value adjustments, where applicable, are based on market swap curves at the reporting date, and were as follows:

	2025	2024
Derivatives	0.7% to 3.7%	0.6% to 4.1%

Notes to the Group Financial Statements *continued*

15 Non-current other receivables

	2025 \$m	2024 \$m
Prepayments	559	356
Accrued income	75	60
Retirement benefit scheme surpluses (Note 22)	106	99
Other receivables	587	415
Non-current other receivables	1,327	930

16 Inventories

	2025 \$m	2024 \$m
Raw materials and consumables	1,857	1,489
Inventories in process	2,777	2,282
Finished goods and goods for resale	1,923	1,517
Inventories	6,557	5,288

The Group recognised \$7,600m (2024: \$7,001m; 2023: \$6,038m) of inventories as an expense within Cost of sales during the year.

Net inventory write-downs in the year amounted to \$314m (2024: \$664m; 2023: \$574m), principally arising from the reassessment of usage or demand expectations prior to inventory expiration. The decreased charge in the year is due to partial reversals of \$407m *Andexxa* provisions previously recognised in 2024 following the decision to cease promotional activities.

17 Current trade and other receivables

	2025 \$m	2024 \$m
Trade receivables	10,289	8,335
Less: Expected credit loss provision (Note 28)	(52)	(33)
	10,237	8,302
Other receivables	2,017	1,579
Prepayments	2,034	1,737
Government grants receivable	45	25
Accrued income	844	1,329
Trade and other receivables	15,177	12,972

Trade receivables include \$2,681m (2024: \$667m) measured at FVOCI classified 'hold to collect and sell' as they are due from customers that the Group has the option to factor, or relate to bank acceptance drafts received in settlement of trade receivables per common practice in China.

All other financial assets included within Current trade and other receivables are held at amortised cost with carrying value being a reasonable approximation of fair value.

18 Cash and cash equivalents

	2025 \$m	2024 \$m	2023 \$m
Cash at bank and in hand	1,332	1,215	1,325
Short-term deposits	4,379	4,273	4,515
Cash and cash equivalents	5,711	5,488	5,840
Unsecured bank overdrafts	(13)	(59)	(203)
Cash and cash equivalents in the Consolidated Statement of Cash Flows	5,698	5,429	5,637

AstraZeneca invests in constant net asset value funds, low-volatility net asset value funds and short-term variable net asset value funds with same day access for subscription and redemption. These investments fail the 'solely payments of principal and interest' test criteria under IFRS 9 'Financial Instruments'. They are therefore measured at FVPL, although the fair value is materially the same as amortised cost.

Non-cash and other movements, within operating activities in the Consolidated Statement of Cash Flows, includes:

	2025 \$m	2024 \$m	2023 \$m
Share-based payments charge for the period (Note 29)	719	660	579
Settlement of share plan awards	(353)	(618)	(650)
Pension contributions	(186)	(166)	(188)
Pension charges recorded in Operating profit	65	86	55
Long-term provision charges recorded in Operating profit	203	106	460
Loss/(gain) on disposal of Property, plant and equipment	13	4	(41)
Update to the contractual relationships for <i>Beyfortus</i>	–	–	(729)
Foreign exchange and other ¹	201	(193)	128
Total operating activities non-cash and other movements	662	(121)	(386)

¹ Foreign exchange and other includes, among other items, the foreign exchange of inter-company transactions, including dividends, across Group entities and the related impact from hedging those transactions.

19 Interest-bearing loans and borrowings

		Repayment dates	2025 \$m	2024 \$m
Current liabilities				
Bank overdrafts		On demand	13	59
Other short-term borrowings excluding overdrafts			158	90
Collateral received from derivative counterparties			473	181
Lease liabilities			382	339
3.375% Callable bond	US dollars	2025	–	1,997
0.7% Callable bond	US dollars	2026	1,200	–
1.2% Callable bond	US dollars	2026	1,250	–
Other loans		Within one year	10	10
Total			3,486	2,676
Non-current liabilities				
Lease liabilities			1,421	1,113
0.7% Callable bond	US dollars	2026	–	1,198
1.2% Callable bond	US dollars	2026	–	1,249
4.8% Callable bond	US dollars	2027	1,248	1,247
3.625% Callable bond	euros	2027	880	780
3.125% Callable bond	US dollars	2027	749	748
4.875% Callable bond	US dollars	2028	1,097	1,096
1.25% Callable bond	euros	2028	936	829
1.75% Callable bond	US dollars	2028	1,248	1,247
4% Callable bond	US dollars	2029	997	996
4.85% Callable bond	US dollars	2029	1,247	1,246
0.375% Callable bond	euros	2029	936	829
4.9% Callable bond	US dollars	2030	647	646
3.121% Callable bond	euros	2030	764	682
1.375% Callable bond	US dollars	2030	1,295	1,295
4.9% Callable bond	US dollars	2031	995	994
2.25% Callable bond	US dollars	2031	748	747
5.75% Non-callable bond	pounds sterling	2031	469	438
3.75% Callable bond	euros	2032	878	778
4.875% Callable bond	US dollars	2033	497	497
3.278% Callable bond	euros	2033	870	786
5% Callable bond	US dollars	2034	1,490	1,489
6.45% Callable bond	US dollars	2037	2,728	2,727
4% Callable bond	US dollars	2042	989	989
4.375% Callable bond	US dollars	2045	982	982
4.375% Callable bond	US dollars	2048	738	738
2.125% Callable bond	US dollars	2050	488	487
3% Callable bond	US dollars	2051	736	735
Other loans	US dollars		63	31
Total			26,136	27,619
Total interest-bearing loans and borrowings¹			29,622	30,295

¹ All loans and borrowings above are unsecured.

	Total loans and borrowings 2025 \$m	Total loans and borrowings 2024 \$m	Total loans and borrowings 2023 \$m
At 1 January	30,295	28,622	29,232
Changes from financing cash flows			
Issue of loans and borrowings	15	6,492	3,816
Repayment of loans and borrowings	(2,029)	(4,652)	(4,942)
Movement in short-term borrowings	364	(31)	161
Repayment of obligations under leases	(372)	(316)	(268)
Total changes in cash flows arising on financing activities from borrowings	(2,022)	1,493	(1,233)
Movement in overdrafts	(47)	(144)	20
New lease liabilities	566	710	444
Additions through business combinations	–	12	–
Exchange	692	(361)	187
Other movements	138	(37)	(28)
At 31 December	29,622	30,295	28,622

Notes to the Group Financial Statements *continued*

19 Interest-bearing loans and borrowings *continued*

Included in prior year cash flows is \$833m in 2024 and \$867m in 2023 relating to the Acerta Pharma share purchase. This liability was fully extinguished in 2024.

Set out below is a comparison by category of carrying values and fair values of all the Group's interest-bearing loans and borrowings:

	Instruments designated in net investment hedge ¹ \$m	Instruments designated in cash flow hedge ² \$m	Instruments designated in fair value hedge ³ \$m	Amortised cost \$m	Total carrying value \$m	Fair value \$m
2024						
Overdrafts	–	–	–	59	59	59
Lease liabilities due within one year	–	–	–	339	339	339
Lease liabilities due after more than one year	–	–	–	1,113	1,113	1,113
Loans and borrowings due within one year	–	–	–	2,278	2,278	2,263
Loans and borrowings due after more than one year	1,267	2,387	1,468	21,384	26,506	25,405
Total at 31 December 2024	1,267	2,387	1,468	25,173	30,295	29,179
2025						
Overdrafts	–	–	–	13	13	13
Lease liabilities due within one year	–	–	–	382	382	382
Lease liabilities due after more than one year	–	–	–	1,421	1,421	1,421
Loans and borrowings due within one year	–	–	–	3,091	3,091	3,068
Loans and borrowings due after more than one year	1,405	2,694	1,634	18,982	24,715	24,337
Total at 31 December 2025	1,405	2,694	1,634	23,889	29,622	29,221

¹ Instruments designated in a net investment hedge are our euro 800m 0.375% 2029 Callable bond and our pounds sterling 350m 5.75% 2031 Non-callable bond. The 2024 value of \$1,267m was previously presented within the Amortised cost column; from 2025 the presentation has been revised to present this within the Instruments designated in net investment hedge column.

² Instruments designated in cash flow hedges are our euro 750m 3.625% 2027 Callable bond, our euro 800m 1.25% 2028 Callable bond, and our euro 750m 3.75% 2032 Callable bond.

³ Instruments designated in fair value hedges are our euro 650m 3.121% 2030 Callable bond, and our euro 750m 3.278% 2033 Callable bond.

The fair value of fixed-rate publicly traded debt is based on year end quoted market prices; the fair value of floating rate debt is nominal value, as mark-to-market differences would be minimal given the frequency of resets. The carrying value of loans designated at FVPL is the fair value; this falls within the Level 1 valuation method as defined in Note 13. For loans designated in a fair value hedge relationship, carrying value is initially measured at fair value and remeasured for fair value changes in respect of the hedged risk at each reporting date. All other loans are held at amortised cost. Fair values, as disclosed in the table above, are all determined using the Level 1 valuation method as defined in Note 13, with the exception of overdrafts and lease liabilities, where fair value approximates to carrying values.

The adjustment to the carrying value of bonds designated in a fair value hedge relationship in the year was a decrease in the liability of \$21m, and the cumulative adjustment was a decrease in the liability of \$5m. A gain of \$4m was made during the year on the fair value of bonds designated in a fair value hedge. Under IFRS 9 'Financial Instruments', the Group records the component of fair value changes relating to the component of own credit risk through Other comprehensive income. Changes in credit risk had no material effect on any other financial assets and liabilities recognised at fair value in the Group Financial Statements. The change in fair value attributable to changes in credit risk is calculated as the change in fair value not attributable to market risk.

The interest rates used to discount future cash flows for fair value adjustments, where applicable, are based on market swap curves at the reporting date, and were as follows:

	2025	2024
Loans and borrowings	1.9% to 2.6%	2.0% to 2.9%

20 Trade and other payables

	2025 \$m	2024 \$m
Current liabilities		
Trade payables	3,820	3,640
Value-added and payroll taxes and social security	580	401
Rebates, chargebacks, returns and other revenue accruals	9,681	7,805
Clinical trial accruals	1,780	1,419
Other accruals	7,258	6,463
Collaboration Revenue contract liabilities	–	7
Vaccine contract liabilities	142	119
Deferred government grant income	2	–
Contingent consideration	346	1,170
Other payables	1,671	1,441
Total	25,280	22,465
Non-current liabilities		
Accruals	85	65
Deferred government grant income	55	–
Contingent consideration	204	581
Other payables	2,035	1,124
Total	2,379	1,770

Included within Rebates, chargebacks, returns and other revenue accruals are contract liabilities of \$63m (2024: \$114m). The revenue recognised in the year from opening contract liabilities is \$107m, comprising \$100m relating to other revenue accruals and \$7m Collaboration Revenue contract liabilities. The major markets with Rebates, chargebacks, returns and other revenue accruals are the US where the liability at 31 December 2025 amounted to \$5,941m (2024: \$4,978m), of which Rare Disease comprises \$336m (2024: \$240m), and China where the liability at 31 December 2025 amounted to \$619m (2024: \$532m).

Trade payables includes \$100m (2024: \$105m) due to suppliers that have signed up to a supply chain financing programme, under which the suppliers can elect on an invoice-by-invoice basis to receive a discounted early payment from the relationship bank rather than being paid in line with the agreed payment terms. If the option is taken, the Group's liability is assigned by the supplier to be due to the relationship bank rather than the supplier. The value of the liability payable by the Group remains unchanged. The Group assesses the arrangement against indicators to assess if debts which vendors have sold to the funder under the supplier financing scheme continue to meet the definition of trade payables or should be classified as borrowings. At 31 December 2025, the payables met the criteria of Trade payables. The supply chain financing programme operates in the US, UK, Sweden, China and Germany, and as at 31 December 2025, the programme had 310 suppliers enrolled across these countries.

Vaccine contract liabilities relate to amounts received from customers, primarily government bodies, in advance of supply of product.

Included within current Other payables are liabilities relating to future sales related payments to Daiichi Sankyo totalling \$673m (2024: \$377m) resulting from the collaboration agreement in relation to *Enhertu* entered into in March 2019. Additionally, included within non-current Other payables are liabilities relating to future sales related payments totalling \$579m (2024: \$456m) as a result of the *Enhertu* collaboration agreement, \$499m (2024: \$462m) owed to Bond Avillion 2 Development LP as a result of the *Airsupra* collaboration agreement entered into in March 2018 and \$201m (2024: \$nil) owed to MSD as a result of the *Koselugo* collaboration agreement entered into in 2017 and amended in August 2025.

In November 2020, *Calquence* received marketing approval in the European Union, which removed all remaining conditionality in respect of the Acerta Pharma put and call options regarding the non-controlling interest; the option was exercised in April 2021. The payments were made in similar annual instalments in 2022 through to 2024, with the final payment of \$833m made in 2024. Interest arising from amortising the liability was included within Finance expense (see Note 4). The associated cash flows were disclosed as financing activities within the Consolidated Statement of Cash Flows.

With the exception of Contingent consideration payables of \$550m (2024: \$1,751m) which are held at fair value within Level 3 of the fair value hierarchy as defined in Note 13, all other financial liabilities are held at amortised cost with carrying value being a reasonable approximation of fair value.

Contingent consideration

	2025 \$m	2024 \$m	2023 \$m
At 1 January	1,751	2,137	2,222
Additions through business combinations	–	198	60
Settlements	(1,164)	(1,008)	(826)
Revaluations	(97)	311	549
Discount unwind (Note 4)	60	113	132
At 31 December	550	1,751	2,137

Contingent consideration arising from business combinations is fair valued using decision-tree analysis, with key inputs including the probability of success, consideration of potential delays and the expected levels of future revenues.

Notes to the Group Financial Statements *continued*

20 Trade and other payables *continued*

Revaluations of Contingent consideration are recognised in Selling, general and administrative expense and include a decrease of \$44m in 2025 (2024: increase of \$260m; 2023: increase of \$520m) based on revenue and royalty forecasts, relating to the acquisition of BMS's share of the Global Diabetes Alliance. Discount unwind on the liability is included within Finance expense (see Note 4).

The discount rates used for the Contingent consideration balances range from 5% to 8%. The most significant Contingent consideration balance is the Global Diabetes Alliance which is discounted at 8% and is reviewed against comparable benchmarks on a regular basis.

Management has identified that reasonably possible changes in certain key assumptions, including the likelihood of achieving successful trial results, obtaining regulatory approval, the projected market share of the therapy area and expected pricing for launched products, may cause the calculated fair value of the above contingent consideration to vary materially in future years.

The contingent consideration balance relating to BMS's share of Global Diabetes Alliance of \$257m (2024: \$1,309m; 2023: \$1,945m) is due for final payment in 2026.

The maximum development and sales milestones payable under outstanding Contingent consideration arrangements arising on business combinations are as follows:

Acquisitions	Year	Nature of contingent consideration	Maximum future milestones \$m
Spirogen Sarl	2013	Milestones	171
Amplimmune, Inc.	2013	Milestones	150
Almirall, S.A.	2014	Milestones and royalties	345
Fusion Pharmaceuticals, Inc.	2024	Milestones	304
Gracell Biotechnologies, Inc.	2024	Milestones	149

The amount of royalties payable under the arrangements is inherently uncertain and difficult to predict, given the direct link to future sales and the range of outcomes. The maximum amount of royalties payable in each year is with reference to net sales.

21 Provisions

	Severance \$m	Environmental \$m	Employee benefits \$m	Legal \$m	Other provisions \$m	Total \$m
At 1 January 2024	176	112	168	1,016	683	2,155
Additions arising on business acquisitions	–	–	–	–	50	50
Charge for year	283	26	30	44	478	861
Cash paid	(101)	(33)	(7)	(189)	(146)	(476)
Reversals	(83)	–	(1)	(9)	(255)	(348)
Exchange and other movements	–	–	(24)	(3)	(25)	(52)
At 31 December 2024	275	105	166	859	785	2,190
Charge for year	190	27	40	252	189	698
Cash paid	(217)	(25)	(5)	(720)	(282)	(1,249)
Reversals	(64)	–	(7)	(18)	(68)	(157)
Exchange and other movements	13	–	(4)	3	110	122
At 31 December 2025	197	107	190	376	734	1,604
					2025 \$m	2024 \$m
Due within one year					686	1,269
Due after more than one year					918	921
Total					1,604	2,190

Provisions are often subject to substantial uncertainties with regard to the timing and final amounts of any payments. These uncertainties can also cause a reversal in previously established provisions once final settlement is reached. Once established, these amounts remain in Provisions even after settlement is reached and uncertainty resolved, with no transfer to Trade and other payables prior to payment. This is to provide more transparent disclosure of subsequent movements in brought forward and carried forward balances. Settled legal claims included within Provisions are held at amortised cost with carrying value being a reasonable approximation of fair value.

Severance provisions arise predominantly in connection with global restructuring initiatives, including the Alexion PAAGR, which involve rationalisation of the global supply chain, the sales and marketing organisation, IT and business support infrastructure, and R&D.

Employee costs in connection with the initiatives are recognised in severance provisions when a detailed formal plan has been communicated to those employees affected. Final severance costs are often subject to the completion of the requisite consultations on the areas impacted, with the majority of the cost expected to be paid within one year. AstraZeneca endeavours to support employees affected by restructuring initiatives to seek alternative roles within the organisation. Where the employee is successful, any severance provisions will be released.

Details of the Environmental provisions totalling \$107m (2024: \$105m) and ongoing matters are provided in Note 30.

A significant proportion of the total legal provision (\$194m (2024: \$626m) due within one year and \$177m (2024: \$210m) due after more than one year¹) relates to matters settled, but not paid, in previous periods; further details are provided in Note 30.

The majority of Employee benefit provisions relate to Executive Deferred Compensation Plans, which include uncertainty over the ultimate timing and amount of payment to be made to the executives.

Other provisions comprise amounts relating to specific contractual or constructive obligations and disputes. Included within Other provisions are amounts associated with long-standing product liability settlements that arose prior to the merger of Astra and Zeneca, which given the nature of the provision, the amounts are expected to be settled over many years; the final settlement values and timings are uncertain. Also included in Other provisions is an amount of \$166m (2024: \$145m), in relation to third-party liability and other risks (including incurred but not yet reported claims); the claims are considered to be uncertain as to timing and amount. Charges to Other provisions in 2025 included \$7m (2024: \$184m) in relation to the PAAGR restructuring programme, which has a closing provision of \$78m (2024: \$80m), including \$59m (2024: \$58m) held in non-current provisions expected to be settled over time by 2028.

No provision has been released or applied for any purpose other than that for which it was established.

¹ The expected profile of future payments of legal provisions due after one year is as follows: in one to two years \$19m (2024: \$167m); in two to three years \$131m (2024: \$9m); in three to four years \$11m (2024: \$12m); in four to five years \$9m (2024: \$9m); and in more than five years \$7m (2024: \$13m).

22 Post-retirement pension and other defined benefit schemes

Background

This section predominantly covers defined benefit (DB) arrangements such as post-retirement pension and medical plans which make up the vast bulk of these liabilities. However, it also incorporates other benefits which fall under IAS 19 'Employee Benefits' rules and which require an actuarial valuation, including but not limited to: lump sum plans, long-service awards and defined contribution pension plans which have some DB characteristics (e.g. a minimum guaranteed level of benefit). In total, over 50 plans in 28 countries are covered.

The Group and most of its subsidiaries offer post-retirement pension plans which cover the majority of employees. The Group's policy is to provide defined contribution (DC) orientated pension provision to its employees unless otherwise compelled by local regulation. As a result, many of these retirement plans are DC, where the Group contribution and resulting charge is fixed at a set level, or is a set percentage of employees' pay. However, several plans, mainly in the UK and Sweden, are DB, where benefits are based on employees' length of service and salary. The major DB plans are largely legacy arrangements as they have been closed to new entrants since 2000, apart from the collectively bargained Swedish plan (which is still open to employees born before 1979). During 2010, following consultation with its UK employees' representatives, the Group introduced a freeze on pensionable pay at 30 June 2010 levels for DB members of the UK Pension Fund. The number of active members in the Fund continues to decline and is now 296 employees.

The Group's DB plans are largely funded through ring-fenced, fiduciary-administered assets. The cash funding of the plans, which may from time to time involve payments from the Group, is designed, in consultation with independent qualified actuaries, to ensure that the assets are sufficient to meet future obligations as and when they fall due. The funding level is monitored by the Group and local fiduciaries, who may take into account various factors, including: the strength of the Group's covenant, local regulation, cash flows, and the solvency and maturity of the pension plan.

Funding Framework

Eighty six per cent of the Group's total DB obligations (or 53% of net obligations) at 31 December 2025 are in plans within the UK and Sweden.

The Group has developed a long-term funding framework for such plans which targets either full funding on a low-risk funding measure, or buyout with an external third party as the pension plans mature, with pragmatic long-term de-risking of investment strategy along the way. Unless local regulation dictates otherwise, this framework determines the cash contributions payable.

UK

The UK Pension Fund represents approximately 64% of the Group's DB obligations at 31 December 2025. The funding framework is modified in light of the UK regulatory requirements (summarised below) and resulting discussions with the Trustee.

Role of Trustee and Regulation

The UK Pension Fund is governed and administered by a corporate Trustee. The Trustee Directors are comprised of representatives appointed by both the employer and Fund members and include an independent professional Trustee Director. The Trustee Directors are required by law to act in the interest of all relevant beneficiaries and are responsible, in particular, for investment strategy and the day-to-day administration of the benefits. They are also responsible for jointly agreeing, with the employer, the level of contributions required to ensure the funding objective is met.

The UK pensions industry is regulated by The Pensions Regulator whose statutory objectives and regulatory powers are described on its website, www.thepensionsregulator.gov.uk.

Guaranteed Minimum Pensions (GMP) equalisation of member benefits, as required by UK legislation, was completed for pensioner and dependent members in 2024 and, for non-pensioner members, a process is in place to equalise their benefits at their point of retirement. An estimate of the impact of these changes has already been recognised in 2018 and 2020, and actual experience is in line with the estimates previously recognised.

Notes to the Group Financial Statements *continued*

22 Post-retirement pension and other defined benefit schemes *continued*

In June 2023, the UK High Court (Virgin Media Limited v NTL Pension Trustees II Limited) ruled that certain historical amendments for contracted-out DB pension plans were invalid if they were not accompanied by the correct actuarial confirmation. In July 2025, the UK Government confirmed that it will introduce legislation to give affected pension schemes the ability to retrospectively obtain written actuarial confirmation that historic benefit changes met the necessary standards. The Trustee has considered this matter with their legal adviser. The Trustee has not conducted any detailed investigations as they have no reason to believe that any such confirmations were not provided and so no impact is expected on the UK Pension Fund.

Funding requirements and security

UK legislation requires that an actuarial valuation is completed for all DB pension schemes every three years, which compares the schemes' liabilities to its assets. As part of the triennial valuation process, the Trustee and the Group must agree on a set of assumptions to value the liabilities and determine the contributions required, if any, to ensure the UK Pension Fund is fully funded over an appropriate time period and on a suitably prudent measure. The assumptions used to value the liabilities for the triennial actuarial valuation are required to be prudent, whereas the assumptions used to prepare an IAS 19 accounting valuation are required to be 'best estimate'.

The last full actuarial valuation of the UK Pension Fund was carried out by a qualified actuary as at 31 March 2022 and finalised in May 2023, ahead of the statutory deadline. The funding assumptions used in this actuarial valuation were set out in the Group's 2023 annual report. The actuarial valuation at 31 March 2025 will be the first valuation under the Pensions Regulator's new DB funding code of practice, and is currently in progress, with a likely timescale for completion during the second quarter of 2026. However, the value of the Fund's obligations disclosed at 31 December 2025 incorporates data from this latest actuarial valuation including updated membership information and demographic assumptions.

Aspects of the triennial actuarial valuation are governed by a long-term funding agreement, effective since October 2016, which sets out a path to full funding on a low-risk measure. Under this agreement, if a deficit exists, the Group is required to provide security. This security takes the form of a charge in favour of the Trustee over all land and buildings on the Group's Cambridge Biomedical Campus site. This charge was enacted in December 2023, and provides long-term security to the Trustee in respect of the Group's future deficit recovery contributions. At the last assessment date (1 December 2023), the value of the charge was £317m (\$427m at December 2025 exchange rates) and it is capped at £350m (\$471m). The value of the charge will vary and is expected to reduce over time, before falling away. Under the terms of the charge, the Trustee can only exercise its right over the ownership of the site in a Group insolvency event.

In relation to deficit recovery contributions, in March 2025, the Group made a lump sum contribution of £39m (\$49m). Further annual contributions of £39m are due before 31 March 2026 and each year up to 31 March 2028. Based on 31 December 2025 IAS 19 assumptions, it is expected that ongoing contributions (excluding past service deficit contributions) during the year ending 31 December 2026 for the UK will be approximately \$17m.

GMP equalisation of member benefits has been completed for pensioner and dependent members and, for non-pensioner members, a process is in place to equalise their benefits at their point of retirement. The method of equalisation converts GMP to non-GMP pension to simplify the structure and administration of benefits.

A new, voluntary, Flexible Pension Option was introduced from 1 July 2025, allowing retiring members to reshape their pension benefit. A \$33m past service credit was taken to the Consolidated Statement of Comprehensive Income in May 2025 reflecting expected take-up of this option.

Under the governing documentation of the UK Pension Fund, any future surplus in the Fund would be returnable to the Group by refund assuming gradual settlement of the liabilities over the lifetime of the Fund. In particular, the Trustee has no unilateral right to wind up the Fund without Company consent nor does it have the power to unilaterally use any surplus to augment benefits prior to wind-up. As such, there are no adjustments required in respect of IFRIC 14 'IAS 19 – The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction'.

Sweden

The Swedish plans account for 22% of the Group's DB obligations. They are governed by Fiduciary Bodies with responsibility for the investment of the assets. These plans are funded in line with the Group's long-term funding framework and local regulations.

The Swedish DB pension plans were actuarially valued at 31 December 2024, when plan obligations were estimated to amount to \$1,508m and plan assets were \$1,056m. The local Swedish GAAP funding position can influence contribution policy. Over 2025, for the largest pension plan, the Group did not request a reimbursement of benefit payments made throughout the year as the funding level was below 100% on the Swedish GAAP basis and so any such reimbursement is not permitted. These benefit payments over 2025, totalling approximately \$60m, are therefore regarded as Group contributions.

Based on 31 December 2025 IAS 19 assumptions, it is expected that contributions during the year ending 31 December 2026 for Sweden will be approximately \$64m.

Other defined benefit plans

The Group provides DB plans other than pensions which are reported under IAS 19. These include lump sum plans, long-service awards and defined contribution pension plans which have a guaranteed minimum benefit. However, the largest category of these 'other' non-pension plans are healthcare benefits.

The cost of post-retirement benefits other than pensions for the Group in 2025 was \$1m (2024: \$1m; 2023: \$1m). Plan assets were \$141m and plan obligations were \$83m at 31 December 2025.

Financial assumptions

Qualified independent actuaries have updated the actuarial valuations under IAS 19 for the major DB plans operated by the Group to 31 December 2025. The assumptions used may not necessarily be borne out in practice, due to the inherent financial and demographic uncertainty associated with making long-term projections. These assumptions reflect the changes which have the most material impact on the results of the Group and were as follows:

	2024		
	UK	Sweden	Rest of Group ¹
Inflation assumption	3.2%	1.8%	2.1%
Rate of increase in salaries	– ³	3.3%	3.6%
Rate of increase in pensions in payment	3.0%	1.8%	2.1%
Discount rate – defined benefit obligation	5.5%	3.5%	3.5%
Discount rate – interest cost	5.4%	3.4%	3.5%
Discount rate – service cost	5.5%	3.5%	3.5%

	2025		
	UK	Sweden	Rest of Group ¹
Inflation assumption	2.8% ²	1.7%	2.0%
Rate of increase in salaries	– ³	3.2%	3.5%
Rate of increase in pensions in payment	2.7%	1.7%	2.0%
Discount rate – defined benefit obligation ⁴	5.5%	3.8%	4.3%
Discount rate – interest cost ⁵	5.1%	3.6%	3.9%
Discount rate – service cost ⁵	5.7%	3.9%	4.5%

¹ Rest of Group reflects the assumptions in Germany as these have the most material impact on the Group.

² The UK inflation assumption includes an allowance for some UK inflation experience over 2025.

³ Pensionable pay frozen at 30 June 2010 levels following UK fund changes.

⁴ Group defined benefit obligation as at 31 December 2025 calculated using discount rates based on market conditions as at 31 December 2025.

⁵ 2025 interest costs and service costs calculated using discount rates based on market conditions as at 31 December 2024.

The weighted average duration of the post-retirement scheme obligations is approximately 10 years in the UK, 16 years in Sweden and 12 years for the Rest of the Group (including Germany).

Demographic assumptions

The mortality assumptions are based on country-specific mortality tables. These are compared to actual experience and adjusted where sufficient data are available. Additional allowance for future improvements in life expectancy is included for all major plans where there is credible data to support a continuing trend.

The table below illustrates life expectancy assumptions at age 65 for male and female members retiring in 2025 and male and female members expected to retire in 2045 (2024: 2024 and 2044 respectively).

Country	Life expectancy assumption for a male member retiring at age 65				Life expectancy assumption for a female member retiring at age 65			
	2025	2045	2024	2044	2025	2045	2024	2044
UK	23.0	24.3	22.1	23.1	24.2	25.6	23.7	24.8
Sweden	22.8	24.3	21.8	24.1	24.4	25.3	23.9	26.3

In the UK, the Group updated the mortality tables used, reflecting analysis carried out as part of the latest actuarial valuation and adopted the CMI Core 2024 Mortality Projections Model with core fitting parameters (H=1.0, SK=7.0), an addition to initial rates of improvement of 0.5% p.a. and a 1.0% p.a. long-term improvement rate. Other demographic assumptions were updated based on analysis carried out as part of the 2025 actuarial valuation. The Group has assumed that 15% of members (2024: 15%) will transfer out of the DB section of the UK Pension Fund at an average age of 59 (2024: 57).

In Sweden, the Group continues to use the most recently published mortality tables, DUS23, for the year.

Notes to the Group Financial Statements *continued*

22 Post-retirement pension and other defined benefit schemes *continued*

Risks associated with the Group's defined benefit pension plans

The UK DB plan accounts for 64% of the Group's DB obligations and exposes the Group to a number of risks, which the Group monitors and works with the Trustee to mitigate (noting it is the Trustee who has the remit and ultimate decision making powers). The most significant of which are:

Risk	Description	Mitigation
1 Asset pricing	The Defined Benefit Obligation (DBO) is calculated using a discount rate set with reference to AA-rated corporate bond yields; asset returns that differ from the discount rate will create an element of volatility in the solvency ratio. Approximately 45% of the UK Pension Fund is exposed to growth assets, including global investments, most of which are not sterling denominated. Although these growth assets are expected to outperform AA-rated corporate bonds in the long term, they can lead to volatility and mismatching risk in the short term. The allocation to growth assets is monitored to ensure it remains appropriate given the UK Pension Fund's long-term objectives and risk budget.	The Trustee invests in a suitably diversified range of asset classes with different return drivers and investment managers. Investment strategy will evolve to further improve the expected risk/return profile as opportunities arise and funding solvency improves. The Trustee has hedged approximately 87% of unintended non-sterling, overseas currency risk within the UK Pension Fund assets.
2 Interest rate	A decrease in corporate bond yields will increase the present value placed on the DBO under IAS 19.	The interest rate hedge of the UK Pension Fund is predominantly implemented via holding gilts (and gilt repurchase agreements or 'gilt repo') of appropriate duration. This hedge protects to a large degree against falls in long-term interest rates and the UK Pension Fund is 100% hedged as a percentage of assets at the end of 2025 (versus target of 100%). Nonetheless, there remain differences in the bonds and instruments held by the UK Pension Fund to hedge interest rate risk on the statutory and long-term funding basis (gilts and 'gilt repo') and the bonds included in the yield curve to set the DBO discount rate on an IAS 19 basis (AA corporate bonds). As such, there remains mismatching risk on an IAS 19 basis should yields on gilts diverge compared to AA corporate bonds.
3 Inflation	The majority of the DBO is indexed in line with price inflation (mainly inflation as measured by the UK Retail Price Index (RPI) but also for some members, a component of pensions is indexed by the UK Consumer Price Index (CPI)) and higher inflation will lead to higher liabilities (although, in the vast majority of cases, this is capped at an annual increase of 5%, known as Limited Price Indexation or LPI).	The UK Pension Fund holds RPI index-linked gilts and 'gilt repo'. The inflation hedge of the UK Pension Fund protects to some degree against higher-than-expected inflation increases on the DBO and is approximately 96% hedged as a percentage of assets at the end of 2025 (versus a target of 100%).
4 Longevity	The majority of the UK Pension Fund's obligations are to provide benefits for the life of the member, so increases in life expectancy will result in an increase in the liabilities.	In 2013, the Trustee entered into a longevity swap to hedge against the risk of increasing life expectancy over the next circa 70 years. The swap currently covers approximately 7,500 of the UK Pension Fund's pensioners, equivalent to \$2.0bn of Pension Fund liability. A one-year increase in life expectancy would result in a \$161m increase in Pension Fund obligations, which would be partially offset by a \$81m increase in the value of the longevity swap and hence the pension fund assets.
5 Cash flow and liquidity	The UK Pension Fund is maturing and is cash flow negative. Assets are liquidated to meet benefit outgo and potentially from time to time, to supplement the collateral pool required to post margin for derivative holdings. There is a risk of the Trustee requesting liquidity support from the Group to meet margin calls or expenditure, if the liquidity position of the UK Pension Fund is not effectively monitored and managed.	The Trustee invests in a diversified portfolio of highly liquid assets to manage sequencing risk and operates a collateral management policy, maintaining a minimum liquidity 'buffer'. As at the end of 2025, the buffer is well above recommended regulatory guidelines and the minimum thresholds, and can be quickly supplemented in an orderly manner. At 31 December 2025, 8% of assets are invested in a cash-flow driven investment portfolio, consisting of investment-grade corporate bonds. The purpose of this portfolio is to generate income to help meet the Fund's benefit outgo. The portfolio is expected to grow over time as further de-risking occurs and when attractive pricing points present.

Other risks

There are a number of other risks of administering the UK Pension Fund which the Trustee manages with Group input. Some of the major risks include counterparty risks from using derivatives (mitigated by using a specialist investment manager to oversee a diversified range of counterparties of high standing and ensuring positions are collateralised daily). Furthermore, there are operational risks (such as paying out the wrong benefits) and regulatory risks (such as the UK Government introducing new legislation). These are mitigated so far as possible via the governance structure in place which oversees and administers the Pension Fund.

Fiduciary Boards who govern the Swedish pension plans also monitor and manage these key risks, where relevant and possible to do so, in a similar way, by investing in a diversified manner (to mitigate the first risk) and employing a framework to hedge interest rate risk where practicable (to mitigate the second risk). It is not possible to hedge inflation risk (third risk) nor longevity risk (fourth risk) due to a lack of available instruments in the local market. As the Swedish plans are less mature and have a longer investment horizon, the fifth risk is not as significant compared to the UK Pension Fund.

Fiduciary boards are aware of Environmental, Social and Governance (ESG) risks as they pertain to investment policy, and where local regulation allows, have policies in place to monitor and manage such risks and comply with local legislation and disclosure requirements.

Assets and obligations of defined benefit plans

The assets and obligations of the DB schemes operated by the Group at 31 December 2025, as calculated in accordance with IAS 19, are shown below.

Scheme assets

									2024
	UK		Sweden		Rest of Group		Total		Total \$m
	Quoted \$m	Unquoted \$m	Quoted \$m	Unquoted \$m	Quoted \$m	Unquoted \$m	Quoted \$m	Unquoted \$m	
Government bonds ¹	1,884	–	–	–	45	–	1,929	–	1,929
Corporate bonds ²	352	–	–	–	6	–	358	–	358
Derivatives ³	–	(355)	–	475	–	–	–	120	120
Investment funds: Listed Equities ⁴	–	374	–	–	38	23	38	397	435
Investment funds: Absolute Return/Multi Strategy ⁴	–	1,051	–	420	5	7	5	1,478	1,483
Investment funds: Corporate Bonds/Credit ⁴	–	601	–	159	182	19	182	779	961
Cash and cash equivalents	32	336	–	2	2	2	34	340	374
Other	–	–	–	–	(6)	194	(6)	194	188
Total fair value of scheme assets⁵	2,268	2,007	–	1,056	272	245	2,540	3,308	5,848

									2025
	UK		Sweden		Rest of Group		Total		Total \$m
	Quoted \$m	Unquoted \$m	Quoted \$m	Unquoted \$m	Quoted \$m	Unquoted \$m	Quoted \$m	Unquoted \$m	
Government bonds ¹	2,231	–	–	–	2	48	2,233	48	2,281
Corporate bonds ²	387	–	–	–	4	1	391	1	392
Derivatives ³	–	(316)	–	(38)	–	(1)	–	(355)	(355)
Investment funds: Listed Equities ⁴	–	215	–	–	51	3	51	218	269
Investment funds: Absolute Return/Multi Strategy ⁴	–	1,021	–	529	–	6	–	1,556	1,556
Investment funds: Corporate Bonds/Credit ⁴	–	628	–	205	186	–	186	833	1,019
Cash and cash equivalents	–	431	–	626	7	7	7	1,064	1,071
Other	–	–	–	–	1	247	1	247	248
Total fair value of scheme assets⁵	2,618	1,979	–	1,322	251	311	2,869	3,612	6,481

¹ Predominantly developed markets in nature.

² Predominantly developed markets in nature and investment grade (AAA-BBB).

³ Includes interest rate swaps, inflation swaps, longevity swaps, equity total return swaps and other contracts. More detail is given in the section Risks associated with the Group's defined benefit pension plans from page 164. Derivative fair values are determined by independent third parties.

⁴ Investment funds are pooled, commingled vehicles, whereby the pension plan owns units in the fund, alongside other investors. The pension plans invest in a number of investment funds, including Listed Equities (primarily developed markets with some emerging markets), Corporate Bonds/Credit (a range of investment-grade and non-investment-grade credit) and Absolute Return/Multi Strategy (actively managed multi-asset exposure both across and within traditional and alternative asset classes). The price of the funds is set by independent administrators/custodians employed by the investment managers and based on the value of the underlying assets held in the fund. Details of pricing methodology is set out within internal control reports provided for each fund. Prices are updated daily, weekly or monthly depending upon the frequency of the fund's dealing.

⁵ None of the Group's own assets were included in the scheme assets (2024: \$nil).

Scheme obligations

				2024
				Total \$m
Present value of scheme obligations in respect of:				
Active membership	(200)	(543)	(481)	(1,224)
Deferred membership	(667)	(393)	(197)	(1,257)
Pensioners	(3,725)	(572)	(301)	(4,598)
Total value of scheme obligations	(4,592)	(1,508)	(979)	(7,079)

				2025
				Total \$m
Present value of scheme obligations in respect of:				
Active membership	(150)	(577)	(532)	(1,259)
Deferred membership	(566)	(431)	(199)	(1,196)
Pensioners	(4,051)	(672)	(302)	(5,025)
Total value of scheme obligations	(4,767)	(1,680)	(1,033)	(7,480)

Notes to the Group Financial Statements *continued*

22 Post-retirement pension and other defined benefit schemes *continued*

Net (deficit)/surplus in the scheme

	2024			
	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m
Total fair value of scheme assets	4,275	1,056	517	5,848
Total value of scheme obligations	(4,592)	(1,508)	(979)	(7,079)
Deficit in the scheme as recognised in the Consolidated Statement of Financial Position	(317)	(452)	(462)	(1,231)
Included in Non-current other receivables (Note 15)	–	–	99 ¹	99
Included in Retirement benefit obligations	(317)	(452)	(561)	(1,330)
	(317)	(452)	(462)	(1,231)

	2025			
	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m
Total fair value of scheme assets	4,597	1,322	562	6,481
Total value of scheme obligations	(4,767)	(1,680)	(1,033)	(7,480)
Deficit in the scheme as recognised in the Consolidated Statement of Financial Position	(170)	(358)	(471)	(999)
Included in Non-current other receivables (Note 15)	–	–	106 ¹	106
Included in Retirement benefit obligations	(170)	(358)	(577)	(1,105)
	(170)	(358)	(471)	(999)

¹ Surpluses were recognised in the US, Ireland and Belgium.

Fair value of scheme assets

	2025				2024			
	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m
At beginning of year	4,275	1,056	517	5,848	4,759	1,068	652	6,479
Interest income on scheme assets	232	40	17	289	214	33	15	262
Expenses	(5)	–	–	(5)	(5)	–	–	(5)
Actuarial gains/(losses)	61	25	(1)	85	(370)	55	–	(315)
Exchange and other adjustments	304	202	37	543	(67)	(98)	(20)	(185)
Employer contributions	65	57	64	186	66	50	50	166
Participant contributions	1	–	12	13	1	–	12	13
Benefits paid	(336)	(58)	(84)	(478)	(323)	(52)	(76)	(451)
Settlements ¹	–	–	–	–	–	–	(116)	(116)
Scheme assets' fair value at end of year	4,597	1,322	562	6,481	4,275	1,056	517	5,848

¹ The 2024 settlement is the buyout of post-retirement pension plans in Norway and the Netherlands.

The actual return on the plan assets was a gain of \$374m (2024: loss of \$53m).

Movement in post-retirement scheme obligations

	2025				2024			
	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m
Present value of obligations in scheme at beginning of year	(4,592)	(1,508)	(979)	(7,079)	(5,161)	(1,602)	(1,144)	(7,907)
Current service cost	(5)	(41)	(40)	(86)	(6)	(26)	(40)	(72)
Past service credit/(cost)	32	(5)	(1)	26	(2)	(8)	1	(9)
Participant contributions	(1)	–	(12)	(13)	(1)	–	(12)	(13)
Benefits paid	336	58	84	478	323	52	76	451
Interest expense on post-retirement scheme obligations	(248)	(55)	(37)	(340)	(231)	(47)	(34)	(312)
Actuarial gains/(losses)	30	149	26	205	416	(23)	2	395
Exchange and other adjustments	(319)	(278)	(87)	(684)	70	146	56	272
Settlements ¹	–	–	13	13	–	–	116	116
Present value of obligations in scheme at end of year	(4,767)	(1,680)	(1,033)	(7,480)	(4,592)	(1,508)	(979)	(7,079)

¹ The 2024 settlement is the buyout of post-retirement pension plans in Norway and the Netherlands.

The obligations arise from the following plans:

	2025				2024			
	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m
Funded – pension schemes ¹	(4,758)	(1,678)	(777)	(7,213)	(4,582)	(1,505)	(717)	(6,804)
Funded – post-retirement healthcare	–	–	(67)	(67)	–	–	(78)	(78)
Unfunded – pension schemes ¹	–	(2)	(179)	(181)	–	(3)	(167)	(170)
Unfunded – post-retirement healthcare	(9)	–	(10)	(19)	(10)	–	(17)	(27)
Total	(4,767)	(1,680)	(1,033)	(7,480)	(4,592)	(1,508)	(979)	(7,079)

¹ Includes defined benefit pension schemes and other plans, such as lump sum, long-service awards and DC plans with underpins.

Consolidated Statement of Comprehensive Income disclosures

The amounts that have been charged to the Consolidated Statement of Comprehensive Income, in respect of DB schemes for the years ended 31 December 2025 and 31 December 2024, are set out below.

	2025				2024			
	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m	UK \$m	Sweden \$m	Rest of Group \$m	Total \$m
Operating profit								
Current service cost	(5)	(41)	(40)	(86)	(6)	(26)	(40)	(72)
Past service credit/(cost)	32	(5)	(1)	26	(2)	(8)	1	(9)
Expenses	(5)	–	–	(5)	(5)	–	–	(5)
Total credit/(charge) to Operating profit	22	(46)	(41)	(65)	(13)	(34)	(39)	(86)
Finance expense								
Interest income on scheme assets	232	40	17	289	214	33	15	262
Interest expense on post-retirement scheme obligations	(248)	(55)	(37)	(340)	(231)	(47)	(34)	(312)
Net interest on post-employment defined benefit plan liabilities	(16)	(15)	(20)	(51)	(17)	(14)	(19)	(50)
Credit/(charge) before taxation	6	(61)	(61)	(116)	(30)	(48)	(58)	(136)
Other comprehensive income								
Difference between the actual return and the expected return on the post-retirement scheme assets	61	25	(1)	85	(370)	55	–	(315)
Experience gains/(losses) arising on the post-retirement scheme obligations	17	60	(18)	59	3	(33)	(10)	(40)
Changes in financial assumptions underlying the present value of the post-retirement scheme obligations	87	89	44	220	414	11	11	436
Changes in demographic assumptions	(74)	–	–	(74)	(1)	(1)	1	(1)
Remeasurement of the defined benefit liability	91	174	25	290	46	32	2	80

Past service cost includes granting early retirement in UK and Sweden.

Total Group pension costs in respect of defined contribution and DB schemes during the year are set out below (see Note 29).

	2025 \$m	2024 \$m
Defined contribution plans	553	528
Defined benefit plans – Current service cost and expenses	91	77
Defined benefit plans – Past service (credit)/cost	(26)	9
Pension costs	618	614

Notes to the Group Financial Statements *continued*

22 Post-retirement pension and other defined benefit schemes *continued*

SE Rate sensitivities

The following tables show the US dollar effect of a change in the significant actuarial assumptions used to determine the retirement benefits obligations in our two main DB pension obligation countries.

	2025		2024	
	+0.5%	-0.5%	+0.5%	-0.5%
Discount rate				
UK (\$m)	219	(238)	219	(239)
Sweden (\$m)	116	(129)	110	(126)
Total (\$m)	335	(367)	329	(365)
	2025		2024	
	+0.5%	-0.5%	+0.5%	-0.5%
Inflation rate¹				
UK (\$m)	(155)	142	(148)	142
Sweden (\$m)	(104)	95	(119)	104
Total (\$m)	(259)	237	(267)	246
	2025		2024	
	+0.5%	-0.5%	+0.5%	-0.5%
Rate of increase in salaries²				
UK (\$m)	n/a	n/a	n/a	n/a
Sweden (\$m)	(33)	32	(46)	43
Total (\$m)	(33)	32	(46)	43
	2025		2024	
	+1 year	-1 year	+1 year	-1 year
Mortality rate³				
UK (\$m)	(161) ⁴	163 ⁵	(178)	175
Sweden (\$m)	(58)	58	(74)	54
Total (\$m)	(219)	221	(252)	229

¹ Rate of increase in pensions in payment follows inflation. The inflation sensitivity allows for the impact of a change in inflation on salary increases and pension increases (where these assumptions are inflation-linked).

² The salary increase sensitivity reflects the impact of an increase of only salary relative to inflation.

³ The sensitivity to the life expectancy assumption is estimated based on a revised mortality assumption that extends/reduces the current life expectancy by one year for a particular age.

⁴ Of the \$161m increase, \$81m is covered by the longevity swap.

⁵ Of the \$163m decrease, \$81m is covered by the longevity swap.

The sensitivity to the financial assumptions shown above has been estimated taking into account the approximate duration of the liabilities and the overall profile of the plan membership.

23 Reserves

Retained earnings

The cumulative amount of goodwill written off directly to reserves resulting from acquisitions, net of disposals, amounted to \$603m (2024: \$580m; 2023: \$595m) using year-end rates of exchange.

At 31 December 2025, 147,547 shares, at a cost of \$25m, have been deducted from Retained earnings (2024: 442,342 shares, at a cost of \$68m; 2023: 1,580,137 shares, at a cost of \$129m) to satisfy future vesting of employee share plans.

There are no significant statutory or contractual restrictions on the distribution of current profits of subsidiaries; undistributed profits of prior years are, in the main, permanently employed in the businesses of these companies. The undistributed income of AstraZeneca companies overseas might be liable to overseas taxes and/or UK taxation (after allowing for double taxation relief) if they were to be distributed as dividends (see Note 5).

	2025 \$m	2024 \$m	2023 \$m
Cumulative translation differences included within Retained earnings			
At 1 January	(4,069)	(3,014)	(3,694)
Foreign exchange arising on consolidation	2,387	(957)	608
Exchange adjustments on goodwill (recorded against Other reserves)	23	(15)	4
Foreign exchange arising on designated liabilities in net investment hedges ¹	18	(122)	24
Fair value movements on derivatives designated in net investment hedges	14	39	44
Net exchange movement in Retained earnings	2,442	(1,055)	680
At 31 December	(1,627)	(4,069)	(3,014)

¹ Foreign exchange arising on designated liabilities in net investment hedges includes \$(137)m in respect of designated bonds and \$155m in respect of designated contingent consideration and other liabilities. The change in value of designated contingent consideration liabilities relates to \$152m in respect of BMS' share of Global Diabetes Alliance.

The cumulative loss with respect to costs of hedging is \$42m (2024: \$43m; 2023: \$22m) and the gain during the year was \$1m (2024: loss of \$21m; 2023: loss of \$19m).

The balance remaining in the foreign currency translation reserve from net investment hedging relationships for which hedge accounting no longer applied is a gain of \$527m. For further detail relating to hedging balances, please see the Hedge accounting section within Note 28, from page 176.

Other reserves

The Other reserves arose from the cancellation of £1,255m of share premium account by the Company in 1993 and the redenomination of share capital of \$157m in 1999. The reserves are available for writing off goodwill arising on consolidation and, subject to guarantees given to preserve creditors at the date of the court order, are available for distribution.

In the prior year, following an amendment to the Employee Benefit Trust (EBT) Deed on 10 June 2024, AstraZeneca obtained control and commenced consolidation of the EBT. The value of shares held by the consolidated EBTs is reflected as an adjustment against Other reserves.

24 Share capital

	Allotted, called-up and fully paid		
	2025 \$m	2024 \$m	2023 \$m
Issued Ordinary Shares (\$0.25 each)	388	388	388
Redeemable Preference Shares (£1 each – £50,000)	–	–	–
At 31 December	388	388	388

The Redeemable Preference Shares carry limited class-voting rights and no dividend rights. This class of shares is capable of redemption at par at the option of the Company on the giving of seven days' written notice to the registered holder of the shares.

The Company does not have a limited amount of authorised share capital.

The movements in the number of Ordinary Shares during the year can be summarised as follows:

		No. of shares	
	2025	2024	2023
At 1 January	1,550,546,239	1,550,162,626	1,549,800,030
Issue of shares (share schemes)	361,688	383,613	362,596
At 31 December	1,550,907,927	1,550,546,239	1,550,162,626

Share issues

Issue of shares (share schemes) represents share capital issued as part of the Group's equity incentivisation schemes (see Note 29).

Share repurchases

No Ordinary Shares were repurchased by the Company in 2025 (2024: nil; 2023: nil).

Shares held by subsidiaries

At 31 December 2025, AstraZeneca-controlled Employee Benefit Trust arrangements held 147,547 (2024: 442,342) Ordinary Shares in the Company at a cost of \$25m (2024: \$68m). The market value of these Ordinary Shares at 31 December 2025 was \$27m (2024: \$58m). No comparable arrangements were in place at 31 December 2023.

25 Dividends to shareholders

	2025 Per share	2024 Per share	2023 Per share	2025 \$m	2024 \$m	2023 \$m
Second interim (March 2025)	\$2.10	\$1.97	\$1.97	3,249	3,052	3,047
First interim (September 2025)	\$1.03	\$1.00	\$0.93	1,597	1,550	1,440
Total	\$3.13	\$2.97	\$2.90	4,846	4,602	4,487

The Company has exercised its authority in accordance with the provisions set out in the Company's Articles of Association, that the balance of unclaimed dividends outstanding past 12 years be forfeited. Unclaimed dividends of \$nil (2024: \$nil; 2023: \$nil) have been adjusted for in Retained earnings in 2025.

The 2024 second interim dividend of \$2.10 per share was paid on 24 March 2025. The 2025 first interim dividend of \$1.03 per share was paid on 8 September 2025.

Reconciliation of dividends charged to equity to the Consolidated Statement of Cash Flows:

	2025 \$m	2024 \$m	2023 \$m
Dividends charged to equity	4,846	4,602	4,487
Exchange losses on payment of dividend	6	3	5
Hedge contracts relating to payment of dividends (Consolidated Statement of Cash Flows)	113	16	(19)
Dividends paid to non-controlling interests	6	4	4
Net movement of unclaimed dividends in the year	–	4	4
Dividends paid (Consolidated Statement of Cash Flows)	4,971	4,629	4,481

Notes to the Group Financial Statements *continued*

26 Non-controlling interests

The Group Financial Statements at 31 December 2025 reflect equity of \$52m (2024: \$85m; 2023: \$23m) and Total comprehensive income of \$16m (2024: \$5m; 2023: \$6m) attributable to the non-controlling interests in AstraZeneca Pharma India Limited, P.T. AstraZeneca Indonesia, AstraZeneca Algeria Pharmaceutical Industries SPA, and VaxNewMo LLC.

On 22 October 2025 AstraZeneca completed the acquisition of the remaining \$35m non-controlling interest in SixPeaks Bio AG in exchange for \$248m. The payment was recognised in equity.

27 Acquisitions of business operations

Acquisitions of business operations in 2025

FibroGen China

On 29 August 2025, AstraZeneca completed the acquisition of FibroGen International (Hong Kong) Limited (FibroGen China) and its subsidiaries, including the existing non-controlling interest in Beijing Falikang Pharmaceutical Co., Ltd. Through this acquisition AstraZeneca obtained control of all rights to roxadustat in China, including manufacturing in China.

The total consideration fair value of \$221m comprised \$189m to acquire the equity of FibroGen China, \$12m for the purchase of an existing non-controlling interest in Beijing Falikang Pharmaceutical Co., Ltd, and \$20m for the settlement of pre-existing net payables from AstraZeneca Group to FibroGen China. The transaction was recorded as a business combination under IFRS 3 'Business Combinations' using the acquisition method of accounting. The purchase price allocation review has been completed. Net assets acquired amounted to \$203m, including cash and cash equivalents of \$120m and intangible assets of \$50m. FibroGen China's results were consolidated into the Group's results from 29 August 2025.

Acquisitions of business operations in 2024

Gracell

On 22 February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune-diseases. Gracell will operate as a wholly-owned subsidiary of AstraZeneca, with operations in China and the US.

The acquisition enriches AstraZeneca's growing pipeline of cell therapies with AZD0120 (formerly GC012F), a novel, clinical-stage T-cell (CAR-T: therapeutic chimeric antigen receptor) therapy. AZD0120 is a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune-diseases, including Systemic Lupus Erythematosus (SLE).

The transaction was recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3. Consequently, the assets acquired, and liabilities assumed are recorded at fair value. The purchase price allocation review has been completed.

	Fair value \$m
Intangible assets	1,038
Cash and cash equivalents ¹	212
Net deferred tax liability	(260)
Other immaterial net balances	(89)
Total net assets acquired	901
Goodwill	136
Consideration	1,037

¹ Cash and cash equivalents acquired includes \$3m relating to marketable securities.

The total consideration fair value of \$1,037m comprises cash consideration of \$983m and future regulatory milestone-based consideration of \$54m. Intangible assets recognised related to products in development, principally AZD0120, and were fair valued using the multi-period excess earnings method, which uses several estimates regarding the amount and timing of future cash flows. The key assumptions in the cash flows were the probability of technical and regulatory success, peak year sales and revenue erosion profiles.

The net deferred tax liability of \$260m principally arose from the deferred tax impact of the uplift in fair value of intangible assets.

Goodwill of \$136m was recognised, which principally comprised the premium attributable to the core technological capabilities and knowledge base of the company. Goodwill was not expected to be deductible for tax purposes.

Gracell's results were consolidated into the Group's results from 22 February 2024.

Fusion

On 4 June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc., (Fusion) a clinical-stage biopharmaceutical company developing next-generation radioconjugates. The acquisition marked a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. As a result of the acquisition, Fusion became a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US.

Immediately prior to the acquisition, AstraZeneca held approximately 1% shareholding in Fusion considered to have a fair value of \$24m.

This acquisition complemented AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of radioconjugates, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based radioconjugates to AstraZeneca.

The transaction was recorded as a business combination using the acquisition method of accounting in accordance with IFRS 3. Consequently, the assets acquired, and liabilities assumed were recorded at fair value. The purchase price allocation review was completed.

	Fair value \$m
Intangible assets	1,326
Cash and cash equivalents	30
Current investments	87
Net deferred tax liability	(246)
Other immaterial net balances	51
Total net assets acquired	1,248
Goodwill	947
Consideration	2,195

The total consideration fair value of \$2,195m included cash consideration of \$2,027m (net of \$24m proceeds from disposal of the existing approximately 1% shareholding) and future regulatory milestone-based consideration of \$144m. Intangible assets relating to products in development comprised the FPI-2265 (\$848m), FPI-2059 (\$165m) and AZD2068 (\$313m) programmes. These were fair valued using the multi-period excess earnings method, which uses several estimates regarding the amount and timing of future cash flows. The key assumptions in the cash flows were the probability of technical and regulatory success, peak year sales and revenue erosion profiles.

The net deferred tax liability of \$246m principally arose from the deferred tax impact of the uplift in fair value of intangible assets.

Goodwill amounting to \$947m was recognised on acquisition and was underpinned by a number of elements, which individually could not be quantified. These included the premium attributable to a pre-existing, well positioned business in the innovation intensive biopharmaceuticals market with a highly skilled workforce, unidentified potential products that future research and development may yield, and the core capabilities and knowledge base of the company including radioisotope supply and manufacturing expertise. Goodwill was not expected to be deductible for tax purposes.

Fusion's results were consolidated into the Group's results from 4 June 2024.

In December 2024, the intangible asset relating to product in development FPI-2059 was fully impaired by \$165m due to decisions made to terminate the related activities and prioritise resources on the development of FPI-2265 and AZD2068 (see Note 11).

28 Financial risk management objectives and policies

The Group's principal financial instruments, other than derivatives, comprise bank overdrafts, loans and other borrowings, lease liabilities, current and non-current investments, cash and short-term deposits. The main purpose of these financial instruments is to manage the Group's funding and liquidity requirements. The Group has other financial assets and liabilities such as trade receivables and trade payables, which arise directly from its operations.

The principal financial risks to which the Group is exposed are those of liquidity, interest rate, foreign currency and credit. Each of these is managed in accordance with Board-approved policies. These policies, together with the Group's approach to capital management, are set out below.

Capital management

The capital structure of the Group consists of Shareholders' equity (Note 24), Debt (Note 19), Other current investments (Note 13) and Cash (Note 18). For the foreseeable future, the Board will maintain a capital structure that supports the Group's strategic objectives through:

- managing funding and liquidity risk
- optimising shareholder return
- maintaining a strong, investment-grade credit rating.

The Group utilises factoring arrangements and bank acceptance draft discounting for selected trade receivables. These arrangements qualify for full derecognition of the associated trade receivables under IFRS 9 'Financial Instruments'. Amounts due on invoices that have not been factored at year end, from customers that are subject to these arrangements, are disclosed in Note 17.

Funding and liquidity risk are reviewed regularly by the Board and managed in accordance with the policies described below.

The Board regularly reviews its shareholders' distribution policy, which comprises a regular cash dividend and potentially a share repurchase component. No share repurchases have been made since 2012.

The Group's net debt position (loans and borrowings net of Cash and cash equivalents, Other investments and Derivative financial instruments) has decreased by \$1,196m from a net debt position of \$24,570m at the beginning of the year to a net debt position of \$23,374m at 31 December 2025. Gross debt decreased from \$30,295m to \$29,622m, principally due to the repayment of \$2,029m debt, partially offset by an increase of \$692m resulting from foreign currency movements.

Notes to the Group Financial Statements *continued*

28 Financial risk management objectives and policies *continued*

Liquidity risk

The Board reviews the Group's ongoing liquidity risks annually as part of the planning process and on an ad hoc basis. The Board considers short-term requirements against available sources of funding, taking into account forecast cash flows. The Group manages liquidity risk by maintaining access to a number of sources of funding which are sufficient to meet anticipated funding requirements. Specifically, the Group uses US and European commercial paper, bank loans, committed bank facilities and cash resources to manage short-term liquidity and manages long-term liquidity by raising funds through the capital markets. At 31 December 2025, the Group was assigned short-term credit ratings of P-1 by Moody's and A-1 by Standard and Poor's. The Group's long-term credit rating was A1 by Moody's and A+ by Standard and Poor's.

In addition to Cash and cash equivalents of \$5,711m, short-term fixed income investments of \$8m, less overdrafts of \$13m at 31 December 2025, the Group has committed bank facilities of \$4,875m available to manage liquidity. These committed bank facilities have no financial covenants. The Group regularly monitors the credit standing of the banks providing the facilities and currently does not anticipate any issue with drawing on the committed facilities should this be necessary. Advances under these facilities currently bear an interest rate per annum based on Secured Overnight Financing Rate (SOFR), plus a margin.

At 31 December 2025, the Group has \$5,733m outstanding from debt issued under a Euro Medium Term Note programme and \$21,369m under an SEC-registered programme. The funds made available under these facility agreements may be used for the general corporate purposes of the Group.

The maturity profile of the anticipated future contractual cash flows including interest in relation to the Group's financial liabilities, on an undiscounted basis, which therefore differs from both the carrying value and fair value, is as follows:

	Bank overdrafts and other loans \$m	Bonds and bank loans \$m	Lease liabilities \$m	Trade and other payables \$m	Total non-derivative financial instruments \$m	Derivative financial instruments receivable \$m	Derivative financial instruments payable \$m	Total derivative financial instruments \$m	Total \$m
Within one year	345	3,045	396	22,501	26,287	(16,227)	16,282	55	26,342
In one to two years	–	3,437	345	1,086	4,868	(207)	250	43	4,911
In two to three years	–	3,670	266	105	4,041	(917)	956	39	4,080
In three to four years	–	3,978	170	750	4,898	(941)	1,044	103	5,001
In four to five years	–	3,780	117	–	3,897	(627)	489	(138)	3,759
In more than five years	–	19,929	406	–	20,335	(2,437)	2,583	146	20,481
	345	37,839	1,700	24,442	64,326	(21,356)	21,604	248	64,574
Effect of interest	(15)	(9,173)	–	–	(9,188)	808	(1,068)	(260)	(9,448)
Effect of discounting, fair values and issue costs	–	(153)	(248)	(207)	(608)	36	(95)	(59)	(667)
31 December 2024	330	28,513	1,452	24,235	54,530	(20,512)	20,441	(71)	54,459
	Bank overdrafts and other loans \$m	Bonds and bank loans \$m	Lease liabilities \$m	Trade and other payables \$m	Total non-derivative financial instruments \$m	Derivative financial instruments receivable \$m	Derivative financial instruments payable \$m	Total derivative financial instruments \$m	Total \$m
Within one year	669	3,495	450	25,282	29,896	(17,182)	17,205	23	29,919
In one to two years	–	3,784	388	473	4,645	(1,031)	944	(87)	4,558
In two to three years	–	4,097	292	1,425	5,814	(1,052)	1,035	(17)	5,797
In three to four years	–	3,898	199	508	4,605	(637)	481	(156)	4,449
In four to five years	–	3,368	156	166	3,690	(849)	1,516	667	4,357
In more than five years	–	16,906	599	–	17,505	(1,913)	2,596	683	18,188
	669	35,548	2,084	27,854	66,155	(22,664)	23,777	1,113	67,268
Effect of interest	(25)	(8,223)	–	–	(8,248)	752	(2,370)	(1,618)	(9,866)
Effect of discounting, fair values and issue costs	–	(150)	(281)	(195)	(626)	10	(12)	(2)	(628)
31 December 2025	644	27,175	1,803	27,659	57,281	(21,902)	21,395	(507)	56,774

It is not expected that the cash flows in the maturity profile could occur significantly earlier or at significantly different amounts, with the exception of \$550m of Contingent consideration held within Trade and other payables (see Note 20).

Market risk

Interest rate risk

The Group maintains a Board-approved mix of fixed and floating rate debt and uses underlying debt, interest rate swaps and forward rate agreements to manage this mix.

The majority of surplus cash is currently invested in US dollar liquidity funds.

The interest rate profile of the Group's interest-bearing financial instruments is set out below. In the case of current and non-current financial liabilities, the profile includes the impact of interest rate swaps which convert the debt to floating rate.

	2025			2024		
	Fixed rate \$m	Floating rate \$m	Total \$m	Fixed rate \$m	Floating rate \$m	Total \$m
Financial liabilities						
Current	2,842	644	3,486	2,346	330	2,676
Non-current	24,502	1,634	26,136	26,151	1,468	27,619
Total	27,344	2,278	29,622	28,497	1,798	30,295
Financial assets						
Cash collateral pledged to counterparties	–	22	22	–	129	129
Cash and cash equivalents	–	5,711	5,711	–	5,488	5,488
Total	–	5,733	5,733	–	5,617	5,617

In addition to the financial assets above, there are \$13,988m (2024: \$11,115m) of other current and non-current asset investments and other financial assets.

The Group is also exposed to market risk on other investments.

	2025 \$m	2024 \$m
Equity securities at fair value through Other comprehensive income (Note 13)	2,212	1,632
Equity securities at fair value through profit and loss (Note 13)	11	–
Total	2,223	1,632

Foreign currency risk

The US dollar is the Group's most significant currency. As a consequence, the Group results are presented in US dollars and exposures are managed against US dollars accordingly.

Translational

Approximately 59% of Group Total Revenue in 2025 was denominated in currencies other than the US dollar, while a significant proportion of manufacturing and research and development costs were denominated in pound sterling and Swedish krona. Surplus cash generated by business units is substantially converted to, and held centrally in, US dollars. As a result, operating profit and total cash flow in US dollars will be affected by movements in exchange rates. This currency exposure is managed centrally, based on forecast cash flows. The impact of movements in exchange rates is mitigated significantly by the correlations which exist between the major currencies to which the Group is exposed and the US dollar. Monitoring of currency exposures and correlations is undertaken on a regular basis and hedging is subject to pre-execution approval.

As at 31 December 2025, before the impact of derivatives or other forms of hedging, the Group held \$564m of interest-bearing loans and borrowings denominated in pound sterling and \$5,620m denominated in euros.

Hedging arrangements for these loans are summarised in the table below:

	2025			2024		
	Euro denominated \$m	Pound sterling denominated \$m	Total \$m	Euro denominated \$m	Pound sterling denominated \$m	Total \$m
Interest-bearing loans						
In a net investment hedge ¹	936	469	1,405	829	438	1,267
In a cash flow hedge ²	2,694	–	2,694	2,387	–	2,387
In a fair value hedge ²	1,634	–	1,634	1,468	–	1,468
Not in a designated IFRS 9 hedge	356	95	451	192	110	302
Total	5,620	564	6,184	4,876	548	5,424

¹ Hedges of underlying net euro and pound sterling investments of the same amount as the loan.

² Loans in cash flow and fair value hedges are hedged by cross-currency swaps of the same notional value as the loan.

For further details of all designated hedging relationships, please refer to the Hedge accounting section within this Note 28, from page 176. The accounting treatment for any hedge ineffectiveness is disclosed in the Bank and other borrowings accounting policy from page 134 and the Foreign currencies accounting policy on page 135 within Group Accounting Policies.

As at 31 December 2025, the Group operates in three countries designated as hyperinflationary, being Argentina, Venezuela and Turkey. The foreign exchange risk of these markets has been assessed and deemed to be immaterial.

Transactional

The Group aims to hedge all its forecasted major transactional currency exposures on working capital balances, which typically extend for up to three months. Where practicable, these are hedged using forward foreign exchange contracts. In addition, external dividend payments in pound sterling to UK shareholders and in Swedish krona to Swedish shareholders are fully hedged from announcement date to payment date. Foreign exchange gains and losses on forward contracts transacted for transactional hedging are taken to profit and loss or to Other comprehensive income if the contract is in a designated cash flow hedge.

Notes to the Group Financial Statements *continued*

28 Financial risk management objectives and policies *continued*

Sensitivity analysis

The sensitivity analysis set out below summarises the sensitivity of the market value of our financial instruments to hypothetical changes in market rates and prices. The range of variables chosen for the sensitivity analysis reflects our view of changes which are reasonably possible over a one-year period. Market values are the present value of future cash flows based on market rates and prices at the valuation date. For long-term debt, an increase in interest rates results in a decline in the fair value of debt.

The sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels at 31 December 2025, with all other variables held constant. Based on the composition of our debt portfolio and cash reserves as at 31 December 2025, a 1% increase in interest rates would result in an additional \$23m in interest expense on the debt and an additional \$57m interest income on the cash reserves.

The exchange rate sensitivity analysis assumes an instantaneous 10% change in foreign currency exchange rates from their levels at 31 December 2025, with all other variables held constant. The +10% case assumes a 10% strengthening of the US dollar against all other currencies and the -10% case assumes a 10% weakening of the US dollar.

Each incremental 10% movement in foreign currency exchange rates would have approximately the same effect as the initial 10% detailed in the table below and each incremental 1% change in interest rates would have approximately the same effect as the 1% detailed in the table below.

31 December 2024	Interest rates		Exchange rates	
	+1%	-1%	+10%	-10%
Increase/(decrease) in fair value of financial instruments (\$m)	1,407	(1,561)	11	(20)
Impact on profit: (loss)/gain (\$m)	–	–	(117)	133
Impact on equity: gain/(loss) (\$m)	–	–	128	(152)

31 December 2025	Interest rates		Exchange rates	
	+1%	-1%	+10%	-10%
Increase/(decrease) in fair value of financial instruments (\$m)	1,266	(1,406)	88	(111)
Impact on profit: (loss)/gain (\$m)	–	–	(13)	16
Impact on equity: gain/(loss) (\$m)	–	–	101	(126)

Credit risk

The Group is exposed to credit risk on financial assets, such as cash investments, derivative instruments, and Trade and other receivables. The Group was also exposed in its Net asset position to its own credit risk in respect of the 2023 debentures which were accounted for at FVPL. Under IFRS 9, the effect of the losses and gains arising from own credit risk on the fair value of bonds designated at FVPL are recorded in Other comprehensive income.

Financial counterparty credit risk

The majority of the Group's cash is centralised within the Group treasury entity and is subject to counterparty risk on the principal invested. The level of the Group's cash investments and hence credit risk will depend on the cash flow generated by the Group and the timing of the use of that cash. The credit risk is mitigated through a policy of prioritising security and liquidity over return and, as such, cash is only invested in high credit-quality investments. Counterparty limits are set according to the assessed risk of each counterparty and exposures are monitored against these limits on a regular basis.

The Group's principal financial counterparty credit risks at 31 December were as follows:

Current assets

	2025 \$m	2024 \$m
Cash at bank and in hand	1,332	1,215
Money market liquidity funds	4,224	4,177
Other short-term cash equivalents	155	96
Total Cash and cash equivalents (Note 18)	5,711	5,488
Fixed income securities at fair value through profit or loss (Note 13)	8	37
Cash collateral pledged to counterparties (Note 13)	22	129
Total derivative financial instruments (Note 14)	90	54
Current assets subject to credit risk	5,831	5,708

Non-current assets

	2025 \$m	2024 \$m
Derivative financial instruments (Note 14)	498	182
Non-current assets subject to credit risk	498	182

The majority of the Group's cash is invested in US dollar AAA-rated money market liquidity funds. The money market liquidity fund portfolios are managed by six external third-party fund managers to maintain an AAA rating. The Group's investments represent no more than 15% of each overall fund value. There were no other significant concentrations of financial credit risk at the reporting date.

All financial derivatives are transacted with commercial banks, in line with standard market practice. The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral, for the benefit of the other, equivalent to the market valuation of the derivative positions above a predetermined threshold. The carrying value of such cash collateral held by the Group at 31 December 2025 was \$473m (2024: \$181m) and the carrying value of such cash collateral posted by the Group at 31 December 2025 was \$22m (2024: \$129m). Cash collateral held by the Group is unencumbered.

The impairment provision for other financial assets at 31 December 2025 was immaterial (2024: immaterial).

Offsetting of financial assets and liabilities

Financial assets and liabilities are offset and the net amount reported in the Consolidated Statement of Financial Position where there is both a legally enforceable right and an intention to settle the balances on a net basis. There are also arrangements that would not normally meet the requirement for offsetting but may be offset in certain circumstances such as the termination of a contract or bankruptcy.

The tables below show the impact on the Consolidated Statement of Financial Position if all offset rights were exercised by the Group or its financial counterparties.

			Related amounts not offset	
	Gross financial assets/(liabilities) \$m	Subject to master netting agreement \$m	Financial instrument collateral \$m	Net amount \$m
31 December 2024				
Financial assets				
Derivatives	236	(45)	(169)	22
Other investments ¹	129	–	(112)	17
Total assets	365	(45)	(281)	39
Financial liabilities				
Derivatives	(165)	45	112	(8)
Other payables ¹	(181)	–	169	(12)
Total liabilities	(346)	45	281	(20)
31 December 2025				
Financial assets				
Derivatives	588	(63)	(448)	77
Other investments ¹	22	–	(17)	5
Total assets	610	(63)	(465)	82
Financial liabilities				
Derivatives	(81)	63	17	(1)
Other payables ¹	(473)	–	448	(25)
Total liabilities	(554)	63	465	(26)

¹ Balances are collateral pledged/received.

Trade receivables

Trade receivable exposures are managed locally in the operating units where they arise and credit limits are set as deemed appropriate for the customer. The Group is exposed to customers ranging from government-backed agencies and large private wholesalers to privately-owned pharmacies, and the underlying local economic and sovereign risks vary throughout the world. Where appropriate, the Group endeavours to minimise risks by the use of trade finance instruments such as letters of credit and insurance. The Group applies the expected credit loss approach to establish an allowance for impairment that represents its estimate of expected losses in respect of Trade receivables.

The Group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance to Trade receivables. To measure expected credit losses, Trade receivables have been grouped based on shared credit characteristics and the days past due.

The expected loss rates are based on payment profiles over a period of 36 months before 31 December 2025 or 31 December 2024 respectively and the corresponding historical credit losses experienced within this period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customer to settle the receivables.

On that basis, the loss allowance was determined as follows:

	Current	0-90 days past due	90-180 days past due	Over 180 days past due	Total
31 December 2024					
Expected loss rate	0.01%	0.6%	3.5%	7.0%	
Gross carrying amount (\$m)	7,679	171	86	399	8,335
Loss allowance (\$m)	1	1	3	28	33
31 December 2025					
Expected loss rate	0.03%	1.8%	3.9%	10.8%	
Gross carrying amount (\$m)	9,529	272	128	360	10,289
Loss allowance (\$m)	3	5	5	39	52

Notes to the Group Financial Statements *continued*

28 Financial risk management objectives and policies *continued*

Trade receivables are written off where there is no reasonable expectation of recovery.

Impairment losses on Trade receivables are presented as net impairment losses within Operating profit, any subsequent recoveries are credited against the same line.

In the US, sales to three wholesalers accounted for approximately 78% (2024: 74%; 2023: 80%) of US sales.

The movements of the Group expected credit losses provision are as follows:

	2025 \$m	2024 \$m	2023 \$m
At 1 January	33	45	59
Net movement recognised in the Consolidated Statement of Comprehensive Income	20	(3)	(14)
Amounts utilised, exchange and other movements	(1)	(9)	–
At 31 December	52	33	45

Given the profile of our customers, including large wholesalers and government-backed agencies, no further credit risk has been identified with the Trade receivables not past due other than those balances for which an allowance has been made.

Hedge accounting

The Group uses foreign currency borrowings, foreign currency forwards and swaps, currency options, interest rate swaps and cross-currency interest rate swaps for the purpose of hedging its foreign currency and interest rate risks. The Group may designate certain financial instruments as fair value hedges, cash flow hedges or net investment hedges in accordance with IFRS 9. Hedge effectiveness is determined at the inception of the hedge relationship, and through periodic prospective effectiveness assessments to ensure that an economic relationship exists between the hedged item and hedging instrument. Sources of hedge effectiveness will depend on the hedge relationship designation but may include:

- a significant change in the credit risk of either party to the hedging relationship
- a timing mismatch between the hedging instrument and the hedged item
- movements in foreign currency basis spread for derivatives in a fair value hedge
- a significant change in the value of the foreign currency-denominated net assets of the Group in a net investment hedge.

The hedge ratio for each designation will be established by comparing the quantity of the hedging instrument and the quantity of the hedged item to determine their relative weighting. For all of the Group's existing hedge relationships, the hedge ratio has been determined as 1:1. Designated hedges are expected to be effective and therefore the impact of ineffectiveness on profit and loss is not expected to be material. The accounting treatment for fair value hedges and debt designated as FVPL is disclosed in the Bank and other borrowings accounting policy in the Group Accounting Policies section from page 134.

The following table represents the Group's continuing designated hedge relationships under IFRS 9.

2023

	Nominal amounts in local currency	Carrying value \$m	Other comprehensive income				Average maturity year	Average USD FX rate	Average pay interest rate
			Opening balance 1 January 2023 \$m	Fair value (gain)/loss deferred to OCI \$m	Fair value (gain)/loss recycled to the Income statement \$m	Closing balance 31 December 2023 \$m			
Cash flow hedges – foreign currency and interest rate risk^{1,3}									
Cross-currency interest rate swaps – Euro bonds	EUR 3,200m	49	34	(210)	139	(37)	2027	1.10	USD 3.80%
FX Forwards – short-term FX risk	USD 2,009m	15	12	(33)	6	(15)	2024	–	–
Net investment hedge – foreign exchange risk^{2,3}									
Transactions matured pre-2023		–	(527)	–	–	(527)	–	–	–
Cross-currency interest rate swap – JPY investment	JPY 58.3bn	100	(55)	(45)	–	(100)	2029	108.03	JPY 1.53%
Cross-currency interest rate swap – CNY investment	CNY 458m	(1)	4	(3)	–	1	2026	6.68	CNY 4.80%
Foreign currency borrowing – GBP investment	GBP 350m	444	(288)	24	–	(264)	2031	n/a	GBP 5.75%
Foreign currency borrowing – EUR investment ⁵	EUR 800m	881	(102)	33	–	(69)	2029	n/a	EUR 0.38%
Contingent consideration liabilities and Acerta Pharma share purchase liability – AZUK and AZAB USD investments	USD 1,937m	(1,937)	2,216	(81)	–	2,135	–	–	–

2024

			Other comprehensive income				Average maturity year	Average USD FX rate	Average pay interest rate
	Nominal amounts in local currency	Carrying value \$m	Opening balance 1 January 2024 \$m	Fair value (gain)/loss deferred to OCI \$m	Fair value (gain)/loss recycled to the Income statement \$m	Closing balance 31 December 2024 \$m			
Cash flow hedges – foreign currency and interest rate risk^{1,3}									
Cross-currency interest rate swaps – Euro bonds	EUR 2,300m	(36)	(37)	151	(180)	(66)	2029	1.08	USD 4.24%
FX Forwards – short-term FX risk	USD 2,252m	4	(15)	8	3	(4)	2025	–	–
Net investment hedge – foreign exchange risk^{2,3}									
Transactions matured pre-2024		–	(527)	–	–	(527)	–	–	–
Cross-currency interest rate swap – JPY investment	JPY 58.3bn	146	(100)	(45)	–	(145)	2029	108.03	JPY 1.53%
Cross-currency interest rate swap – CNY investment	CNY 458m	2	1	(4)	–	(3)	2026	6.68	CNY 4.80%
Foreign currency borrowing – GBP investment	GBP 350m	438	(264)	(7)	–	(271)	2031	n/a	GBP 5.75%
Foreign currency borrowing – EUR investment ⁵	EUR 800m	829	(69)	(52)	–	(121)	2029	n/a	EUR 0.38%
Contingent consideration liabilities and Acerta Pharma share purchase liability – AZUK and AZAB USD investments	USD 1,367m	(1,367)	2,135	181	–	2,316	–	–	–

2025

	Nominal amounts in local currency	Carrying value \$m	Other comprehensive income				Average maturity year	Average USD FX rate	Average pay interest rate
			Opening balance 1 January 2025 \$m	Fair value (gain)/loss deferred to OCI \$m	Fair value (gain)/loss recycled to the Income statement \$m	Closing balance 31 December 2025 \$m			
Cash flow hedges – foreign currency and interest rate risk^{1, 3, 4}									
Cross-currency interest rate swaps – Euro bonds	EUR 2,300m	203	(66)	(242)	305	(3)	2029	1.08	USD 4.24%
FX Forwards – short-term FX risk	USD 1,769m	6	(4)	(11)	9	(6)	2026	–	–
Net investment hedge – foreign exchange risk^{2, 3}									
Transactions matured pre-2025		–	(527)	–	–	(527)	–	–	–
Cross-currency interest rate swap – JPY investment	JPY 58.3bn	171	(145)	(26)	–	(171)	2029	108.03	JPY 1.53%
Cross-currency interest rate swap – CNY investment	CNY 458m	2	(3)	1	–	(2)	2026	6.68	CNY 4.80%
Foreign currency borrowing – GBP investment	GBP 350m	469	(271)	31	–	(240)	2031	n/a	GBP 5.75%
Foreign currency borrowing – EUR investment ⁵	EUR 800m	936	(121)	106	–	(15)	2029	n/a	EUR 0.38%
Contingent consideration liabilities – AZUK and AZAB USD investments	USD 323m	(323)	2,316	(155)	–	2,161	–	–	–

¹ Hedge ineffectiveness recognised on swaps designated in a cash flow hedge during the period was \$nil (2024: \$nil; 2023: \$nil).

² Hedge ineffectiveness recognised on swaps designated in a net investment hedge during the period was \$nil (2024: \$nil; 2023: \$nil).

³ Fair value movements on cross-currency interest rate swaps in cash flow hedge and net investment hedge relationships are shown inclusive of the impact of costs of hedging.

⁴ Nominal amount of FX forwards in a cash flow hedge of \$1,769m represents the USD equivalent notional of the FX forwards. By currency, the nominal amounts were SEK 8,319m at FX rate 9.2158, JPY 14,730m at 156.57, GBP 243m at 0.7430, CNY 1,926m at 6.9901 and EUR 144m at 0.9605. All FX forwards in a cash flow hedge mature on 27 January 2026.

⁵ The EUR 800m 0.375% 2029 Non-callable bond is designated in a net investment hedge of the foreign currency exposure in relation to an equivalent amount of EUR-denominated net assets.

Key controls applied to transactions in derivative financial instruments are to use only instruments where good market liquidity exists, to revalue all financial instruments regularly using current market rates and to sell options only to offset previously purchased options or as part of a risk management strategy. The Group is not a net seller of options, and does not use derivative financial instruments for speculative purposes.

The table below summarises the change in the fair value of hedging instruments and the hedged item designated in a fair value hedging relationship used to calculate ineffectiveness in the period.

As at 31 December 2024	Nominal amounts in currency	Change in fair value of hedging instrument used to calculate ineffectiveness	Change in fair value of hedged item used to calculate ineffectiveness	Hedge ineffectiveness recognised in profit and loss
Interest rate and foreign currency risk on finance debt	EUR 1,400m	(56)	54	(2)
As at 31 December 2025				
Interest rate and foreign currency risk on finance debt	EUR 1,400m	Change in fair value of hedging instrument used to calculate ineffectiveness	Change in fair value of hedged item used to calculate ineffectiveness	Hedge ineffectiveness recognised in profit and loss
		172	(168)	4

Notes to the Group Financial Statements *continued*

29 Employee costs and share plans for employees

Employee costs

The monthly average number of people, to the nearest hundred, employed by the Group is set out in the table below. In accordance with the Companies Act 2006, this includes part-time employees.

	2025	2024	2023
Employees			
UK	10,600	11,100	10,700
Rest of Europe	26,900	25,500	23,000
The Americas	25,200	24,700	22,400
Asia, Africa & Australasia	32,400	31,600	30,300
Continuing operations	95,100	92,900	86,400

Geographical distribution described in the table above is by location of legal entity employing staff. Certain staff will undertake some or all of their activity in a different location.

The number of people employed by the Group at the end of 2025 was 96,100 (2024: 94,300; 2023: 89,900).

The costs incurred during the year in respect of these employees were:

	2025 \$m	2024 \$m	2023 \$m
Wages and salaries	10,974	10,340	9,341
Social security costs	1,348	1,224	1,100
Pension costs	618	614	537
Other employment costs	1,608	1,531	1,357
Total	14,548	13,709	12,335

Severance costs of \$190m are not included above (2024: \$283m; 2023: \$123m).

The charge for share-based payments in respect of share plans is \$719m (2024: \$660m; 2023: \$579m). During 2025, payments totalling \$521m (2024: \$81m) made to the EBT for the purchase of shares are recognised within financing cashflows. Prior to an amendment to the EBT on 10 June 2024, after which AstraZeneca obtained control and commenced consolidation of the EBT, \$354m of payments to the EBT were recognised during 2024 within operating cash flows. The plans are equity settled.

Bonus and share plans

US

In the US, there are two employee short-term, cash settled, performance bonus plans in operation. In addition, the AstraZeneca Performance Share Plan and the AstraZeneca Global Restricted Share Plan, which are both equity settled, operate in respect of relevant employees in the US.

UK

The AstraZeneca UK Performance Bonus Plan

Employees of participating AstraZeneca UK companies are invited to participate in this cash settled bonus plan.

The AstraZeneca UK All-Employee Share Plans

AstraZeneca Share Incentive Plan (SIP)

The Company offers UK employees the opportunity to buy Partnership Shares (Ordinary Shares). Employees may invest up to £150 a month to purchase Partnership Shares in the Company at the current market value. One Matching Share is awarded for every four Partnership Shares purchased. Partnership Shares and Matching Shares are held in the HM Revenue & Customs (HMRC)-approved All-Employee Share Plan. New shares are issued for the purposes of the All-Employee Share Plan.

AstraZeneca Sharesave Plan

The Company provides UK employees with the opportunity to participate in the HMRC-approved Sharesave Plan. Employees can choose between a 3-year or 5-year savings contract, allowing them to contribute a minimum of £5 and a maximum of £500 per month. At the end of the savings term, participants have the option to purchase AstraZeneca shares at a predetermined share price.

Sweden

Bonuses are paid 50% into a fund investing in AstraZeneca equities and 50% in cash, with the exception of certain senior management who are paid 100% in cash.

Other bonus and share plans that operate across the Group are described below.

The AstraZeneca Executive Annual Bonus Scheme

This scheme is a performance bonus scheme for Directors and senior employees who do not participate in the AstraZeneca UK Performance Bonus Plan. Annual bonuses are paid in cash and reflect both corporate and individual performance measures. The Remuneration Committee has discretion to reduce or withhold bonuses if business performance falls sufficiently short of expectations in any year such as to make the payment of bonuses inappropriate.

The AstraZeneca Deferred Bonus Plan

A portion of the bonus earned under the AstraZeneca Executive Annual Bonus Scheme is deferred into AstraZeneca shares in the Company for a period of three years. The plan currently operates only in respect of Executive Directors and members of the SET (with awards granted as AstraZeneca ADRs for members of the SET employed within the US). Awards of shares under this plan are typically made in March each year.

The AstraZeneca Performance Share Plan

This plan was approved by shareholders in 2020 for a period of 10 years, and subsequently amended by approval of shareholders in 2021 and 2024. Generally, awards can be granted at any time, but not during a closed period of the Company. Awards granted under the plan vest after three years, or in the case of Executive Directors and members of the SET, after an additional two-year holding period, and is subject to the achievement of performance conditions. For awards granted to all participants in 2025, vesting is subject to a combination of measures focused on science and innovation, revenue growth, financial performance and carbon reduction. The Remuneration Committee has responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated, including agreeing performance targets and which employees should be eligible to participate.

The AstraZeneca Global Restricted Stock Plan

The Global Restricted Stock Plan (GRSP) was introduced in 2010. This plan provides for the grant of restricted stock unit (RSU) awards to selected below SET-level employees and is used in conjunction with the AstraZeneca Performance Share Plan to provide a mix of RSUs and performance share units (PSUs). Awards typically vest on the third anniversary of the date of grant and are contingent on continued employment with the Company. The Remuneration Committee has responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated.

The AstraZeneca Restricted Share Plan

This plan was introduced in 2008 and provides for the grant of restricted stock unit (RSU) awards to key employees, excluding Executive Directors. Awards are made on an ad hoc basis with variable vesting dates. The plan has been used four times in 2025 to make awards to 1,503 employees. The Remuneration Committee has responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated.

The AstraZeneca Extended Incentive Plan

This plan was introduced in 2018 and provides for the grant of awards to key employees, excluding Executive Directors. Awards are made on an ad hoc basis and 50% of the award will normally vest on the fifth anniversary of grant, with the balance vesting on the tenth anniversary of grant. The award can be subject to the achievement of performance conditions. The Remuneration Committee has responsibility for agreeing any awards under the plan and for setting the policy for the way in which the plan should be operated, including agreeing performance targets (if any) and which employees should be invited to participate.

Alexion employee share award plan

At acquisition in 2021 Alexion employee share awards were converted into AstraZeneca restricted stock awards that continued to have, and were subject to, the same terms and conditions as applied in the corresponding Alexion awards immediately prior to completion. The fair value at the grant date was \$57.54. In 2023 an additional 267,000 shares were issued with a grant date fair value of \$65.62 which vested in 2023. During 2023, 2,060,000 shares vested, 531,000 were forfeited/cancelled and the closing balance of these awards as of 31 December 2023 was 3,022,000. During 2024, 2,047,000 shares vested, 156,000 were forfeited and the closing balance of these awards as of 31 December 2024 was 819,000. During 2025, 792,000 shares vested, 27,000 were forfeited and the closing balance of these awards as of 31 December 2025 was nil. No further awards will be granted under this plan.

Details of share incentive awards outstanding during the year for the main share plans are shown below:

	The AstraZeneca Performance Share Plan		The AstraZeneca Global Restricted Stock Plan		The AstraZeneca Restricted Share Plan		The AstraZeneca Extended Incentive Plan	
	Ordinary Shares '000	ADR Shares '000	Ordinary Shares '000	ADR Shares ¹ '000	Ordinary Shares '000	ADR Shares '000	Ordinary Shares '000	ADR Shares '000
Outstanding at 1 January 2023	3,630	5,724	2,469	11,683	233	678	259	195
Granted	976	2,071	1,185	6,343	208	436	71	95
Forfeited	(148)	(437)	(187)	(1,417)	(20)	(59)	(8)	–
Cancelled	–	–	–	(3)	–	–	–	(34)
Exercised	(813)	(1,470)	(570)	(2,738)	(86)	(288)	(107)	(9)
Outstanding at 31 December 2023	3,645	5,888	2,897	13,868	335	767	215	247
Granted	1,064	2,250	1,262	7,014	100	699	–	–
Forfeited	(137)	(400)	(235)	(1,414)	(8)	(57)	(31)	–
Cancelled	(2)	(2)	–	(6)	(1)	–	–	–
Exercised	(999)	(1,586)	(755)	(3,296)	(88)	(352)	(22)	–
Outstanding at 31 December 2024	3,571	6,150	3,169	16,166	338	1,057	162	247
Granted	904	1,974	1,045	6,428	298	386	–	–
Forfeited	(99)	(553)	(250)	(1,616)	(33)	(214)	–	(48)
Exercised	(986)	(1,781)	(1,030)	(4,809)	(114)	(343)	–	–
Outstanding at 31 December 2025	3,390	5,790	2,934	16,169	489	886	162	199

¹ Shares issued to Alexion employees under the GRSP are covered under the Alexion employee share award below.

Notes to the Group Financial Statements *continued*

29 Employee costs and share plans for employees *continued*

	The AstraZeneca Performance Share Plan		The AstraZeneca Global Restricted Stock Plan		The AstraZeneca Restricted Share Plan		The AstraZeneca Extended Incentive Plan	
	WAFV ¹ pence	WAFV \$	WAFV pence	WAFV \$	WAFV pence	WAFV \$	WAFV pence	WAFV \$
WAFV of 2023 grants	9929	59.95	10822	65.38	11135	65.37	11,748	74.78
WAFV of 2024 grants	9028	57.99	10085	64.91	11111	75.23	–	–
WAFV of 2025 grants	11054	70.34	11961	75.91	12142	78.96	–	–

¹ Weighted average fair value.

The weighted average fair value for awards granted under the AstraZeneca Performance Share Plan is primarily based on the market price at the point of grant adjusted for the market-based performance elements which are valued using a Monte Carlo valuation model. The fair values of all other plans are set using the market price at the point of award. These awards are settled in equity including dividends accumulated from the date of award to vesting.

30 Commitments, contingent liabilities and contingent assets

Commitments	2025 \$m	2024 \$m
Contracts placed for future capital expenditure on Property, plant and equipment and software development costs not provided for in these Financial Statements	1,727	1,575

Guarantees and contingencies arising in the ordinary course of business, for which no security has been given, are not expected to result in any material financial loss.

Research and development collaboration payments

The Group has various ongoing collaborations, including in-licensing and similar arrangements with development partners. Such collaborations may require the Group to make payments on achievement of stages of development, launch or revenue milestones, although the Group generally has the right to terminate these agreements at no cost. The Group recognises research and development milestones as an intangible asset once it is committed to payment, which is generally when the Group reaches set trigger points in the development cycle. Revenue-related milestones are recognised as intangible assets on product launch at a value based on the Group's long-term revenue forecasts for the related product. The table below indicates potential development and revenue-related payments that the Group may be required to make under such collaborations.

	Total \$m	Under 1 year \$m	Years 1 and 2 \$m	Years 3 and 4 \$m	Years 5 and greater \$m
Future potential research and development milestone payments	10,182	1,226	3,698	3,013	2,245
Future potential revenue milestone payments	21,301	45	1,290	4,742	15,224

The table includes all potential payments for achievement of milestones under ongoing research and development arrangements. Revenue-related milestone payments represent the maximum possible amount payable on achievement of specified levels of revenue as set out in individual contract agreements, but exclude variable payments that are based on unit sales (e.g. royalty-type payments) which are expensed as the associated sale is recognised. The table excludes any payments already capitalised in the Financial Statements for the year ended 31 December 2025 which have been capitalised with reference to the latest Group sales forecasts for approved indications.

The future payments we disclose represent contracted payments and, as such, are not discounted and are not risk-adjusted. As detailed in the Risk Overview section from page 47, the development of any pharmaceutical product candidate is a complex and risky process that may fail at any stage in the development process due to a number of factors (including items such as failure to obtain regulatory approval, unfavourable data from key studies, adverse reactions to the product candidate or indications of other safety concerns). The timing of the payments is based on the Group's current best estimate of achievement of the relevant milestone.

Environmental costs and liabilities

The Group's expenditure on environmental protection, including both capital and revenue items, relates to costs that are necessary for implementing internal systems and programmes, and meeting legal and regulatory requirements for processes and products. This includes investment to conserve natural resources and otherwise minimise the impact of our activities on the environment. They are an integral part of normal ongoing expenditure for carrying out the Group's research, manufacturing and commercial operations and are not separated from overall operating and development costs. There are no known changes in legal, regulatory or other requirements resulting in material changes to the levels of expenditure for 2023, 2024 or 2025.

In addition to expenditure for meeting current and foreseen environmental protection requirements, the Group incurs costs in investigating and cleaning up legacy land and groundwater contamination. In particular, AstraZeneca has environmental liabilities at some currently or formerly owned, leased and third-party sites.

In the US, Zeneca Inc., and/or its indemnitees, have been named as potentially responsible parties (PRPs) or defendants at a number of sites where Zeneca Inc. is likely to incur future environmental investigation, remediation, operation and maintenance costs under federal, state, statutory or common law environmental liability allocation schemes (together, US Environmental Consequences). Similarly, Stauffer Management Company LLC (SMC), which was established to own and manage certain assets and liabilities of Stauffer Chemical Company, and/or its indemnitees, have been named as PRPs or defendants at a number of sites where SMC is likely to incur US Environmental Consequences.

AstraZeneca has also given indemnities to third parties for a number of sites outside the US. These environmental liabilities arise from legacy operations that are not currently part of the Group's business and, at most of these sites, remediation, where required, is either completed or in progress. AstraZeneca has made provisions for the estimated costs of future environmental investigation, remediation, operation and maintenance activity beyond normal ongoing expenditure for maintaining the Group's R&D and manufacturing capacity and product ranges, where a present obligation exists, it is probable that such costs will be incurred and they can be estimated reliably. With respect to such estimated future costs, there were provisions at 31 December 2025 in the aggregate of \$107m (2024: \$105m), mainly relating to the US. Where we are jointly liable or otherwise have cost-sharing agreements with third parties, we reflect only our share of the obligation. Where the liability is insured in part or in whole by insurance or other arrangements for reimbursement, an asset is recognised to the extent that this recovery is virtually certain.

It is possible that AstraZeneca could incur future environmental costs beyond the extent of our current provisions. The extent of such possible additional costs is inherently difficult to estimate due to a number of factors, including: (1) the nature and extent of claims that may be asserted in the future; (2) whether AstraZeneca has or will have any legal obligation with respect to asserted or unasserted claims; (3) the type of remedial action, if any, that may be selected at sites where the remedy is presently not known; (4) the potential for recoveries from or allocation of liability to third parties; and (5) the length of time that the environmental investigation, remediation and liability allocation process can take. As per our Provisions accounting policy on page 135, Provisions for these costs are made when there is a present obligation and where it is probable that expenditure on remedial work will be required and a reliable estimate can be made of the cost. Notwithstanding and subject to the foregoing, we estimate the potential additional loss for future environmental investigation, remediation, remedial operation and maintenance activity above and beyond our provisions to be, in aggregate, between \$115m and \$192m (2024: \$113m and \$190m) which relates mainly to the US.

Legal proceedings

AstraZeneca is involved in various legal proceedings considered typical to its business, including actual or threatened litigation and actual or potential government investigations relating to employment matters, product liability, commercial disputes, pricing, sales and marketing practices, infringement of IP rights, and the validity of certain patents and competition laws. The more significant matters are discussed below.

Most of the claims involve highly complex issues. Often these issues are subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an estimate of the amount of any loss is difficult to ascertain.

Unless specifically identified below that a provision has been taken, AstraZeneca considers each of the claims to represent a contingent liability and discloses information with respect to the nature and facts of the cases in accordance with IAS 37 'Provisions, Contingent Liabilities and Contingent Assets'.

We do not believe that disclosure of the amounts sought by plaintiffs, if known, would be meaningful with respect to these legal proceedings. This is due to a number of factors, including (i) the stage of the proceedings (in many cases trial dates have not been set) and the overall length and extent of pre-trial discovery; (ii) the entitlement of the parties to an action to appeal a decision; (iii) clarity as to theories of liability, damages and governing law; (iv) uncertainties in timing of litigation; and (v) the possible need for further legal proceedings to establish the appropriate amount of damages, if any.

While there can be no assurance regarding the outcome of any of the legal proceedings referred to in this Note 30, based on management's current and considered view of each situation, we do not currently expect them to have a material adverse effect on our financial position including within the next financial year. This position could of course change over time, not least because of the factors referred to above.

In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed and which are not subject to appeal (or other similar forms of relief), or where a loss is probable and we are able to make a reasonable estimate of the loss, we generally indicate the loss absorbed or make a provision for our best estimate of the expected loss.

Where it is considered that the Group is more likely than not to prevail, legal costs involved in defending the claim are charged to profit as they are incurred.

Where it is considered that the Group has a valid contract which provides the right to reimbursement (from insurance or otherwise) of legal costs and/or all or part of any loss incurred or for which a provision has been established, and we consider recovery to be virtually certain, the best estimate of the amount expected to be received is recognised as an asset.

KJ Assessments as to whether or not to recognise provisions or assets, and of the amounts concerned, usually involve a series of complex judgements about future events and can rely heavily on estimates and assumptions. AstraZeneca believes that the provisions recorded are adequate based on currently available information and that the insurance recoveries recorded will be received. However, given the inherent uncertainties involved in assessing the outcomes of these cases, and in estimating the amount of the potential losses and the associated insurance recoveries, we could in the future incur judgments or insurance settlements that could have a material adverse effect on our results in any particular period.

IP claims include challenges to the Group's patents on various products or processes and assertions of non-infringement of patents. A loss in any of these cases could result in loss of patent protection on the related product.

Notes to the Group Financial Statements *continued*

30 Commitments, contingent liabilities and contingent assets *continued*

The consequences of any such loss could be a significant decrease in Product Sales, which could have a material adverse effect on our results. The lawsuits filed by AstraZeneca for patent infringement against companies that have filed abbreviated new drug applications (ANDAs) in the US, seeking to market generic forms of products sold by the Group prior to the expiry of the applicable patents covering these products, typically also involve allegations of non-infringement, invalidity and unenforceability of these patents by the ANDA filers. In the event that the Group is unsuccessful in these actions or the statutory 30-month stay expires before a ruling is obtained, the ANDA filers involved will also have the ability, subject to US Food and Drug Administration (FDA) approval, to introduce generic versions of the product concerned.

AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP.

Over the course of the past several years, including in 2025, a significant number of commercial litigation claims in which AstraZeneca is involved have been resolved, particularly in the US, thereby reducing potential contingent liability exposure arising from such litigation. Similarly, in part due to patent litigation and settlement developments, greater certainty has been achieved regarding possible generic entry dates with respect to some of our patented products. At the same time, like other companies in the pharmaceutical sector and other industries, AstraZeneca continues to be subject to government investigations around the world.

Patent litigation

Legal proceedings brought against AstraZeneca

Enhertu patent proceedings	Considered to be a contingent liability
US	- In October 2020, Seagen Inc. (Seagen) filed a complaint against Daiichi Sankyo Company, Limited (Daiichi Sankyo) in the US District Court for the Eastern District of Texas (District Court) alleging that <i>Enhertu</i> infringes a Seagen patent. AstraZeneca co-commercialises <i>Enhertu</i> with Daiichi Sankyo in the US. After trial in April 2022, the jury found that the patent was infringed and awarded Seagen \$41.82m in past damages. In July 2022, the District Court entered final judgment and declined to enhance damages on the basis of wilfulness. In October 2023, the District Court entered an amended final judgment that requires Daiichi Sankyo to pay Seagen a royalty of 8% on US sales of <i>Enhertu</i> from 1 April 2022 through to 4 November 2024, in addition to the past damages previously awarded by the District Court. AstraZeneca and Daiichi Sankyo have appealed the District Court's decision. - In December 2020 and January 2021, AstraZeneca and Daiichi Sankyo filed post-grant review (PGR) petitions with the US Patent and Trademark Office (USPTO) alleging, among other things, that the Seagen patent is invalid for lack of written description and enablement. The USPTO initially declined to institute the PGRs, but, in April 2022, the USPTO granted the rehearing requests and instituted both PGR petitions. Seagen subsequently disclaimed all patent claims at issue in one of the PGR proceedings. In July 2022, the USPTO reversed its institution decision and declined to institute the other PGR petition. AstraZeneca and Daiichi Sankyo requested reconsideration of the decision not to institute review of the patent. In February 2023, the USPTO reinstituted the PGR proceeding. In February 2024, the USPTO issued a decision that the claims were unpatentable. Seagen has appealed this decision; the USPTO has intervened in the appeal. - In December 2025, the US Court of Appeals for the Federal Circuit issued decisions in both the District Court and PGR appeals finding that Seagen's patent is invalid and vacating the District Court's prior judgment and damages award.
Factor Bioscience patent proceedings	Considered to be a contingent liability
US	- In September 2025, Factor Bioscience Inc. (Factor) filed a complaint against AstraZeneca, and others in the US District Court for the District of Delaware, alleging infringement of several Factor patents related to technology for producing gene-edited cells using synthetic messenger ribonucleic acid (mRNA) molecules encoding transcription activator-like effector nuclease (TALEN) gene-editing proteins. - The complaint alleges that certain drug research, design and development activities by AstraZeneca and others infringe Factor's patents.
Forxiga patent proceedings	Considered to be a contingent liability
Europe	- In November 2025, in France, Biogaran SAS challenged one of AstraZeneca's patents covering <i>Forxiga</i>. No trial date has been set. - In Poland and in Portugal, multiple generic companies have challenged one of AstraZeneca's patents covering <i>Forxiga</i>. No trial date has been set. - In Poland, in January 2026, AstraZeneca obtained interim injunctions against the generic companies that have challenged the patent.
Forxiga patent proceedings	Matter concluded
UK	- In the UK, one of AstraZeneca's patents relating to <i>Forxiga</i> was challenged by Generics (UK) Limited, Teva Pharmaceutical Industries Limited, and Glenmark Pharmaceuticals Europe Limited. - Trial regarding patent validity occurred in March 2025. In April 2025, the UK Patents Court held the patent invalid. AstraZeneca appealed the decision. In July 2025, the UK Court of Appeal dismissed AstraZeneca's appeal and upheld the lower court's invalidity decision. AstraZeneca's application for permission to appeal to the UK Supreme Court was denied. - In March 2025 and onward, AstraZeneca obtained injunctions against generic manufacturers' at-risk sales of dapagliflozin products in the UK. All injunctions have since been lifted. - This matter has concluded.

Soliris patent proceedings	Considered to be a contingent liability
Turkey	In November 2024, Salute HC İlaçları Sanayi ve Ticaret A.Ş served an action in the Industrial and Intellectual Property Rights Court in Turkey seeking to invalidate and enjoin enforcement of AstraZeneca's patent relating to eculizumab.
Tagrisso patent proceedings	Considered to be a contingent liability
China	- In January 2025, an individual filed invalidity challenges against several Chinese patents protecting <i>Tagrisso</i>. - A hearing before the Chinese Patent Office (Patent Office) was held in July 2025. - In November 2025, the Patent Office issued decisions maintaining the compound patents. - In January 2026, the Patent Office dismissed the invalidity case against the formulation patent.
Tagrisso patent proceedings	Considered to be a contingent liability
US	- In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a patent infringement lawsuit in the US District Court for the District of Delaware (District Court) against AstraZeneca relating to <i>Tagrisso</i>. In March 2024, the District Court dismissed Puma. - The jury trial, with Wyeth as the plaintiff, took place in May 2024. The jury found Wyeth's patents infringed and awarded Wyeth \$107.5m in past damages. The jury also found that the infringement was not wilful. - In proceedings following the jury award, the District Court rejected AstraZeneca's indefiniteness and equitable defences but granted judgment as a matter of law in favour of AstraZeneca on the grounds that the patents were invalid for lack of written description and enablement. - Wyeth has filed an appeal.
Legal proceedings brought by AstraZeneca	
Brilinta patent proceedings	Considered to be a contingent asset
US	- In 2015 and subsequently, in response to Paragraph IV notices from ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of Delaware (District Court). In its complaints, AstraZeneca alleged that a generic version of <i>Brilinta</i>, if approved and marketed, would infringe patents that are owned or licensed by AstraZeneca. - In 2024, AstraZeneca entered into separate settlements and the District Court entered consent judgments to dismiss each of the corresponding litigations. - Additional proceedings are ongoing in the District Court. - No trial date has been set.
Calquence patent proceedings	Considered to be a contingent asset
US	- AstraZeneca received Paragraph IV notices relating to patents listed in the FDA Orange Book with reference to <i>Calquence</i> tablets from Cipla USA, Inc. and Cipla Limited (collectively, Cipla) in April 2024 and from MSN Pharmaceuticals Inc. and MSN Laboratories Pvt. Ltd. (collectively, MSN) in November 2024. - In response to these Paragraph IV notices, AstraZeneca filed patent infringement lawsuits against Cipla in May 2024 and against MSN in January 2025 in the US District Court for the District of Delaware (District Court). In the complaints, AstraZeneca alleges that a generic version of <i>Calquence</i> tablets, if approved and marketed, would infringe patents that are owned or licensed by AstraZeneca. Trial has been scheduled for April 2027. - In December 2025, AstraZeneca entered into a settlement agreement with MSN and the District Court dismissed the corresponding litigation. The litigation with Cipla is ongoing.
Daliresp patent litigation	Considered to be a contingent asset
US	- In 2015 and subsequently, in response to Paragraph IV notices from ANDA filers, AstraZeneca filed patent infringement lawsuits in the US District Court for the District of New Jersey (District Court) relating to patents listed in the FDA Orange Book with reference to <i>Daliresp</i>. - AstraZeneca has entered into separate settlement agreements and the District Court entered a consent judgment to dismiss the corresponding litigation. Additional ANDA challenges are pending.
Farxiga patent proceedings	Considered to be a contingent asset
US	- In May 2021, AstraZeneca proceeded to trial against ANDA filer Zydus Pharmaceuticals (USA) Inc. (Zydus) in the US District Court for the District of Delaware (District Court). In October 2021, the District Court issued a decision finding the asserted claims of AstraZeneca's patent as valid and infringed by Zydus's ANDA product. In August 2022, Zydus appealed the District Court decision. Zydus's appeal has been dismissed. - In December 2023, AstraZeneca initiated ANDA litigation against Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. in the District Court. No trial date has been set.
Forxiga patent proceedings	Considered to be a contingent asset
Australia	- In December 2025, in the Federal Court of Australia, AstraZeneca initiated patent infringement litigation against Pharmacor Pty Limited in reference to one of the patents that protects <i>Forxiga</i>. - No trial date has been set.

Notes to the Group Financial Statements *continued*

30 Commitments, contingent liabilities and contingent assets *continued*

Lokelma patent proceedings	Matter concluded
US	- In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA litigation against five generic filers in the US District Court for the District of Delaware. - AstraZeneca alleged that a generic version of <i>Lokelma</i> would infringe patents that are owned or licensed by AstraZeneca. - AstraZeneca has entered into separate settlement agreements with the five generic manufacturers which resulted in dismissal of the corresponding litigations. - This matter is now concluded.
Lynparza patent proceedings	Considered to be a contingent asset
Canada	- In July 2025, AstraZeneca was served with a Notice of Allegation from Cipla Ltd. challenging a patent relating to <i>Lynparza</i>. AstraZeneca commenced an action in response in August 2025. Trial is scheduled to begin in April 2027. - In August 2025, AstraZeneca was served with a Notice of Allegation from Natco Pharma (Canada) Inc. challenging a patent relating to <i>Lynparza</i>. AstraZeneca commenced an action in response in October 2025. Trial is scheduled to begin in June 2027. - In November 2025, AstraZeneca was served with a Notice of Allegation from Zydus Lifesciences Limited challenging a patent relating to <i>Lynparza</i>. AstraZeneca commenced an action in response in December 2025. No trial date has been set.
Lynparza patent proceedings	Considered to be a contingent asset
US	- AstraZeneca received a Paragraph IV notice relating to <i>Lynparza</i> patents from Natco Pharma Limited (Natco) in December 2022, Sandoz Inc. (Sandoz) in December 2023, Cipla USA, Inc. and Cipla Limited (collectively, Cipla) in May 2024, and Zydus Pharmaceuticals (USA) Inc. (Zydus) in November 2024. - In response to these Paragraph IV notices, AstraZeneca, MSD International Business GmbH, and the University of Sheffield initiated ANDA litigations against Natco, Sandoz, Cipla, and Zydus in the US District Court for the District of New Jersey. In the complaints, AstraZeneca alleged that the defendants' generic versions of <i>Lynparza</i>, if approved and marketed, would infringe AstraZeneca's patents. - No trial date has been scheduled.
Soliris patent proceedings	Matter concluded
Canada	- In May 2023, AstraZeneca initiated patent litigation in Canada alleging that Amgen Canada Inc.'s (Amgen) biosimilar eculizumab product infringed AstraZeneca's patents. - In September 2023, AstraZeneca initiated patent litigations in Canada alleging that Samsung Bioepis Co. Ltd.'s (Samsung) biosimilar eculizumab product infringed AstraZeneca's patents. - In June and November 2025, AstraZeneca settled with Samsung and Amgen, respectively.
Soliris patent proceedings	Matter concluded
Europe	In March 2024, AstraZeneca filed motions for provisional measures against the relevant corporate entities of Amgen Inc. (Amgen) and Samsung Bioepis Co. Ltd. (Samsung) at the Hamburg Local Division of the Unified Patent Court (UPC) on the basis that Amgen's and Samsung's biosimilar eculizumab products infringe an AstraZeneca patent. In November 2025 and January 2026, AstraZeneca entered into global settlement agreements with Amgen and Samsung, respectively, resolving all eculizumab patent disputes between the parties.
Soliris patent proceedings	Matter concluded
UK	- In May 2024, AstraZeneca initiated patent infringement proceedings against Amgen Ltd. (Amgen) and Samsung Bioepis UK Limited (Samsung) in the UK High Court of Justice alleging that their respective biosimilar eculizumab products infringe an AstraZeneca patent; on the same day, Samsung initiated a revocation action for the same patent. - In November 2025 and January 2026, AstraZeneca settled the UK eculizumab patent matters with Amgen and Samsung, respectively.

Tagrisso patent proceedings	Considered to be a contingent asset
Russia	- In August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the Moscow region (Court) against the Russian Ministry of Health (MOH) and Axelpharm LLC (Axelpharm) for improper use of AstraZeneca information in the authorisation of a generic version of <i>Tagrisso</i>. The suit against the MOH was dismissed in July 2024, after two appeals. The case against Axelpharm was dismissed in September 2024, and a subsequent appeal by AstraZeneca was also dismissed. - In November 2023, Axelpharm sought a compulsory licence under a patent related to <i>Tagrisso</i>; the action remains pending. The Axelpharm patent on which the compulsory licensing action was based was held invalid by the Russian Patent and Trademark Office (PTO) in August 2024 following challenge by AstraZeneca. The PTO's decision was upheld in June 2025, following an appeal by Axelpharm. At a further appeal hearing in November 2025, the Intellectual Property Court Presidium reversed earlier decisions and held Axelpharm's patent valid. In January 2026, AstraZeneca appealed to the Supreme Court, which was rejected. AstraZeneca expects to file a further appeal. - In July 2024, AstraZeneca filed a patent infringement claim against Axelpharm in relation to a generic version of <i>Tagrisso</i>. The action was stayed by the court pending resolution of the compulsory licensing action. - In August 2024, after AstraZeneca filed a complaint, the Federal Anti-Monopoly Service of Russia (FAS) initiated a case against Axelpharm and OncoTarget LLC (OncoTarget). In November 2024, the FAS found Axelpharm (but not OncoTarget) to have committed unfair competition. In June 2025, the finding against Axelpharm was reversed on appeal. In December 2025, on appeal by AstraZeneca, the appellate decision was affirmed. Also in December 2025, AstraZeneca filed a further appeal.

Product liability litigation

Legal proceedings brought against AstraZeneca

Farxiga and Xigduo XR	Considered to be a contingent liability
US	- AstraZeneca has been named as a defendant in lawsuits involving plaintiffs claiming physical injury, including Fournier's Gangrene and necrotising fasciitis, from treatment with <i>Farxiga</i> and/or <i>Xigduo XR</i>. - The parties have reached a settlement in principle for a non-material amount to resolve the single case scheduled for trial in March 2026. - All remaining claims are filed in Delaware State Court and the earliest trial is now scheduled for September 2026.
Nexium and Prilosec	A provision has been taken
US	- AstraZeneca has defended lawsuits brought in federal and state courts involving claims that plaintiffs have been diagnosed with various injuries following treatment with proton pump inhibitors (PPIs), including <i>Nexium</i> and <i>Prilosec</i>. Most of the lawsuits alleged kidney injury. - Between 2022 and 2024, AstraZeneca resolved the claims by way of settlement agreements. - A relatively small number of plaintiffs have opted out of the settlement.
Nexium and Losec	Matter concluded
Canada	- In Canada, in July and August 2017, AstraZeneca was served with three putative class action lawsuits. - As of September 2025, all three lawsuits have been dismissed. - The Canada proceedings are concluded.
Vaxzevria	Considered to be a contingent liability
UK	- AstraZeneca is defending lawsuits in multiple jurisdictions, including the UK, involving multiple claimants alleging injuries following vaccination with AstraZeneca's COVID-19 vaccine. Most of the lawsuits involve claims of thrombosis with thrombocytopenia syndrome. - No trial dates have been scheduled.

Commercial litigation

Legal proceedings brought against AstraZeneca

340B Antitrust litigation	Considered to be a contingent liability
US	- In September 2021, AstraZeneca was served with a class-action antitrust complaint filed in the US District Court for the Western District of New York (District Court) by Mosaic Health, Inc. alleging a conspiracy to restrict access to 340B discounts in the diabetes market through contract pharmacies. In September 2022, the District Court granted AstraZeneca's motion to dismiss the complaint. In February 2024, the District Court denied Plaintiffs' request to file an amended complaint and entered an order closing the matter. In March 2024, Plaintiffs filed an appeal. - In August 2025, the US Court of Appeals for the Second Circuit decided in the plaintiffs' favour, ordering the District Court to accept the amended complaint.
Amyndas Trade Secrets Litigation	Considered to be a contingent liability
US	- AstraZeneca has been defending a matter filed by Amyndas Pharmaceuticals Member P.C. and Amyndas Pharmaceuticals, LLC (collectively Amyndas), in the US District Court for the District of Massachusetts alleging trade secret misappropriation and breach of contract claims against AstraZeneca and Zealand Pharma U.S. Inc. related to Amyndas' C3 inhibitor candidate. - No trial date has been scheduled.

Notes to the Group Financial Statements *continued*

30 Commitments, contingent liabilities and contingent assets *continued*

Anti-Terrorism Act Civil Lawsuit Considered to be a contingent liability

- | | |
|----|---|
| US | <ul style="list-style-type: none"> In the US, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device companies were named as defendants in a complaint filed in the US District Court for the District of Columbia (District Court) by US nationals (or their estates, survivors, or heirs) who were killed or wounded in Iraq between 2005 and 2013. The plaintiffs allege that the defendants violated the US Anti-Terrorism Act and various state laws by selling pharmaceuticals and medical supplies to the Iraqi Ministry of Health. In July 2020, the District Court granted AstraZeneca's and the other defendants' motion to dismiss the lawsuit, which the DC Circuit Court of Appeals (the Appellate Court) reversed in January 2022. In June 2024, the United States Supreme Court issued an order vacating the 2022 decision and remanding to the Appellate Court for reconsideration under new case law. In January 2026, after reconsideration, the Second Circuit issued a decision again allowing the claims to proceed and returning the matter to the District Court, where AstraZeneca has a separate motion to dismiss pending. |
|----|---|

Definiens Considered to be a contingent liability

- | | |
|---------|--|
| Germany | <ul style="list-style-type: none"> In July 2020, AstraZeneca received a notice of arbitration filed with the German Institution of Arbitration from the sellers of Definiens AG (Sellers) regarding the 2014 share purchase agreement (SPA) between AstraZeneca and the Sellers. The Sellers claim that they are owed approximately \$140m in earn-outs under the SPA. In December 2023, after an arbitration hearing, the arbitration panel made a final award of \$46m in favour of the Sellers. In March 2024, AstraZeneca filed an application with the Bavarian Supreme Court (Court) to set aside the arbitration award. In April 2025, the Court ruled in favour of AstraZeneca, annulled the arbitration award, and referred the dispute back to the same arbitration panel for a second determination. In May 2025, the Sellers appealed the Court's decision to the German Federal Court of Justice (Court of Justice). AstraZeneca also appealed the decision to refer the dispute back to the same arbitration panel. In January 2026, the Court of Justice upheld the Court's decision to annul the arbitration award and referred the dispute back to the same arbitration panel. |
|---------|--|

Employment Litigation Considered to be a contingent liability

- | | |
|----|---|
| US | <ul style="list-style-type: none"> AstraZeneca is defending against numerous other litigation matters pending in federal and state courts asserting claims of discrimination in connection with AstraZeneca's vaccine requirement. All but one claim has been resolved by settlement or disposed of by motion practice. |
|----|---|

Novartis Advertising Litigation Considered to be a contingent liability

- | | |
|----|---|
| US | <ul style="list-style-type: none"> In October 2025, Novartis Pharmaceuticals Corp. filed a lawsuit in the US District Court for the District of Delaware alleging false and misleading representation claims under the Lanham Act and state law unfair competition and deceptive practices claims. The complaint alleges that statements in AstraZeneca's marketing for treatment for paroxysmal nocturnal hemoglobinuria are false and misleading. |
|----|---|

Pay Equity Litigation Considered to be a contingent liability

- | | |
|----|--|
| US | <ul style="list-style-type: none"> AstraZeneca is defending a putative class and collective action in the US District Court for the Northern District of Illinois (District Court) brought by three named plaintiffs, who are former AstraZeneca employees. The case involves claims under the federal and Illinois Equal Pay Acts, with the plaintiffs alleging they were paid less than male employees who performed substantially similar and/or equal work. In May 2024, the District Court conditionally certified a collective under the federal Equal Pay Act and authorised the sending of notice to potential collective action members. The notice was distributed in June 2024, and the opt-in period has closed. |
|----|--|

Securities Litigation Considered to be a contingent liability

- | | |
|----|--|
| US | <ul style="list-style-type: none"> In December 2024, a putative securities class action lawsuit was filed in the US District Court for the Central District of California against AstraZeneca PLC and certain officers, on behalf of purchasers of AstraZeneca publicly traded securities between February 2022 and December 2024. The case was subsequently transferred to the US District Court for the Southern District of New York. |
|----|--|

Seroquel XR Antitrust Litigation Matter concluded

- | | |
|----|---|
| US | <ul style="list-style-type: none"> In 2019, AstraZeneca was named in several related complaints in US District Court in Delaware (District Court), including several putative class action lawsuits brought on behalf of classes of direct purchasers or end payors of Seroquel XR, alleging AstraZeneca and generic drug manufacturers violated US antitrust laws when settling patent litigation related to Seroquel XR. In July 2022, the District Court dismissed claims relating to one of the generic manufacturers while allowing claims relating to the second generic manufacturer to proceed. In September 2024, AstraZeneca reached a settlement agreement with one of the plaintiff classes which the court approved. In May 2025, AstraZeneca resolved the matter with all remaining plaintiffs for a total payment of \$97m. In September 2025, the District Court approved the class-related portion of the settlement. This matter is now concluded. |
|----|---|

Soliris Antitrust Class Action	Considered to be a contingent liability
US	- In April 2025, AstraZeneca was named in a lawsuit filed in the US District Court for the District of Massachusetts (District Court) alleging antitrust claims on behalf of a potential class of end payors for <i>Soliris</i> from March 2022. - The plaintiff alleges that AstraZeneca violated federal and state antitrust and business practices laws by obtaining improper patents for <i>Soliris</i>, delaying biosimilar entry and improperly extending <i>Soliris</i>' market exclusivity. - In December 2025, the District Court partially granted AstraZeneca's motion to dismiss.
Syntimmune Milestone Litigation	Considered to be a contingent liability
US	- In connection with AstraZeneca's acquisition of Syntimmune, Inc. (Syntimmune) in December 2020, AstraZeneca was served with a lawsuit filed by the stockholders' representative for Syntimmune in Delaware State Court (Court) that alleged, among other things, breaches of the 2018 merger agreement (Merger Agreement). - The stockholders' representative alleges that AstraZeneca failed to meet its obligations under the Merger Agreement to use commercially reasonable efforts to achieve the milestones. AstraZeneca also filed a claim for breach of the representations in the Merger Agreement. - A trial was held in July 2023. - In September 2024, the Court issued a partial decision, concluding that the first milestone in the amount of \$130m was achieved, and that AstraZeneca had breached its contractual obligation to use commercially reasonable efforts to achieve the milestones. The Court requested additional briefing regarding damages and further proceedings regarding AstraZeneca's claim for breach. - In June 2025, the Court issued a further partial decision awarding an additional \$181m in damages on its September 2024 breach determination. - Additional proceedings regarding AstraZeneca's claim are ongoing.
University of Sheffield Contract Dispute	Considered to be a contingent liability
UK	- In June 2024, AstraZeneca was served with a lawsuit filed by the University of Sheffield (Sheffield). In its complaint, Sheffield alleges that AstraZeneca made misrepresentations to induce Sheffield to amend a patent licence agreement relating to <i>Lynparza</i>. - Trial has been scheduled to begin in June 2026.
Viela Bio, Inc. Shareholder Litigation	Matter concluded
US	- In February 2023, AstraZeneca was served with a lawsuit filed in the Delaware State Court (Court) against AstraZeneca and certain officers (collectively, Defendants), on behalf of a putative class of Viela Bio, Inc. (Viela) shareholders. The complaint alleged that the Defendants breached their fiduciary duty to Viela shareholders in the course of Viela's 2021 merger with Horizon Therapeutics, plc. - In July 2024, the Court granted with prejudice AstraZeneca's motion to dismiss. - In August 2024, plaintiffs appealed the dismissal. - In March 2025, the Delaware Supreme Court affirmed the dismissal. - This matter is now concluded.
Legal proceedings brought by AstraZeneca	
PARP Inhibitor Royalty Dispute	Considered to be a contingent asset
UK	- In October 2012, Tesaro, Inc. (now wholly owned by GlaxoSmithKline plc (GSK)) entered into two worldwide, royalty-bearing patent license agreements with AstraZeneca related to GSK's product, niraparib. - In May 2021, AstraZeneca filed a lawsuit against GSK in the Commercial Court of England and Wales (Trial Court) alleging that GSK had failed to pay all of the royalties due on niraparib sales under the license agreements. - In April 2023, after trial, the Trial Court issued a decision in AstraZeneca's favour. - In February 2024, the Court of Appeal reversed the decision. - In March 2024, AstraZeneca filed a request for permission to appeal with the Supreme Court of the United Kingdom. In May 2024, the Supreme Court denied permission to appeal. - The case will return to the Trial Court for further proceedings.

Notes to the Group Financial Statements *continued*

30 Commitments, contingent liabilities and contingent assets *continued*

Government investigations and proceedings

Legal proceedings brought against AstraZeneca

340B Qui Tam	Considered to be a contingent liability
US	- In July 2023, AstraZeneca was served with an unsealed civil lawsuit brought by a qui tam relator on behalf of the United States, several states, and the District of Columbia in the US District Court for the Central District of California (District Court). The complaint alleges that AstraZeneca violated the US False Claims Act and state law analogues. In March 2024, the District Court granted AstraZeneca's motion to dismiss the First Amended Complaint without leave to amend. - In April 2024, the relator filed an appeal.
Beyfortus Civil Investigative Demand	Considered to be a contingent liability
US	- In March 2025, AstraZeneca received a subpoena from the US Attorney's Office seeking certain records relating to <i>Beyfortus</i>. The subpoena requests that the Company produce various documents from January 2020 to present, including communications related to specific batches of <i>Beyfortus</i>, customer complaints, and FDA inspection reports. - AstraZeneca is cooperating with this enquiry.
Boston US Attorney Investigation	Considered to be a contingent liability
US	- In June 2024, AstraZeneca was served with a subpoena issued by the US Attorney's Office in Boston, seeking documents and information relating to payments by AstraZeneca to healthcare providers. - AstraZeneca is cooperating with this enquiry.
Brazilian Tax Assessment Matter	Considered to be a contingent liability
Brazil	- In connection with an ongoing matter, in August 2019, the Brazilian Federal Revenue Service provided a Notice of Tax and Description of the Facts (the Tax Assessment) to two AstraZeneca subsidiaries in Brazil, as well as to two additional entities, a logistics provider utilised by AstraZeneca and a distributor. The Tax Assessment focuses on the importation of <i>Soliris</i> vials pursuant to AstraZeneca's free drug supply to patients' programme in Brazil. - AstraZeneca prevailed in the first level of administrative appeals in the Brazilian federal administrative proceeding system. The decision was subject to an automatic appeal to the second level of the administrative courts. - In March 2023, the second level of the administrative courts issued a decision to remand the matter to the first level of administrative courts for a determination on the merits.
China Personal Information Infringement and Illegal Trade Matters	Considered to be a contingent liability
China	- In relation to the personal information infringement allegation, in April 2025, AstraZeneca Investment (China) Co., Ltd. received a Notice of Transfer to the Prosecutor from the Shenzhen Bao'an District Public Security Bureau regarding suspected unlawful collection of personal information. - In relation to the illegal trade allegation, in October 2025, AstraZeneca Investment (China) Co., Ltd. received a final appraisal opinion from the Shenzhen City Customs Office, informing AstraZeneca Investment (China) Co., Ltd. that the total amount of unpaid import taxes is RMB 24m (approximately USD \$3.5m). The import taxes mentioned in the Appraisal Opinion relate to <i>Imfinzi</i>, <i>Imjudo</i>, and <i>Enhertu</i>. In October 2025, AstraZeneca Investment (China) Co., Ltd. prepaid the full amount as voluntary compensation to the State. A fine of between one and five times the amount of these paid importation taxes may also be levied if AstraZeneca Investment (China) Co., Ltd. is found liable for illegal trade. - In November 2025, the Shenzhen Prosecutor concluded its evaluation. AstraZeneca Investment (China) Co., Ltd., the former EVP and one former senior employee were indicted on charges of unlawful collection of personal information and illegal trade, although no illegal gain to AstraZeneca Investment (China) Co., Ltd. was alleged resulting from unlawful collection of personal information. - The former EVP and former senior employee were additionally indicted on charges of medical insurance fraud. AstraZeneca Investment (China) Co., Ltd. has not been indicted on charges of medical insurance fraud. - The matters have been consolidated into one proceeding before the Shenzhen City Intermediate Court. No trial date has been scheduled.
Texas Qui Tam	Considered to be a contingent liability
US	- In December 2022, AstraZeneca was served with an unsealed civil lawsuit brought by qui tam relators on behalf of the State of Texas in Texas State Court in Harrison County, which alleges that AstraZeneca engaged in unlawful marketing practices. - In July 2025, the State of Texas intervened in the matter and filed an amended petition. - In November 2025, the case was transferred to the Texas State Court in Travis County. - No trial date has been scheduled.

US Department of Justice Civil Investigative Demand	Considered to be a contingent liability
US	- In January 2026, AstraZeneca was served with a civil investigative demand issued by the US Department of Justice, seeking documents and information relating to AstraZeneca's data purchases and quality improvement projects. - AstraZeneca is cooperating with this enquiry.
Vermont US Attorney Investigation	Considered to be a contingent liability
US	- In April 2020, AstraZeneca received a Civil Investigative Demand from the US Attorney's Office in Vermont and the Department of Justice, Civil Division, seeking documents and information relating to AstraZeneca's relationships with electronic health-record vendors. - AstraZeneca is cooperating in this enquiry.

Legal proceedings brought by AstraZeneca

340B State Litigation	Considered to be a contingent asset
US	- AstraZeneca has filed lawsuits against Arkansas, Colorado, Hawaii, Kansas, Louisiana, Maine, Maryland, Minnesota, Mississippi, Missouri, Nebraska, New Mexico, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, and West Virginia challenging the constitutionality of each state's 340B statute. - AstraZeneca has ongoing enforcement actions in Arkansas and Louisiana for alleged non-compliance with each state's 340B statute. In April 2025, an order was issued in the Arkansas proceeding requiring AstraZeneca to pause its contract pharmacy policy, which AstraZeneca has appealed. - In Arkansas, the Court denied a motion to dismiss. - In Colorado, the Court denied AstraZeneca's motion for a preliminary injunction, which AstraZeneca has appealed. - In Kansas, after obtaining a stipulation from the state that AstraZeneca's policy does not violate the Kansas 340B statute, AstraZeneca agreed to dismiss its complaint. - In Louisiana, the Court denied AstraZeneca's motion for summary judgement, which AstraZeneca has appealed. - In Maryland and Mississippi, the Court denied AstraZeneca's motion for a preliminary injunction. - In Minnesota, the Court found that the government officials lacked enforcement authority and dismissed AstraZeneca's complaint for lack of standing. - In Missouri, the Court granted in part and denied in part the state's motion to dismiss. - In Oklahoma, the Court granted AstraZeneca's motion for a preliminary injunction, which Oklahoma has appealed. - AstraZeneca's lawsuits are stayed in Rhode Island, Utah, and West Virginia.
Calquence Inflation Reduction Act Litigation	Considered to be a contingent asset
US	In December 2025, AstraZeneca filed a lawsuit in the US District Court for the District of Maryland challenging the US Department of Health and Human Services' interpretation of "qualifying single source drug" under the Inflation Reduction Act and its application in selecting <i>Calquence</i> for drug price negotiation.
Farxiga Inflation Reduction Act Litigation	Considered to be a contingent asset
US	- In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware (District Court) against the US Department of Health and Human Services (HHS) challenging aspects of the drug price negotiation provisions of the Inflation Reduction Act and the implementing guidance and regulations. In March 2024, the District Court granted HHS' motions and dismissed AstraZeneca's lawsuit. - In May 2025, the US Court of Appeals for the Third Circuit affirmed the District Court's dismissal of AstraZeneca's challenge. - In September 2025, AstraZeneca sought review by the US Supreme Court.

Other

Additional government inquiries

As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, various law enforcement offices have, from time to time, requested information from the Group. There have been no material developments in those matters.

Tax

AstraZeneca considers whether it is probable that a taxation authority will accept an uncertain tax treatment. Where acceptance of an uncertain tax treatment is not considered probable, a tax liability is recognised based on either the most likely amount method or the expected value method depending on which method management expects to better predict the resolution of the uncertainty. Due to inherent complexities in the resolution of the uncertain tax treatments and the resulting liabilities due, management exercise judgement in the measurement of the potential liability, based on information available at the present time.

Tax liabilities for uncertain tax treatments can be built up over a long period of time but the resolution occurs at a point in time. Therefore, to the extent the information changes in future periods, there may be adjustments to the liabilities, which may have either a negative or positive effect on our results. Such changes could arise from commencement, progress or conclusion of tax authority challenge, negotiations under competent authority arrangements in relevant double tax treaties and expiry of relevant statutes of limitation. Details of the movements of material uncertain tax treatments are included below.

Notes to the Group Financial Statements *continued*

30 Commitments, contingent liabilities and contingent assets *continued*

KJ AstraZeneca faces a number of audits and reviews in jurisdictions around the world and, in some cases, is in dispute with the tax authorities. The issues under discussion are often complex and can require many years to resolve. Tax liabilities recognised for uncertain tax treatments require management to make key judgements with respect to the outcome of current and potential future tax audits, and actual results could vary from these estimates. Management does not believe a significant risk exists of material change to uncertain tax positions in the next 12 months.

The total net tax liability recognised in the Group Financial Statements in respect of uncertain tax positions is \$1,104m (2024: \$1,321m). The net tax liability consists of \$1,126m (2024: \$1,157m) included within income tax payable, \$1,628m (2024: \$1,304m) included within deferred tax asset, partially offset by \$205m (2024: \$122m) included within deferred tax liabilities, and \$1,445m (2024: \$1,018m) included within income tax receivable.

Transfer pricing

The net tax liability included in the Group Financial Statements in relation to management's current assessment of tax risks in relation to worldwide transfer pricing exposures is \$120m (2024: \$384m). The decrease in the net tax liability for uncertain tax positions relating to transfer pricing of \$264m compared with 2024 is mainly as a result of a decrease of tax liabilities arising from updates to estimates of prior period tax liabilities following progression of tax authority reviews.

The liability includes uncertain tax treatments which are estimated using the expected value method and depend on AstraZeneca's assessment of the likelihood of the approach taken by the tax authorities. These matters can be complex and judgemental and could change in the future, as discussed above.

For transfer pricing matters, including items under tax audit, AstraZeneca estimates the potential for additional tax liabilities above the amount provided where the possibility of the additional liabilities falling due is more than remote, to be up to \$79m (2024: \$422m) including associated interest.

Management continues to believe that AstraZeneca's positions on all its transfer pricing positions, audits and disputes are robust, and that AstraZeneca has recognised appropriate tax balances, including consideration of whether corresponding relief will be available under Mutual Agreement procedures or unilaterally.

Other uncertain tax treatments

Included in the net tax liability is \$984m (2024: \$937m) relating to a number of other uncertain tax treatments. The increase of \$47m in the net tax liability relating to the other uncertain tax treatments mainly relates to an update to tax liabilities following progress of reviews by tax authorities which are offset by movements relating to uncertainty over the timing of tax deductions. This uncertainty includes movements between income taxes receivable of \$1,391m (2024: \$742m), and deferred tax liabilities of \$234m (2024: \$133m) offset by related deferred tax assets of \$1,611m (2024: \$929m) and income taxes payable of \$496m (2024: \$269m). The liability includes tax liabilities in respect of uncertain tax treatments which are estimated using the most likely amount method and the expected value method and depend on AstraZeneca's assessment of the likelihood of the approach taken by the tax authorities.

AstraZeneca estimates the potential for additional liabilities due to other uncertain tax treatments above the amount provided where the possibility of the additional liabilities falling due is more than remote, to be up to \$127m (2024: \$214m) including associated interest. AstraZeneca does not believe there are any significant other uncertain tax treatments where the possibility of the additional liabilities falling due is more than remote (2024: \$nil). Management believes that it is unlikely that these additional liabilities will arise.

Timing of cash flows and interest

The Group is currently under audit in several countries and the timing of any resolution of these audits is uncertain.

It is possible that tax payments may be required in relation to a number of disputes which may be resolved over the next one to two years. AstraZeneca considers the tax liabilities set out above to appropriately reflect the expected value of any final settlement. Some of the items discussed above are not currently within the scope of tax authority audits and may take longer to resolve.

Included within other payables is a net amount of interest arising on tax contingencies of \$126m (2024: \$164m).

31 Statutory and other information

	2025 \$m	2024 \$m	2023 \$m
Fees payable to PricewaterhouseCoopers LLP and its associates:			
Group audit fee	12.5	10.6	10.2
Fees payable to PricewaterhouseCoopers LLP and its associates for other services:			
The audit of subsidiaries pursuant to legislation	15.8	14.8	15.0
Attestation under s404 of Sarbanes-Oxley Act 2002	3.7	3.5	3.3
Audit-related assurance services	1.3	2.2	1.1
Other assurance services	0.2	0.3	0.2
Fees payable to PricewaterhouseCoopers Associates in respect of the Group's pension schemes:			
The audit of subsidiaries' pension schemes	0.3	0.4	0.3
	33.8	31.8	30.1

Fees payable in the year of \$0.8m (2024: \$0.2m) are in respect of the Group audit and audit of subsidiaries related to prior years.

Sustainability assurance

KPMG were appointed the Group's sustainability assurance provider for the year ended 31 December 2025, with \$2.8m fees payable for the service. Fees of \$0.5m for the audit of subsidiaries and \$0.1m for other assurance services were also payable to KPMG and its associates in the year.

Related party transactions

The Group had no material related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements.

Key management personnel compensation

Key management personnel are defined for the purpose of disclosure under IAS 24 'Related Party Disclosures' as the members of the Board and the members of the SET.

	2025 \$'000	2024 \$'000	2023 \$'000
Short-term employee benefits	39,483	40,893	38,636
Post-employment benefits	995	1,045	1,354
Share-based payments	58,915	49,121	58,242
	99,393	91,059	98,232

Total remuneration is included within employee costs (see Note 29).

32 Subsequent events

There were no material subsequent events.

Group Subsidiaries and Holdings

In accordance with section 409 of the Companies Act 2006, a full list of subsidiaries, partnerships, associates, joint ventures and joint arrangements, the place of incorporation, registered office address, and the effective percentage of equity owned as at 31 December 2025 are disclosed below. Unless otherwise stated, the share capital disclosed comprises ordinary shares which are indirectly held by AstraZeneca PLC.

Unless otherwise stated, the accounting year ends of subsidiaries are 31 December. The Group Financial Statements consolidate the Financial Statements of the Company and its subsidiaries at 31 December 2025.

At 31 December 2025	Group Interest	At 31 December 2025	Group Interest	At 31 December 2025	Group Interest
Wholly owned subsidiaries		British Virgin Islands		AstraZeneca Pharmaceutical (Beijing) Co., Ltd.	
Algeria		Gracell Biotechnologies Holdings Limited	100%		100%
AAPM SARL	100%			1F, Building No. 4, No. 8 Courtyard, No. 1 Kegou Street, Beijing Economic-Technological Development Area, Beijing, China	
20, Zone Macro-Economique, Hydra, Dar El Medina, Algiers, Algeria					
Argentina		Bulgaria		AstraZeneca Pharmaceutical (Chengdu) Co., Ltd.	100%
AstraZeneca S.A.	100%	AstraZeneca Bulgaria EOOD	100%		
Olga Cossettini 363, 3° floor, Buenos Aires, Argentina		51 Cherni Vrah Bld., Business Garden Office X, floor 10, Lozenets district, 1407 Sofia, Bulgaria		10th Floor, Building 11 (Building E11), No. 366, Hemin Street, Chengdu High-tech Zone, China (Sichuan) Pilot Free Trade Zone, China	
Alexion Pharma Argentina SRL	100%	Canada		AstraZeneca Pharmaceutical (Guangzhou) Co., Ltd.	100%
Avenida Leandro N. Alem 592 Piso 6, Buenos Aires, Argentina		AstraZeneca Canada Inc.	100%		
Australia		Evinova Canada Inc.	100%	Room 406-178, No. 1, Yichuang Street, (China-Singapore Guangzhou Knowledge City) Huangpu District, Guangzhou City, China	
AstraZeneca Holdings Pty Limited	100%			AstraZeneca Pharmaceutical (Hangzhou) Co., Ltd.	100%
AstraZeneca Pty Limited	100%	Suite 5000, 1004 Middlelegat Road, Mississauga, ON, L4Y 1M4, Canada			
Alexion Pharmaceuticals Australasia Pty Ltd	100%	Alexion Pharma Canada Corp.	100%	12F & 14F, Building 1, Shuli Plaza, 758 Fei Jia Tang Road, Gongshu District, Hangzhou, Zhejiang Province, China	
66 Talavera Road, Macquarie Park, NSW 2113, Australia				AstraZeneca Pharmaceutical Manufacturing (Qingdao) Co., Ltd.	100%
LogicBio Australia Pty Limited	100%	Fusion Pharmaceuticals Inc.	100%	AstraZeneca Pharmaceutical (Qingdao) Co., Ltd.	100%
Level 40, 2-26 Park Street, Sydney, NSW 2000, Australia					
Austria		Cayman Islands		Floor 8, Building 2, 82 Juxianqiao Road, High-tech Zone, Qingdao, Shandong Province, China	
AstraZeneca Österreich GmbH	100%	AZ Reinsurance Limited	100%	AstraZeneca Pharmaceutical (Shanghai) Co., Ltd.	100%
Alexion Pharma Austria GmbH	100%	18 Forum Lane, 2nd Floor, Camana Bay, Grand Cayman, P.O. Box 69, Cayman Islands			
Rechte Wienzeile 223, 1120 Wien, Austria		Gracell Biotechnologies Inc.	100%	B1F, 8F & 9F, 88 Xizang North Road, Jing'an District, Shanghai, China	
Belgium		P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands		AstraZeneca Pharmaceuticals (China) Co., Ltd.	100%
AstraZeneca S.A. / N.V.	100%	Chile			
Alfons Gossetlaan 40, bus 201, 1702 Groot-Bijgaarden, Belgium		AstraZeneca S.A.	100%	88 Yaocheng Avenue, Jiangsu Province, Taizhou, China	
Alexion Pharma Belgium Sprl	100%	AstraZeneca Farmaceutica Chile Limitada	100%	AstraZeneca Rare Disease R&D (Beijing) Co., Ltd	100%
Alexion Services Europe Sprl	100%	Av. Isidora Goyenechea 3477, 2nd Floor, Las Condes, Santiago, Chile			
Rue des Deux Eglises 29-33, 1000 Brussels, Belgium		China		Room 1102, Floor 11, Building No. 4, No. 8 Courtyard, No. 1 Kegou Street, Beijing Economic-Technological Development Area, Beijing, China	
EsoBiotec SA¹	100%	Alexion Pharmaceuticals (Shanghai) Company Limited (in liquidation)	100%	AstraZeneca (Wuxi) Trading Co., Ltd.	100%
Rue André Dumont 5, 1435 Mont-Saint-Guibert, Belgium		Room 1703, Level 17, No. 88 Xizang North Road, Jing'an District, Shanghai, China			
Bermuda		AstraZeneca Global R&D (Beijing) Co., Ltd	100%	Building E (Building No. 5), Huirong Commercial Plaza, East Jinghui Road, Xinwu District, Wuxi, China	
Alexion Bermuda Holding ULC	100%			Beijing Falikang Pharmaceutical Co., Ltd.	100%
Alexion Bermuda Limited	100%	Room 1101, Floor 11, Building No. 4, No. 8 Courtyard, No. 1 Kegou Street, Beijing Economic-Technological Development Area, Beijing, China			
Alexion Bermuda Partners LP	100%	AstraZeneca Global R&D (China) Co., Ltd.	100%	Room 113, Floor 1, Unit 1, Building No. 6, No. 88 Kechuang 6th Street, Beijing Economic-Technological Development Area, Beijing, China	
Victoria Place, 5th Floor, 31 Victoria Street, Hamilton, HM 10, Bermuda				FibroGen (China) Medical Technology Development Co., Ltd	100%
Brazil		16F, 88 Xizang North Road, Jing'an District, Shanghai, China			
AstraZeneca do Brasil Limitada	100%	AstraZeneca Investment (China) Co., Ltd.	100%	Building A2, No. 88 Kechuang 6th Street, Beijing Economic-Technological Development Area, Beijing, China	
Rod. Raposo Tavares, KM 26, 9, Cotia, Brazil				Gracell Biomedicine (Shanghai) Co., Ltd.²	100%
Alexion Farmacêutica América Latina Serviços de Administração de Vendas Ltda.	100%	199 Liangjing Road, Pilot Free Trade Zone, Shanghai, China			
Alexion Serviços e Farmacêutica do Brasil Ltda.	100%	AstraZeneca Investment Consulting (Wuxi) Co., Ltd.	100%	12th Floor, Building 1, No. 926, Yishan Road, Xuhui District, Shanghai 200233, China	
Av. Dr Chucuri Zaidan, 1240, 15° andar, CEP 04711-130, Ed. Morumbi Corporate – Golden Tower Vila São Francisco, São Paulo, Brazil					
		Room 808, 8F, Building 99-2 Linghu Avenue, Xinwu District, Wuxi, Jiangsu, China			
		AstraZeneca Pharmaceutical Co., Ltd.	100%		
		No. 2, Huangshan Road, Wuxi, Jiangsu Province, China			

At 31 December 2025	Group Interest
Shanghai Evinova Medical Technology Co., Ltd.²	100%
Building C, No. 888, Huanhu 2nd Road West, Lingang New District, Shanghai, Pilot Free Trade Zone, China	
Gracell Bioscience (Shanghai) Co., Ltd.	100%
1st-4th Floor, Building 1, No. 418 Guilin Road, Xuhui District, Shanghai 200233, China	
Suzhou Gracell Bioscience Co., Ltd.	100%
Unit E547, 5th Floor, Lecheng Plaza, Phase II, Biobay Industrial Park, 218 Sangtian Street, Suzhou Industrial Park, Suzhou Area, Jiangsu, Pilot Free Trade Zone 215123, China	
Colombia	
AstraZeneca Colombia S.A.S.	100%
Av Carrera 9 No. 101-67 Office 601, Bogotá, 110231, Colombia	
Costa Rica	
AstraZeneca CAMCAR Costa Rica, S.A.	100%
San José, Escazú, Roble Corporate Center, 5to piso, Costa Rica	
Croatia	
AstraZeneca d.o.o.	100%
Ulica Vjekoslava Heinzela 70, 10 000 Zagreb, Croatia	
Czech Republic	
AstraZeneca Czech Republic, s.r.o.	100%
Alexion Pharma Czech s.r.o.	100%
U Trezorky 921/2, 158 00 Prague 5, Czech Republic	
Denmark	
AstraZeneca A/S	100%
Johanne Møllers Passage 1, Dk-1799, Copenhagen V, Denmark	
Egypt	
AstraZeneca Egypt for Pharmaceutical Industries SAE	100%
6th of October City, 6th Industrial Zone, Plot 2, Giza, Egypt	
AstraZeneca Egypt LLC	100%
47 St. 270 New Maadi, Cairo, Egypt	
Drimex LLC	100%
Plot 133, Banks' District, 5th Settlement, New Cairo, Cairo, Egypt	
Estonia	
AstraZeneca Eesti OÜ	100%
Harju maakond, Tallinn, Lasnamäe linnaosa, Valukoja tn 8/1, 11415, Estonia	
Finland	
AstraZeneca Oy.	100%
Keilaranta 18, 02150 Espoo, Finland	
France	
Amolyt Pharma SAS¹	100%
15 Chemin du Saquin, Espace Européen, 69130 Écully, France	
AstraZeneca SAS	100%
Tour Carpe Diem-31, Place des Corolles, 92400 Courbevoie, France	
AstraZeneca Reims Production SAS	100%
Chemin de Vrilly Parc, Industriel de la Pompelle, 51100 Reims, France	

At 31 December 2025	Group Interest
AstraZeneca Dunkerque Production SCS	100%
224 Avenue de la Dordogne, 59640 Dunkerque, France	
Alexion Europe SAS	100%
Alexion Pharma France SAS	100%
15 Chemin du Saquin, Espace Européen, 69130 Écully, France	
Germany	
AstraZeneca GmbH	100%
AstraZeneca Holding GmbH³	100%
Friesenweg 26, 22763, Hamburg, Germany	
AstraZeneca Computational Pathology GmbH¹	100%
Alexion Pharma Germany GmbH	100%
Landsberger Straße 300, 80687, Munich, Germany	
Greece	
AstraZeneca S.A.	100%
Agisilaou 6-8 Marousi, Athens, Greece	
Hong Kong	
AstraZeneca HK Holdings Company Limited	100%
AstraZeneca Hong Kong Limited	100%
Unit 1 – 3, 11/F., China Taiping Finance Centre, 18 King Wah Road, North Point, Hong Kong	
FibroGen International (Hong Kong) Limited	100%
26th Floor, Three Exchange Square, 8 Connaught Place Central, Hong Kong	
Gracell Biotechnologies (HK) Limited	100%
C&F Secretarial Services Limited, Unit 3A, 12/F, Kaiser Centre, No. 18 Centre Street, Sai Ying Pun, Hong Kong	
Hungary	
AstraZeneca Kft	100%
1st floor, 4 building B, Aliz str., Budapest, 1117, Hungary	
India	
AstraZeneca India Private Limited⁴	100%
Block A, Neville Tower, 11th Floor, Ramanujan IT SEZ, Taramani, Chennai, Tamil Nadu, PIN 600113, India	
Alexion Business Services Private Limited	100%
9th Floor, Platina, G Block Plot No. C-59, Bandra-Kurla Complex Bandra (East), Mumbai 400051, India	
Evinova Health Tech India Private Limited⁴	100%
496/4, II Floor, 10th Cross, Near Bashyam Circle, Sadashivanagar, Bangalore – 560080, Karnataka, India	
Indonesia	
P.T. AstraZeneca Indonesia	100%
Perkantoran Hijau Arkadia, Tower G, 16th Floor, Unit 02-05, Jl. T.B. Simatupang Kav. 88, Kebagusan, Pasar Minggu, South Jakarta 12520, DKI Jakarta, Indonesia	
Iran	
AstraZeneca Pars Company	100%
Suite 1, 1st Floor No. 39, Alvand Ave., Argantin Sq., Tehran 1516673114, Iran	

At 31 December 2025	Group Interest
Ireland	
AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company	100%
4th Floor, South Bank House, Barrow Street, Dublin 4, Republic of Ireland	
Alexion Pharma Holding Limited	100%
Alexion Pharma International Operations Limited	100%
Alexion Pharma Development Limited	100%
AstraZeneca Ireland Limited	100%
College Business & Technology Park, Blanchardstown Road North, Dublin 15, Republic of Ireland	
Israel	
AstraZeneca (Israel) Ltd	100%
Atirei Yeda 1, Building O-Tech 2, POB 8044, Kfar Saba, 4464301, Israel	
Alexion Pharma Israel Ltd	100%
1 Atirei Yeda Street O-Tech Building No. 2, 5th Floor Kfar Saba, 4464301, Israel	
Italy	
Simesa SpA	100%
AstraZeneca SpA	100%
Alexion Pharma Italy Srl	100%
Viale Decumano 39, 20157 Milan, Italy	
Japan	
AstraZeneca K.K.	100%
3-1, Ofuka-cho, Kita-ku, Osaka, 530-0011, Japan	
Alexion Pharma GK	100%
Tamachi Station Tower N 3-1-1, Shibaura, Minato-ku Tokyo 108-0023, Japan	
Kazakhstan	
AstraZeneca Kazakhstan Limited Liability Partnership	100%
Office 101, 77 Kunayev Street, Almaty 050000, Kazakhstan	
Kenya	
AstraZeneca Pharmaceuticals Limited	100%
L.R. No.1/1327, Avenue 5, 1st Floor, Rose Avenue, Nairobi, Kenya	
Latvia	
AstraZeneca Latvija SIA	100%
Skanstes iela 50, Riga, LV-1013, Latvia	
Lithuania	
AstraZeneca Lietuva UAB	100%
Spaudos g., Vilnius, LT-05132, Lithuania	
Luxembourg	
AstraZeneca Luxembourg S.A.	100%
Rue Nicolas Bové 2A – L-1253, Luxembourg	
Malaysia	
AstraZeneca Asia-Pacific Business Services Sdn Bhd	100%
12th Floor, Menara Symphony, No. 5 Jalan Prof, Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia	
AstraZeneca Sdn Bhd	100%
The Bousteador, Level 11 & 12, No. 10, Jalan PJU 7/6, Mutiara Damansara, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia	

Group Subsidiaries and Holdings *continued*

At 31 December 2025	Group Interest	At 31 December 2025	Group Interest	At 31 December 2025	Group Interest
Mexico		Pakistan		Saudi Arabia	
AstraZeneca Health Care Division, S.A. de C.V.	100%	AstraZeneca Pharmaceuticals Pakistan (Private) Limited ⁵	100%	AstraZeneca Continent – Regional Headquarter	100%
AstraZeneca, S.A. de C.V.	100%	Office No 1, 2nd Floor, Sasi Arcade, Block 7, Main Clifton Road, Karachi, Pakistan		Al-Nakhlah Tower, Floor 13th Ath Thumamah Road, Al Sahafa District, P.O. Box 42150, Riyadh, Kingdom of Saudi Arabia	
Av. Periferico Sur 4305 interior 5, Colonia Jardines en la Montaña, Mexico City, Tlalpan Distrito Federal, CP 14210, Mexico		Panama		AstraZeneca Trading Company	100%
Alexion Pharma Mexico S. de R.L. de C.V.	100%	AstraZeneca CAMCAR, S.A.	100%	8125 Prince Sultan, 2086 Ar Rawdah District, 23435, Jeddah, Kingdom of Saudi Arabia	
Paseo de los Tamarindos 90, Torre 1 piso 6 - A Col., Bosques de la Lomas, CP 05120 D.F, Mexico		Bodega #1, Parque Logistico MIT, Carretera Hacia Coco Solo, Colon, Panama		Singapore	
Morocco		Peru		AstraZeneca Pharmaceuticals Singapore Pte. Limited	100%
AstraZeneca Maroc SARLAU	100%	AstraZeneca Peru S.A.	100%	AstraZeneca Singapore Pte Ltd	100%
CFC (Casablanca Finance City), Le Continental Business Center, Bâtiment C, 7ème étage, Quartier Hay Hassani, Casablanca, Morocco		Calle Las Orquídeas N° 675, Int. 802, Edificio Pacific Tower, San Isidro, Lima, Peru		10 Kallang Avenue #12-10, Aperia Tower 2, 339510, Singapore	
The Netherlands		Philippines		South Africa	
Alexion Holding B.V.	100%	AstraZeneca Pharmaceuticals (Phils.) Inc.	100%	AstraZeneca Pharmaceuticals (Pty) Limited	100%
Alexion Pharma Foreign Holdings, B.V.	100%	18th Floor, EcoPrime Tower, 32nd Street corner 9th Avenue, Bonifacio Global City, Taguig City, 1634, Philippines		17 Georgian Crescent West, Northdowns Office Park, Bryanston, 2191, South Africa	
Alexion Pharma Netherlands B.V.	100%	Poland		South Korea	
AstraZeneca B.V.	100%	AstraZeneca Pharma Poland Sp.z.o.o.	100%	AstraZeneca Korea Co. Ltd	100%
AstraZeneca Continent B.V.	100%	Alexion Pharma Poland Sp.z.o.o.	100%	21st Floor, Asem Tower, 517, Yeongdong-daero, Gangnam-gu, Seoul 06164, Republic of Korea	
AstraZeneca Gamma B.V.	100%	Evinova Poland sp. z o.o	100%	Alexion Pharma Korea LLC	100%
AstraZeneca Holdings B.V.	100%	Postępu 14, 02-676, Warszawa, Poland		41 FL., 152 Teheran-ro (Yeoksam-dong Gangnam Finance Center), Gangnam-gu, Seoul 06164, Republic of Korea	
AstraZeneca Jota B.V.	100%	Portugal		Spain	
AstraZeneca Rho B.V.	100%	Astra Alpha Produtos Farmacêuticos Lda	100%	AstraZeneca Farmaceutica Holding Spain SA	100%
AstraZeneca Sigma B.V.	100%	AstraZeneca Produtos Farmacêuticos Lda	100%	AstraZeneca Farmaceutica Spain SA	100%
AstraZeneca Treasury B.V.	100%	Novastra Promoção e Comércio Farmacêutico Lda	100%	Evinova Spain SL	100%
AstraZeneca Zeta B.V.	100%	Novastuart Produtos Farmacêuticos Lda	100%	Fundación AstraZeneca	100%
Prinses Beatrixlaan 582, 2595 BM, The Hague, The Netherlands		Stuart-Produtos Farmacêuticos Lda	100%	Laboratorio Beta SA	100%
AstraZeneca Nijmegen B.V.	100%	Zeneca Epsilon – Produtos Farmacêuticos Lda	100%	Laboratorio Lailan SA	100%
Lagelandseweg 78, 6545 CG Nijmegen, The Netherlands		Zenecapharma Produtos Farmacêuticos, Unipessoal Lda	100%	Laboratorio Tau SA	100%
Acerta Pharma B.V.	100%	Rua Humberto Madeira, No 7, Queluz de Baixo, 2730-097, Barcarena, Portugal		Calle del Puerto de Somport, 21-23, Madrid 28050, Spain	
Aspire Therapeutics B.V.	100%	Puerto Rico		Alexion Pharma Spain SL	100%
Kloosterstraat 9, 5349 AB, Oss, The Netherlands		IPR Pharmaceuticals, Inc.	100%	Avinguda de Roma, 81, Floor 7, Barcelona 08028, Spain	
Portola Netherlands B.V. (in liquidation)	100%	Road 188, San Isidro Industrial Park, Canóvanas, 00729, Puerto Rico		Sweden	
Basisweg 10, 1043 AP, Amsterdam, The Netherlands		Romania		AstraZeneca AB	100%
Neogene Therapeutics B.V.	100%	AstraZeneca Pharma S.R.L.	100%	AstraZeneca Biotech AB	100%
35C Tafelbergweg, 1105 BC, Amsterdam, The Netherlands		Bucharest, 1A Tipografilor Street, MUSE Offices, 2nd and 3rd Floor, District 1, 013714, Romania		AstraZeneca BioVentureHub AB	100%
New Zealand		Russia		AstraZeneca International Holdings Aktiebolag	100%
AstraZeneca Limited	100%	AstraZeneca Industries OOO LLC	100%	AstraZeneca Pharmaceuticals Aktiebolag	100%
Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics, 58 Richard Pearse Drive, Mangere, Auckland, 1142, New Zealand		81 Vostochniy Lane, Dobrino Village, Borovskiy District, Kaluga Region, 249006, Russian Federation		AstraZeneca Södertälje 2 AB	100%
Nigeria		AstraZeneca Pharmaceuticals LLC	100%	SE-151 85 Södertälje, Sweden	
AstraZeneca Nigeria Limited	100%	1 Krasnogvardeyskiy Lane 21, Bld.1, Floors 20-30, Moscow, 123112, Russian Federation		Evinova AB	100%
42 Vibranium Valley, Local Airport Road, Ikeja, Lagos, Nigeria		Alexion Pharma LLC	100%	431, 53 Mölndal, Stockholm, Södertälje, Sweden	
Norway		12 Presnenskaya Embankment, Premises 1/36, Moscow, 123112, Russian Federation		Alexion Pharma Nordics Holding AB	100%
AstraZeneca AS	100%			Alexion Pharma Nordics AB	100%
Karvesvingen 7, 0579 Oslo, Norway				Hagaplan 4, 113 68 Stockholm, Sweden	

At 31 December 2025	Group Interest	At 31 December 2025	Group Interest	At 31 December 2025	Group Interest
Switzerland		AstraZeneca Share Trust Limited		AZ-Mont Insurance Company	
Alexion Pharma GmbH	100%	AstraZeneca Sweden Investments Limited	100%	100 Bank Street, Suite 630, Burlington, VT 05401, United States	
AstraZeneca AG	100%	AstraZeneca Treasury Limited	100%	Caelum Biosciences Inc.	100%
Evinova AG	100%	AstraZeneca UK Limited	100%	1200 Florence Columbus Road, Bordentown, NJ 08505, United States	
Neuhofstrasse 34, 6340 Baar, Switzerland		AstraZeneca US Investments Limited ⁶	100%	Evinova Inc.	100%
SixPeaks Bio AG	100%	AZENCO4 Limited	100%	101 Orchard Ridge Drive, Gaithersburg, MD 20878, United States	
Aeschenvorstadt 36, 4501 Basel, Switzerland		AZENCO6 Limited	100%	Fusion Pharmaceuticals US Inc.	100%
Spirogen Sarl (in liquidation)	100%	Cambridge Antibody Technology Group Limited	100%	2 International Place, Suite 2310, Boston, MA 02110, United States	
Rue du Grand-Chêne 5, CH-1003 Lausanne, Switzerland		Evinova Limited	100%	Gracell Biopharmaceuticals, Inc.	100%
Taiwan		KuDOS Horsham Limited	100%	530 Lytton Avenue, 2nd Floor, Palo Alto, CA 94301, United States	
Alexion Pharma Taiwan Ltd	100%	KuDOS Pharmaceuticals Limited	100%	Icosavax, Inc.	100%
AstraZeneca Taiwan Limited	100%	Syntimmune Limited	100%	1930 Boren Avenue, Suite 1000, Seattle, WA 98101, United States	
21st Floor, Taipei Metro Building 207, Tun Hwa South Road, SEC 2 Taipei, Taiwan		Zenco (No. 8) Limited	100%	MedImmune, LLC⁷	100%
Thailand		Zeneca Finance (Netherlands) Company	100%	MedImmune Ventures, Inc.	100%
AstraZeneca (Thailand) Limited	100%	MedImmune Limited	100%	One MedImmune Way, Gaithersburg, MD 20878, United States	
Asia Centre 19th floor, 173/20, South Sathorn Rd, Khwaeng Thungmahamek, Khet Sathorn, Bangkok, 10120, Thailand		1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom		Modella AI, Inc.	100%
Tunisia		MedImmune U.K. Limited	100%	72, Winthrop Street, Charlestown, MA 02129, United States	
AstraZeneca Tunisie SaRL	100%	Plot 6, Renaissance Way, Boulevard Industry Park, Liverpool, L24 9JW, United Kingdom		Pearl Therapeutics, Inc.	100%
Lot n°1.5.5 les jardins du lac, bloc B les berges du lac Tunis, Tunisia		United States		200 Cardinal Way, Redwood City, CA 94063, United States	
Turkey		Acerta Pharma LLC⁷	100%	Portola Pharmaceuticals LLC⁷	100%
AstraZeneca İlaç Sanayi ve Ticaret Limited Şirketi	100%	121 Oyster Point Boulevard, South San Francisco, CA 94080, United States		ZS Pharma, Inc.	100%
Zeneca İlaç Sanayi ve Ticaret Anonim Şirketi (in liquidation)	100%	Alexion Pharmaceuticals, Inc.	100%	1100 Park Place, Suite 300, San Mateo, CA 94403, United States	
Esentepe Mah. Büyükdere Cad. Levent 199 No: 199 İç Kapı No: 93 Şişli, İstanbul, Turkey		Achillion Pharmaceuticals Inc.	100%	Uruguay	
Alexion İlaç Ticaret Limited Şirketi	100%	Alexion US1 LLC⁷	100%	AstraZeneca S.A.	100%
İçerenköy Mahallesi Umut SK. and Ofis Sit. No: 10 12/73 Ataşehir, İstanbul 10-12/73, Turkey		Syntimmune LLC⁷	100%	Yaguarón 1407 of 1205, 11.100, Montevideo, Uruguay	
Ukraine		TeneoTwo, Inc.	100%	Venezuela	
AstraZeneca Ukraina LLC	100%	121 Seaport Boulevard Boston, MA 02210, United States		AstraZeneca Venezuela S.A.	100%
54 Simi Prakhovykh Street, Kyiv, 01033, Ukraine		AlphaCore Pharma, LLC^{7, 12}	100%	Gotland Pharma S.A.	100%
United Arab Emirates		333 Parkland Plaza, Suite 5, Ann Arbor, MI 48103, United States		Av. La Castellana, Torre La Castellana, Piso 5, Oficina 5-G, 5-H, 5-I, Urbanización La Castellana, Municipio Chacao, Estado Bolivariano de Miranda, Venezuela	
AstraZeneca FZ-LLC	100%	Amolyt Pharma Inc.	100%	Vietnam	
Dubai Sciences Park Towers, Tower South, S1706S, Dubai Sciences Park, Dubai, United Arab Emirates		185 Alewife Brook Pkwy, Suite 210, Cambridge, MA 02138, United States		AstraZeneca Vietnam Company Limited	100%
United Kingdom		Amylin Ohio LLC⁷	100%	18th Floor, A&B Tower, 76 Le Lai, Ben Thanh Ward, District 1, Ho Chi Minh City, Vietnam	
Alexion Pharma UK Limited	100%	Amylin Pharmaceuticals, LLC⁷	100%		
Ardea Biosciences Limited	100%	Ardea Biosciences, Inc.	100%		
Astra Pharmaceuticals Limited	100%	AstraZeneca Collaboration Ventures, LLC⁷	100%		
AstraPharm	100%	AstraZeneca Finance and Holdings Inc.	100%		
AstraZeneca China UK Limited	100%	AstraZeneca Finance LLC⁷	100%		
AstraZeneca Death In Service Trustee Limited	100%	AstraZeneca Pharmaceuticals LP⁸	100%		
AstraZeneca Employee Share Trust Limited	100%	Atkemix Nine Inc.	100%		
AstraZeneca Finance Limited	100%	Atkemix Ten Inc.	100%		
AstraZeneca Intermediate Holdings Limited⁶	100%	AZ Biotech Holdings, Inc.	100%		
AstraZeneca Investments Limited	100%	Cincor Pharma Inc.	100%		
AstraZeneca Japan Limited	100%	Corpus Christi Holdings Inc.	100%		
AstraZeneca Nominees Limited	100%	LogicBio Therapeutics, Inc.	100%		
AstraZeneca Quest Limited	100%	Omthera Pharmaceuticals, Inc.	100%		
		Optein, Inc.	100%		
		Stauffer Management Company LLC⁷	100%		
		Zeneca Inc.	100%		
		Zeneca Holdings Inc.	100%		
		Zeneca Wilmington Inc.⁶	100%		
		1800 Concord Pike, Wilmington, DE 19803, United States			

continued

At 31 December 2025	Group Interest
Sweden	
Swedish Orphan Biovitrum AB (publ)	9.72%
Norra Stationsgatan 93A, Stockholm, Sweden	
OnDosis AB	19.80%
GoCo House, 5 tr, Gemenskapens gata 9, 431 53 Mölndal, Sweden	
CCRM Nordic AB	19.90%
Förändringens Gata 10, 431 53 Mölndal, Sweden	
Sferical AI Holding AB ¹¹	20.00%
Arsenalsgatan 8C, Box 16066, 103 22 Stockholm, Sweden	
United Kingdom	
Niox Group plc	15.82%
Magdalen Centre, 1 Robert Robinson Ave, Science Park, Oxford, OX4 4GA, United Kingdom	
United States	
AbMed Corporation ¹	18.00%
68 Cummings Park Drive, Woburn, MA 01801, United States	
Amani Therapeutics, Inc. ¹⁰	15.00%
251 Little Falls Drive, Wilmington, DE 19808, United States	
Pathos AI, Inc ¹⁰	11.26%
600 W Chicago Ave, 510 Chicago, IL 60654, United States	
Regio Biosciences, Inc. ¹⁰	19.54%
5237 River Road, #361 Bethesda, MD 20816, United States	
Employee Benefit Trusts	
The AstraZeneca Employee Benefit Trust	
AstraZeneca PSP/GRSP EBP for Canadian Employees	

² Ownership held by way of capital contribution.

³ 10% directly held by AstraZeneca PLC.

⁴ Accounting year end is 31 March.

⁵ Accounting year end is 30 June.

⁶ Directly held by AstraZeneca PLC

⁷ Ownership held as membership in

⁸ Ownership held as partnership interest.

⁹ Consolidated due to Zeneca Inc. having

¹⁰ Ownership held in preference shares.

¹¹ 7.14% voting rights and preference share

¹² Liquidated on 09 January 2026.

Company Balance Sheet

at 31 December

AstraZeneca PLC

	Notes	2025 \$m	2024 \$m
Fixed assets			
Fixed asset investments	1	60,446	62,019
		60,446	62,019
Current assets			
Debtors – other		6	8
Debtors – amounts owed by Group undertakings		6,659	5,807
Cash and cash equivalents		17	–
		6,682	5,815
Creditors: Amounts falling due within one year			
Other payables	2	(203)	(202)
Income tax payable		(36)	–
Interest-bearing loans and borrowings	3	(1,200)	(1,997)
		(1,439)	(2,199)
Net current assets		5,243	3,616
Total assets less current liabilities		65,689	65,635
Creditors: Amounts falling due after more than one year			
Interest-bearing loans and borrowings	3	(13,801)	(14,549)
Income tax payable		–	(36)
Other payables	2	(37)	(47)
		(13,838)	(14,632)
Net assets		51,851	51,003
Capital and reserves			
Called-up share capital	4	388	388
Share premium account		35,266	35,226
Capital redemption reserve		153	153
Other reserves		1,583	1,741
Profit and loss account		14,461	13,495
Shareholders' funds		51,851	51,003

\$m means millions of US dollars.

The Company's profit for the year was \$5,812m (2024: \$457m).

The Company Financial Statements from pages 197 to 203 were approved by the Board and were signed on its behalf by

Pascal Soriot

Director

10 February 2026

Aradhana Sarin

Director

Company's registered number 02723534

Company Statement of Changes in Equity

for the year ended 31 December

	Share capital \$m	Share premium account \$m	Capital redemption reserve \$m	Other reserves ¹ \$m	Profit and loss account ² \$m	Total equity \$m
At 1 January 2024	388	35,188	153	1,779	17,640	55,148
Total comprehensive income for the period						
Profit for the period	–	–	–	–	457	457
Total comprehensive income for the period	–	–	–	–	457	457
Transactions with owners, recorded directly in equity						
Dividends	–	–	–	–	(4,602)	(4,602)
Capital reimbursements for share-based payments	–	–	–	(38)	–	(38)
Issue of Ordinary Shares	–	38	–	–	–	38
Total contributions by and distributions to owners	–	38	–	(38)	(4,602)	(4,602)
At 31 December 2024	388	35,226	153	1,741	13,495	51,003
Total comprehensive income for the period						
Profit for the period	–	–	–	–	5,812	5,812
Total comprehensive income for the period	–	–	–	–	5,812	5,812
Transactions with owners, recorded directly in equity						
Dividends	–	–	–	–	(4,846)	(4,846)
Capital reimbursements for share-based payments	–	–	–	(158)	–	(158)
Issue of Ordinary Shares	–	40	–	–	–	40
Total contributions by and distributions to owners	–	40	–	(158)	(4,846)	(4,964)
At 31 December 2025	388	35,266	153	1,583	14,461	51,851

¹ The Other reserves arose from the cancellation of £1,255m share premium by the Company in 1993 and the redenomination of share capital of \$157m in 1999. Included within Other reserves at 31 December 2025 is a debit of \$258m (31 December 2024: debit of \$100m) in respect of cumulative share-based payment awards, which reduces the Company's ability to make distributions out of its distributable reserves by an equivalent amount.

² At 31 December 2025, all of the Profit and loss account reserve of \$14,461m (31 December 2024: the overwhelming majority of \$13,495m) was available for distribution, subject to filing these Financial Statements with Companies House. When making a distribution to shareholders, the Directors determine profits available for distribution by reference to guidance on realised and distributable profits under the Companies Act 2006 issued by the Institute of Chartered Accountants in England and Wales and the Institute of Chartered Accountants of Scotland in April 2017. The profits of the Company have been received in the form of receivables due from subsidiaries. The availability of distributable reserves in the Company is dependent on those receivables meeting the definition of qualifying consideration within the guidance, and in particular on the ability of subsidiaries to settle those receivables within a reasonable period of time. The Directors consider that, based on the nature of these receivables and the available cash resources of the Group and other accessible sources of funds, at 31 December 2025 all (31 December 2024: the overwhelming majority) of the Company's profit and loss reserves were available for distribution.

Company Accounting Policies

Basis of presentation of financial information

The Company is a public limited company, limited by shares, incorporated and domiciled in England & Wales. The registered address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

These financial statements were prepared in accordance with FRS 101 'Reduced Disclosure Framework'.

In preparing these financial statements, the Company applied the recognition, measurement and disclosure requirements of International Financial Reporting Standards as adopted by the UK (UK-adopted International Accounting Standards), but made amendments where necessary in order to comply with the Companies Act 2006 and to take advantage of FRS 101 disclosure exemptions.

In these financial statements, the Company has applied the exemptions available under FRS 101 in respect of the following disclosures:

- Statement of Cash Flows and related notes
- disclosures in respect of transactions with wholly owned subsidiaries
- disclosures in respect of capital management
- the effects of new but not yet effective IFRSs
- disclosures in respect of the compensation of Key Management Personnel.

As the Group Financial Statements (presented on pages 125 to 196) include the equivalent disclosures, the Company has also taken the exemptions under FRS 101 available in respect of the following disclosures:

- IFRS 2 'Share-based Payment' in respect of Group settled share-based payments
- certain disclosures required by IFRS 13 'Fair Value Measurement' and the disclosures required by IFRS 7 'Financial Instruments: Disclosures'.

No individual profit and loss account is prepared as provided by section 408 of the Companies Act 2006.

Basis of accounting

The Company Financial Statements are prepared under the historical cost convention and on a going concern basis, in accordance with the Companies Act 2006.

The following paragraphs describe the main accounting policies, which have been applied consistently.

Estimates and judgements

The preparation of the Company Financial Statements in conformity with generally accepted accounting principles requires management to make estimates and judgements that affect the reported amounts of assets and liabilities at the date of the Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. There are no key judgements or significant estimates.

Foreign currencies

Foreign currency transactions, being transactions denominated in a currency other than the Company's functional currency, are translated into US dollars at average rates for the relevant monthly accounting periods, which approximate to actual rates.

Monetary assets and liabilities arising from foreign currency transactions are retranslated at exchange rates prevailing at the reporting date. Exchange gains and losses on loans and on short-term foreign currency borrowings and deposits are included within Finance expense. Exchange differences on all other foreign currency transactions are recognised in Operating profit.

Non-monetary items arising from foreign currency transactions are not retranslated in the Company's accounting records.

Taxation

The current tax payable is based on taxable profit for the year. Taxable profit differs from reported profit because taxable profit excludes items that are either never taxable or tax deductible or items that are taxable or tax deductible in a different period. The Company's current tax assets and liabilities are calculated using tax rates that have been enacted or substantively enacted by the reporting date. Current tax includes the Company's charge for any Pillar Two income taxes.

Deferred tax is provided using the balance sheet liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax liabilities are recognised unless they arise from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. Deferred tax liabilities are not recognised to the extent they arise from the initial recognition of non-tax deductible goodwill. Deferred tax assets are recognised to the extent that there are future taxable temporary differences or it is probable that future taxable profit will be available against which the asset can be utilised. This requires judgements to be made in respect of the availability of future taxable income.

No deferred tax asset or liability is recognised in respect of temporary differences associated with investments in subsidiaries and branches where the Company is able to control the timing of reversal of the temporary differences and it is probable that the temporary differences will not reverse in the foreseeable future.

The Company's deferred tax assets and liabilities are calculated using tax rates that are expected to apply in the period when the liability is settled or the asset realised based on tax rates that have been enacted or substantively enacted by the reporting date.

The Company applies the exception to recognising and disclosing information about deferred tax assets and liabilities related to Pillar Two income taxes, as provided in the amendments to IAS 12 'Income Taxes' issued in May 2023.

Liabilities for uncertain tax positions require management to make judgements of potential exposures in relation to tax audit issues based upon interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Tax benefits are recognised when it is probable the tax positions will be accepted by the tax authorities. When a position is not considered probable of being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable result. This is measured using either the most likely amount or the expected value amount depending on which method the entity expects to better predict the resolution of the uncertainty.

Company Accounting Policies *continued*

Investments

Fixed asset investments, including investments in subsidiaries, are stated at cost and reviewed for impairment if there are indications that the carrying value may not be recoverable.

Debtors

Amounts owed by Group undertakings are recognised initially at fair value. Subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses.

The recoverability of these balances has been assessed in accordance with IFRS 9 'Financial Instruments' and no impairment has been identified. The amounts owed by Group undertakings are considered to have low credit risk, due to timely payment of interest and settlement of principal amounts on agreed due dates, limiting the loss allowance to 12-month expected credit losses.

Amounts owed by Group undertakings are written off where there is no reasonable expectation of recovery. Impairment losses are presented as net impairment losses within Operating profit, any subsequent recoveries are credited against the same line.

Other payables

Liabilities included in Other payables are recognised initially at fair value. Subsequent to initial recognition they are remeasured at either amortised cost using the effective interest method or at fair value using an expected credit loss model.

Financial instruments

Interest-bearing loans are initially measured at fair value (with direct transaction costs being amortised over the life of the loan) and are subsequently measured at amortised cost using the effective interest method at each reporting date. Changes in carrying value are recognised in profit.

Share-based payments

The issuance by the Company to employees of its subsidiaries of a grant of awards over the Company's shares, represents additional capital contributions by the Company to its subsidiaries (or capital reimbursement from those subsidiaries). An additional investment/divestment in subsidiaries results in a corresponding increase/decrease in shareholders' equity. The additional capital contribution/reimbursement is based on the fair value of the grant issued, allocated over the underlying grant's vesting period, less the market cost of shares charged to subsidiaries in settlement of such share awards.

Litigation

Through the normal course of business, the AstraZeneca Group is involved in legal disputes, the settlement of which may involve cost to the Company. A provision is made where an adverse outcome is probable and associated costs, including related legal costs, can be estimated reliably. In other cases, appropriate disclosures are included.

Notes to the Company Financial Statements

1 Fixed asset investments

	Investments in subsidiaries		
	Shares \$m	Loans \$m	Total \$m
At 1 January 2024	49,059	15,130	64,189
Additions during the year	33,745	–	33,745
Disposals during the year	(33,745)	–	(33,745)
Transfer to Debtors – amounts owed by Group undertakings	–	(1,997)	(1,997)
Capital reimbursement	(54)	–	(54)
Exchange	–	(156)	(156)
Amortisation	–	11	11
Other movements	26	–	26
At 31 December 2024	49,031	12,988	62,019
Return of capital from subsidiaries	(500)	–	(500)
Transfer to Debtors – amounts owed by Group undertakings	–	(1,199)	(1,199)
Capital reimbursement	(207)	–	(207)
Exchange	–	335	335
Amortisation	–	8	8
Other movements	(10)	–	(10)
At 31 December 2025	48,314	12,132	60,446

Loans to subsidiaries consists of bonds which are issued externally and are issued back to Group undertakings with comparable terms on interest rates and are repayable on maturity, details of which are disclosed in Note 3. The recoverability of these inter-company loans has been assessed in accordance with IFRS 9 'Financial Instruments' with no impairment identified. The inter-company balances are considered to have low credit risk due to timely payment of interest and settlement of principal amount on agreed due dates, limiting the loss allowance to 12-month expected credit losses. In 2025, there have been no credit losses (2024: \$nil).

Return of capital from subsidiaries relates to an income dividend received, which has been accounted for as return of capital due to a potential future simplification of the organisational structure.

The other movements comprise a reduction of \$10m representing revaluation of carrying value of guarantees provided by the Company to its subsidiary as explained in Notes 2 and 3.

2 Other payables

	2025 \$m	2024 \$m
Amounts falling due within one year		
Other creditors	200	199
Deferred income	3	3
	203	202
Amounts falling due after more than one year		
Other creditors	37	47

Other creditors due after more than one year comprise an amount representing the carrying value of the guarantees provided by the Company to its subsidiary for the bonds issued externally as explained in Note 3. As at 31 December 2025, the carrying value of the guarantees was \$37m (2024: \$47m).

Notes to the Company Financial Statements *continued*

3 Loans and borrowings

		Repayment dates	2025 \$m	2024 \$m
Amounts due within one year				
Interest-bearing loans and borrowings (unsecured)				
3.375% Callable bond	US dollars	2025	–	1,997
0.7% Callable bond	US dollars	2026	1,200	–
Total amounts due within one year			1,200	1,997
Amounts due after more than one year				
Interest-bearing loans and borrowings (unsecured)				
0.7% Callable bond	US dollars	2026	–	1,198
3.625% Callable bond	euros	2027	880	780
3.125% Callable bond	US dollars	2027	749	748
1.25% Callable bond	euros	2028	936	829
4% Callable bond	US dollars	2029	997	996
0.375% Callable bond	euros	2029	936	829
1.375% Callable bond	US dollars	2030	1,295	1,295
5.75% Non-callable bond	pounds sterling	2031	469	438
3.75% Callable bond	euros	2032	878	778
6.45% Callable bond	US dollars	2037	2,728	2,727
4% Callable bond	US dollars	2042	989	989
4.375% Callable bond	US dollars	2045	982	982
4.375% Callable bond	US dollars	2048	738	738
2.125% Callable bond	US dollars	2050	488	487
3% Callable bond	US dollars	2051	736	735
Total amounts due after more than one year			13,801	14,549
Total loans and borrowings			15,001	16,546
			2025 \$m	2024 \$m
Loans and borrowings are repayable:				
After five years from balance sheet date			8,008	9,169
From two to five years			4,164	4,182
From one to two years			1,629	1,198
Within one year			1,200	1,997
Total unsecured			15,001	16,546

All borrowings are issued with fixed interest rates.

In addition, the Company acts as guarantor for bonds issued by its wholly-owned subsidiary, AstraZeneca Finance LLC. AstraZeneca Finance LLC is the issuer of \$1,250m 1.200% Notes due 2026, \$1,250m 4.800% Notes due 2027, \$1,100m 4.875% Notes due 2028, \$1,250m 1.750% Notes due 2028, \$1,250m 4.850% Notes due 2029, \$650m 4.900% Notes due 2030, €650m 3.121% Notes due 2030, \$1,000m 4.900% Notes due 2031, \$750m 2.250% Notes due 2031, \$500m 4.875% Notes due 2033, €750m 3.278% Notes due 2033 and \$1,500m 5.000% Notes due 2034 (the 'AstraZeneca Finance Notes'). Each series of AstraZeneca Finance Notes has been fully and unconditionally guaranteed by the Company. Each of the guarantees by AstraZeneca PLC is full and unconditional and joint and several.

The guarantee by AstraZeneca PLC of the AstraZeneca Finance Notes is the senior unsecured obligation of AstraZeneca PLC and ranks equally with all of AstraZeneca PLC's existing and future senior unsecured and unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured indebtedness of AstraZeneca PLC to the extent of the value of the assets securing such indebtedness. The AstraZeneca Finance Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance Notes.

4 Called-up share capital

Details of share capital movements in the year are included in Note 24 to the Group Financial Statements.

5 Contingent liabilities

Securities Litigation	Considered to be a contingent liability
US	- In December 2024, a putative securities class action lawsuit was filed in the US District Court for the Central District of California against AstraZeneca PLC and certain officers, on behalf of purchasers of AstraZeneca publicly traded securities between February 2022 and December 2024. - The case was subsequently transferred to the US District Court for the Southern District of New York.
University of Sheffield Contract Dispute	Considered to be a contingent liability
UK	- In June 2024, AstraZeneca was served with a lawsuit filed by the University of Sheffield (Sheffield). In its complaint, Sheffield alleges that AstraZeneca made misrepresentations to induce Sheffield to amend a patent licence agreement relating to <i>Lynparza</i>. - Trial has been scheduled to begin in June 2026.

6 Statutory and other information

The Directors of the Company were paid by another Group company in 2025 and 2024.

7 Subsequent events

There were no material subsequent events.

Sustainability Statement

Contents

General disclosures	205
Topical disclosures	211
Environmental disclosures	211
Social disclosures	217
Governance disclosures	219
Independent Sustainability Assurance Report	220



General disclosures

Basis for preparation

UK statutory sustainability reporting Non-Financial and Sustainability Information Statement and the Task Force on Climate-related Financial Disclosures (TCFD) recommended disclosures

The areas listed below include references to our relevant policies, due diligence processes and information on how we are performing against various measures. Information on the key non-financial performance indicators relevant to our business is presented alongside the material sustainability matters.

- Business model, pages 8 and 9
- Environmental matters, pages 42 to 45, and 211 to 214
- Climate-related disclosures, pages 42 to 44, and 211 to 214
- Employees, pages 39, 217 and 218
- Social matters, pages 30, 31, 39, 41, 217 and 218
- Human rights, pages 39, 206, 207 and 217
- Anti-corruption and anti-bribery matters, pages 34 and 219
- Principal Risks, pages 48 to 49.

We have made disclosures within the Annual Report consistent with the four recommendations of the TCFD, the 11 recommended disclosures and all sector guidance, and in compliance with the requirements of UK Listing Rule 6.6.6(8) of the UK Financial Conduct Authority. The table on page 208 sets out the required climate-related disclosures from ESRS E1 Climate Change, the TCFD framework and UK Companies Act 2006, section 414CB, and shows where further information can be found.

Sustainability reporting in accordance with European Sustainability Reporting Standards (ESRS)

The Group's sustainability disclosures have been prepared on a consolidated basis. The scope of consolidation is consistent with the scope of the Consolidated Financial Statements. For the Group's accounting policies, Basis of accounting and preparation of financial information, see page 129.

The Group's sustainability disclosures address material impacts, risks and opportunities (IROs) across its value chain, including the Group's own operations.

The Group's sustainability disclosures have been prepared in accordance with the ESRS as required by the Swedish Annual Accounts Act Sections 12-12f. Data points in the ESRS are disclosed to the extent information is material.

The time horizons used for the Group's sustainability disclosures are: short term as up to one year, medium term as one to three years and long term as more than three years. This is consistent with the Group's financial planning and risk management.

Metrics, including when upstream and downstream value chain data is included, are described in the individual metric methodologies. Metrics which have a high level of measurement uncertainty are:

- Scope 3 GHG emissions estimate based on expenses – see page 213
- Average level of patient adherence assumption used in number of patients treated estimate – see page 218.

Any forward-looking information included in this Statement, including assumptions and conclusions of the double materiality assessment, is subject to the Cautionary statement regarding forward-looking statements on page 228.

Incorporation by reference

For ESRS disclosures incorporated by reference to other sections of the Annual Report, see the table Cross-references to other parts of the Annual Report on pages 208 to 210.

Use of phase-in provisions in accordance with Appendix C of ESRS 1

We have used the phase-in provisions as described in the Delegated Regulation (EU) 2025/1416 for disclosures relating to E4 Biodiversity and ecosystems, and S4 Consumers and end-users. We have also opted to use the phase-in provisions listed in ESRS 1 Appendix C applicable to AstraZeneca.

Governance

Statement on due diligence

At AstraZeneca, sustainability due diligence is embedded across our Code of Ethics and supporting standard and core business processes, ensuring that sustainability IROs are identified, assessed, and addressed throughout decision making and execution. Sustainability matters are considered as part of the Group's Enterprise Risk Management process and in the due diligence processes of larger acquisitions.

Risk management and internal controls over sustainability reporting

We have continued our work this year to design and implement a robust controls framework which aims to ensure that risks to accurate sustainability reporting are appropriately mitigated. Our approach is to align controls to key aspects of the sustainability reporting process, including the scope of reporting, data collection and review, and the preparation and review of sustainability disclosures contained in the Annual Report.

We continue to evaluate our processes and adapt the control environment where needed. To ensure that the control environment remains appropriate, we assess where sustainability reporting could be misstated based on the materiality of disclosures, the complexity of processes, the nature of the data being collected and the probability of errors, omissions or fraud, and adjust the control environment where required.

Our governance mechanisms for sustainability reporting are similar to the existing governance over financial reporting and cover our continued process to implement and monitor controls. Any findings are reported to the Audit Committee.

Core elements of environmental and social due diligence*

Due diligence element	Page references
a Embedding due diligence in governance, strategy and business model	Pages 206 to 207, 208 to 210 (GOV-2, GOV-3, SBM-3)
b Engaging with affected stakeholders	Pages 206 to 207, 208 to 210 (GOV-2, SBM-2, S1-2, S1-3, BP-2 Patient safety and product quality), 211
c Identifying and assessing negative impacts on people and the environment	Pages 206 to 207, 208 to 210 (SBM-3, G1-1)
d Taking action to address negative impact	Pages 208 to 210 (E2-2, S1-4, E1-3, MDR-A, BP-2 17d)
e Tracking effectiveness of these efforts	Pages 208 to 210 (MDR-M, MDR-T, BP-2 17b and 17e, G1-4, E1-6, E1-4), 211 to 213, 217 to 218, 219

* Data points derived from other EU legislation: SFDR.

General disclosures *continued*

Impact, risk and opportunity management

In 2024, we performed a double materiality assessment in compliance with the ESRS. The assessment considered both the Group's impacts on people and the environment as well as sustainability-related risks and opportunities to the Group's prospects. We have identified and assessed IROs consistent with our functional activities which take place (and are managed) globally on a highly integrated basis.

The Group's impacts on people and the environment were identified through research using sources such as sector guidance and benchmarking, as well as understanding the interests and views of stakeholders through dialogue. The identification of water and pollution-related impacts was informed by the geography of the Group's sites, suppliers and our commercial footprint.

Findings from our due diligence processes were used to inform scoring of negative and positive IROs. Our due diligence processes include monitoring the compliance of our suppliers with our Code of Conduct for Third Parties, through our third-party risk management (3PRM) system. Before and after we contract with third parties, we assess whether their reputation and actions align with our expectations and address concerns.

Material impacts, risks and opportunities

Location in the value chain

Summarised IRO	Type of IRO	Raw materials and supply chain	Own operations	Distribution	Patients	Disposal	Time horizon	Applicable ESRS	Viability scenario	Further details on the IRO can be found in the Business Review
Financial and reputational risks due to climate credentials	⬇️						●●●	E1 Climate change	4	Transition plan for climate change, page 42.
Potential impacts on patients due to climate disasters	⬇️						●●●			Climate change adaptation, page 44.
Patient discharge of persistent pharmaceuticals	⬇️						●●●	E2 Pollution		Pharmaceuticals in the environment, page 45.
Regulatory risks due to PFAS restrictions	⬇️						●●			PFAS restrictions, page 45.
Opportunities from the creation of new medicines	✓						●●●	S4 Consumers and end-users and S1 Own workforce	3	Sustainable innovation, page 30, and Developing skills and capabilities, page 39.
Financial and compliance risks related to ethical violations	⬇️						●●●	G1 Business conduct and S1 Own workforce		Developing skills and capabilities, page 39, and Business conduct, pages 34 and 35.
Financial risk due to irresponsible marketing	⬇️						●●●			
Cybersecurity incidents affecting product delivery and patients' health	⬇️						●●●	G1 Business conduct		Cybersecurity and data privacy, page 36.
Financial and reputational risks related to disruption to IT systems, including cybersecurity breaches	⬇️						●●●	G1 Business conduct and S1 Own workforce	5	Cybersecurity and data privacy, page 36, and Developing skills and capabilities, page 39.
Reputational risks related to data privacy and data management	⬇️						●●●			
Potential data privacy incidents affecting stakeholders' privacy rights	⬇️						●●●	G1 Business conduct		Cybersecurity and data privacy, page 36.

Key: ⬇️ Risk ⬆️ Transitional risk ⬇️ Potential negative impact ✓ Opportunity
 ● Short: up to one year ● Medium: one to three years ● Long: more than three years

Additional material IROs were also identified across the ESRS in scope of Delegated Regulation (EU) 2025/1416. The interaction between the material topics, our strategy and business model are outlined in the topical disclosures, see page references in the table on page 207.

For more information on the Viability Statement, see page 46.

Once contracted, we undertake supplier site audits of selected suppliers, using the Pharmaceutical Supply Chain Initiative (PSCI) Audit processes and documentation. Collectively, these processes assess topics such as human and labour rights, safety, health and environment, anti-bribery and anti-corruption, data privacy and IT security, suppliers' management systems, employment principles, as well as risk management processes. We also conduct biannual human rights labour reviews in all countries where we have employees, focused on the International Labour Organization's core themes.

The results of due diligence findings, as well as internal assessments and research, inform the double materiality assessment.

Negative and positive impacts were initially scored using results of due diligence findings, internal assessments and research. Subsequently, findings were confirmed by internal and external stakeholders. External stakeholders represented patient groups, suppliers, investors, academia and non-governmental organisations. Their input was used to refine and validate the assessments and scores, in line with defined scoring criteria.

The identification and assessment of sustainability-related risks and opportunities was carried out based on prevailing exposures, taking account of mitigations

in place at the reporting date. This approach is aligned to the Group's risk management framework (see our Risk Overview from page 47).

The double materiality assessment utilised quantitative and qualitative thresholds, aligned with the Group's risk appetite, to determine material IROs. The assessment was then reviewed by representatives of the SET and the Board.

In 2025, we updated our double materiality assessment utilising the same methodology as in 2024. This resulted in Use and sourcing of raw materials being determined to be material. People is a material topic based on the dependency on our people to deliver on our Ambition 2030 and uphold the Company's values. However, Talent attraction and retention was not determined to be a material topic in 2025.

Material impacts, risks and opportunities

The material IROs identified in the double materiality assessment are presented on page 40. These material IROs are integrated into our business strategy and processes, see the topical disclosures. The Board assesses the Group's resilience through a viability assessment, see the Viability Statement on page 46. Our viability scenarios have been formulated taking sustainability risks into consideration where appropriate.

For information on the impact of material sustainability topics on the Group's financial statements, see the Group Accounting Policies in the Financial Statements from page 129.

Materiality of metrics in the Sustainability Statement

Metrics related to the IROs are included if they are used to track effectiveness of our progress internally and they are complete to the extent of the material impact, risk or opportunity for the Group. These principles apply to both metrics that derive from the ESRS and for entity-specific metrics. Data points derived from other EU legislation and environmental metrics under an operational control boundary, where not material, have not been disclosed.

List of ESRS Disclosure Requirements complied with

ESRS 2 – General disclosures	Page
BP-1 – Basis for preparation	205
BP-2 – Specific circumstances	205, 208-210, 213, 218
GOV-1 – Governance roles	208-210
GOV-2 – Governance	205, 208-210
GOV-3 – Incentive schemes	208-210
GOV-4 – Due diligence	205
GOV-5 – Risk management	205
SBM-1 – Strategy, business model and value chain	208-210
SBM-2 – Stakeholders	206-207, 208-210
SBM-3 – Interaction of material IROs with strategy	206, 208-210
IRO-1 – Processes	206-207
IRO-2 – ESRS Disclosure Requirements (DR) covered	205, 207-208
S1 – Own workforce (People)	Page
S1-1, MDR-P – Policies	206-207, 208-210, 217
S1-2 – Engaging own workforce	208-210
S1-3 – Channels to raise concerns	208-210
S1-4, MDR-A – Actions	208-210
MDR-M – Metrics	208-210, 218
MDR-T – Targets	211

G1 – Business conduct	Page
G1.GOV-1 – Role of supervisory bodies	208-210
G1-1, MDR-P – Policies	208-210, 219
G1-3 – Procedures	208-210, 219
MDR-A – Actions	208-210
G1-4, MDR-M – Metrics	208-210
MDR-T – Targets	211
E2 – Pollution (Nature)	Page
MDR-P – Policies	211
E2.IRO-1 – Processes	206-207
E2-2, MDR-A – Actions	208-210
MDR-T – Targets	211
E4 – Biodiversity and ecosystems (Nature)	Page
ESRS 2 17 a, c-d	206, 208-210, 211
S4 – Consumers and end-users (Sustainable Innovation)	Page
ESRS 2 17 a-e	206, 208-210, 217-218

S4 – Consumers and end-users (Patient safety and product quality)	Page
ESRS 2 17 a, c-e	206, 208-210, 217-218
S4 – Consumers and end-users (Accessible and affordable healthcare)	Page
ESRS 2 17 a-e	206, 208-210, 217-218
G1 – Business conduct (Cybersecurity and data privacy)	Page
MDR-P – Policies	219
MDR-A – Actions	208-210
MDR-M – Metrics	208-210, 219
MDR-T – Targets	211

General disclosures *continued*

E1 – Climate change	TCFD	Companies Act	
Disclosure Requirements			Page
E1.GOV-3: Incentive schemes	Governance: The Board's oversight of climate-related risks and opportunities, and management's role in assessing and managing climate-related risks and opportunities	Governance arrangements for climate-related risks and opportunities	42, 82, 83, 85, 86, 208-210
E1-1: Transition plan E1.SBM-3: Material IROs	Strategy: Climate-related risks and opportunities identified over short, medium and long term	Principal climate-related risks and opportunities	46, 47, 206, 208-210, 214
	Strategy: Impact of climate-related risks and opportunities on the company's businesses, strategy and financial planning	Impacts of the principal climate-related risks and opportunities on the business model and strategy	
	Strategy: Resilience of the organisation's strategy	Resilience of the company's business model and strategy	
E1.IRO-1: Processes E1-2: Policies MDR-P: Policies E1-3: Actions MDR-A: Actions	Risk Management: Processes for identifying and assessing climate-related risks	Identification and assessment of climate-related risks and opportunities	46, 47, 205, 206-207, 208-210, 211
	Risk Management: Processes for managing climate-related risks	Management of climate-related risks and opportunities	
	Risk Management: How processes for identifying, assessing and managing climate-related risks are integrated into overall risk management	Integration into the company's overall risk management process	
E1-6: Scopes 1, 2 and 3 MDR-M: Metrics	Metrics and Targets: Metrics to assess climate-related risks and opportunities	Key performance indicators used to assess progress against targets and calculations behind the key performance indicators	208-210, 212-213
	Metrics and Targets: Scope 1, Scope 2 and Scope 3 GHG emissions, and the related risks		
E1-4: Targets MDR-T: Targets	Metrics and Targets: Targets used by the organisation to manage climate-related risks and opportunities	Targets used by the company	208-210, 211

In the double materiality assessment, we did not identify any material IROs related to ESRS E3, E5, S2 and S3. As such, these standards are not referenced in this Sustainability Statement.

Cross-references to other parts of the Annual Report

ESRS	DR	Paragraph	Cross-reference
General disclosures			
ESRS 2	GOV-1	21a, 21c, 21d ¹ , 21e ¹	People: Inclusion and diversity, page 39. Board of Directors as at 10 February 2026, pages 68 and 69, Senior Executive Team (SET) as at 10 February 2026, page 70, Compliance with the UK Corporate Governance Code: G. Board composition, independence and division of responsibilities, page 71. Nomination and Governance Committee Report: Non-Executive Directors' experience, page 79, and Table 1 and Table 2, page 80.
		21b	Global reach and presence – Employees by reporting region, page 27.
		22a	Corporate Governance Overview, page 67.
		22b	Sustainability Committee Report: The full role of the Sustainability Committee is set out in its terms of reference, page 82.
		22c	Sustainability Committee Report: Chair's introduction, page 82.
		22c(i), 22c(ii), 22d	Sustainability Committee Report: Chair's introduction and Activities during the year, page 82.
		22b	Audit Committee Report: The full role of the Audit Committee is set out in its terms of reference, page 84.
		22c	Audit Committee Report: Chair's introduction, page 83, and Committee overview – Role of the Committee, page 84.
		22c(i), 22c(ii)	Audit Committee Report: Committee overview – Role of the Committee, page 84.
		22c(iii)	Compliance with the UK Corporate Governance Code: 4. Audit, risk and internal control, page 73.
		22b	Directors' Remuneration Committee: The role of the Remuneration Committee is set out in its terms of reference, page 90.
		22c	Compliance with the UK Corporate Governance Code: 5. Remuneration, page 73.
		22c(i), 22c(ii)	Directors' Remuneration Report: Key Committee activities in 2025, page 93.
		22c(iii)	Directors' Remuneration Report: Key Committee activities in 2025, page 93, and How the Remuneration Committee ensures targets are stretching, page 96.
		22d	Directors' Remuneration Report: How the Remuneration Committee ensures targets are stretching, page 96.
		23	Nomination and Governance Committee Report: Committee's role, page 79.

¹ Data points derived from other EU legislation: SFDR, Benchmark Regulation.

ESRS	DR	Paragraph	Cross-reference
General disclosures			
ESRS 2	GOV-1	23a, 23b	Board performance evaluation: 2025 overview, page 78, Board of Directors as at 10 February 2026, pages 68 and 69, SET as at 10 February 2026, page 70, Sustainability Committee Report: Chair's introduction, page 82.
	GOV-2	26a, 26b, 26c	Sustainability Committee Report: Activities during the year, page 82.
		26a	Audit Committee Report: Risk identification and management, page 84, Internal Audit, page 85, and Engagement with employees and other stakeholders, page 85.
		26b	Compliance with the UK Corporate Governance Code: 4. Audit, risk and internal control, page 73 Sustainability Committee Report: Chair's introduction, page 82.
		26c	Audit Committee Report: Chair's introduction, page 83, Cybersecurity risk, digital security and information governance, page 84, and Sustainability reporting, page 85.
	GOV-3	29, 29a, 29b, 29c	Directors' Remuneration Report: How our performance measures for 2026 support the delivery of our strategy, page 95.
		29c, 29d	Directors' Remuneration Report: Annual bonus, pages 98 to 102, and long-term incentives, pages 102 to 105.
		29e	Directors' Remuneration Report: Key Committee activities in 2025, page 93, and How the Remuneration Committee ensures targets are stretching, page 96.
	SBM-1	40a(i), 40a(ii)	Therapy Area Review: 2025 overview, pages 13, 17 and 23.
		40a(iii)	Global reach and presence, page 27.
		40e, 40f, 40g	Our Strategy and Key Performance Indicators, pages 10 and 11, Therapy Area Review: 2025 overview, pages 13, 17 and 23.
		42, 42a, 42b, 42c	Our Purpose, Values and Business Model, pages 8 and 9.
	SBM-2	45a, 45a(i), 45a(ii), 45a(iii), 45a(iv), 45a(v)	Connecting with our stakeholders, pages 74 to 76.
		45d	How the Board engages with stakeholders, page 76.
	SBM-3	48b, 48c(i), 48c(ii), 48c(iv)	Business conduct: AZ Ethics, Anti-bribery and anti-corruption, and Responsible sales and marketing, pages 34 and 35, Cybersecurity and data privacy, page 36, People: Enabling an agile organisation, and Developing skills and capabilities, page 39, Climate change, pages 42 to 44, Nature, page 45.
		48d	Group Accounting Policies, page 129.
		48f	Viability Statement, page 46.
Climate change			
E1	E1-1	14, 16a, 16d	Climate change: Transition plan for climate change, page 42.
		16b	Climate change: Scope 1 and 2 decarbonisation levers, page 42, and Scope 3 decarbonisation levers, page 43.
		16h, 16i	Climate change: Governance, page 42.
		16j	Climate change: Climate performance, page 43, Scope 1 and 2 decarbonisation levers, page 42, and Scope 3 decarbonisation levers, page 43.
	E1-2	25	Climate change: Governance, page 42 and Climate change adaptation, page 44.
	E1-3	29a, 29b	Climate change: Climate performance, page 43, Scope 1 and 2 decarbonisation levers, page 42, Scope 3 decarbonisation levers, page 43.
	E1-4	34e, 16a	Climate change: Transition plan for climate change, page 42.
		34a, 34b	
	E1-6	48a, 49a, 49b, 50a, 51, 52a, 52b, AR 45d	Climate change: Climate performance, page 43.
		AR 46g	Climate change: Highlighted sustainability metrics, page 42.
ESRS 2	MDR-A	68a, 68b, 68c	Climate change: Scope 1 and 2 decarbonisation levers, page 42, Scope 3 decarbonisation levers, page 43, and Climate change adaptation, page 44.
	MDR-T	80f, 80g	Climate change: Transition plan for climate change, page 42.
		80d, 80j	Climate change: Climate performance, page 43.
	MDR-M	75	Climate change: Highlighted sustainability metrics, page 42.

General disclosures *continued*

ESRS	DR	Paragraph	Cross-reference
E1	E1.GOV-3	13	Directors' Remuneration Report: How our performance measures for 2026 support the delivery of our strategy, page 95, and Long-term incentives, pages 102 to 105.
	E1.SBM-3	19a, 19b, 19c, AR 7b, AR 8b	Viability Statement, page 46.
	E1.IRO-1	20a, AR 9, 20b, 20c, 21, AR: 11a, 11c, 11d, 12a, 12b, 12c, 12d, 13, 14	Climate change: Climate change adaptation, page 44.
Nature			
E2	E2-2	AR 13	Nature: Pharmaceuticals in the environment, and PFAS restrictions, page 45.
ESRS 2	MDR-A	68a, 68b, 68c	
	BP-2	17a, 17d	Nature: Use and sourcing of raw materials, page 45.
People			
S1	S1-1	21	People: Human Resources Standards, page 39.
	S1-1	20b	People: Listening to our workforce, page 39, Engaging with our workforce, page 78.
	S1-2	27, 27a, 27b, 27c, 27e, 28	
	S1-2	27, 27a, 27b, 27e	Business conduct: AZ Ethics, page 34.
	S1-3	32b, 32c, 32d, 32e, 33	
	S1-4	38a, 38c, 38d, 40a, 40b	
ESRS 2	MDR-A	68a, 68b, 68c	People: Developing skills and capabilities, page 39, Sustainable innovation, page 30, Cybersecurity and data privacy, page 36.
	MDR-M	75	People: Highlighted sustainability metrics, page 39.
Accessible and affordable healthcare			
ESRS 2	BP-2	17a, 17b, 17c, 17d, 17e	Accessible and affordable healthcare, page 41.
Patient safety and product quality			
ESRS 2	BP-2	17a, 17c, 17d, 17e	Patient safety and product quality, page 31.
Sustainable innovation			
ESRS 2	BP-2	17a, 17c, 17d, 17e	Science and Innovation: Our performance in 2025, page 28, Sustainable innovation, page 30, Therapy Area Review: 2025 overview, pages 13, 17 and 23.
Business conduct			
G1	G1-1	9, 10a, 10c, 10c(i), 10c(ii), 10e	Business conduct: AZ Ethics, page 34.
		10g, 10h	Business conduct: Anti-bribery and anti-corruption, page 34.
	G1-3	18a, 18b, 18c	Business conduct: AZ Ethics, page 34.
		18c	Further information on risk management and controls – Global Compliance and GIA, page 73.
		21a, 21b, 21c	Business conduct: Anti-bribery and anti-corruption, page 34.
ESRS 2	MDR-A	68a, 68b, 68c	Business conduct: Anti-bribery and anti-corruption, page 34, Responsible sales and marketing, page 34.
ESRS 2	MDR-M	75	Note 30: Commercial litigation, pages 185 to 187, and Government investigations and proceedings, page 188.
G1	G1-4	24a	Business conduct: Anti-bribery and anti-corruption, page 34.
		24b	
	G1.GOV-1	5a	Corporate Governance Overview, page 67.
		5b	Board of Directors as at 10 February 2026, pages 68 and 69, SET as at 10 February 2026, page 70.
Cybersecurity and data privacy			
ESRS 2	MDR-A	68a, 68b, 68c	Cybersecurity and data privacy, page 36.
	MDR-M	75	Cybersecurity and data privacy: Highlighted sustainability metrics, page 36.

Topical disclosures

On the following pages we present our key policies, targets and metrics relating to our material IROs.

Policies

AstraZeneca's approach to our material sustainability topics is guided by a framework of policies and standards, anchored by our Code of Ethics. Following the Code of Ethics and supporting requirements, we deliver lasting benefits to patients and other stakeholders. The policies below are published on our website

(www.astrazeneca.com/sustainability/resources.html) and/or in use internally.

Sustainability targets

The tables below present sustainability targets aligned with our material sustainability topics. Where no targets or policies are in place due to being implicit in the existing policy or due to being in development pending regulatory updates, they are not listed.

Material sustainability metrics

Definitions and methodology of quantitative metrics used to track the effectiveness of our actions related to managing our material sustainability topics are detailed on pages 212 to 213, 217 to 219. The metrics cover the Group, unless otherwise stated, and are subject to limited assurance by KPMG.

Environmental disclosures

Environmental policies

Key contents	Scope	Accountability	Material topics
Global Safety, Health and Environment (SHE) Standards and OneSHE Framework of internal standards, procedures and guidelines			
Our SHE management system ensures the environmental risks of our activities are assessed, operational controls are in place, checks are completed through a risk-based audit programme guided by an independent organisation and there is an annual management review process.	Applies to all employees, temporary staff and contractors across AstraZeneca sites.	VP, Global Sustainability and SHE	Climate change and nature
Business Continuity Standard			
Sets out our principles for consistent business continuity process and governance, in order to support effective and sustainable business resilience across AstraZeneca.	Each SET area/enabling function must have an effective business continuity arrangement in place coordinated by a Business Continuity Champion.	CFO/Chief Risk Officer	Climate change

Environmental targets

Target and relations to policy	Year	Notes
Climate change*		
By 2026, reduce absolute Scope 1 and 2 GHG emissions by 98%.	2026	Category 9 is excluded from the target boundary for 2030 target. Categories 10 and 14 assessed as not relevant. Category 15 assessed as not material. Reductions are unlikely to be linear.
Baseline year: 2015		The baseline years are representative of normal operating conditions and the difference in baseline years between emission scopes is due to the availability of data.
By 2030, reduce absolute Scope 3 GHG emissions by 50%. By 2045, reduce absolute Scope 3 GHG emissions by 90% and reach net-zero.	2030 & 2045	Recalculations to baseline GHG data occurs to ensure that real changes to emissions are captured rather than a result of AstraZeneca structural (acquisitions, divestments, mergers) or methodology changes (error correction or calculation adjustments). This enables consistency to be maintained over time. Recalculation will be considered dependent upon significance to GHG emissions with updates disclosed. An internal procedure sets out the thresholds and process for recalculation and that adjustments are logged and communicated to our assurance providers as part of annual reporting.
Baseline year: 2019		An acquisition that has a material impact on our emissions is an example of a future development that could trigger a review of sustainability targets and base year data.

* Data points derived from other EU legislation: SFDR, Pillar 3, Benchmark Regulation.

Environmental disclosures *continued*

Environmental sustainability metrics

Metric	Definitions and calculations (if applicable)	Methodology
Climate change		
Gross Scope 1 and 2 (Market-based) GHG emissions (tonnes CO ₂ e) ^{1,2}	This is the combined Scope 1 and Scope 2 (Market-based) GHG emissions during the reporting period. 'Scope 1 GHG emissions' are direct emissions that occur from sources that are controlled or owned by AstraZeneca. This includes GHGs from direct fuel combustion, process and engineering fugitive emissions at sites (e.g. from refrigerants and solvents) and from fuel use in AstraZeneca's commercial fleet (leased vehicles). 'Scope 2 GHG emissions' are indirect emissions from the generation of purchased energy consumed by AstraZeneca, and includes electricity and imported steam, imported or district heat and cooling systems. 'Market-based' refers to factors that are more specific to the site and local energy market, taking account of the residual energy mix and any certified renewable power purchased by a site.	All GHG emissions are reported in accordance with the World Resource Institute/World Business Council for Sustainable Development Greenhouse Gas (GHG) Protocol: A Corporate Accounting and Reporting Standard, Revised Edition (2015) and Corporate Value Chain (Scope 3), Accounting and Reporting Standard (2011). Intergovernmental Panel on Climate Change (IPCC) Fifth Assessment Report (AR5) GWP values on a 100-year period (GWP100) excluding feedback loops were considered, as agreed by the United Nations Framework Convention on Climate Change. All GHG emissions are reported on a financial-control basis for the consolidated accounting group. Investees and other entities which are not fully consolidated in the financial statements, as well as contractual arrangements, are not material. This covers all owned sites and leased assets that trigger inclusion based on area, full-time employees and lease length. Investees and other entities not fully consolidated, as well as contractual arrangements, are not material. Estimates, any value derived through calculation or modelling rather than direct measurement, are used where complete, accurate, or directly measured data is unavailable. Uncertainty may arise due to limitations in underlying data sources, variations in measurement methodologies, or assumptions about future operations or supply chain activities. Scope 2 also includes electricity use for charging electric vehicles (battery and plug-in hybrid) in our Commercial leased fleet. Data is captured through the centralised SHE reporting system. Scope 1 is calculated with UK Government Greenhouse Gas Conversion Factors, with CO₂e estimates covering direct fuel use and fleet operations. AstraZeneca purchases biomethane certificates for some fossil gas usage in the UK, US and Europe. We aim for these certificates to be sourced from the area of gas consumption and annual matching of generation to ensure relevance and impact. In the UK, Renewable Gas Guarantees of Origin are retired through the Green Gas Certification Scheme, while in the US, Renewable Thermal Certificates are tracked via the Midwest Renewable Energy Tracking System. A small number of certificates are also acquired directly through suppliers in Europe. The reported Scope 1 emissions are calculated following the Greenhouse Gas Protocol's guidance on biogenic fuels, with AstraZeneca accounting for non-CO₂ greenhouse gases in our Scope 1 emissions. Fugitive emissions from process and engineering activities are calculated based on the IPCC AR5 GWP100 values. Our Commercial fleet emissions are derived from direct fuel consumption data or calculated using average fleet fuel consumption factors and distance travelled, with third-party fleet intensity factors used for certain markets. Non-business vehicle use is excluded, and emissions relating to electricity use for battery electric vehicles are reported in Scope 2. Our Scope 2 emissions reporting follows a market-based approach, which reflects procurement of renewable electricity and contractual instruments in line with RE100 criteria. Market-based emission factors are derived from energy providers and sector databases, while location-based emissions are calculated using regional emission factors from the International Energy Agency (IEA), US Environmental Protection Agency eGRID, and other recognised sources. Near-zero emissions are reported for purchased renewable electricity where eligible, and electricity from on-site solar generation is counted as zero emissions, subject to confirmation that energy certificates are not issued or are retired. Energy consumption is the aggregate of: (i) the annual quantity of energy consumed from activities for which the Group is responsible, including the combustion of fuel at a facility; (ii) the annual quantity of energy consumed resulting from the purchase of electricity, heat, steam or cooling by the Group for its own use; (iii) the combustion of fuel from the operation of vehicle fleet; and (iv) the annual quantity of energy consumed resulting from the purchase of electricity to operate electric vehicles as part of the Commercial vehicle fleet.

Metric	Definitions and calculations (if applicable)	Methodology
Climate change		
Gross Scope 3 GHG emissions (tonnes CO ₂ e) ²	'Scope 3 GHG emissions' are all indirect emissions (not included in Scope 2) that occur in the value chain of AstraZeneca, including both upstream and downstream emissions.	AstraZeneca reports on 12 relevant Scope 3 categories in accordance with the GHG Protocol, with Categories 10 and 14 assessed as not relevant and Category 15 assessed as not material. Data for Scope 3 is captured from multiple sources. Category 1 (Purchased Goods and Services) (2025: 3,394,405 tCO₂e) include emissions associated with AstraZeneca's sourcing of goods and investments throughout its supply chain. A hierarchical approach is used to ensure the highest quality data informs emissions calculations. Wherever possible, product manufacturing data is combined with emission factors derived from detailed Life-Cycle Assessments (LCAs), providing a comprehensive 'cradle-to-gate' footprint. For products not directly covered by LCAs, proxy data is assigned based on product classification and modality to maintain relevant coverage. For other spend and, where supplier-specific emission data exists, spend figures are multiplied by supplier intensity factors. Where supplier-specific data is not available, multi-regional spend-based emissions factors are applied to procurement categories. Expenditure not directly linked to purchases, or attributable to other Scope 3 categories (such as logistics and business travel), is excluded to avoid double counting. Emission factors and data sources for Category 1 are drawn from supplier disclosures such as CDP reports, whereby an emission factor is generated based on kgCO₂e per USD revenue for the supplier, detailed AstraZeneca product LCAs (actual and proxy), and spend-based emission factors from an environmentally extended input output model (CEDA). Category 2 (Capital Goods) (2025: 480,217 tCO₂e) include emissions associated with capital expenditure aligned with our financial reporting. Where available, AstraZeneca utilises embodied carbon reports based on the final design of projects to calculate emissions. Embodied carbon emissions cover the product stage (raw materials, transport, manufacturing) as well as the assembly stage (transport and construction process). Emissions are proportioned across the years construction occurs. Remaining emissions are calculated by grouping project spend into sustainability categories. Emissions are then calculated using multi-regional spend-based emissions factors. Intangible assets and right of use assets are excluded on the basis of having no attributable emissions. Category 11 (Use of Sold Products) (2025: 1,621,632 tCO₂e) covers emissions resulting from the end-use of AstraZeneca's inhalation devices containing hydrofluorocarbon (F-Gas) propellants. Emissions are calculated based on production volumes, using the nominal propellant content for each device and multiplying by GWP factors from the IPCC AR5. Calculations use data substantiated by third-party LCAs to ensure accuracy. It is assumed, conservatively, that the full propellant charge is released during use. Emissions are reported by manufacturing date to maintain consistency. For all other Scope 3 categories, emissions are calculated using GHG Protocol-aligned methods based on activity data, supplier information, and recognised emission factors. Where specific data are not available, spend-based or industry-average factors are applied. This approach covers energy use, transportation, waste, business travel, commuting, leased assets, and end-of-life treatment.
Scope 1 and 2 (Market-based) GHG emissions intensity (tonnes CO ₂ e per million of Total Revenue) ^{1,2}	Scope 1 and 2 intensity metric normalises the Scope 1 and 2 (Market-based) GHG footprint relative to revenue. 'Emissions intensity' refers to the amount of CO₂ emitted per unit of economic output or activity. Calculation: Gross Scope 1 and 2 (Market-based) GHG emissions divided by Total Revenue.	Data is captured through the centralised SHE reporting system.
Share of primary activity data in Scope 3 reporting (%)	'Primary data' is data from specific activities within AstraZeneca's value chain. 'Secondary data' is data that is not from specific activities within AstraZeneca's value chain. Calculation: Scope 3 GHG emissions from primary data divided by total Scope 3 GHG emissions.	Supplier data is captured through several supplier and third-party systems, including CDP.

¹ Entity-specific metrics.² Data points derived from other EU legislation: SFDR, Pillar 3, Benchmark Regulation.

Environmental disclosures *continued*

Climate risk scenarios

To assess the potential impacts of climate change on our business, we have used the scenarios listed below.

Physical risks and temperature scenarios by 2100

Physical climate system conditions represented in the scenario analysis below, are based on a set of assumptions about driving forces (such as demographic

and socio-economic development, policymaking, technological change, energy and land use) and their key relationships that correlate with how the emission pathways impact elements of society or ecosystems.

Description	Key forces and drivers included in the scenario
Low emission scenario, +1.8°C (SSP1-RCP2.6)¹	
This scenario lays out a pathway and emissions trajectory that is aligned with the objectives of the Paris Agreement to limit global warming to well below 2°C, preferably to 1.5°C, by 2100, compared with pre-industrial levels.	This scenario assumes a rapid transition to a low-carbon economy, reducing the risk of extreme climate change and its potential hazards (such as sea level rise, increasing temperatures, extreme weather conditions and loss of biodiversity).
Current trajectory scenario, +2.7°C (SSP2-RCP4.5)¹	
This is an intermediate scenario with emissions peaking in 2040 and falling rapidly thereafter until 2080. Deemed to be the 'most likely' scenario.	In this scenario, the Paris Agreement of keeping temperature increases 'well below 2°C above pre-industrial levels' is breached. This scenario leads to an increase in the frequency and intensity of extreme weather events, rising sea levels, loss of biodiversity and other negative consequences of climate change. This scenario model assumes a degree of adaptation and mitigation of emissions, which helps mitigate some hazards compared to more high-risk scenarios.
High emission scenario, +4.4°C (SSP5-RCP8.5)¹	
This is a worst-case scenario consistent with no policy changes to reduce emissions, where CO ₂ concentrations in the atmosphere are approximately doubled by 2050 and continue to increase until 2100.	The dangers of a significant and rapid increase in the global average temperature leads to extreme climate conditions, such as severe warming, sea level rise, loss of ice masses, changes in precipitation patterns and increased risk of extreme weather events. This scenario also implies a high degree of impact on ecosystems and communities, including loss of biodiversity, altered habitats and disruption of community infrastructure. It is the most extreme scenario in terms of climate change. Metrics to quantify exposure to hazards in this scenario are used in deep-dive risk assessments for certain sites to pressure test how effective existing mitigations will be in 2030 and 2050. For new projects, data modelling is used for the life-cycle of an asset.

¹ Key inputs and constraints of the scenarios: In the three scenarios, the main metrics considered to quantify hazards are: heat, cold, fire, flood, wind, convective storms, water scarcity and water quality. Flood depth estimates assume no existing flood defences.

Transition risks and opportunities scenarios used

Description	Key forces and drivers included in the scenario
1.5°C (IEA World Energy Outlook (WEO) Net-Zero Emissions by 2050 Scenario (NZE) – equivalent to RCP1.9)²	
The IEA WEO NZE is a normative IEA scenario that shows a narrow but achievable pathway for the global energy sector to achieve net-zero CO ₂ emissions by 2050, with advanced economies reaching NZE in advance of others.	1. Significant low-carbon investment and policy implementation 2. Rapid decarbonisation 3. Extensive increases in energy efficiency
1.7°C (IEA WEO Announced Pledges Scenario (APS) – equivalent to RCP2.6)²	
The IEA WEO APS was used as the primary low-carbon future scenario. As a 'well below 2°C' pathway, the APS represents a gateway to the outcomes targeted by the Paris Agreement. The APS assumes that governments will meet, in full and on time, all the climate-related commitments they have announced, including longer-term net-zero emissions targets and pledges in Nationally Determined Contributions.	1. Widespread policy implementation 2. Technological advancements 3. Significant emissions reductions
2.4°C (IEA WEO Stated Policies Scenario – (STEPS) – equivalent to RCP4.5)²	
The IEA WEO STEPS provides a more conservative benchmark for the future because it does not take for granted that governments will reach all announced goals.	1. Current policy implementation 2. Energy demand growth 3. Widespread fossil fuel use 4. Technological developments

² Key inputs and constraints of the scenarios: The three scenarios are used for projections of energy cost, forecasting of carbon price, change in raw material costs and supply-demand of renewable energy to see how those will relate to our roadmap to net-zero GHG emissions and impact our transition risks and opportunities, and cost of goods and profits.

The EU Taxonomy

The EU Taxonomy (Regulation (EU) 2020/852) and associated Delegated Acts¹ represent an evolving classification system for sustainable economic activities. An economic activity is Taxonomy-eligible if it is described in the Taxonomy Delegated Acts. An economic activity is Taxonomy-aligned if it makes a substantial contribution to one or more of the specified environmental objectives, meets specified 'Do no significant harm' (DNSH) criteria and is carried out in compliance with minimum safeguards.

Eligibility assessment

The Group has identified its Taxonomy-eligible activities by screening the economic activities in the Climate Delegated Act and the Environmental Delegated Act. The Group is eligible for a revenue-generating economic activity included in the Environmental Delegated Act for the environmental objective of Pollution Prevention and Control (PPC), namely, PPC 1.2 Manufacture of medicinal products.

AstraZeneca is engaged in a single business activity of pharmaceuticals and hence the Group's capital expenditure (Capex)² and operating expenditure (Opex)³ is materially eligible for the 'Manufacture of medicinal products' activity.

Capex was assessed for Taxonomy-eligibility on a project basis based on a set quantitative threshold.

Alignment assessment

Substantial contribution

The 'Manufacture of medicinal products' criteria requires that, in order to be aligned, products be both biodegradable and a substitute for an existing non-degradable product. The Group's portfolio of eligible products includes both biologics and small molecule APIs. Innovative medicines by their very nature are not alternatives to existing products, hence they do not meet the substantial contribution criteria. Eligible products where the APIs are small molecules are generally considered to be not readily biodegradable. The biologics used in the Group's APIs are mostly naturally occurring and generally considered to be degradable. However, in some instances excipients used in products may not be considered degradable.

We have therefore assessed that, overall, our products do not meet the substantial contribution criteria and do not align with the 'Manufacture of medicinal products' activity criteria.

Interpretation of the EU Taxonomy and company-specific assumptions are required to fulfil the reporting requirements.

Revenue

The Taxonomy-eligible Revenue KPI is defined as Taxonomy-eligible Revenue divided by Total Revenue, which corresponds to 'Total Revenue' in our Consolidated Statement of Comprehensive Income as detailed on page 125.

The Group's Product Sales and sales milestones within Collaboration Revenue are associated with the manufacture of medicinal products, which we consider in total for Taxonomy-eligibility under the activity 'Manufacture of medicinal products'. Consequently, our Taxonomy-eligible Revenue KPI for the year ended 31 December 2025 is 95% (2024: 96%).

Capital expenditure

The Taxonomy-eligible Capex KPI is defined as Taxonomy-eligible Capex divided by Total Capex.

- Taxonomy-eligible Capex is Capex related to assets or processes associated with Taxonomy-eligible activities. Property, purchase of plant and equipment, right-of-use buildings, intangible assets, purchase of marketing and distribution rights over medicinal products are considered in total for Taxonomy-eligibility under the activity 'Manufacture of medicinal products'.
- Total Capex corresponds to the total of the 'Additions through business combinations' and 'Capital expenditure' movement types, the total of the 'Additions – separately acquired' and 'Additions through business combinations' movement types as detailed in Note 8 Property, plant and equipment (page 149), the total of the 'Additions – separately acquired' and 'Additions through business combinations' movement types as detailed in Note 9 Leases (page 150), and the total of the 'Additions – separately acquired' and 'Additions through business combinations' movement types as detailed in Note 11 Intangible assets (page 151).

The Group's Taxonomy-eligible Capex KPI for the year ended 31 December 2025 is 83% (2024: 86%).

Operating expenditure

The Taxonomy-eligible Opex KPI is defined as Taxonomy-eligible Opex divided by Total Opex.

- The Group's Taxonomy-eligible Opex is expenses related to assets or processes associated with Taxonomy-eligible economic activities. R&D expenses associated with functional areas which are involved directly in the manufacture and procurement of medicinal products are considered Taxonomy-eligible under the activity 'Manufacture of medicinal products'.
- The Group's Taxonomy-defined Opex is the total of R&D expenses, and other direct non-capitalised costs that relate to building renovation measures, short-term leases, maintenance and repair, and any other direct expenditures incurred in the day-to-day servicing of property, plant and equipment.

The Group's Taxonomy-eligible Opex KPI for the year ended 31 December 2025 is 21% (2024: 18%).

¹ On 8 January 2026, the EU Commission published a delegated act amending the Disclosures, Climate, and Environmental Delegated Acts that supplement the Taxonomy Regulation, which introduces a materiality threshold for eligibility and alignment as well as a simplified reporting table.

² As part of our materiality assessment in the current year we have categorised construction and renovation project Capex towards the manufacture of medicinal products, with the exception of R&D functional areas, which is not assessed as it is considered not material (in the prior year, construction and renovation project Capex was categorised as an individual measure against individual real estate activities).

³ As part of our materiality assessment in the current year we have categorised maintenance Opex towards the manufacture of medicinal products (in the prior year, this was categorised as an individual measure against individual real estate activities).

Environmental disclosures *continued*

EU Taxonomy tables

Financial year	2025	Breakdown by environmental objectives of Taxonomy-aligned activities													
KPI	Total	Proportion of Taxonomy-eligible activities	Taxonomy-aligned activities	Proportion of Taxonomy-aligned activities	Climate Change Mitigation	Climate Change Adaptation	Water	Pollution	Circular Economy	Biodiversity	Proportion of enabling activities	Proportion of transitional activities	Not assessed activities considered non-material	Taxonomy-aligned activities in 2024	Proportion of Taxonomy-aligned activities in 2024
	\$m	%	\$m	%	%	%	%	%	%	%	%	%	%	\$m	%
Revenue	58,739	95	0	0	0	0	0	0	0	0	0	0	0	0	0
Capex	7,595	83	0	0	0	0	0	0	0	0	0	0	7	0	0
Opex	14,818	21	0	0	0	0	0	0	0	0	0	0	0	0	0

Revenue

Financial year	2025	Breakdown by environmental objectives of Taxonomy-aligned activities											
Economic Activities	Code	Taxonomy-eligible KPI (proportion of Taxonomy-eligible Revenue)	Taxonomy-aligned KPI (monetary value of Revenue)	Taxonomy-aligned KPI (proportion of Taxonomy-aligned Revenue)	Climate Change Mitigation	Climate Change Adaptation	Water	Pollution	Circular Economy	Biodiversity	Enabling activity	Transitional activity	Proportion of Taxonomy-aligned in Taxonomy-eligible
		%	\$m	%	%	%	%	%	%	%	E	T	%
Manufacture of medicinal products	PPC 1.2	95	0	0	0	0	0	0	0	0			0
Total KPI		95	0	0	0	0	0	0	0	0			0

Capex

Financial year	2025				Breakdown by environmental objectives of Taxonomy-aligned activities								
Economic Activities	Code	Taxonomy-eligible KPI (proportion of Taxonomy-eligible Capex)	Taxonomy-aligned KPI (monetary value of Capex)	Taxonomy-aligned KPI (proportion of Taxonomy-aligned Capex)	Climate Change Mitigation	Climate Change Adaptation	Water	Pollution	Circular Economy	Biodiversity	Enabling activity	Transitional activity	Proportion of Taxonomy-aligned in Taxonomy-eligible
		%	\$m	%	%	%	%	%	%	%	E	T	%
Manufacture of medicinal products	PPC 1.2	83	0	0	0	0	0	0	0	0			0
Total KPI		83	0	0	0	0	0	0	0	0			0

Opex

Financial year	2025	Breakdown by environmental objectives of Taxonomy-aligned activities											
Economic Activities	Code	Taxonomy-eligible KPI (proportion of Taxonomy-eligible Opex)	Taxonomy-aligned KPI (monetary value of Opex)	Taxonomy-aligned KPI (proportion of Taxonomy-aligned Opex)	Climate Change Mitigation	Climate Change Adaptation	Water	Pollution	Circular Economy	Biodiversity	Enabling activity	Transitional activity	Proportion of Taxonomy-aligned in Taxonomy-eligible
		%	\$m	%	%	%	%	%	%	%	E	T	%
Manufacture of medicinal products	PPC 1.2	21	0	0	0	0	0	0	0	0			0
Total KPI		21	0	0	0	0	0	0	0	0			0

Social disclosures

Social policies

Key contents	Scope	Accountability	Material topics
Global Human Resources Standards			
Sets out our principles for Employment, HR Data, Inclusion and Diversity, Recruitment, Reward, Talent Management, and Bullying and Harassment.	The Employment, Talent Management, and HR Data Standards apply to AstraZeneca employees. The Talent Acquisition and Rewards Standards apply to line managers. The Inclusion and Diversity, and Bullying and Harassment Standards apply to all employees, managers and contingent workers.	Chief HR Officer	People
Human Rights Standard*			
Mandatory principles for upholding human rights across the organisation, guided by the principles of the Universal Declaration of Human Rights, the International Labour Organization's Declaration on Fundamental Principles and Rights at Work, Covenant on Civil and Political Rights, International Covenant on Economic, Social and Cultural Rights, the United Nations Guiding Principles on Business and Human Rights and the Organisation for Economic Co-operation and Development Guidelines for Multinational Enterprises.	All AstraZeneca employees including workers and any agents acting on AstraZeneca's behalf.	Approved by the CEO, implemented through the Global Compliance function	All
Product to Patient Governance Pathway			
Comprises vital investment decisions and other key development milestones from the Candidate Drug Investment Decision to health authority approval.	All therapeutic areas within R&D.	Global Portfolio and Project Management	Sustainable innovation
Quality Policy			
Identifies our Company's Quality responsibilities and commitments to the health of our patients.	Applies to all AstraZeneca employees and contractors involved in, or supporting, Good Pharmaceutical Practice (GxP) activities, external partners, GxP material suppliers and GxP service providers.	Head of Global Quality, Head of R&D Quality Assurance	Patient safety and product quality
Global Standard – Quality Management Systems (QMS)			
Defines our QMS and explains how the functions involved in GxP activities meet the requirements set by regulators, third parties, patients, and ourselves.	Applies to all AstraZeneca employees and contractors involved in, or supporting, GxP activities, external partners, GxP material suppliers and GxP service providers.	Head of Global Quality, Head of R&D Quality Assurance	Patient safety and product quality

Social sustainability targets

Target and relations to policy	Year	Notes
Sustainable innovation		
By 2030, we aim to launch at least 20 new medicines.	2030	Our Ambition 2030 workstreams focus on accelerating our strategic priorities, exploring new ones and building for the future. Our scientific measures incentivise the development of new molecular entities (NMEs) and maximise the potential of existing medicines. Oncology, BioPharmaceuticals and Rare Disease are all in scope.
Accessible and affordable healthcare		
By 2030, we aim to positively impact one billion people, including 400 million people from underserved groups.	2030	In May 2025, we updated our health equity strategy, embedding health equity across science (including genomics and clinical trials), healthcare delivery and community investment, with a 2030 ambition to positively impact one billion people, including 400 million from underserved communities.

Social sustainability metrics

Metric	Definitions and calculations (if applicable)	Methodology
Sustainable innovation		
Number of NMEs (approvals cumulative) ¹	'NME approvals' refers to medicines approved since October 2022 to meet our Ambition 2030.	Data is collected via a monthly reporting process, captured on AstraZeneca's project planning and forecasting tool, and maintained by the Global Portfolio and Project Management team. Approvals for the same drug in different countries are considered distinct regulatory events.
Number of pipeline progression events ¹	'Pipeline progression events' refers to the commencement of Phase II, and progression to an investment decision. The commencement of Phase II refers to when the first patient consents in Phase II of the trial. An investment decision may be a Phase II pivotal investment decision or a Phase III investment decision, where a positive outcome is expected to proceed to regulatory filing in the subsequent phase. For further information on Phase II and III, see page 9.	
Number of regulatory events ¹	'Regulatory events' refers to submissions or approvals for our medicines in major markets.	

¹ Entity-specific metrics.

* Data point derived from other EU legislation: SFDR, Benchmark Regulation.

Social disclosures *continued*

Social sustainability metrics *continued*

Metric	Definitions and calculations (if applicable)	Methodology
Patient safety and product quality		
Number of inspections from all health authorities relating to Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) ¹	'Health authorities' refers to government agencies that are responsible for protecting and promoting public health through the supervision of pharmaceutical products. 'Inspections' refers to assessments of manufacturing facilities and processes for regulated products to verify compliance with relevant regulations, by health authorities. GMP is part of a quality management system which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorisation. This covers commercial product manufacture and marketing companies' GDP, products in development going into clinical trials, and device manufacturing. Inspection is counted once observations have been received.	Data is captured on an internal quality management system by the Operations Quality Assurance team.
Number of critical findings from health authorities relating to GMP and GDP ¹	'Critical findings' are deficiencies with GMP or GDP reported by health authorities, that provide an immediate and significant risk to patient safety. A 'critical finding' can also be a combination or repetition of major findings that indicate a critical failure of GMP or GDP.	
Number of product recalls ¹	'Recalls' can be initiated at various levels: • Level 1 is at wholesale level • Level 2 is at pharmacy/hospital level • Level 3 is at patient level.	
People		
Employee belief that AstraZeneca is a great place to work (%) ¹	'Employee belief' refers to the positive response (agree and tend to agree) to each respective statement in our annual employee opinion survey, Pulse. Calculation: Total number of responses that either agree or tend to agree divided by total number of responses, then multiplied by 100.	Data is captured annually through our Pulse survey conducted by HR and shared Company-wide.
Employee belief that in the last 12 months, I have improved my existing skills, or learned new skills, or had a development opportunity (%) ¹		
Accessible and affordable healthcare		
Number of people positively impacted (cumulative, million) ¹	'People positively impacted' includes: patients treated by our Oncology, BioPharmaceuticals, and Rare Disease medicines which is an estimate of the average number of patients on therapy in the reporting year; people reached through awareness initiatives; people screened through health equity programmes; and healthcare workers trained.	The number of patients treated by our medicines is estimated based on volume of inventory sold, assumed days of therapy and average level of patient adherence to the treatment. An individual patient may be treated for different diseases with more than one medicine. Average patient adherence rates are defined by the AstraZeneca Global Insights team by therapy area and are a key assumption used in the estimate. As an average, actual patient adherence rates may differ.
Number of people positively impacted from underserved groups (cumulative, million) ¹	'Underserved groups' are defined as all patients in low- and middle-income countries in line with the World Bank Group country classification by income level, in addition to Rare Disease patients. We recognise that underserved communities exist in all countries regardless of income classification, however current publicly available data do not provide a detailed breakdown of underserved populations in high-income and upper-middle-income countries.	The number of people reached is aggregated from each programme and each market as relevant. The number of healthcare workers trained refers to those who receive education through in-person classroom-style sessions, online courses and attending symposiums. Figures are cumulative, with 2024 as the baseline year, and encompass all historical data since then.

¹ Entity-specific metrics.

Governance disclosures

Governance policies

Key contents	Scope	Accountability	Material topics
Code of Ethics			
• Our Values • Our Science • Our Interactions • Our Workplace • Our Sustainability	Applies to all Executive and Non-Executive Directors, officers, employees and contract staff of our Group.	Approved by the Audit Committee, implemented through our Chief Compliance Officer and CEO	All
Code of Conduct for Third Parties			
Translates our Code of Ethics into content applicable and relevant to our supply chain, across the topics: ethics, human and labour rights, health and safety, environment, management systems, and reporting.	Applies to all our suppliers.	Approved by the Chief Procurement Officer and implemented through the Global Procurement function	All
Anti-Bribery and Anti-Corruption Global Standard			
Outlines our key anti-bribery and anti-corruption principles and provides guidance on how to apply our Values.	Applies to all our employees, contractors and third parties.	Approved, implemented, and reported on to the Board and Audit Committee through our Deputy Chief Compliance Officer	Business conduct
Promoting our Products Global Standard			
Key principles pertaining to product promotion at the Company.	Applies to all our employees and contract staff engaged in the promotion of our products.	Deputy Chief Compliance Officer approves and implements the Standard	Business conduct
IT Security Policy Framework			
IT Security Policy, Standards, Standard Operating Procedures and Secure Baseline Configurations, based on the US National Institute of Standards and Technology Cybersecurity Framework, EU NIS2 Directive and General Data Protection Regulation.	Applies to all information assets and underlying IT and operational technologies and services that we own and/or utilise are covered by the policy, along with all our employees and external/third-party companies and personnel.	Chief Information Security Officer	Cybersecurity and data privacy
Data Privacy Standard			
Privacy risks, data collection, transparency and consent, data minimisation, legitimacy, accuracy, security, data subject rights and requests, retention, international transfers, third-party access, and marketing and promotional activities.	Applies to all entities within the Group, the Company and all our employees and temporary staff who have access to personal data as part of their business activities.	Senior Executive Team	Data privacy

Governance metrics

Metric	Definitions and calculations (if applicable)	Methodology
Cybersecurity and data privacy		
Number of material cybersecurity incidents ¹	A 'material cybersecurity incident' is defined as material unauthorised access, disclosure or disruption of information systems of data that significantly impacts the confidentiality, integrity or availability of critical assets, operations, or stakeholders.	Data is collected through incident reports, security logs and continuous monitoring tools. Designated cybersecurity and data privacy members are responsible for data collection.
Number of material security breaches involving personal data ¹	'Material security breaches' refers to material unauthorised access to personal data. A reported breach alone does not constitute a material breach.	

¹ Entity-specific metrics.

Independent Sustainability Assurance Report

Sustainability assurance providers' limited assurance report of AstraZeneca PLC's Sustainability Statement prepared in accordance with the European Sustainability Reporting Standards (ESRS)

To the Board of Directors of AstraZeneca PLC, corporate identity number 02723534.

Conclusion

We have conducted a limited assurance engagement of the Sustainability Statement for AstraZeneca PLC (the Company) for the financial year 2025. The Sustainability Statement is included on pages 204 to 221 in this document, as well as in the sections noted in the table 'Cross-references to other parts of the Annual Report' on pages 208 to 210 of the Sustainability Statement.

Based on our limited assurance engagement as described in the section Sustainability assurance provider's responsibility, nothing has come to our attention that causes us to believe that the Sustainability Statement does not, in all material respects, meet the requirements of the Swedish Annual Accounts Act (Sw: Årsredovisningslagen (1995:1554)) which includes:

- whether the Sustainability Statement meets the requirements of ESRS,
- whether the process the Company has carried out to identify reported sustainability information has been conducted as described in the Sustainability Statement, and
- compliance with the reporting requirements of the EU's Green Taxonomy Regulation Article 8.

Basis for conclusion

We have conducted the assurance engagement in accordance with the Institute for the Accountancy Profession in Sweden, Föreningen Auktoriserade Revisorer (FAR's) recommendation (standard) RevR 19 *The auditor's limited assurance regarding the statutory Sustainability Statement*.

Our responsibility according to this recommendation is further described in the section Sustainability assurance providers' responsibility.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion.

Other matters – Comparative information

The comparative information included in the Sustainability Statement of the Company, was subject to an assurance engagement performed by Bureau Veritas UK Limited who submitted a limited assurance report in accordance with ISAE 3000 (revised) *Assurance engagements other than audits*

or reviews of historical financial information and ISAE 3410 *Assurance Engagements on Greenhouse Gas (GHG)* dated 5th February 2025, with unmodified conclusion. Our conclusion is not modified in respect of this matter.

Information other than the Sustainability Statement

This Annual Report and Form 20-F information also contains information other than the Sustainability Statement and is found on pages 1 to 203, 222 to 228, with the exception of the sections disclosed in the table 'Cross-references to other parts of the Annual Report' on pages 208 to 210. The Directors are responsible for this other information.

Our conclusion on the Sustainability Statement does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our limited assurance engagement on the Sustainability Statement, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the Sustainability Statement. In this procedure we also take into account our knowledge otherwise obtained in the limited assurance engagement and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors

The Directors are responsible for the preparation of the Sustainability Statement in accordance with Chapter 6, Sections 12–12f of the Swedish Annual Accounts Act, and for such internal control as they determine is necessary to enable the preparation of the Sustainability Statement that is free from material misstatements, whether due to fraud or error.

Sustainability assurance providers' responsibility

Our responsibility is to express a conclusion on whether the Sustainability Statement has been prepared in accordance with Chapter 6, Sections 12–12f of the Swedish Annual Accounts Act based on our limited assurance review. The assurance engagement has been conducted in accordance with FAR's recommendation (standard) RevR 19 *The auditor's limited assurance regarding the statutory Sustainability Statement*.

This recommendation requires that we plan and perform our procedures to obtain limited assurance that the Sustainability Statement is prepared in accordance with these requirements.

The procedures in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed. This means that it is not possible for us to obtain such assurance that we become aware of all significant matters that could have been identified if a reasonable assurance engagement had been performed.

Our firm applies ISQM 1 (International Standard on Quality Management), which requires the firm to design, implement and operate a system of quality management, including policies and procedures regarding compliance with ethical requirements, professional standards, and applicable legal and regulatory requirements.

We have complied with the independence and other ethical requirements of the International Code of Ethics for Professional Accountants (including International Independent Standards) issued by the International Ethics Standards Board of Accountants (IESBA), together with the professional ethics requirements for accountants in Sweden.

A limited assurance engagement involves performing procedures to obtain evidence to support the Sustainability Statement. The sustainability assurance provider selects the procedures to be performed, including assessing the risks of material misstatements in the Sustainability Statement, whether due to fraud or error. In this risk assessment, the sustainability assurance provider considers the parts of the internal control that are relevant to how the Directors prepare the Sustainability Statement, in order to design procedures that are appropriate under the circumstances, but not for the purpose of providing a conclusion on the effectiveness of the Company's internal control. The review consists of making inquiries, primarily of persons responsible for the preparation of the Sustainability Statement, performing analytical review, and conducting other limited review procedures.

In conducting our limited assurance engagement, with respect to the process undertaken to identify the sustainability information to be reported, we have:

- Obtained an understanding of the process by:
 - performing inquiries to understand the sources of the information used by management; and
 - reviewing the Company's internal documentation of its process; and
- Evaluated whether the evidence obtained from our review procedures about the process implemented by the Company was consistent with the description of the process set out in the Sustainability Statement.

In conducting our limited assurance engagement, with respect to the Sustainability Statement, we have performed, but were not limited to, the following:

- Obtained an understanding of the Company's reporting processes relevant to the preparation of its Sustainability Statement including the consolidation processes by obtaining an understanding of the Company's control environment, processes and information systems relevant to the preparation of the Sustainability Statement;
- Evaluated whether material information identified by the process is included in the Sustainability Statement;
- Evaluated whether the structure and the presentation of the Sustainability Statement are in accordance with ESRS;
- Performed inquiries of relevant personnel and analytical procedures on selected information in the Sustainability Statement;
- Performed substantive assurance procedures on a selected sample of information in the Sustainability Statement;
- Evaluated selected methods, assumptions and data for developing material estimates and forward-looking information and how these methods were applied;
- Obtained an understanding of the process to identify Taxonomy-eligible and Taxonomy-aligned economic activities and the corresponding disclosures in the Sustainability Statement; and
- Where applicable, compared disclosures in the Sustainability Statement with the corresponding disclosures in the financial statements.
- Evaluated whether material information disclosed in accordance with ESRS E1 Climate change meets the compliance requirements of the UK Companies Act and aligns with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).

Inherent limitations in preparing the Sustainability Statement

In reporting forward-looking information in accordance with ESRS, the Directors of AstraZeneca PLC are required to prepare the forward-looking information on the basis of disclosed assumptions about events that may occur in the future and possible future actions by AstraZeneca PLC. Actual outcomes are likely to be different since anticipated events frequently do not occur as expected.


Stockholm 10 February 2026
KPMG AB
Ola Larsmon
Authorised Public Accountant

London 10 February 2026
Paul Nichols
Chartered Accountant

Additional Information

Contents

Shareholder information	223
Directors' Report	224
Glossary	227
Cautionary statement regarding forward-looking statements	228



Shareholder information

This section of the Annual Report contains information for shareholders that is required by regulation in the UK. Further information that may be of use to shareholders is available on the Shareholder information page of our website at www.astrazeneca.com. Additional information required by SEC regulations is included in AstraZeneca's Form 20-F filing for 2025, which is available on the SEC website at www.sec.gov.

Shareholders approved proposals to harmonise AstraZeneca's equity listing structure at a general meeting of the Company on 3 November 2025. Following implementation of the listing harmonisation on 2 February 2026, the principal markets for trading in AstraZeneca shares are the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange. Ordinary Shares of US \$0.25 each in AstraZeneca PLC are listed directly on all three exchanges under the stock symbol AZN and the shareholder register is maintained by Computershare Trust Company, N.A., the Company's transfer agent. Shares trading on the London Stock Exchange are settled in the form of Depositary Interests (DIs) issued by the Company's DI Depositary, Computershare Investor Services PLC, with each DI representing an entitlement to one Ordinary Share. The DI Depositary maintains a register of DIs which is accessible to AstraZeneca. Shares traded on Nasdaq Stockholm are held through Euroclear Bank SA/NV as custodian for Euroclear Sweden AB, the Swedish Central Securities Depositary.

Transfer Agent

Computershare Investor Services
PO Box 43078
Providence, RI 02940-3078
USA
Tel (general): +1 888 697 8018
Tel (outside US): +1 781 575 2844

DI Depositary and Corporate Sponsored Nominee (CSN) Provider

Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol
BS99 6ZY
United Kingdom
Tel (inside UK): 0370 707 1682
Tel (outside UK): +44 (0) 370 707 1682

Swedish Central Securities Depositary

Euroclear Sweden AB
PO Box 191
SE-101 23 Stockholm
Sweden
Tel: +46 (0)8 402 9000

Annual General Meeting (AGM)

The 2026 AGM will be held on 9 April 2026 and further details will be set out in the Notice of AGM.

Dividends

A first interim dividend is normally announced in July/August and paid in September and a second interim dividend is normally announced in February and paid in March. Dividends are paid in GBP, SEK and USD, depending on where the eligible shares are listed. Dates for the second interim dividend for 2025 are shown below.

Event	Date
Second interim dividend for 2025	
Ex-dividend date (for shares traded on the London Stock Exchange or Nasdaq Stockholm)	19 February 2026
Ex-dividend date (for shares traded on the New York Stock Exchange)	20 February 2026
Record date	20 February 2026
Payment date	23 March 2026

Other dates, including expected announcement dates, are available in the Investors section of our website, www.astrazeneca.com.

The completion of cross-border movements of shares by intermediaries between the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange is subject to the receiving broker identifying and confirming such movements. Where a cross-border movement of shares is initiated but not completed by the relevant dividend record date, the dividend in respect of those shares will be received in the originating market on the relevant dividend payment date.

Related party transactions

During the period 1 January 2026 to 31 January 2026, there were no transactions, loans, or proposed transactions between the Company and any related parties which were material to either the Company or the related party, or which were unusual in their nature or conditions (see also Note 31 to the Financial Statements on page 191).

Conflicts of interest

The Articles of Association of the Company enable the Directors to authorise any situation in which a Director has an interest that conflicts or has the potential to conflict with the Company's interests and which would otherwise be a breach of the Director's duty, under section 175 of the Companies Act 2006. The Board has a formal system in place for Directors to declare such situations to be considered for authorisation by those Directors who have no interest in the matter being considered.

In deciding whether to authorise a situation, the non-conflicted Directors must act in the way they consider, in good faith, would be most likely to promote the success of the Company, and they may impose limits or conditions when giving the authorisation, or subsequently, if they think this is appropriate. Situations considered by the Board and authorisations given are recorded in the Board minutes and in a register of conflicts maintained by the Company Secretary and are reviewed annually by the Board. The Board believes that this system operates effectively.

Shareholder fraud warning

Shareholders of AstraZeneca and many other companies have reported receiving unsolicited calls and correspondence relating to their shareholdings and investment matters. Shareholders are advised to be very cautious of any unsolicited approaches and to note that reputable firms authorised by the Financial Conduct Authority (FCA) are very unlikely to make such approaches. Such approaches are likely to be part of a 'boiler room scam' attempting to defraud shareholders.

Shareholders are advised to familiarise themselves with the information on scams available on the FCA website, www.fca.org.uk/consumers and with the FAQs in the Investors section of our website, www.astrazeneca.com.

Any suspected scams or fraudulent approaches should be reported to the FCA via its website and to AstraZeneca's DI Depositary and CSN Provider contact listed on this page.

 For more information on dividends declared, see the Shareholder information section of our website, www.astrazeneca.com.

Directors' Report

The Directors' Report includes information required to be given in accordance with the Companies Act 2006.

Relevant information below, which is contained elsewhere in the Annual Report, is incorporated by cross reference herein.

Subsidiaries and principal activities

The Company is the holding company for a group of subsidiaries whose principal activities are described in this Annual Report. The Group's subsidiaries and their locations are set out in Group Subsidiaries and Holdings in the Financial Statements from page 192.

Branches and countries in which the Group conducts business

In accordance with the Companies Act 2006, we disclose below countries of our representative, scientific or branch offices outside of the UK, established through various subsidiaries of the Company:

Algeria, Angola, China, Costa Rica, Cuba, Denmark, Egypt, Georgia, Ghana, Jordan, Lebanon, Norway, Portugal, Romania, Russia, Saudi Arabia, Slovakia, Slovenia, Switzerland, Syria, Ukraine, United Arab Emirates, the US and Vietnam.

Disclosure of information to auditors

The Directors who held office at the date of approval of this Annual Report confirm that, so far as they are each aware, there is no relevant audit information of which the Company's auditors are unaware; and each Director has taken all the steps that he or she ought to have taken as a Director to make himself or herself aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

Going concern accounting basis

Information on the business environment in which AstraZeneca operates, including the factors underpinning the industry's future growth prospects, is included in the Strategic Report. Details of the product portfolio of the Group are contained in the Strategic Report (in the Therapy Area Review from page 12). For information on patent expiry dates for key marketed products, see the Patent Expiries of Key Marketed Products Supplement on our website, www.astrazeneca.com/annualreport2025.

Our approach to product development is covered in detail, with additional information by therapy area, in the Strategic Report. For information on our development pipeline, see the Development Pipeline Supplement on our website, www.astrazeneca.com/annualreport2025.

The financial position of the Group, its cash flows, liquidity position and borrowing facilities are described in the Financial Review from page 50. In addition, Note 28 to the Financial Statements from page 171 includes the Group's objectives, policies and processes for: managing capital; financial risk management objectives; details of its financial instruments and hedging activities; and its exposures to credit, market and liquidity risk. Further details of the Group's cash balances and borrowings are included in Notes 18 and 19 to the Financial Statements on pages 156 to 158.

Having assessed the Principal Risks and other matters considered in connection with the Viability Statement on page 46, the Board considers it appropriate to adopt the going concern basis of accounting in preparing the Annual Report and Financial Statements.

Shares

A shareholders' resolution was passed at the 2025 AGM authorising the Company to purchase its own shares. The Company did not purchase any of its own shares in 2025. On 31 December 2025, the Company did not hold any shares in treasury.

Rights, preferences and restrictions attaching to shares

As at 31 December 2025, the Company had 1,550,907,927 Ordinary Shares and 50,000 Redeemable Preference Shares in issue. The Ordinary Shares represent 99.98% and the Redeemable Preference Shares represent 0.02% of the Company's total share capital (these percentages have been calculated by reference to the 8am WM/Reuters USD/GBP exchange rate on 31 December 2025).

As agreed by the shareholders at the Company's AGM held on 29 April 2010, the Articles of Association of the Company were amended with immediate effect to remove the requirement for the Company to have an authorised share capital, the concept of which was abolished under the Companies Act 2006. The rights and restrictions attaching to the shares (in addition to those imposed by law) are set out in the Company's Articles. Each Ordinary Share carries the right to vote at general meetings of the Company, subject to certain temporary limitations applicable to AstraZeneca shares held through a temporary holding facility on behalf of persons resident in certain jurisdictions who were certificated holders of AstraZeneca shares or registered holders of AstraZeneca ADRs prior to implementation of the Company's listing harmonisation. The rights and restrictions attaching to the Redeemable Preference Shares differ from those attaching to Ordinary Shares as follows:

- The Redeemable Preference Shares carry no rights to receive dividends.
- The holders of Redeemable Preference Shares have no rights to receive notices of, attend or vote at general meetings, except in certain limited circumstances. They have one vote for every 50,000 Redeemable Preference Shares held.
- On a distribution of assets of the Company, on a winding-up or other return of capital (subject to certain exceptions), the holders of Redeemable Preference Shares have priority over the holders of Ordinary Shares to receive the capital paid up on those shares.
- Subject to the provisions of the Companies Act 2006, the Company has the right to redeem the Redeemable Preference Shares at any time on giving not less than seven days' written notice.

There are no specific restrictions on the transfer of shares in the Company, which is governed by the Articles and prevailing legislation.

The Company is not aware of any agreements between holders of shares that may result in restrictions on the transfer of shares or that may result in restrictions on voting rights. The Company is also not aware of any arrangements under which financial rights are held by a person other than the holder of the shares.

Action necessary to change the rights of shareholders

In order to vary the rights attached to any class of shares, the consent in writing of the holders of three quarters in nominal value of the issued shares of that class or the sanction of a special resolution passed at a general meeting of such holders is required.

Changes in share capital

Changes in the Company's Ordinary Share capital during 2025, including details of the allotment of new shares under the Company's share plans, are given in Note 24 to the Financial Statements from page 169.

Employee share trust ownership rights

The trustee of the AstraZeneca Employee Benefit Trust (the EBT, the Trustee) will not exercise voting rights attached to shares held in the EBT (Shares). Any decision as to acceptance or rejection of an offer for Shares subject to subsisting awards would be made by the Trustee, having regard to the interests of award holders.

There is a further employee benefit trust for the benefit of employees who are residents in Canada (the Canada EBT). The trustees of the Canada EBT will not exercise voting rights attached to shares held in the Canada EBT.

Major shareholdings

At 31 December 2025, the following persons had disclosed an interest in the issued Ordinary Share capital of the Company in accordance with the requirements of rules 5.1.2 or 5.1.5 of the UK Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rules.

Changes in the percentage ownerships disclosed by major shareholders are set out below. Major shareholders do not have different voting rights.

Shareholder	Date of the latest disclosure to the Company ¹	Number of Ordinary Shares disclosed	The date of the latest disclosure to the Company	Number of Ordinary Shares disclosed as a percentage of issued share capital at:			
				31 December 2023	31 December 2024	31 December 2025	31 January 2026
BlackRock, Inc.	4 December 2009	100,885,181	6.96	6.51	6.51	6.50	6.50
Investor AB	3 April 2019	51,587,810	3.93	3.33	3.33	3.33	3.33
The Capital Group Companies, Inc.	3 December 2025	77,125,348	4.97	4.12	4.11	4.97	4.97
Wellington Management Group LLP ²	21 July 2020	65,120,892	4.96	4.20	4.20	4.20	4.20
Wellington Management Company LLP ²	21 July 2020	65,118,411	4.96	4.20	4.20	4.20	4.20

¹ Since the date of disclosure to the Company, the interest of any person listed above in Ordinary Shares may have increased or decreased. No requirement to notify the Company of any increase or decrease arises unless the holding passes a notifiable threshold in accordance with rules 5.1.2 or 5.1.5 of the UK FCA's Disclosure Guidance and Transparency Rules.

² The Company was notified at the time of the disclosure that Wellington Management Company LLP was a subsidiary of Wellington Management Group LLP and that the shareholding percentage notified by Wellington Management Company LLP was included within the aggregate shareholding percentage notified by Wellington Management Group LLP.

The Company has not been notified of any other person holding a notifiable interest in the issued Ordinary Share capital of the Company. No changes to major shareholdings were disclosed to the Company between 31 December 2025 and 31 January 2026.

So far as the Company is aware, it is neither directly nor indirectly owned or controlled by one or more corporations or by any government.

The Company does not know of any arrangements, the operation of which might result in a change in the control of the Company.

Distributions to shareholders – dividends for 2025

Details of our distribution policy are set out in the Financial Review from page 50 and Note 28 to the Financial Statements from page 171.

The Company's dividend for 2025 of \$3.20 (236.2 pence, 29.30 SEK) per Ordinary Share is estimated to amount to, in aggregate, a total dividend payment to shareholders of \$4,963 million. The AstraZeneca EBT waived its right to receive the dividend on the Ordinary Shares and ADRs it holds.

The Canadian EBT waived its right to receive the dividend on the Ordinary Shares it holds. The AstraZeneca Share Trust waived its right to receive the dividend on the Ordinary Shares it holds and instead received nominal dividends.

Articles of Association

AstraZeneca PLC's current Articles were adopted by shareholders at a general meeting of the Company held on 3 November 2025. Any amendment to the Articles requires the approval of shareholders by a special resolution at a general meeting of the Company, other than Article 40. Article 40 requires resolutions put to the vote of a general meeting to be decided on a poll, for so long as any AstraZeneca shares are held in a settlement system operated by Depository Trust Company (DTC). Article 40 can only be removed, amended or varied by unanimous resolution of the members at a general meeting of the Company.

Objects

The Company's objects are unrestricted.

Directors

The Board has the authority to manage the business of the Company, for example, through powers to allot and repurchase its shares, subject where required to shareholder resolutions. Subject to certain exceptions, Directors do not have power to vote at Board meetings on matters in which they have a material interest.

The quorum for meetings of the Board is a majority of the full Board, of whom at least four must be Non-Executive Directors. In the absence of a quorum, the Directors do not have power to determine compensation arrangements for themselves or any member of the Board.

The Board may exercise all the powers of the Company to borrow money. Variation of these borrowing powers would require the passing of a special resolution of the Company's shareholders.

All Directors must retire from office at the Company's AGM each year and may present themselves for election or re-election. Directors are not prohibited, upon reaching a particular age, from submitting themselves for election or re-election.

General meetings

AGMs require 21 clear days' notice to shareholders. Subject to the Companies Act 2006, other general meetings require 14 clear days' notice.

For all general meetings, a quorum of two shareholders present in person or by proxy, and entitled to vote on the business transacted, is required unless each of the two persons present is a corporate representative of the same corporation, or each of the two persons present is a proxy of the same shareholder.

Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to general meetings.

Limitations on the rights to own shares

There are no limitations on the rights to own shares.

Directors' Report *continued*

Stakeholder engagement

The discussion on stakeholder engagement and the impact of these interactions is contained in Connecting with our stakeholders from page 74 and throughout the Strategic Report. This includes engagement with our employees, suppliers and other stakeholders, as well as the impact of our operations on the community and environment.

Information on how we encourage employee involvement in the Company's performance is set out in People and Sustainability from page 38. Details of some of the employee share plans are described in the Directors' Remuneration Report from page 90, and in Note 29 to the Financial Statements from page 178. All employees are provided with information on matters of concern to them through regular meetings and updates on the Group's internal communication platform. 'Townhall' meetings and Q&A sessions are hosted regularly by members of senior management, including global and targeted broadcasts. During 2025, these broadcasts provided updates on the business, including pipeline developments and strategic initiatives, as well as the Group's response to global issues. In addition, information about the Group's quarterly results and key regulatory matters are shared with employees. These updates inform employees of the financial and economic factors which affect the performance of the Group.

Political donations

Neither the Company nor its subsidiaries made any EU or UK political donations or incurred any EU or UK political expenditure in 2025 and they do not intend to do so in the future in respect of which shareholder authority is required, or for which disclosure in this Annual Report is required, under the Companies Act 2006. However, to enable the Company and its subsidiaries to continue to support interest groups or lobbying organisations concerned with the review of government policy or law reform without inadvertently breaching the Companies Act 2006, which defines political donations and other political expenditure in broad terms, a resolution will be put to shareholders at the

2026 AGM, similar to that passed at the 2025 AGM, to authorise the Company and its subsidiaries to:

- Make donations to political parties or independent election candidates.
- Make donations to political organisations other than political parties.
- Incur political expenditure, up to an aggregate limit of \$250,000.

Corporate political contributions in the US are permitted in defined circumstances under the First Amendment of the US Constitution and are subject to both federal and state laws and regulations. In 2025, the Group's US legal entities made contributions amounting in aggregate to \$1,104,925 (2024: \$1,156,800) to national political organisations, state-level political committees, candidate campaign committees or other entities. Corporate political contributions were made in accordance with all applicable US federal and state laws. We publicly disclose details of our corporate US political contributions, which can be found on our website, www.astrazeneca-us.com.

The annual corporate contributions budget is reviewed and approved by the US VP, Corporate Affairs and the President of our US business to ensure robust governance and oversight. US citizens or individuals holding valid green cards exercised decision making over the contributions and the funds were not provided or reimbursed by any non-US legal entity. Such contributions do not constitute political donations or political expenditure for the purposes of the Companies Act 2006 and were made without any involvement of persons or entities outside the US.

Significant agreements

There are no significant agreements to which the Company is a party that take effect, alter or terminate on a change of control of the Company following a takeover bid. There are no persons with whom we have contractual or other arrangements, who are deemed by the Directors to be essential to our business.

Use of financial instruments

The Notes to the Financial Statements, including Note 28 from page 171, include further information on our use of financial instruments.

Insurance and indemnities

The Company maintained directors' and officers' liability insurance cover throughout 2025. The Directors are also able to obtain independent legal advice at the expense of the Company, as necessary, in their capacity as Directors.

Since 2006, the Company has entered into a deed of indemnity in favour of each Board member. These deeds of indemnity are still in force and provide that the Company shall indemnify the Directors to the fullest extent permitted by law and the Articles, in respect of all losses arising out of, or in connection with, the execution of their powers, duties and responsibilities as Directors of the Company or any of its subsidiaries. This is in line with current market practice and helps us attract and retain high-quality, skilled Directors.

Compliance requirements under UK Listing Rule 6.6.1

The only matter to report is the shareholder waiver of dividends on page 225.

Directors' Report

The Directors' Report, which has been prepared in accordance with the requirements of the Companies Act 2006, comprises the following sections:

- Chair's Statement
- Chief Executive Officer's Review
- Therapy Area Review
- Business Review
- Risk Overview
- Financial Review: Financial risk management
- Corporate Governance: including the Corporate Governance Overview, Corporate Governance Report, Nomination and Governance Committee Report, Science Committee Report, Sustainability Committee Report and Audit Committee Report
- Directors' responsibility statement
- Sustainability Statement
- Shareholder information

and has been approved by the Board and signed on its behalf.

On behalf of the Board

M S Bowden

Company Secretary
10 February 2026

For more information on dividend distributions and the AGM, see page 223.

For more information on the Directors, see Board of Directors on pages 68 and 69.

Glossary

US equivalents

Terms used in this Annual Report	US equivalent or brief description
Accruals	Accrued expenses
Called-up share capital	Issued share capital
Earnings	Net income
Employee share schemes	Employee stock benefit plans
Fixed asset investments	Non-current investments
Freehold	Ownership with absolute rights in perpetuity
Loans	Long-term debt
Prepayments	Prepaid expenses
Profit	Income
Share premium account	Additional paid-in capital or paid-in surplus (not distributable)
Short-term investments	Redeemable securities and short-term deposits
Trade payables	Accounts payable
Trade receivables	Accounts receivable

The following abbreviations and expressions have the meanings given below when used in this Annual Report:

ADRs/ADSs – American Depositary Receipts/American Depositary Shares.

API – active pharmaceutical ingredient.

Articles – the Articles of Association of the Company.

biologic(s) or biologic medicine(s) – a class of drugs that are produced in living cells.

CER – constant exchange rates.

Company or Parent Company – AstraZeneca PLC (formerly Zeneca Group PLC (Zeneca)).

CVRM – Cardiovascular, Renal & Metabolism.

DTR – UK Disclosure Guidance and Transparency Rules.

EFPIA – European Federation of Pharmaceutical Industries and Associations.

EMA – European Medicines Agency.

F-gas – fluorinated greenhouse gases include: hydrofluorocarbons (HFCs), perfluorocarbons (PFCs) and sulphur hexafluoride (SF6).

FDA – the US Food and Drug Administration, which is part of the US Department of Health and Human Services Agency, which is the regulatory authority for all pharmaceuticals (including biologics and vaccines) and medical devices in the US.

FRC – the UK Financial Reporting Council.

GAAP – Generally Accepted Accounting Principles.

GIA – the Group's Internal Audit function.

Group – AstraZeneca PLC and its subsidiaries.

GWP – Global Warming Potential.

IAS – International Accounting Standards.

IASB – International Accounting Standards Board.

IFRS – International Financial Reporting Standards or International Financial Reporting Standard, as the context requires.

LCM – significant life-cycle management projects (as determined by potential revenue generation), or line extensions.

mAb – monoclonal antibody, a biologic that is specific, meaning it binds to and modulates one particular antigen.

major market – US, Europe, Japan and China.

Orphan Drug – a drug that has been approved for use in a relatively low-incidence indication (an orphan indication) and has been rewarded with a period of market exclusivity; the period of exclusivity and the available orphan indications vary between markets.

OS – overall survival.

PAAGR – post Alexion Acquisition Group Review.

Paediatric Exclusivity – in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry. Analogous provisions are available in certain other territories (such as European Supplementary Protection Certificate paediatric extensions).

PFS – progression-free survival. The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease without it getting worse.

pMDI – pressurised metered-dose inhaler.

primary care – general healthcare provided by physicians who ordinarily have first contact with patients and who may have continuing care for them.

R&I – Respiratory & Immunology.

rare disease – the EU defines a disease or condition as rare if it affects fewer than 1 in 2,000 people within the general population and in the US, the Orphan Drug Act defines a rare disease as a disease or condition that affects less than 200,000 people in the US.

RoW – rest of world.

SBTi/s – Science Based Targets initiative/science-based targets.

SEC – the US Securities and Exchange Commission, the governmental agency that regulates the US securities industry and stock markets.

SET – Senior Executive Team.

specialty care – specific healthcare provided by medical specialists who do not generally have first contact with patients.

SoC – standard of care. Treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals.

TSR – total shareholder return, being the total return on a share over a period of time, including dividends reinvested.

V&I – Vaccines & Immune Therapies.

Important information for readers of this Annual Report

Cautionary statement regarding forward-looking statements

The purpose of this Annual Report is to provide information to the members of the Company. The Company and its Directors, employees, agents and advisers do not accept or assume responsibility for any other person to whom this Annual Report is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed. In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995 and the UK Companies Act 2006, we are providing the following cautionary statement:

This Annual Report contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Forward-looking statements are statements relating to the future which are based on information available at the time such statements are made, including information relating to risks and uncertainties. Although we believe that the forward-looking statements in this Annual Report are based on reasonable assumptions, the matters discussed in the forward-looking statements may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of the preparation of this Annual Report and the Company undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things:

- the risk of failure or delay in delivery of pipeline or launch of new medicines
- the risk of failure to meet regulatory or ethical requirements for medicine development or approval
- the risk of failures or delays in the quality or execution of the Group's commercial strategies
- the risk of pricing, affordability, access and competitive pressures

- the risk of failure to maintain supply of compliant, quality medicines
- the risk of illegal trade in our Group's medicines
- the risk of reliance on third-party goods and services
- the risk of failure in IT or cybersecurity
- the risk of failure of critical processes
- the risk of failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives
- the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce
- the risk of failure to meet our sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment
- the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery/anti-corruption, anti-fraud and scientific exchanges
- the risk of the safety and efficacy of marketed medicines being questioned
- the risk of adverse outcome of litigation and/or governmental investigations
- intellectual property-related risks to the Group's products
- the risk of failure to achieve strategic plans or meet targets or expectations
- the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business
- the risk of failure in internal control, financial reporting or the occurrence of fraud
- the risk of unexpected deterioration in the Group's financial position.

Certain of these factors are discussed in more detail, without limitation, in the Risk Supplement available on our website, www.astrazeneca.com/annualreport2025, and reproduced in AstraZeneca's Form 20-F filing for 2025, available on the SEC website www.sec.gov. Nothing in this Annual Report should be construed as a profit forecast.

Inclusion of Reported performance, Core financial measures and constant exchange rate growth rates

AstraZeneca's determination of non-GAAP measures, together with our presentation of them within our financial information, may differ from similarly titled non-GAAP measures of other companies.

Statements of competitive position, growth rates and sales

In this Annual Report, except as otherwise stated, market information regarding the position of our business or products relative to its or their competition is based upon published statistical sales data for the 12 months ended 30 September 2025 obtained from IQVIA, a leading supplier of statistical data to the pharmaceutical industry. Except as otherwise stated, these market share and industry data from IQVIA have been derived by comparing our sales revenue with competitors' and total market sales revenues for that period, and except as otherwise stated, growth rates are given at CER. For the purposes of this Annual Report, unless otherwise stated, references to the world pharmaceutical market or similar phrases are to the 63 countries contained in the IQVIA database, which amounted to approximately 85% (in value) of the countries audited by IQVIA.

Information on websites

Information on or accessible through AstraZeneca websites (including www.astrazeneca.com and any websites referenced in this Annual Report) or any external/third-party websites does not form part of and is not incorporated into this Annual Report.

Consultancy, design
and production by
Design Bridge and Partners
www.designbridge.com

Board photography
Igor Emmerich
Marcus Lyon
Alex Telfer

This Annual Report is printed on
Revive Silk 100 paper, manufactured
from FSC® Recycled certified fibre
derived from 100% pre- and
post-consumer waste and Carbon
Balanced with the World Land Trust.

Printed in the UK by Pureprint using
its pureprint® environmental printing
technology, and vegetable inks were
used throughout. Pureprint is a
CarbonNeutral® company. Both the
manufacturing mill and the printer
are registered to the Environmental
Management System ISO14001 and
are FSC® chain-of-custody certified.



**Registered office and
corporate headquarters**

AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
UK
Tel: +44 (0)20 3749 5000



This Annual Report is also available on our website,
www.astrazeneca.com/annualreport2025